<SEC-DOCUMENT>0001520138-25-000249.txt : 20250811
<SEC-HEADER>0001520138-25-000249.hdr.sgml : 20250811
<ACCEPTANCE-DATETIME>20250811162518
ACCESSION NUMBER:		0001520138-25-000249
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20250807
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250811
DATE AS OF CHANGE:		20250811

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOVIE INC.
		CENTRAL INDEX KEY:			0001580149
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				462510769
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39015
		FILM NUMBER:		251202373

	BUSINESS ADDRESS:	
		STREET 1:		680 W NYE LANE
		STREET 2:		SUITE 201
		CITY:			CARSON CITY
		STATE:			NV
		ZIP:			89703
		BUSINESS PHONE:		775-888-3162

	MAIL ADDRESS:	
		STREET 1:		680 W NYE LANE
		STREET 2:		SUITE 201
		CITY:			CARSON CITY
		STATE:			NV
		ZIP:			89703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NANOANTIBIOTICS, INC.
		DATE OF NAME CHANGE:	20130625
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>bivi-20250807_8k.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:bivi="http://bioviepharma.com/20250807">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02E_US%2DGAAP%2D2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_03F_bivi_bioviepharma.com_20250807 -->
<!-- Field: Set; Name: xdx; ID: xdx_04D_20250807_20250807 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05D_edei%2D%2DEntityCentralIndexKey_0001580149 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-08-07" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-08-07" id="Fact000004" name="dei:EntityCentralIndexKey">0001580149</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="bivi-20250807.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-08-07">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-08-07</xbrli:startDate>
        <xbrli:endDate>2025-08-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES<br/>
SECURITIES AND EXCHANGE COMMISSION<br/>
</b>WASHINGTON, D.C. 20549</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_902_edei--DocumentType_c20250807__20250807_zwlW7TjZfkQ4"><ix:nonNumeric contextRef="AsOf2025-08-07" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT PURSUANT<br/>
TO SECTION 13 OR 15(d) OF<br/>
THE SECURITIES EXCHANGE ACT OF 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported)
<b><span id="xdx_906_edei--DocumentPeriodEndDate_c20250807__20250807_z6ocAoQsosk8"><ix:nonNumeric contextRef="AsOf2025-08-07" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">August 7, 2025</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 18pt"><b><span id="xdx_906_edei--EntityRegistrantName_c20250807__20250807_zKzR8RMyQOge"><ix:nonNumeric contextRef="AsOf2025-08-07" id="Fact000011" name="dei:EntityRegistrantName">BioVie Inc.</ix:nonNumeric></span><span style="text-decoration: underline"><br/>
</span></b></span><span style="font-size: 10pt">(Exact Name of Registrant as Specified in Its Charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; text-align: center; width: 32%"><span style="font-size: 10pt"><b><span id="xdx_90E_edei--EntityIncorporationStateCountryCode_c20250807__20250807_zZEfAJqYa9U7"><ix:nonNumeric contextRef="AsOf2025-08-07" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; text-align: center; width: 32%"><span style="font-size: 10pt"><b><span id="xdx_90B_edei--EntityFileNumber_c20250807__20250807_zyXfXmxHu0R6"><ix:nonNumeric contextRef="AsOf2025-08-07" id="Fact000013" name="dei:EntityFileNumber">001-39015</ix:nonNumeric></span></b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; text-align: center; width: 32%"><span style="font-size: 10pt"><b><span id="xdx_90C_edei--EntityTaxIdentificationNumber_c20250807__20250807_zCIYmxxpOSVi"><ix:nonNumeric contextRef="AsOf2025-08-07" id="Fact000014" name="dei:EntityTaxIdentificationNumber">46-2510769</ix:nonNumeric></span></b></span></td></tr>
  <tr>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">(State or Other Jurisdiction of Incorporation)</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">(Commission File Number)</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">(I.R.S. Employer Identification No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 66%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_904_edei--EntityAddressAddressLine1_c20250807__20250807_zefe8MGiZ7Z4"><ix:nonNumeric contextRef="AsOf2025-08-07" id="Fact000015" name="dei:EntityAddressAddressLine1">680 W Nye Lane Suite 201</ix:nonNumeric></span></b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90C_edei--EntityAddressCityOrTown_c20250807__20250807_znjl4sFjtKX6"><ix:nonNumeric contextRef="AsOf2025-08-07" id="Fact000016" name="dei:EntityAddressCityOrTown">Carson City</ix:nonNumeric></span>, <span id="xdx_905_edei--EntityAddressStateOrProvince_c20250807__20250807_zwtcBuhUgMg5"><ix:nonNumeric contextRef="AsOf2025-08-07" id="Fact000017" name="dei:EntityAddressStateOrProvince">NV</ix:nonNumeric></span></b></p></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 32%"><span style="font-size: 10pt"><b><span id="xdx_902_edei--EntityAddressPostalZipCode_c20250807__20250807_zqTmuCJqulKb"><ix:nonNumeric contextRef="AsOf2025-08-07" id="Fact000018" name="dei:EntityAddressPostalZipCode">89703</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">(Address of Principal Executive Offices)</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">(Zip Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(<span id="xdx_904_edei--CityAreaCode_c20250807__20250807_zpbv51UMGUke"><ix:nonNumeric contextRef="AsOf2025-08-07" id="Fact000019" name="dei:CityAreaCode">775</ix:nonNumeric></span>) <span id="xdx_90B_edei--LocalPhoneNumber_c20250807__20250807_zrGdMtlzZDx8"><ix:nonNumeric contextRef="AsOf2025-08-07" id="Fact000020" name="dei:LocalPhoneNumber">888-3162</ix:nonNumeric></span><br/>
</b>(Registrant&#8217;s Telephone Number, Including Area Code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former Name or Former Address, if Changed Since
Last Report)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0pt"/><td style="width: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--WrittenCommunications_c20250807__20250807_zofiUdLs3OM"><ix:nonNumeric contextRef="AsOf2025-08-07" format="ixt:booleanfalse" id="Fact000021" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-size: 10pt">Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425)</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0pt"/><td style="width: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_edei--SolicitingMaterial_c20250807__20250807_zxDCbfcRWfCe"><ix:nonNumeric contextRef="AsOf2025-08-07" format="ixt:booleanfalse" id="Fact000022" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-size: 10pt">Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0pt"/><td style="width: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--PreCommencementTenderOffer_c20250807__20250807_zDB8D1ZjNiM6"><ix:nonNumeric contextRef="AsOf2025-08-07" format="ixt:booleanfalse" id="Fact000023" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0pt"/><td style="width: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--PreCommencementIssuerTenderOffer_c20250807__20250807_zWcLMKV3ll67"><ix:nonNumeric contextRef="AsOf2025-08-07" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Securities registered pursuant to Section 12(b)
of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="2" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border: black 1.5pt solid; white-space: nowrap; text-align: center; width: 40%"><span style="font-size: 10pt">Title of each class</span></td>
    <td style="border-top: black 1.5pt solid; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; white-space: nowrap; text-align: center; width: 20%"><span style="font-size: 10pt">Trading Symbol(s)</span></td>
    <td style="border-top: black 1.5pt solid; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; white-space: nowrap; text-align: center; width: 40%"><span style="font-size: 10pt">Name of each exchange on which registered</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; border-left: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><span id="xdx_90A_edei--Security12bTitle_c20250807__20250807_zi057UOwECli"><ix:nonNumeric contextRef="AsOf2025-08-07" id="Fact000025" name="dei:Security12bTitle">Class A Common Stock, par value $0.0001 per share</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><span id="xdx_905_edei--TradingSymbol_c20250807__20250807_zYfqgEdlXo28"><ix:nonNumeric contextRef="AsOf2025-08-07" id="Fact000026" name="dei:TradingSymbol">BIVI</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt">The <span id="xdx_90B_edei--SecurityExchangeName_c20250807__20250807_zGUgoInwNAta"><ix:nonNumeric contextRef="AsOf2025-08-07" format="ixt-sec:exchnameen" id="Fact000027" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Stock Market, LLC</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Indicate by check mark whether
the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Emerging growth company <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_edei--EntityEmergingGrowthCompany_c20250807__20250807_zxoI0Fnk8VFc"><ix:nonNumeric contextRef="AsOf2025-08-07" format="ixt:booleanfalse" id="Fact000028" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 1.01 Entry Into a Material Definitive Agreement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On August 7, 2025, BioVie Inc. (the &#8220;<b>Company</b>&#8221;) entered into an underwriting
agreement (the &#8220;<b>Underwriting Agreement</b>&#8221;) with ThinkEquity LLC, as the sole underwriter (the &#8220;<b>Underwriter</b>&#8221;),
in connection with the issuance and sale (the &#8220;<b>Offering</b>&#8221;) of 5,620,000 units (the &#8220;<b>Units</b>&#8221;) and 380,000
pre-funded units (the &#8220;<b>Pre-Funded Units</b>&#8221;), resulting in net proceeds of approximately $10.4 million, after deducting
underwriting discounts and commissions and other estimated offering expenses. The Underwriter also exercised the Over-Allotment Option
(as defined below) in part and purchased 667,300 Warrants (as defined below) for nominal additional gross proceeds of approximately $667.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each Unit consisted of (i) one share of common stock, par value $0.0001
(the &#8220;<b>Common Stock</b>&#8221;), of the Company and (ii) one warrant (the &#8220;<b>Warrants</b>&#8221;). Each Pre-Funded Unit
consisted of (i) one pre-funded warrant (the &#8220;<b>Pre-Funded Warrants</b>&#8221;) and (ii) one Warrant. Each Unit was sold to the
public at a price of $2.00 per Unit and each Pre-Funded Unit was sold to the public at a price of $1.999 per Pre-Funded Unit (which represents
the public offering price of each Unit less the $0.0001 per share nominal exercise price for each Pre-Funded Warrant).&#160; The Units;
the&#160;Pre-Funded Units; the shares of Common Stock comprising the Units; the Warrants; the Pre-Funded Warrants; the shares of Common
Stock, the Warrants and the Pre-Funded Warrants issuable upon exercise of the Over-Allotment Option; and the shares of Common Stock issuable
upon exercise of the Warrants and the Pre-Funded Warrants are collectively referred to herein as the &#8220;<b>Securities</b>.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On August 8, 2025, the Warrants commenced trading on The Nasdaq Capital
Market under the symbol &#8220;BIVIW.&#8221; Each Warrant is immediately exercisable, entitles the holder to purchase one share of Common
Stock at an exercise price of $2.50 per share and expires five years from the date of issuance. Each Pre-Funded Warrant is immediately
exercisable, entitles the holder to purchase one share of Common Stock and may be exercised at any time until exercised in full. The Common
Stock and accompanying Warrants included in each Unit were issued separately, and the Pre-Funded Warrants and the accompanying Warrants
included in each Pre-Funded Unit were issued separately.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Offering closed on August 11, 2025 (the &#8220;<b>Closing Date</b>&#8221;).
The Company intends to use the proceeds for working capital and general corporate purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the Underwriting Agreement, the Company granted the Underwriter
an option to purchase up to an additional 900,000 shares of Common Stock and/or Pre-Funded Warrants and/or Warrants, or any combination
thereof, solely to cover over-allotments, if any, at the public offering price, less underwriting discounts and commissions (the &#8220;<b>Over-Allotment
Option</b>&#8221;). The Underwriter may exercise the Over-Allotment Option one or more times in whole or in part for forty-five (45) days
from the Closing Date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the Offering, the Company issued to the Underwriter warrants (the &#8220;<b>Underwriter&#8217;s
Warrants</b>&#8221;) to purchase 300,000 shares of Common Stock. The Underwriter&#8217;s Warrants have an exercise price of $2.50 per
share. The Underwriter&#8217;s Warrants are immediately exercisable, in whole or in part, and expire on the four- and one-half year anniversary
of the date that is one hundred eighty (180) days from the date of the Underwriting Agreement. The Underwriter&#8217;s Warrants provide
for registration rights (including a one-time demand registration right and unlimited piggyback rights) and customary anti-dilution provisions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On the Closing Date, the Company also entered into a warrant agent
agreement (the &#8220;<b>Warrant Agent Agreement</b>&#8221;) with West Coast Stock Transfer, Inc., as warrant agent (the &#8220;<b>Warrant
Agent</b>&#8221;). The Warrant Agent Agreement sets forth certain terms and conditions with respect to the Warrant Agent&#8217;s service
as warrant agent for the Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Underwriting Agreement contains customary representations, warranties
and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriter, including
for liabilities under the Securities Act of 1933, as amended (the &#8220;<b>Securities Act</b>&#8221;), other obligations of the parties
and termination provisions. In addition, pursuant to the terms of the Underwriting Agreement, the Company has agreed, for a period of
three (3) months from the date of the Underwriting Agreement, subject to customary exceptions and without the prior written consent of
the Underwriter, not to (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract
to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares
of capital stock of the Company or any securities convertible into or exercisable or exchangeable for shares of capital stock of the
Company; (ii) file or cause to be filed any registration statement with the Commission relating to the offering of any shares of capital
stock of the Company or any securities convertible into or exercisable or exchangeable for shares of capital stock of the Company; (iii)
complete any offering of debt securities of the Company or (iv) enter into any swap or other arrangement that transfers to another, in
whole or in part, any of the economic consequences of ownership of capital stock of the Company. Moreover, the Company&#8217;s executive
officers and directors entered into lock-up agreements, pursuant to which they agreed, for a period of three (3) months from the date
of the Underwriting Agreement, subject to customary exceptions and without the prior written consent of the Underwriter, not to sell
or transfer any securities of the Company that they hold.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Securities were offered and sold by the Company pursuant to the
Company&#8217;s Registration Statement on Form S-1, as amended (File No. 333-288525), filed by the Company with the U.S. Securities and
Exchange Commission (the &#8220;SEC&#8221;) under the&#160;Securities Act, and declared effective on August 7, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The foregoing does not purport to be a complete description of each
of the Underwriting Agreement, the Warrants, the Pre-Funded Warrants, the Underwriter&#8217;s Warrants and the Warrant Agent Agreement,
and each is qualified in its entirety by reference to the full text of each of such document, which are filed as Exhibits 1.1, 4.1, 4.2,
4.3 and 10.1, respectively, to this Current Report on Form 8-K, and are incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 3.02 Unregistered Sales of Equity Securities</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The information contained above in Item 1.01 related to the Underwriter&#8217;s
Warrants is hereby incorporated by reference into this Item 3.02. The offer and sale of the Underwriter&#8217;s Warrants have not been
registered under the&#160;Securities Act&#160;and were instead offered pursuant to the exemption provided in Section 4(a)(2) under the&#160;Securities
Act&#160;and/or Rule 506(b) promulgated thereunder. The Underwriter&#8217;s Warrants and the shares of Common Stock underlying the Underwriter&#8217;s
Warrants may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act
and any applicable state securities laws.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item&#8201;7.01 Regulation FD Disclosure.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On August 7, 2025 and August 11, 2025, the Company issued press releases
announcing the pricing of the Offering and the closing of the Offering, respectively. Copies of the press releases are attached hereto
as Exhibit 99.1 and Exhibit 99.2, respectively, and are incorporated by reference herein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The information in this Item 7.01, including Exhibit 99.1 attached
hereto, is being furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934,
as amended (the &#8220;<b>Exchange Act</b>&#8221;), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated
by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a
filing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 9.01 Financial Statements and Exhibits</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(d) Exhibits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 8%"><span style="font-size: 10pt"><b>Exhibit <br/>
No.</b></span></td>
    <td style="vertical-align: top; width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 90%"><span style="font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="bivi-20250807_ex1z1.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">1.1</span></a></td>
    <td>&#160;</td>
    <td><a href="bivi-20250807_ex1z1.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">Underwriting Agreement, dated as of August 7, 2025, by and between the Company and the Underwriter</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><a href="bivi-20250807_ex10z1.htm#annexb" style="-sec-extract: exhibit"><span style="font-size: 10pt">4.1</span></a></td>
    <td>&#160;</td>
    <td><a href="bivi-20250807_ex10z1.htm#annexb" style="-sec-extract: exhibit"><span style="font-size: 10pt">Form of Warrant (included as Annex B to Exhibit 10.1)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="bivi-20250807_ex4z2.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">4.2</span></a></td>
    <td>&#160;</td>
    <td><a href="bivi-20250807_ex4z2.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">Form of Pre-Funded Warrant </span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><a href="bivi-20250807_ex4z3.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">4.3</span></a></td>
    <td>&#160;</td>
    <td><a href="bivi-20250807_ex4z3.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">Form of Underwriter&#8217;s Warrant.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="bivi-20250807_ex10z1.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">10.1</span></a></td>
    <td>&#160;</td>
    <td><a href="bivi-20250807_ex10z1.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">Warrant Agent Agreement, dated as of August 7, 2025, by and between the Company and the Warrant Agent</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><a href="bivi-20250807_ex99z1.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">99.1</span></a></td>
    <td>&#160;</td>
    <td><a href="bivi-20250807_ex99z1.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">Pricing Press Release dated August 7, 2025</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="bivi-20250807_ex99z2.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">99.2</span></a></td>
    <td>&#160;</td>
    <td><a href="bivi-20250807_ex99z2.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">Closing Press Release dated August 11, 2025</span></a></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>


<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated: August 11, 2025</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-size: 10pt"><b>BIOVIE INC.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 50%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 47%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-size: 10pt">/s/ Joanne Wendy Kim</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Name:&#160;&#160; </span></td>
    <td><span style="font-size: 10pt">Joanne Wendy Kim</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Title:</span></td>
    <td><span style="font-size: 10pt">Chief Financial Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KwjAMhZ9g7xB6LboOJrI7HTrEKTJEvC0uk2LXjLT+PZJvad0QQyAk53w5QoxEQSttkOG0qEo4YNsZ5REqbJDRnjE48vUmgzArvGjnWVnfrz9wb24OpmOpwq133bXDOoN4NpFykqQgZZbOYL4V0VfPyTa6Ruu1MqBsDXumjjV6xa/hw0E9yVL76lOOyE6TzUCO40F+QxLLBHZ0Vw/iq4OyzEU06isSBdOtC67l06P9krA02IY4N9D/jj5G7Ei8 -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>bivi-20250807_ex1z1.htm
<DESCRIPTION>EXHIBIT 1.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 1.1<I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><I>Execution Version</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDERWRITING AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>between</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>BioVie Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>and</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ThinkEquity LLC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>as Representative of the Several Underwriters</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDERWRITING AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">New York, New York</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">August 7, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ThinkEquity LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt">as Representative of the several Underwriters named on Schedule
1 hereto</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">17 State Street, 22<SUP>nd</SUP> Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, NY 10004</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned, BioVie Inc., a Nevada corporation
(the&nbsp;&rdquo;<B>Company</B>&rdquo;), hereby confirms its agreement (this &ldquo;<B>Agreement</B>&rdquo;) with ThinkEquity LLC (hereinafter
referred to as &ldquo;you&rdquo; (including its correlatives) or the &ldquo;<B>Representative</B>&rdquo;) and with the other underwriters
named on&nbsp;Schedule 1&nbsp;hereto for which the Representative is acting as representative (the Representative and such other underwriters
being collectively called the &ldquo;<B>Underwriters</B>&rdquo; or, individually, an &ldquo;<B>Underwriter</B>&rdquo;) as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt"></TD><TD STYLE="width: 20pt">1.</TD><TD STYLE="text-align: justify"><B><U>Purchase and Sale</U></B>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: -20pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 40pt"></TD><TD STYLE="width: 40pt; text-align: left">1.1.</TD><TD STYLE="text-align: justify"><B><U>Firm Securities</U></B><I>.</I></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">1.1.1. <U>Purchase
of Firm Securities</U>. On the basis of the representations and warranties set forth herein, and subject to the terms and conditions set
forth herein, the Company agrees to issue and sell to the several Underwriters, severally and not jointly,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 80pt"></TD><TD STYLE="width: 20pt">(a)</TD><TD STYLE="text-align: justify">an aggregate of 5,620,000 units (the &ldquo;<B>Firm Units</B>&rdquo;), each Firm Unit consisting of one
(1) share of the Company&rsquo;s common stock, par value $0.0001 per share (such share being the &ldquo;<B>Firm Share</B>&rdquo; and such
common stock being the &ldquo;<B>Common Stock</B>&rdquo;), and one (1) common stock purchase warrant (the &ldquo;<B>Firm Common Warrant</B>&rdquo;),
exercisable for one (1) share of Common Stock at an exercise price of $2.50 per share; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -20pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 80pt"></TD><TD STYLE="width: 20pt">(b)</TD><TD STYLE="text-align: justify">an aggregate of 380,000 pre-funded units (the &ldquo;<B>Firm Pre-Funded Units</B>&rdquo;), each Firm Pre-Funded
Unit consisting of one (1) pre-funded common stock purchase warrant (the &ldquo;<B>Firm Pre-Funded Warrant</B>&rdquo;), exercisable for
one (1) share of Common Stock at an exercise price of $0.0001 per share, and one (1) Firm Common Warrant,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify">and the Underwriters agree to purchase
from the Company, severally and not jointly, the number of Firm Units and Firm Pre-Funded Units set forth opposite their respective names
on Schedule 1 hereto at a purchase price (net of underwriting discounts and commissions) equal to (i) $1.86 per Firm Unit (such purchase
price being equal to 93.0% of the public offering price per Firm Unit), which purchase price will be allocated as $1.859 per Firm Share
and $0.001 per Firm Common Warrant and (ii) $1.86 per Firm Pre-Funded Unit (such purchase price being equal to 93.0% of the public offering
price per Firm Pre-Funded Unit), which purchase price will be allocated as $1.859 per Firm Pre-Funded Warrant and $0.001 per Firm Common
Warrant. The Firm Units and the Firm Pre-Funded Units are collectively referred to herein as the &ldquo;<B>Firm Securities</B>&rdquo;.
The Firm Securities are to be offered initially to the public at the respective public offering prices set forth on the cover page of
the Prospectus (as defined in Section 2.1.1 hereof).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">The Firm Common
Warrants shall be immediately exercisable upon issuance until the fifth (5<SUP>th</SUP>) anniversary of their issuance. The Firm Pre-Funded
Warrants shall be immediately exercisable upon issuance until such time as the Firm Pre-Funded Warrants are exercised in full. No Firm
Units will be certificated, and the Firm Shares and the Firm Common Warrants comprising the Firm Units will be separated immediately upon
issuance. No Firm Pre-Funded Units will be certificated, and the Firm Pre-Funded Warrants and the Firm Common Warrants comprising the
Firm Pre-Funded Units will be separated immediately upon issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">1.1.2.&nbsp;&nbsp;<U>Payment
and Delivery</U>. Delivery and payment for the Firm Securities shall be made at 10:00 a.m., New York City time, on the first (1st) Business
Day (as defined below) following the effective date (the &ldquo;<B>Effective Date</B>&rdquo;) of the Registration Statement (as defined
in Section 2.1.1 below) (or the second (2nd) Business Day following the Effective Date if the Registration Statement is declared effective
after 4:01 p.m., New York City time) or at such earlier time as shall be agreed upon by the Representative and the Company, at the offices
of Sheppard, Mullin, Richter &amp; Hampton LLP, counsel to the Underwriters, or at such other place (or remotely by facsimile or other
electronic transmission) as shall be agreed upon by the Representative and the Company. The hour and date of delivery and payment for
the Firm Securities is called the &ldquo;<B>Closing Date</B>&rdquo;. Payment for the Firm Securities shall be made on the Closing Date
by wire transfer in federal (same day) funds, payable to the order of the Company upon delivery to the Representative of the Firm Shares
and the Firm Common Warrants through the facilities of the Depository Trust Company (&ldquo;<B>DTC</B>&rdquo;) for the account of the
Underwriters and of certificates (in form and substance satisfactory to the Representative) representing the Firm Pre-Funded Warrants
registered in such name or names and in such authorized denominations as the Representative may request in writing at least one (1) Business
Day prior to the Closing Date. The Company shall not be obligated to sell or deliver the Firm Securities except upon tender of payment
by the Representative for all of the Firm Securities. The term &ldquo;<B>Business Day</B>&rdquo; means any day other than Saturday, Sunday
or other day on which commercial banks in The City of New York are authorized or required by law to remain closed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 40pt"></TD><TD STYLE="width: 40pt; text-align: left">1.2.</TD><TD STYLE="text-align: justify"><B><U>Over-allotment Option</U></B>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">1.2.1. <U>Option
Securities</U>. For the purposes of covering any over-allotments in connection with the distribution and sale of the Firm Securities,
the Company hereby grants to the Underwriters an option to purchase up to an additional 900,000 shares of Common Stock (the &ldquo;<B>Option
Shares</B>&rdquo;) and/or up to an additional 900,000 pre-funded common stock purchase warrants (the &ldquo;<B>Option Pre-Funded Warrants</B>&rdquo;),
each exercisable for one (1) share of Common Stock at an exercise price of $0.0001 per share, and/or up to an additional 900,000 common
stock purchase warrants (the &ldquo;<B>Option Common Warrants</B>&rdquo; and together with the Option Shares and the Option Pre-Funded
Warrants, the &ldquo;<B>Option Securities</B>&rdquo;), each exercisable for one (1) share of Common Stock at an exercise price of $2.50
per share, in each case representing fifteen percent (15%) of the Firm Shares, Firm Pre-Funded Warrants, and Firm Common Warrants sold
in the offering, from the Company (the &ldquo;<B>Over-allotment Option</B>&rdquo;). The Option Shares, Option Pre-Funded Warrants, and
Option Common Warrants shall be identical in all respects to the Firm Shares, Firm Pre-Funded Warrants, and Firm Common Warrants, respectively.
The Over-allotment Option is, at the Underwriters&rsquo; sole discretion, for Option Shares and Option Common Warrants together, Option
Pre-Funded Warrants and Option Warrants together, solely Option Shares, solely Option Pre-Funded Warrants, solely Option Common Warrants,
or any combination thereof. No Option Securities shall be sold or delivered unless the Firm Securities previously have been, or simultaneously
are, sold and delivered. The right to purchase the Option Securities, or any portion thereof, may be exercised from time to time and to
the extent not previously exercised may be surrendered and terminated at any time upon notice by the Representative to the Company. The
purchase price to be paid per Option Share, Option Pre-Funded Warrant, and Option Common Warrant shall be equal to the purchase price
therefor (net of underwriting discounts and commissions) per Firm Share, Firm Pre-Funded Warrant, and Firm Common Warrant, respectively,
set forth in Section 1.1.1 hereof. The shares issuable upon exercise of the Firm Common Warrants and Option Common Warrants (collectively,
the &ldquo;<B>Common Warrants</B>&rdquo;) are hereinafter referred to as the &ldquo;<B>Common Warrant Shares</B>&rdquo;. The shares issuable
upon exercise of the Firm Pre-Funded Warrants and Option Pre-Funded Warrants (collectively, the &ldquo;<B>Pre-Funded Warrants</B>&rdquo;)
are hereinafter referred to as the &ldquo;<B>Pre-Funded Warrant Shares</B>&rdquo;. The Pre-Funded Warrant Shares and the Common Warrant
Shares are hereinafter referred to as the &ldquo;<B>Warrant Shares</B>&rdquo;. The Firm Shares and the Option Shares are hereinafter referred
to as the &ldquo;<B>Public Shares</B>&rdquo;; the Public Shares, the Warrant Shares and the Representative&rsquo;s Shares as defined in
Section 1.3 are herein after referred to as the &ldquo;<B>Shares</B>&rdquo; and the Firm Securities and the Option Securities are hereinafter
referred to together as the &ldquo;<B>Public Securities</B>&rdquo;. The offering and sale of the Public Securities is hereinafter referred
to as the &ldquo;<B>Offering</B>&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">1.2.2. <U>Exercise
of Option</U>. The Over-allotment Option granted pursuant to Section 1.2.1 hereof may be exercised by the Underwriters as to all (at any
time) or any part (from time to time) of the Option Securities within forty-five (45) days after the Effective Date. The Underwriters
shall not be under any obligation to purchase any Option Securities prior to the exercise of the Over-allotment Option. The Over-allotment
Option granted hereby may be exercised by the giving of oral notice to the Company from the Representative, which must be confirmed in
writing by overnight mail or facsimile or other electronic transmission setting forth the number of Option Shares, Option Pre-Funded Warrants,
and Option Common Warrants to be purchased and the date and time for delivery of and payment therefor (the &ldquo;<B>Option Closing Date</B>&rdquo;),
which shall not be later than five (5) full Business Days after the date of the notice or such other time as shall be agreed upon by the
Company and the Representative, at the offices of counsel to the Underwriters or at such other place (including remotely by facsimile
or other electronic transmission) as shall be agreed upon by the Company and the Representative. If such delivery and payment for the
Option Securities does not occur on the Closing Date, the Option Closing Date will be as set forth in the notice. Upon exercise of the
Over-allotment Option with respect to all or any portion of the Option Securities, subject to the terms and conditions set forth herein,
the Company shall become obligated to sell to the Underwriters the number of Option Shares, Option Pre-Funded Warrants, and Option Common
Warrants specified in such notice and, subject to the terms and conditions set forth herein, the Underwriters, acting severally and not
jointly, shall purchase the number of Option Shares, Option Pre-Funded Warrants, and Option Common Warrants specified in such notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">1.2.3.&nbsp;&nbsp;&nbsp;<U>Payment
and Delivery</U>. Payment for the Option Securities shall be made on the Option Closing Date by wire transfer in federal (same day) funds,
payable to the order of the Company upon delivery to the Representative of any Option Shares and any Option Common Warrants through the
facilities of DTC for the account of the Underwriters and of certificates (in form and substance satisfactory to the Representative) representing
any Option Pre-Funded Warrants registered in such name or names and in such authorized denominations as the Representative may request
in writing at least one (1) Business Day prior to the Option Closing Date. The Company shall not be obligated to sell or deliver the Option
Securities except upon tender of payment by the Underwriters for applicable Option Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 40pt"></TD><TD STYLE="width: 40pt; text-align: left">1.3.</TD><TD STYLE="text-align: justify"><B><U>Representative&rsquo;s Warrant</U></B>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">1.3.1.&nbsp;&nbsp;<U>Purchase
Warrants</U>. The Company hereby agrees to issue and sell to the Representative (and/or its designees) on the Closing Date, and on each
Option Closing Date, if any, a warrant or warrants (the &ldquo;<B>Representative&rsquo;s Warrants</B>&rdquo;) to purchase an aggregate
of 300,000 shares of Common Stock (or 345,000 shares of Common Stock if the Underwriters exercise the Over-allotment Option in full) equal
to 5% of the aggregate number of Firm Securities and Option Securities sold in the Offering and issued on such Closing Date and Option
Closing Date, as applicable, pursuant to a warrant agreement substantially in the form set forth in <B><U>Exhibit A</U></B> hereto (the
&ldquo;<B>Representative&rsquo;s Warrant Agreement</B>&rdquo;). Each Representative&rsquo;s Warrant entitles the holder thereof to purchase
shares of Common Stock at the exercise price thereof. The Representative&rsquo;s Warrants shall be immediately exercisable, in whole or
in part, and will expire on the four- and one-half year anniversary of the date that is 180 days from the date of commencement of sales
in the Offering at an initial exercise price of $2.50 per share, which is equal to 125% of the public offering price of the Firm Units.
The Representative&rsquo;s Warrants and the shares of Common Stock issuable upon exercise of the Representative&rsquo;s Warrants (the
&ldquo;<B>Representative&rsquo;s Shares</B>&rdquo;) are hereinafter referred to together as the &ldquo;<B>Representative&rsquo;s Securities</B>&rdquo;.
The Representative understands and agrees that there are restrictions pursuant to Rule 5110(e) of the Financial Industry Regulatory Authority,
Inc. (&ldquo;<B>FINRA</B>&rdquo;) on the transfer of the Representative&rsquo;s Securities during the period of one hundred eighty (180)
days beginning on the date of commencement of sales in the Offering and by its acceptance thereof shall agree that it will not sell, transfer,
assign, pledge or hypothecate the Representative&rsquo;s Securities, or any portion thereof, or be the subject of any hedging, short sale,
derivative, put or call transaction that would result in the effective economic disposition of such securities for such period to anyone
other than (i) an Underwriter or a selected dealer in connection with the Offering, or (ii) a <I>bona fide</I> officer or partner of the
Representative or of any such Underwriter or selected dealer; and only if any such transferee agrees to the foregoing restrictions and
those in the Representative&rsquo;s Warrant Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">1.3.2.&nbsp;&nbsp;<U>Delivery</U>.
Delivery of the Representative&rsquo;s Warrants shall be made on the Closing Date and Option Closing Date, as applicable, and shall be
issued in the name or names and in such authorized denominations as the Representative may request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">1.4. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Right
of First Refusal</U></B>. Provided that the Firm Units are sold in accordance with the terms of this Agreement, the Representative shall
have a right of first refusal (the &quot;<B>Right of First Refusal</B>&quot;), for a period of twelve (12) months after the Closing Date,
to act, except as set forth below, as sole investment banker, sole book- runner and/or sole placement agent, at the Representative&rsquo;s
sole discretion, for each and every future public and private equity offering that is not an &ldquo;at-the-market&rdquo; offering (an
&ldquo;at-the-market&rdquo; offering executed through a broker dealer as sales agent (such future public and private equity offering,
a &ldquo;<B>Future Transaction</B>&rdquo;), including all equity linked financings, during such twelve (12) month period for the Company,
or any successor to or any subsidiary of the Company, on reasonable and customary terms. If the Company intends to enter into a definitive
agreement with a third party for a Future Transaction, the Company shall provide the Representative with a written notice (the &ldquo;<B>ROFR
Notice</B>&quot;) describing in detail all the material commercial terms and conditions of the proposed agreement, including the scope
of the financial advisory, underwriting or placement services, the pricing and payment terms, and the duration and termination rights.
The Company shall provide the ROFR Notice to the Representative at least thirty (30) days before the anticipated execution date of the
proposed agreement. Within ten (10) days after receiving the ROFR Notice, the Representative may elect, by written notice to the Company,
to exercise the ROFR pursuant to which the Representative shall have the right to act as sole investment banker, sole book-runner and/or
sole placement agent for such Future Transaction on commercial terms that are substantially the same as those set forth in in ROFR Notice
and on such other reasonable and customary terms for such Future Transaction as the Company and the Representative shall mutually agree.
If the Representative exercises the Right of First Refusal, the parties shall negotiate in good faith to execute an underwriting or placement
agent agreement for the Future Transaction within twenty (20) days after the Representative's notice to the Company exercising the Right
of First Refusal, unless otherwise mutually agreed by the Company and the Representative. If the Representative does not exercise the
Right of First Refusal within the 10-day period set forth above, the Company shall be free to enter into the proposed agreement with the
third party for such Future Transaction. The Representative shall have the sole right to determine whether or not any other broker dealer
shall have the right to participate in any such Future Transaction and the economic terms of any such participation; provided that the
Representative shall consider in good faith any broker dealer(s) proposed by the Company. The parties also agree that a Future Transaction
shall not be deemed to include, and no Right of First Refusal is granted to the Representative in connection with, any of the following:
(a) any equity securities directly issued by the Company pursuant to acquisitions or strategic transactions, including as part of any
grant funding from a third party, or (b) any offer or sale of equity securities by the Company directly to non-U.S. persons domiciled
in the following jurisdictions: China, Korea, Latin America (excluding Caribbean and the Cayman Islands) and Middle East, in each case,
in a private placement not otherwise involving a public offering. The Representative may elect, in its sole and absolute discretion, not
to exercise its Right of First Refusal with respect to any Future Transaction; provided that any such election by the Representative shall
not adversely affect the Representative's Right of First Refusal with respect to any other Future Transaction during the twelve (12) month
period agreed to above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Representations
and Warranties of the Company</U></B>. The Company represents and warrants to the Underwriters as of the Applicable Time (as defined below),
as of the Closing Date and as of the Option Closing Date, if any, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 40pt"></TD><TD STYLE="width: 40pt; text-align: left">2.1.</TD><TD STYLE="text-align: justify"><B><U>Filing of Registration Statement</U></B><I>.</I></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">2.1.1.&nbsp;&nbsp;<U>Pursuant
to the Securities Act</U>. The Company has filed with the U.S. Securities and Exchange Commission (the &ldquo;<B>Commission</B>&rdquo;)
a registration statement, and any amendment or amendments thereto, on Form S-1 (File No. 333-288525), including any related prospectus
or prospectuses, for the registration of the Public Securities under the Securities Act of 1933, as amended (the &ldquo;<B>Securities
Act</B>&rdquo;), which registration statement and any amendment or amendments have been prepared by the Company in all material respects
in conformity with the requirements of the Securities Act and the rules and regulations of the Commission under the Securities Act (the
&ldquo;<B>Securities Act Regulations</B>&rdquo;). Except as the context may otherwise require, such registration statement, and any amendment
or amendments thereto, on file with the Commission at the time the registration statement became effective (including the Preliminary
Prospectus included in the registration statement, financial statements, schedules, exhibits and all other documents filed as a part thereof
and all information deemed to be a part thereof as of the Effective Date pursuant to paragraph (b) of Rule 430A of the Securities Act
Regulations (the &ldquo;<B>Rule 430A Information</B>&rdquo;)), is referred to herein as the &ldquo;<B>Registration Statement</B>&rdquo;.
References in this Agreement to the Registration Statement shall be deemed to refer to and include the documents incorporated by reference
therein (the &ldquo;<B>Incorporated Documents</B>&rdquo;) on or before the date of this Agreement; and any reference in this Agreement
to the terms &ldquo;amend,&rdquo; &ldquo;amendment&rdquo; or &ldquo;supplement&rdquo; with respect to the Registration Statement shall
be deemed to refer to and include the filing of any document under the Securities Exchange Act of 1934, as amended (the &ldquo;<B>Exchange
Act</B>&rdquo;), after the date of this Agreement, deemed to be incorporated therein by reference. If the Company files any registration
statement pursuant to Rule 462(b) of the Securities Act Regulations, then after such filing, the term &ldquo;Registration Statement&rdquo;
shall include such registration statement filed pursuant to Rule 462(b) of the Securities Act Regulations. The Registration Statement
has been declared effective by the Commission on the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify">Each prospectus used prior to the effectiveness
of the Registration Statement, and each prospectus that omitted the Rule 430A Information that was used after such effectiveness and prior
to the execution and delivery of this Agreement, is herein called a &ldquo;<B>Preliminary Prospectus</B>&rdquo;. The Preliminary Prospectus,
subject to completion, dated August 4, 2025, that was included in the Registration Statement immediately prior to the Applicable Time
is hereinafter called the &ldquo;<B>Pricing Prospectus</B>&rdquo;. The final prospectus in the form first furnished to the Underwriters
for use in the Offering is hereinafter called the &ldquo;<B>Prospectus</B>&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify">References in this Agreement to a Preliminary
Prospectus, the Pricing Prospectus, the Pricing Disclosure Package (as defined below) and the Prospectus shall be deemed to refer to and
include the documents incorporated by reference therein as of their respective dates; and any reference in this Agreement to the terms
&ldquo;amend,&rdquo; &ldquo;amendment&rdquo; or &ldquo;supplement&rdquo; with respect to a Preliminary Prospectus, the Pricing Prospectus,
the Pricing Disclosure Package and the Prospectus shall be deemed to refer to and include any document under Exchange Act, filed after
their respective dates up to and including the date of such amendment or supplement and deemed to be incorporated therein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&ldquo;<B>Applicable
Time</B>&rdquo; means 8:00 p.m., New York City time, on the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&ldquo;<B>Bona Fide
Electronic Road Show</B>&rdquo; means a &ldquo;<I>bona fide </I>electronic road show&rdquo;, as defined in Rule 433(h)(5) of the Securities
Act Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&ldquo;<B>Issuer
Free Writing Prospectus</B>&rdquo; means any &ldquo;issuer free writing prospectus,&rdquo; as defined in Rule 433 of the Securities Act
Regulations (&ldquo;<B>Rule 433</B>&rdquo;), including, without limitation, any &ldquo;free writing prospectus&rdquo; (as defined in Rule
405 of the Securities Act Regulations) relating to the Public Securities that is (i) required to be filed with the Commission by the Company,
(ii) a &ldquo;road show that is a written communication&rdquo; within the meaning of Rule 433(d)(8)(i) of the Securities Act Regulations,
whether or not required to be filed with the Commission, or (iii) exempt from filing with the Commission pursuant to Rule 433(d)(5)(i)
because it contains a description of the Public Securities or of the Offering that does not reflect the final terms, in each case in the
form filed or required to be filed with the Commission or, if not required to be filed, in the form retained in the Company&rsquo;s records
pursuant to Rule 433(g) of the Securities Act Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&ldquo;<B>Issuer
General Use Free Writing Prospectus</B>&rdquo; means any Issuer Free Writing Prospectus that is intended for general distribution to prospective
investors (other than a Bona Fide Electronic Road Show), as evidenced by its being specified in Schedule 2-B hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&ldquo;<B>Issuer
Limited Use Free Writing Prospectus</B>&rdquo; means any Issuer Free Writing Prospectus that is not an Issuer General Use Free Writing
Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&ldquo;<B>Pricing
Disclosure Package</B>&rdquo; means any Issuer General Use Free Writing Prospectus issued at or prior to the Applicable Time, the Pricing
Prospectus and the information included on Schedule 2-A hereto, all considered together.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">2.1.2.&nbsp;&nbsp;<U>Pursuant
to the Exchange Act</U>. The Company filed with the Commission a Form 8-A12B (File No. 001-39015) on August 25, 2020 for the registration
of the Common Stock pursuant to Section 12(b) under the Exchange Act. The Company has filed with the Commission a Form 8-A12B (File No.
001-39015) on August 7, 2025, for the registration of the Common Warrants pursuant to Section 12(b) under the Exchange Act. Such registrations
have become effective prior to the date hereof. The Company has taken no action designed to terminate, or likely to have the effect of
terminating, such registrations, nor has the Company received any notification that the Commission is contemplating terminating such registrations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">2.2. <B><U>Stock Exchange
Listing</U></B>. The Public Shares, the Common Warrants and the Warrant Shares have been approved for listing and/or are listed on The
Nasdaq Capital Market LLC (the &ldquo;<B>Exchange</B>&rdquo;), subject only to official notice of issuance. The Company has taken no action
designed to delist, or likely to have the effect of delisting, the Public Shares, the Common Warrants or the Warrant Shares from the Exchange,
nor has the Company received any notification that the Exchange is contemplating terminating such listing except as described in the Registration
Statement, the Pricing Disclosure Package and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">2.3. <B><U>No Stop Orders,
etc</U></B>. Neither the Commission nor, to the Company&rsquo;s knowledge, any state regulatory authority has issued any order preventing
or suspending the use of the Registration Statement, any Preliminary Prospectus or the Prospectus or has instituted or, to the Company&rsquo;s
knowledge, threatened to institute, any proceedings with respect to such an order. The Company has complied with each request (if any)
from the Commission for additional information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">2.4. <B><U>Disclosures in
Registration Statement</U></B><I>.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">2.4.1. <U>Compliance
with Securities Act, Exchange Act and 10b-5 Representation</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 80pt; text-align: justify; text-indent: 40pt">(i) At the time of
effectiveness of the Registration Statement (or at the time of any post-effective amendments thereto) and at all times subsequent thereto
up to the Closing Date and the Option Closing Date, if any, each of the Registration Statement, the Pricing Prospectus and the Prospectus
contains and will contain all material statements that are required to be stated therein in accordance with the Securities Act and the
Securities Act Regulations, and conforms or will conform, in all material respects, to the requirements of the Securities Act and the
Securities Act Regulations. Each of the Registration Statement and each post-effective amendment thereto, if any, at the time it became
effective, complied in all material respects with the requirements of the Securities Act and the Securities Act Regulations. Each Preliminary
Prospectus, including the prospectus filed as part of the Registration Statement as originally filed or as part of any amendment or supplement
thereto, and the Prospectus, at the time each was filed with the Commission, complied in all material respects with the requirements of
the Securities Act and the Securities Act Regulations. Each Preliminary Prospectus delivered to the Underwriters for use in connection
with this Offering and the Prospectus was or will be identical to the electronically transmitted copies thereof filed with the Commission
pursuant to the Commission&rsquo;s EDGAR filing system (&ldquo;<B>EDGAR</B>&rdquo;), except to the extent permitted by Regulation S-T
promulgated under the Securities Act (&ldquo;<B>Regulation S-T</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 80pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 80pt; text-align: justify; text-indent: 40pt">(ii) Neither the Registration
Statement nor any amendment thereto, at its effective time, as of the Applicable Time, at the Closing Date or at any Option Closing Date,
contained, contains or will contain an untrue statement of a material fact or omitted, omits or will omit to state a material fact required
to be stated therein or necessary to make the statements therein not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 80pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 80pt; text-align: justify; text-indent: 40pt">(iii) The Pricing
Disclosure Package, as of the Applicable Time, at the Closing Date or at any Option Closing Date (if any), did not, does not and will
not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein,
in the light of the circumstances under which they were made, not misleading; and each Issuer Limited Use Free Writing Prospectus hereto
does not conflict with the information contained in the Registration Statement, any Preliminary Prospectus, the Pricing Prospectus or
the Prospectus, and each such Issuer Limited Use Free Writing Prospectus, as supplemented by and taken together with the Pricing Prospectus
as of the Applicable Time, did not include an untrue statement of a material fact or omit to state a material fact necessary in order
to make the statements therein, in light of the circumstances under which they were made, not misleading; provided, however, that this
representation and warranty shall not apply to statements made or statements omitted in reliance upon and in conformity with written information
furnished to the Company with respect to the Underwriters by the Representative expressly for use in the Registration Statement, the Pricing
Prospectus or the Prospectus or any amendment thereof or supplement thereto. The parties acknowledge and agree that such information provided
by or on behalf of any Underwriter consists solely of the following disclosure contained in the &ldquo;Underwriting&rdquo; section of
the Prospectus: the names of the Underwriters, the first sentence following the table set forth under the sub-caption &ldquo;Underwriting
Discount, Commissions and Expenses&rdquo;, the information set forth under the sub-captions &ldquo;Stabilization&rdquo; and &ldquo;Passive
Market Making&rdquo; and the table showing the number of securities to be purchased by each Underwriter <B>(</B>the &ldquo;<B>Underwriters&rsquo;
Information</B>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 80pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 80pt; text-align: justify; text-indent: 40pt">(iv) The Incorporated
Documents, when they were filed with the Commission, conformed in all material respects to the requirements of the Exchange Act and the
applicable Rules and Regulations, and none of such documents, when they were filed with the Commission, contained any untrue statement
of a material fact or omitted to state a material fact necessary to make the statements therein, in the light of the circumstances under
which they were made not misleading; and any further documents so filed and incorporated by reference in the Registration Statement, when
such documents are filed with the Commission, will conform in all material respects to the requirements of the Exchange Act and the applicable
Rules and Regulations, as applicable, and will not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements therein, in the light of the circumstances under which they were made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 80pt; text-align: justify; text-indent: 40pt">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 80pt; text-align: justify; text-indent: 40pt">(v) Neither the Prospectus
nor any amendment or supplement thereto, as of its issue date, at the time of any filing with the Commission pursuant to Rule 424(b) of
the Securities Act Regulations, at the Closing Date or at any Option Closing Date, included, includes or will include an untrue statement
of a material fact or omitted, omits or will omit to state a material fact necessary in order to make the statements therein, in the light
of the circumstances under which they were made, not misleading; provided, however, that this representation and warranty shall not apply
to the Underwriters&rsquo; Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 80pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">2.4.2. <U>Disclosure
of Agreements</U>. The agreements and documents described in the Registration Statement, the Pricing Disclosure Package and the Prospectus
conform in all material respects to the descriptions thereof contained or incorporated by reference therein and there are no agreements
or other documents required by the Securities Act and the Securities Act Regulations to be described in the Registration Statement, the
Pricing Disclosure Package and the Prospectus or to be filed with the Commission as exhibits to the Registration Statement, or to be incorporated
by reference in the Registration Statement, the Pricing Disclosure Package or the Prospectus that have not been so described or filed
or incorporated by reference. Each agreement or other instrument (however characterized or described) to which the Company is a party
or by which it is or may be bound or affected and (i) that is referred to or incorporated by reference in the Registration Statement,
the Pricing Disclosure Package and the Prospectus, or (ii) is material to the Company&rsquo;s business, has been duly authorized and validly
executed by the Company, is in full force and effect in all material respects and is enforceable against the Company and, to the Company&rsquo;s
knowledge, the other parties thereto, in accordance with its terms, except (x) as such enforceability may be limited by bankruptcy, insolvency,
reorganization or similar laws affecting creditors&rsquo; rights generally, (y) as enforceability of any indemnification or contribution
provision may be limited under the federal and state securities laws, and (z) that the remedy of specific performance and injunctive and
other forms of equitable relief may be subject to the equitable defenses and to the discretion of the court before which any proceeding
therefor may be brought. None of such agreements or instruments have been assigned by the Company, and neither the Company nor, to the
Company&rsquo;s knowledge, any other party is in default thereunder and, to the Company&rsquo;s knowledge, no event has occurred that,
with the lapse of time or the giving of notice, or both, would constitute a default thereunder except for any such default or event which
would not reasonably be expected to result in a Material Adverse Change (as such term is defined in Section 2.5.1 below). Performance
by the Company of the material provisions of such agreements or instruments will not result in a violation of any existing applicable
law, rule, regulation, judgment, order or decree of any governmental or regulatory agency or court, domestic or foreign, having jurisdiction
over the Company or any of its assets or businesses (each, a &ldquo;<B>Governmental Entity</B>&rdquo;), including, without limitation,
those relating to environmental laws and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">2.4.3. <U>Prior
Securities Transactions</U>. During the period starting three (3) years prior to the date of this Agreement, no securities of the Company
have been sold by the Company or by or on behalf of, or for the benefit of, any person or persons controlling, controlled by or under
common control with the Company, except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Preliminary
Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">2.4.4. <U>Regulations</U>.
The disclosures in the Registration Statement, the Pricing Disclosure Package and the Prospectus concerning the effects of federal, state,
local and all foreign regulation on the Offering and the Company&rsquo;s business as currently contemplated are correct in all material
respects and no other such regulations are required to be disclosed in the Registration Statement, the Pricing Disclosure Package and
the Prospectus which are not so disclosed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">2.4.5. <U>No Other
Distribution of Offering Materials</U>. The Company has not, directly or indirectly, distributed and will not distribute any offering
material in connection with the Offering other than any Preliminary Prospectus, any Issuer Free Writing Prospectus, the Prospectus and
other materials, if any, permitted under the Securities Act and consistent with Section 3.2 below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">2.5. <B><U>Changes After Dates
in Registration Statement</U></B><I>.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">2.5.1. <U>No Material
Adverse Change</U>. Since the respective dates as of which information is given in the Registration Statement, the Pricing Disclosure
Package and the Prospectus, except as otherwise specifically stated therein: (i) there has been no material adverse change in the financial
position or results of operations of the Company, nor any change or development that, singularly or in the aggregate, would involve a
material adverse change or a prospective material adverse change in or affecting the business, general affairs, management, condition
(financial or otherwise), results of operations, stockholders&rsquo; equity, business, assets, properties or prospects of the Company
(a &ldquo;<B>Material Adverse Change</B>&rdquo;); (ii) there have been no material transactions entered into by the Company, other than
as contemplated pursuant to this Agreement; and (iii) no officer or director of the Company has resigned from any position with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">2.5.2. <U>Recent
Securities Transactions, etc</U>. Subsequent to the respective dates as of which information is given in the Registration Statement, the
Pricing Disclosure Package and the Prospectus, and except as may otherwise be indicated or contemplated herein or disclosed in the Registration
Statement, the Pricing Disclosure Package and the Prospectus, the Company has not: (i) issued any securities or incurred any liability
or obligation, direct or contingent, for borrowed money; or (ii) declared or paid any dividend or made any other distribution on or in
respect to its capital stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">2.5.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Disclosure
in Commission Filings</U>. Since January 1, 2022, (i) none of the Company&rsquo;s filings with the Commission contained any untrue statement
of a material fact or omitted to state any material fact necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading, except to the extent such filings with the Commission were subsequently amended; and (ii)
the Company has made all filings with the Commission required under the Exchange Act and the rules and regulations promulgated thereunder
(the &ldquo;<B>Rules and Regulations</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">2.6. <B><U>Independent Accountants</U>.
</B>EisnerAmper LLP (the &ldquo;<B>Auditor</B>&rdquo;), whose reports are filed with the Commission as part of the Registration Statement,
the Pricing Disclosure Package and the Prospectus, is an independent registered public accounting firm as required by the Securities Act
and the Securities Act Regulations and the Public Company Accounting Oversight Board (the &ldquo;<B>PCAOB</B>&rdquo;), including the rules
and regulations promulgated by such entity. To the Company&rsquo;s knowledge, after reasonable inquiry, the Auditor is currently registered
and in good standing with the PCAOB and the PCAOB has not made any determination with respect to the Auditor under the Holding Foreign
Companies Accountable Act. The Auditor has not, during the periods covered by the financial statements included in the Registration Statement,
the Pricing Disclosure Package and the Prospectus, provided to the Company any non-audit services, as such term is used in Section 10A(g)
of the Exchange Act. To the Company&rsquo;s knowledge, no person who has been suspended or barred from being associated with a registered
public accounting firm, or who has failed to comply with any sanction pursuant to Rule 5300 promulgated by the PCAOB, has participated
in or otherwise aided the preparation of, or audited, the financial statements, supporting schedules or other financial data filed with
the Commission as a part of the Registration Statement, the Pricing Disclosure Package or the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">2.7. <B><U>Financial Statements,
etc</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">2.7.1. <U>Financial
Statements</U>. The financial statements, including the notes thereto and supporting schedules included or incorporated by reference in
the Registration Statement, the Pricing Disclosure Package and the Prospectus, fairly present the financial position and the results of
operations of the Company at the dates and for the periods to which they apply; and such financial statements have been prepared in conformity
with U.S. generally accepted accounting principles (&ldquo;<B>GAAP</B>&rdquo;), consistently applied throughout the periods involved (provided
that unaudited interim financial statements are subject to year-end audit adjustments that are not expected to be material in the aggregate
and do not contain all footnotes required by GAAP); and the supporting schedules included or incorporated by reference in the Registration
Statement, the Pricing Disclosure Package or the Prospectus present fairly the information required to be stated therein. Except as included
or incorporated by reference therein, no historical or pro forma financial statements or supporting schedules are required to be included
or incorporated by reference in the Registration Statement, the Pricing Disclosure Package or the Prospectus under the Securities Act
or the Securities Act Regulations. The pro forma and pro forma as adjusted financial information and the related notes, if any, included
or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus have been properly compiled
and prepared in accordance with the applicable requirements of the Securities Act, the Securities Act Regulations, the Exchange Act and
the Exchange Act Regulations and present fairly the information shown therein, and the assumptions used in the preparation thereof are
reasonable and the adjustments used therein are appropriate to give effect to the transactions and circumstances referred to therein.
All disclosures contained in the Registration Statement, the Pricing Disclosure Package or the Prospectus, or incorporated or deemed incorporated
by reference therein, regarding &ldquo;non-GAAP financial measures&rdquo; (as such term is defined by the rules and regulations of the
Commission), if any, comply with Regulation G of the Exchange Act and Item 10 of Regulation S-K of the Securities Act, to the extent applicable.
Each of the Registration Statement, the Pricing Disclosure Package and the Prospectus discloses all material off-balance sheet transactions,
arrangements, obligations (including contingent obligations), and other relationships of the Company with unconsolidated entities or other
persons that may have a material current or future effect on the Company&rsquo;s financial condition, changes in financial condition,
results of operations, liquidity, capital expenditures, capital resources, or significant components of revenues or expenses. Except as
disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, (a) neither the Company nor any of its direct
and indirect subsidiaries, including each entity disclosed or described in the Registration Statement, the Pricing Disclosure Package
and the Prospectus as being a subsidiary of the Company (each, a &ldquo;<B>Subsidiary</B>&rdquo; and, collectively, the &ldquo;<B>Subsidiaries</B>&rdquo;),
has incurred any material liabilities or obligations, direct or contingent, or entered into any material transactions other than in the
ordinary course of business, (b) the Company has not declared or paid any dividends or made any distribution of any kind with respect
to its capital stock, (c) there has not been any change in the capital stock of the Company or any of its Subsidiaries, or, other than
in the course of business or any grants under any stock compensation plan, and (d) there has not been any material adverse change in the
Company&rsquo;s long-term or short-term debt.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">2.7.2. <U>Company&rsquo;s
Accounting System</U>. The Company makes and keeps accurate books and records and maintains a system of internal accounting controls designed,
and which the Company reasonably believes is sufficient, to provide reasonable assurance that: (i) transactions are executed in accordance
with management&rsquo;s general or specific authorization; (ii) transactions are recorded as necessary to permit preparation of financial
statements in conformity with GAAP and to maintain accountability for assets; (iii) access to assets is permitted only in accordance with
management&rsquo;s general or specific authorization; and (iv) the recorded accountability for assets is compared with existing assets
at reasonable intervals and appropriate action is taken with respect to any differences. The Company has not received any notice, oral
or written, from the Company&rsquo;s board of directors stating that it is reviewing or investigating, and neither the Company&rsquo;s
independent auditors nor its internal auditors have recommended that the Company&rsquo;s board of directors review or investigate, (i)
adding to, deleting, changing the application of, or changing the Company&rsquo;s disclosure with respect to, any of the Company&rsquo;s
material accounting policies; or (ii) any matter which could result in a restatement of the Company&rsquo;s financial statements for any
annual or interim period during the current or prior two (2) fiscal years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">2.8. <B><U>Authorized Capital;
Options, etc</U></B>. The Company had, at the date or dates indicated in the Registration Statement, the Pricing Disclosure Package and
the Prospectus, the duly authorized, issued and outstanding capitalization as set forth therein. Based on the assumptions stated in the
Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company will have on the Closing Date the adjusted stock
capitalization set forth therein. Except as set forth in, or contemplated by, the Registration Statement, the Pricing Disclosure Package
and the Prospectus, on the Effective Date, as of the Applicable Time and on the Closing Date and any Option Closing Date, there was, or
will be, no stock options, warrants, or other rights to purchase or otherwise acquire any authorized, but unissued shares of Common Stock
of the Company or any security convertible or exercisable into shares of Common Stock of the Company, or any contracts or commitments
to issue or sell shares of Common Stock or any such options, warrants, rights or convertible securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">2.9. <B><U>Valid Issuance
of Securities, etc</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">2.9.1. <U>Outstanding
Securities</U>. All issued and outstanding securities of the Company issued prior to the transactions contemplated by this Agreement have
been duly authorized and validly issued and are fully paid and non-assessable; the holders thereof have no rights of rescission, rights
of first refusal, rights of participation or similar rights with respect thereto, and are not subject to personal liability by reason
of being such holders; and none of such securities were issued in violation of any such rights of any holders of any security of the Company
or similar contractual rights granted by the Company. The authorized shares of Common Stock conform in all material respects to all statements
relating thereto contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus. The offers and sales of the
outstanding shares of Common Stock were at all relevant times either registered under the Securities Act and applicable state securities
or &ldquo;blue sky&rdquo; laws or, based in part on the representations and warranties of the purchasers of such shares, exempt from such
registration requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">2.9.2. <U>Securities
Sold Pursuant to this Agreement</U>. The Shares have been duly authorized for issuance and sale and, when issued and paid for, will be
validly issued, fully paid and non-assessable; the Common Warrants, Pre-Funded Warrants and Representative&rsquo;s Warrants have been
duly authorized for issuance and, when issued in accordance with their terms and the terms of this Agreement and that certain warrant
agent agreement dated August 11, 2025 between the Company and West Coast Stock Transfer, Inc. (the &ldquo;<B>Warrant Agent Agreement</B>&rdquo;),
as applicable, will be valid and binding obligations of the Company, enforceable against the Company in accordance with their terms, except
(x) as such enforceability may be limited by bankruptcy, insolvency, reorganization or similar laws affecting creditors&rsquo; rights
generally, (y) as enforceability of any indemnification or contribution provision may be limited under the federal and state securities
laws, and (z) that the remedy of specific performance and injunctive and other forms of equitable relief may be subject to the equitable
defenses and to the discretion of the court before which any proceeding therefor may be brought. The Company has reserved from its duly
authorized capital stock the maximum number of shares of Common Stock issuable pursuant to this Agreement, the Warrant Agent Agreement
and the Representative&rsquo;s Warrant Agreement. The holders of the Shares are not and will not be subject to personal liability by reason
of being such holders; the Shares are not and will not be subject to the pre-emptive rights of any holders of any security of the Company
or similar contractual rights granted by the Company. The Shares conform in all material respects to all statements with respect thereto
contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">2.10. <B><U>Registration Rights
of Third Parties</U></B>. Except as set forth in the Registration Statement, the Pricing Disclosure Package and the Prospectus, no holders
of any securities of the Company or any rights exercisable for or convertible or exchangeable into securities of the Company have the
right to require the Company to register any such securities of the Company under the Securities Act or to include any such securities
in a registration statement to be filed by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">2.11. <B><U>Validity and Binding
Effect of Agreements</U></B>. The execution, delivery and performance of this Agreement, the Common Warrants, the Pre-Funded Warrants,
the Representative&rsquo;s Warrant Agreement and the Warrant Agent Agreement have been duly and validly authorized by the Company, and,
when executed and delivered, will constitute, the valid and binding agreements of the Company, enforceable against the Company in accordance
with their respective terms, except: (i) as such enforceability may be limited by bankruptcy, insolvency, reorganization or similar laws
affecting creditors&rsquo; rights generally; (ii) as enforceability of any indemnification or contribution provision may be limited under
the federal and state securities laws; and (iii) that the remedy of specific performance and injunctive and other forms of equitable relief
may be subject to the equitable defenses and to the discretion of the court before which any proceeding therefor may be brought. Each
of this Agreement, the Common Warrants, the Pre-Funded Warrants, the Representative&rsquo;s Warrant Agreement, the Warrant Agent Agreement
and each Lock-Up Agreement (as defined in Section 2.24) conforms in all material respects to the description thereof contained in the
Registration Statement, the Pricing Disclosure Package and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">2.12. <B><U>No Conflicts,
etc</U></B>. The execution, delivery and performance by the Company of this Agreement, the Common Warrants, the Pre-Funded Warrants, the
Representative&rsquo;s Warrant Agreement and the Warrant Agent Agreement and all documents ancillary thereto, the consummation of the
transactions contemplated hereby and thereby, by the Registration Statement, the Pricing Disclosure Package or the Prospectus, the issuance
and sale of the Public Securities (including the use of proceeds from the Offering as described in the Registration Statement, the Pricing
Disclosure Package or the Prospectus) and the compliance by the Company with the terms hereof and thereof do not and will not, (i) result
in any violation of the provisions of the Company&rsquo;s certificate of incorporation (as amended or restated from time to time, the
&ldquo;<B>Charter</B>&rdquo;) or the by-laws (as amended or restated from time to time, the &ldquo;<B>Bylaws</B>&rdquo;) of the Company;
(ii) result in breach of, is in default (or, with the giving of notice or lapse of time, would be in default) (&ldquo;<B>Default</B>&rdquo;)
or a Debt Repayment Triggering Event (as defined below) under, conflict with any of the terms and provisions of, or result in the creation,
modification, termination or imposition of any lien, charge or encumbrance upon any property or assets of the Company pursuant to the
terms of, any indenture, loan, credit agreement, note, lease, license agreement, contract, franchise or other instrument (including, without
limitation, any pledge agreement, security agreement, mortgage or other instrument or agreement evidencing, guaranteeing, securing or
relating to indebtedness) to which the Company or any of its subsidiaries is a party or by which it or any of them may be bound, or to
which any of their respective properties or assets are subject (each, an &ldquo;<B>Existing Instrument</B>&rdquo;) or (iii) violate any
existing applicable law, rule, regulation, judgment, order or decree of any Governmental Entity as of the date hereof (including, without
limitation, those promulgated by the Food and Drug Administration of the U.S. Department of Health and Human Services (the &ldquo;<B>FDA</B>&rdquo;)
or by any foreign, federal, state or local regulatory authority performing functions similar to those performed by the FDA), except in
the case of clauses (ii) and (iii) above, for such breaches, defaults, conflicts or such liens, charges or encumbrances which, individually
or in the aggregate, would not have or would not reasonably be expected to result in a Material Adverse Change. As used herein, a &ldquo;<B>Debt
Repayment Triggering Event</B>&rdquo; means any event or condition which gives, or with the giving of notice or lapse of time would give,
the holder of any note, debenture or other evidence of indebtedness (or any person acting on such holder&rsquo;s behalf) the right to
require the purchase redemption or repayment of all or a portion of such indebtedness by the Company or any of its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">2.13. <B><U>No Defaults; Violations</U></B>.
Except as set forth in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company is not in Default in
the due performance and observance of any term, covenant or condition of any Existing Instrument, except for such Defaults as would not
reasonably be expected, individually or in the aggregate, to have a Material Adverse Change. The Company is not in violation of any franchise,
license, permit, applicable law, rule, regulation, judgment or decree of any Governmental Entity, except for such violations, individually
or in the aggregate, which would not have or would not reasonably be expected to result in a Material Adverse Change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">2.14. <B><U>Corporate Power;
Licenses; Consents</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">2.14.1. <U>Conduct
of Business</U>. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company has
all requisite corporate power and authority, and has all requisite consents, authorizations, approvals, licenses, certificates, clearances,
permits and orders and supplements and amendments thereto (collectively, &ldquo;<B>Authorizations</B>&rdquo;) required of and from all
Governmental Entities as of date hereof to conduct its business as described in the Registration Statement, the Pricing Disclosure Package
and the Prospectus, except, in each case, where the failure to have such Authorizations (individually or in the aggregate) would not have
or would not reasonably be expected to have a Material Adverse Change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">2.14.2. <U>Transactions
Contemplated Herein</U>. The Company has all corporate power and authority to enter into this Agreement, the Common Warrants, the Pre-Funded
Warrants, the Representative&rsquo;s Warrant Agreement and the Warrant Agent Agreement and to carry out the provisions and conditions
hereof and thereof. No Authorization of, and no filing with, any Governmental Entity, the Exchange or another body is required for the
valid issuance, sale and delivery of the Public Securities and the consummation of the transactions and agreements contemplated by this
Agreement, the Common Warrants, the Pre-Funded Warrants, the Representative&rsquo;s Warrant Agreement and the Warrant Agent Agreement
and as contemplated by the Registration Statement, the Pricing Disclosure Package and the Prospectus, except with respect to those that
have been obtained or made by the Company and with respect to applicable federal and state securities laws and the rules and regulations
of the Exchange and FINRA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">2.15. <B><U>D&amp;O Questionnaires</U></B>.
To the Company&rsquo;s knowledge, all information contained in the questionnaires (the &ldquo;<B>Questionnaires</B>&rdquo;) completed
by each of the Company&rsquo;s directors and officers immediately prior to the offering&nbsp;&nbsp;(the &ldquo;<B>Insiders</B>&rdquo;)
as supplemented by all information concerning the Company&rsquo;s directors, officers and principal stockholders as described in the Registration
Statement, the Pricing Disclosure Package and the Prospectus, provided to the Underwriters, is true and correct in all material respects
and the Company has not become aware of any information which would cause the information disclosed in the Questionnaires to become materially
inaccurate and incorrect in any respect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">2.16. <B><U>Litigation; Governmental
Proceedings</U></B>. There is no action, suit, proceeding, inquiry, arbitration, investigation, litigation or governmental proceeding
pending or, to the Company&rsquo;s knowledge, threatened against, or involving the Company, or, to the Company&rsquo;s knowledge, any
executive officer or director which has not been disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus
or in connection with the Company&rsquo;s listing application for the listing of the Public Shares, the Common Warrants or the Warrant
Shares on the Exchange and which is required to be disclosed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">2.17. <B><U>Due Incorporation;
Valid Existence</U></B>. The Company has been duly incorporated and is validly existing and in good standing under the laws of the State
of Nevada, and has the corporate power and authority to own, lease and operate its properties and to conduct its business as described
in the Registration Statement, the Pricing Disclosure Package and the Prospectus, and to enter into and perform its obligations under
this Agreement, the Common Warrants, the Pre-Funded Warrants, the Representative&rsquo;s Warrant Agreement and the Warrant Agent Agreement.
The Company is duly qualified as a foreign corporation to transact business and is in good standing in each other jurisdiction in which
such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business or otherwise, except
where the failure to so qualify or be in good standing, would not have or would not reasonably be expected to result in a Material Adverse
Change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">2.18. <B><U>Insurance</U></B>.
Each of the Company and its Subsidiaries carries or is entitled to the benefits of insurance (including, without limitation, as to directors&rsquo;
and officers&rsquo; insurance coverage), with reputable insurers, in such amounts and covering such risks as is customary for companies
engaged in similar business which the Company believes are adequate to protect the Company and its business, and, to the Company&rsquo;s
knowledge, all such insurance is in full force and effect. None of the Company or any of its Subsidiaries (i) has received written notice
from any insurer or agent of such insurer that capital improvements or other expenditures are required or necessary to be made in order
to continue such insurance or (ii) has any reason to believe that it will not be able to renew its existing insurance coverage as and
when such coverage expires or to obtain similar coverage at reasonable cost from similar insurers as may be necessary to continue its
business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">2.19. <B><U>Transactions Affecting
Disclosure to FINRA</U></B><I>.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">2.19.1. <U>Finder&rsquo;s
Fees</U>. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, there are no claims, payments,
arrangements, agreements or understandings relating to the payment of a finder&rsquo;s, consulting or origination fee by the Company or
any Insider with respect to the sale of the Public Securities hereunder or any other arrangements, agreements or understandings of the
Company or, to the Company&rsquo;s knowledge, any of its shareholders that may affect the Underwriters&rsquo; compensation, as determined
by FINRA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">2.19.2. <U>Payments
Within Twelve (12) Months</U>. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the
Company has not made any direct or indirect payments (in cash, securities or otherwise) in connection with the Offering to: (i) any person,
as a finder&rsquo;s fee, consulting fee or otherwise, in consideration of such person raising capital for the Company or introducing to
the Company persons who raised or provided capital to the Company; (ii) any FINRA member; or (iii) any person or entity that has any direct
or indirect affiliation or association with any FINRA member, within the twelve (12) months prior to the Effective Date, other than the
payment to the Underwriters as provided hereunder in connection with the Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">2.19.3. <U>Use of
Proceeds</U>. None of the net proceeds of the Offering will be paid by the Company to any participating FINRA member or its affiliates,
except as specifically authorized herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">2.19.4. <U>FINRA
Affiliation</U>. Except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, there is no (i)
officer or director of the Company, (ii) beneficial owner of 10% or more of any class of the Company&rsquo;s securities or (iii) beneficial
owner of the Company&rsquo;s unregistered equity securities which were acquired during the 180-day period immediately preceding the filing
of the Registration Statement that is an affiliate or associated person of a FINRA member participating in the Offering (as determined
in accordance with the rules and regulations of FINRA).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">2.20. <B><U>Foreign Corrupt
Practices Act</U></B>. None of the Company and its Subsidiaries or, to the Company&rsquo;s knowledge, any director, officer, agent, employee
or affiliate of the Company and its Subsidiaries or any other person acting on behalf of, and with authority from, the Company and its
Subsidiaries, has, directly or indirectly, given or agreed to give any money, gift or similar benefit (other than legal price concessions
to customers in the ordinary course of business) to any customer, supplier, employee or agent of a customer or supplier, or official or
employee of any Governmental Entity (domestic or foreign) or any political party or candidate for office (domestic or foreign) or other
person who was, is, or may be in a position to help or hinder the business of the Company or any of its Subsidiaries (or assist any of
them in connection with any actual or proposed transaction) that (i) might subject the Company or any of its Subsidiaries to any damage
or penalty in any civil, criminal or governmental litigation or proceeding, (ii) if not given in the past, might have had a Material Adverse
Change or (iii) if not continued in the future, might adversely affect the assets, business, operations or prospects of the Company. The
Company has taken reasonable steps to ensure that its accounting controls and procedures are sufficient to cause the Company to comply
in all material respects with the U.S. Foreign Corrupt Practices Act of 1977, as amended, and the Convention on Combating Bribery of Foreign
Public Officials in International Business Transactions of the Organisation for Economic Co-operation and Development (OECD).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">2.21. <B><U>Compliance with
Sanction Laws</U></B>. None of the Company, any of its Subsidiaries or, to the knowledge of the Company, any directors, officers or employees
of the Company or any of its Subsidiaries or any agent, affiliate or other person associated with or acting on behalf of the Company or
any of its Subsidiaries is currently the subject or the target of any sanctions administered or enforced by the U.S. government, (including,
without limitation, the Office of Foreign Assets Control (OFAC) of the U.S. Department of the Treasury or the U.S. Department of State
and including, without limitation, the designation as a &ldquo;specially designated national&rdquo; or &ldquo;blocked person&rdquo;),
the United Nations Security Council, the European Union, the Office of Financial Sanctions Implementation of the United Kingdom of Great
Britain and Northern Ireland (OFSI) or other relevant sanctions authority (collectively, &ldquo;<B>Sanctions</B>&rdquo;), nor is the Company
or any of its Subsidiaries located, organized or resident in a country or territory that is the subject or target of Sanctions, including,
without limitation, the Republic of Belarus, Crimea, the Russian Federation, Republic of Cuba, the Islamic Republic of Iran, Democratic
People&rsquo;s Republic of Korea (North Korea), the Libyan Arab Republic, the Syrian Arab Republic, the Bolivarian Republic of Venezuela
and the Republic of Yemen (each, a &ldquo;<B>Sanctioned Country</B>&rdquo;); and the Company will not directly or indirectly use the proceeds
of the Offering, or lend, contribute or otherwise make available such proceeds to any Subsidiary, joint venture partner or other person
or entity (i) to fund or facilitate any activities of or business with any person that, at the time of such funding or facilitation, is
the subject or target of Sanctions, (ii) to fund or facilitate any activities of or business in any Sanctioned Country or (iii) in any
other manner that will result in a violation by any person (including any person participating in the transaction, whether as underwriter,
advisor, investor or otherwise) of Sanctions. For the past three years, the Company has not knowingly engaged in and is not now knowingly
engaged in any dealings or transactions with any person that at the time of the dealing or transaction is or was the subject or the target
of Sanctions or with any Sanctioned Country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">2.22. <B><U>Compliance with
Anti-Money Laundering Laws</U></B>. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance
with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as
amended, including the Money Laundering Control Act of 1986, as amended, the rules and regulations thereunder and any related or similar
rules, regulations or guidelines, issued, administered or enforced by any Governmental Entity (collectively, the &ldquo;<B>Money Laundering
Laws</B>&rdquo;); and no action, suit or proceeding by or before any Governmental Entity involving the Company or any of its Subsidiaries
with respect to the Money Laundering Laws is pending or, to the best knowledge of the Company, threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">2.23. <B><U>Officers&rsquo;
Certificates</U></B>. Any certificate signed by any duly authorized officer of the Company and delivered to the Underwriters or to counsel
to the Underwriters shall be deemed a representation and warranty by the Company to the Underwriters as to the matters covered thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">2.24. <B><U>Lock-Up Agreements</U></B>.
<B><U>Schedule 3</U></B> hereto contains a complete and accurate list of the Company&rsquo;s officers and directors (collectively, the
&ldquo;<B>Lock-Up Parties</B>&rdquo;). The Company has caused each of the Lock-Up Parties to deliver to the Representative an executed
Lock-Up Agreement, in the form set forth in Exhibit B (the &ldquo;<B>Lock-Up Agreement</B>&rdquo;), on or prior to the execution of this
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">2.25. <B><U>Subsidiaries</U></B>.
Each of the Subsidiaries has been duly incorporated or organized, as the case may be, and is validly existing as a corporation, partnership
or limited liability company, as applicable, in good standing under the laws of the jurisdiction of its incorporation or organization
and has the power and authority (corporate or other) to own, lease and operate its properties and to conduct its business as described
in the Registration Statement, the Pricing Disclosure Package and the Prospectus. Each of the Company&rsquo;s Subsidiaries is duly qualified
as a foreign corporation, partnership limited liability company or similar corporate entity, as applicable, to transact business and is
in good standing in each jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property
or the conduct of business, except where the failure to so qualify or be in good standing would not reasonably be expected, individually
or in the aggregate, to have a Material Adverse Change. All of the issued and outstanding share capital or other equity or ownership interests
of each of the Company&rsquo;s Subsidiaries have been duly authorized and validly issued, are fully paid and nonassessable and are owned
by the Company, directly or through Subsidiaries, free and clear of any security interest, mortgage, pledge, lien, encumbrance or adverse
claim. None of the outstanding share capital or equity interest in any Subsidiary was issued in violation of pre-emptive or similar rights
of any security holder of such Subsidiary. The constitutive or organizational documents of each of the Subsidiaries comply in all material
respects with the requirements of applicable laws of its jurisdiction of incorporation or organization and are in full force and effect.
The Company does not own or control, directly or indirectly, any corporation, association or other entity other than the Subsidiaries
set forth in Exhibit 21.1 to the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">2.26. <B><U>Related Party
Transactions</U></B>. There are no business relationships or related party transactions involving the Company or any other person required
to be described in the Registration Statement, the Pricing Disclosure Package and the Prospectus that have not been described as required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">2.27. <B><U>Board of Directors</U></B>.
The Board of Directors of the Company is comprised of the persons set forth under the heading of the Pricing Prospectus and the Prospectus
captioned &ldquo;Management.&rdquo; The qualifications of the persons serving as board members and the overall composition of the board
comply with the Exchange Act, the Exchange Act Regulations, the Sarbanes-Oxley Act of 2002 and the rules promulgated thereunder (the &ldquo;<B>Sarbanes-Oxley
Act</B>&rdquo;) applicable to the Company and the listing rules of the Exchange. At least one member of the Audit Committee of the Board
of Directors of the Company qualifies as an &ldquo;audit committee financial expert,&rdquo; as such term is defined in Item 407 of Regulation
S-K and the listing rules of the Exchange. In addition, at least a majority of the persons serving on the Board of Directors qualify as
&ldquo;independent&rdquo; as defined under the listing rules of the Exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">2.28. <B><U>Sarbanes-Oxley
Compliance</U></B>. The Company is, or at the Applicable Time and on the Closing Date will be, in material compliance with the provisions
of the Sarbanes-Oxley Act applicable to it, and has implemented or will implement such programs and taken reasonable steps to ensure the
Company&rsquo;s future compliance (not later than the relevant statutory and regulatory deadlines therefor) with all of the material provisions
of the Sarbanes-Oxley Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">2.29. <B><U>Disclosure Controls
and Procedures; Deficiencies in or Changes to Internal Control Over Financial Reporting</U>. </B>The Company and its Subsidiaries maintain
systems of &ldquo;internal control over financial reporting&rdquo; (as defined under Rules 13a-15 and 15d-15 under the Exchange Act Regulations)
that comply with the requirements of the Exchange Act and have been designed by, or under the supervision of, their respective principal
executive and principal financial officers, or persons performing similar functions, to provide reasonable assurance regarding the reliability
of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP, including, but not limited
to, internal accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management&rsquo;s
general or specific authorizations; (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity
with GAAP and to maintain asset accountability; (iii) access to assets is permitted only in accordance with management&rsquo;s general
or specific authorization; and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals
and appropriate action is taken with respect to any differences. Since the end of the Company&rsquo;s most recent audited fiscal year,
except as set forth in the Registration Statement, the Pricing Disclosure Package and the Prospectus, there have been no significant deficiencies
or material weakness in the Company&rsquo;s internal control over financial reporting (whether or not remediated) and no change in the
Company&rsquo;s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect,
the Company&rsquo;s internal control over financial reporting. Except as set forth in the Registration Statement, the Pricing Disclosure
Package and the Prospectus, the Company is not aware of any change in its internal control over financial reporting that has occurred
during its most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company&rsquo;s
internal control over financial reporting. Except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus,
the Company is not aware of any material weaknesses in its internal controls. The Company&rsquo;s auditors and the Audit Committee of
the Board of Directors of the Company have been advised of (i) all significant deficiencies and material weaknesses in the design or operation
of internal controls over financial reporting which are known to the Company&rsquo;s management and that have adversely affected or are
reasonably likely to adversely affect the Company&rsquo;s ability to record, process, summarize and report financial information and (ii)
any fraud known to the Company&rsquo;s management, whether or not material, that involves management or other employees who have a significant
role in the Company&rsquo;s internal controls over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">2.30. <B><U>No Investment
Company Status</U></B>. The Company is not and, after giving effect to the Offering and the application of the proceeds thereof as described
in the Registration Statement, the Pricing Disclosure Package and the Prospectus, will not be, required to register as an &ldquo;investment
company&rdquo; as defined in and pursuant to the Investment Company Act of 1940, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">2.31. <B><U>No Labor Disputes</U></B>.
No labor dispute with the employees of the Company or any of its Subsidiaries exists or, to the knowledge of the Company, is imminent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">2.32. <B><U>Intellectual Property
Rights</U></B>. Each of the Company and its Subsidiaries owns or possesses or has valid rights to use or has the right to acquire on reasonable
terms, all patents, patent applications, trademarks, service marks, trade names, trademark registrations, service mark registrations,
copyrights, licenses, inventions, trade secrets and similar rights (&ldquo;<B>Intellectual Property Rights</B>&rdquo;) necessary for the
conduct of the business of the Company and its Subsidiaries as currently carried on and as described in the Registration Statement, the
Pricing Disclosure Package and the Prospectus, except where the failure to own or possess, have a valid right license to or have the ability
to acquire on reasonable terms any of the foregoing would not have or would not reasonably be expected to result in a Material Adverse
Change. To the knowledge of the Company, no action or use by the Company or any of its Subsidiaries necessary for the conduct of its business
as currently carried on and as described in the Registration Statement and the Prospectus will involve or give rise to any infringement
of, or license or similar fees for, any Intellectual Property Rights of others. Neither the Company nor any of its Subsidiaries has received
any notice alleging any such infringement, fee or conflict with asserted Intellectual Property Rights of others. Except as would not reasonably
be expected to result, individually or in the aggregate, in a Material Adverse Change (A) to the knowledge of the Company, there is no
infringement, misappropriation or violation by third parties of any of the Intellectual Property Rights owned by the Company; (B) there
is no pending or, to the knowledge of the Company, threatened action, suit, proceeding or claim by others challenging the rights of the
Company in or to any such Intellectual Property Rights, and the Company is unaware of any facts which would form a reasonable basis for
any such claim, that would, individually or in the aggregate, together with any other claims in this Section 2.32, reasonably be expected
to result in a Material Adverse Change; (C) the Intellectual Property Rights owned by the Company and, to the knowledge of the Company,
the Intellectual Property Rights licensed to the Company have not been adjudged by a court of competent jurisdiction invalid or unenforceable,
in whole or in part, and there is no pending or, to the Company&rsquo;s knowledge, threatened action, suit, proceeding or claim by others
challenging the validity or scope of any such Intellectual Property Rights, and the Company is unaware of any facts which would form a
reasonable basis for any such claim that would, individually or in the aggregate, together with any other claims in this Section 2.32,
reasonably be expected to result in a Material Adverse Change; (D) there is no pending or, to the Company&rsquo;s knowledge, threatened
action, suit, proceeding or claim by others that the Company infringes, misappropriates or otherwise violates any Intellectual Property
Rights or other proprietary rights of others, the Company has not received any written notice of such claim and the Company is unaware
of any other facts which would form a reasonable basis for any such claim that would, individually or in the aggregate, together with
any other claims in this Section 2.32, reasonably be expected to result in a Material Adverse Change; and (E) to the Company&rsquo;s knowledge,
no employee of the Company is in or has ever been in violation in any material respect of any term of any employment contract, patent
disclosure agreement, invention assignment agreement, non-competition agreement, non-solicitation agreement, nondisclosure agreement or
any restrictive covenant to or with a former employer where the basis of such violation relates to such employee&rsquo;s employment with
the Company, or actions undertaken by the employee while employed with the Company and could reasonably be expected to result, individually
or in the aggregate, in a Material Adverse Change. To the Company&rsquo;s knowledge, all material technical information developed by and
belonging to the Company which has not been patented has been kept confidential. To the Company&rsquo;s knowledge, the Company has taken
all actions reasonably necessary to protect, and where necessary register, the copyrights, trademarks, patent rights and trade secrets
owned by or licensed exclusively to the Company (solely where the Company has the right to take such actions as to in-licensed intellectual
property rights). The Company is not a party to or bound by any options, licenses or agreements with respect to the Intellectual Property
Rights of any other person or entity that are required to be set forth in the Registration Statement, the Pricing Disclosure Package and
the Prospectus and are not described therein. The Registration Statement, the Pricing Disclosure Package and the Prospectus contain in
all material respects the same description of the matters set forth in the preceding sentence. None of the technology employed by the
Company has been obtained or is being used by the Company in violation of any contractual obligation binding on the Company or, to the
Company&rsquo;s knowledge, any of its officers, directors or employees, or otherwise in violation of the rights of any persons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">2.33. <B><U>Taxes</U></B>.
Each of the Company and its Subsidiaries has filed all returns (as hereinafter defined) required to be filed with taxing authorities prior
to the date hereof or has duly obtained extensions of time for the filing thereof. Each of the Company and its Subsidiaries has paid all
taxes (as hereinafter defined) shown as due on such returns that were filed and has paid all taxes imposed on or assessed against the
Company or such respective Subsidiary, except those that are being contested in good faith or as would not have or would not reasonably
be expected to result, individually or in the aggregate, in a Material Adverse Change. The provisions for taxes payable, if any, shown
on the financial statements filed with or as part of the Registration Statement are sufficient for all accrued and unpaid taxes, whether
or not disputed, and for all periods to and including the dates of such consolidated financial statements. Except as disclosed in writing
to the Underwriters, (i) no issues have been raised (and are currently pending) by any taxing authority in connection with any of the
returns or taxes asserted as due from the Company or its Subsidiaries, and (ii) no waivers of statutes of limitation with respect to the
returns or collection of taxes have been given by or requested from the Company or its Subsidiaries. The term &ldquo;<B>taxes</B>&rdquo;
means all federal, state, local, foreign and other net income, gross income, gross receipts, sales, use, ad valorem, transfer, franchise,
profits, license, lease, service, service use, withholding, payroll, employment, excise, severance, stamp, occupation, premium, property,
windfall profits, customs, duties or other taxes, fees, assessments or charges of any kind whatever, together with any interest and any
penalties, additions to tax or additional amounts with respect thereto. The term &ldquo;<B>returns</B>&rdquo; means all returns, declarations,
reports, statements and other documents required to be filed in respect to taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">2.34. <B><U>Compliance with
Laws</U></B>. The Company: (A) is and at all times has been in compliance with all statutes, rules, or regulations applicable to the conduct
of its business as described in the Registration Statement, Pricing Disclosure Package and the Prospectus (&ldquo;<B>Applicable Laws</B>&rdquo;),
except as could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Change; (B) has not received
any notice from any governmental authority alleging or asserting noncompliance with any Applicable Laws or any Authorizations required
of and from all Governmental Entities as of date hereof to conduct its business as described in the Registration Statement, the Pricing
Disclosure Package and the Prospectus; (C) possesses all material Authorizations and such Authorizations are valid and in full force and
effect and are not in material violation of any term of any such Authorizations; (D) has not received notice of any claim, action, suit,
proceeding, hearing, enforcement, investigation, arbitration or other action from any governmental authority or third party alleging that
any product operation or activity is in violation of any Applicable Laws or Authorizations and has no knowledge that any such governmental
authority or third party is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding; (E) has not
received written notice that any governmental authority has taken, is taking or intends to take action to limit, suspend, modify or revoke
any Authorizations and has no knowledge that any such governmental authority is considering such action; (F) has filed, obtained, maintained
or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments
as required by any Applicable Laws or Authorizations and that all such reports, documents, forms, notices, applications, records, claims,
submissions and supplements or amendments were complete and correct in all material respects on the date submitted (or were corrected
or supplemented by a subsequent submission); and (G) has not, either voluntarily or involuntarily, initiated, conducted, or issued or
caused to be initiated, conducted or issued, any recall, market withdrawal or replacement, safety alert, post-sale warning, or other notice
or action relating to the alleged lack of safety or efficacy of any product or any alleged product defect or violation and, to the Company&rsquo;s
knowledge, no third party has initiated, conducted or intends to initiate any such notice or action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">2.35. <B><U>ERISA Compliance</U>.
</B>The Company and any &ldquo;employee benefit plan&rdquo; (as defined under the Employee Retirement Income Security Act of 1974, as
amended, and the regulations and published interpretations thereunder (collectively, &ldquo;<B>ERISA</B>&rdquo;)) established or maintained
by the Company or its &ldquo;ERISA Affiliates&rdquo; (as defined below) are in compliance in all material respects with ERISA. &ldquo;<B>ERISA
Affiliate</B>&rdquo; means, with respect to the Company, any member of any group of organizations described in Sections 414(b), (c), (m)
or (o) of the Internal Revenue Code of 1986, as amended, and the regulations and published interpretations thereunder (the &ldquo;<B>Code</B>&rdquo;)
of which the Company is a member. No &ldquo;reportable event&rdquo; (as defined under ERISA) has occurred or is reasonably expected to
occur with respect to any &ldquo;employee benefit plan&rdquo; established or maintained by the Company or any of its ERISA Affiliates.
No &ldquo;employee benefit plan&rdquo; established or maintained by the Company or any of its ERISA Affiliates, if such &ldquo;employee
benefit plan&rdquo; were terminated, would have any &ldquo;amount of unfunded benefit liabilities&rdquo; (as defined under ERISA). Neither
the Company nor any of its ERISA Affiliates has incurred or reasonably expects to incur any material liability under (i) Title IV of ERISA
with respect to termination of, or withdrawal from, any &ldquo;employee benefit plan&rdquo; or (ii) Sections 412, 4971, 4975 or 4980B
of the Code. Each &ldquo;employee benefit plan&rdquo; established or maintained by the Company or any of its ERISA Affiliates that is
intended to be qualified under Section 401(a) of the Code is so qualified and, to the knowledge of the Company, nothing has occurred,
whether by action or failure to act, which would cause the loss of such qualification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">2.36. <B><U>Environmental
Laws</U><I>. </I></B>The Company is in compliance with all foreign, federal, state and local rules, laws and regulations relating to the
use, treatment, storage and disposal of hazardous or toxic substances or waste and protection of health and safety or the environment
which are applicable to their businesses (&ldquo;<B>Environmental Laws</B>&rdquo;), except where the failure to comply would not, singularly
or in the aggregate, result in a Material Adverse Change. There has been no storage, generation, transportation, handling, treatment,
disposal, discharge, emission, or other release of any kind of toxic or other wastes or other hazardous substances by, due to, or caused
by the Company (or, to the Company&rsquo;s knowledge, any other entity for whose acts or omissions the Company is or may otherwise be
liable) upon any of the property now or previously owned or leased by the Company, or upon any other property, in violation of any law,
statute, ordinance, rule, regulation, order, judgment, decree or permit or which would, under any law, statute, ordinance, rule (including
rule of common law), regulation, order, judgment, decree or permit, give rise to any liability, except for any violation or liability
which would not have, singularly or in the aggregate with all such violations and liabilities, a Material Adverse Change; and there has
been no disposal, discharge, emission or other release of any kind onto such property or into the environment surrounding such property
of any toxic or other wastes or other hazardous substances with respect to which the Company has knowledge, except for any such disposal,
discharge, emission, or other release of any kind which would not have, singularly or in the aggregate with all such discharges and other
releases, a Material Adverse Change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">2.37. <B><U>Title to Property</U></B>.
Except as set forth in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company has good and marketable
title in fee simple to, or have valid rights to lease or otherwise use, all items of real or personal property which are material to the
business of the Company, in each case free and clear of all liens, encumbrances, security interests, claims and defects that do not, singly
or in the aggregate, materially affect the value of such property and do not materially interfere with the use made and proposed to be
made of such property by the Company; and all of the leases and subleases material to the business of the Company, and under which the
Company holds properties described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, are in full force
and effect, and the Company has not received any notice of any material claim of any sort that has been asserted by anyone adverse to
the rights of the Company under any of the leases or subleases mentioned above, or affecting or questioning the rights of the Company
to the continued possession of the leased or subleased premises under any such lease or sublease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">2.38. <B><U>Contracts Affecting
Capital</U></B>. There are no transactions, arrangements or other relationships between and/or among the Company, any of its affiliates
(as such term is defined in Rule 405 of the Securities Act Regulations) and any unconsolidated entity, including, but not limited to,
any structured finance, special purpose or limited purpose entity that could reasonably be expected to materially affect the Company&rsquo;s
liquidity or the availability of or requirements for their capital resources required to be described or incorporated by reference in
the Registration Statement, the Pricing Disclosure Package and the Prospectus which have not been described or incorporated by reference
as required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">2.39. <B><U>Loans to Directors
or Officers</U></B>. There are no outstanding loans, advances (except normal advances for business expenses in the ordinary course of
business) or guarantees or indebtedness by the Company to or for the benefit of any of the officers or directors of the Company, or any
of their respective family members, except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">2.40. <B><U>Ineligible Issuer</U>.
</B>At the time of filing the Registration Statement and any post-effective amendment thereto, at the time of effectiveness of the Registration
Statement and any amendment thereto, at the earliest time thereafter that the Company or another offering participant made a <I>bona fide</I>
offer (within the meaning of Rule 164(h)(2) of the Securities Act Regulations) of the Public Securities and at the date hereof, the Company
was not and is not an &ldquo;ineligible issuer,&rdquo; as defined in Rule 405 of the Securities Act Regulations, without taking account
of any determination by the Commission pursuant to such rule that it is not necessary that the Company be considered an ineligible issuer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">2.41. <B><U>Smaller Reporting
Company</U></B>. As of the time of filing of the Registration Statement, the Applicable Time, the date hereof and the Closing Date, the
Company was and is a &ldquo;smaller reporting company&rdquo;, as defined in Item 10(f)(1) of Regulation S-K and Rule 12b-2 of the Exchange
Act Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">2.42. <B><U>Free Writing Prospectus
and Testing-the-Waters Communications</U></B>. The Company has not, without the prior written consent of the Representative, made any
offer relating to the Public Securities that would constitute an issuer free writing prospectus, as defined in Rule 433, or that would
otherwise constitute a &ldquo;free writing prospectus&rdquo; as defined in Rule 405 of the Securities Act Regulations. The Company: (a)
has not engaged in any Testing-the-Waters Communication (as defined herein) other than with the consent of the Representative with entities
that are &ldquo;qualified institutional buyers&rdquo; within the meaning of Rule 144A of the Securities Act Regulations or institutions
that are &ldquo;accredited investors&rdquo; within the meaning of Rule 501 of the Securities Act Regulations and (b) has not authorized
anyone to engage in Testing-the-Waters Communications other than its officers and the Representative and individuals engaged by the Representative.
The Company has not distributed any written Testing-the-Waters Communications. &ldquo;<B>Testing-the-Waters Communication</B>&rdquo; means
any oral or written communication with potential investors undertaken in reliance on Section 5(d) of the Securities Act or Rule 163B of
the Securities Act Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">2.43. <B><U>Industry Data</U></B>.
The statistical and market-related data included in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus
are based on or derived from sources that the Company reasonably and in good faith believes are reliable and accurate or represent the
Company&rsquo;s good faith estimates that are made on the basis of data derived from such sources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">2.44. <B><U>Electronic Road
Show</U></B>. The Company has made available a Bona Fide Electronic Road Show in compliance with Rule 433(d)(8)(ii) of the Securities
Act Regulations such that no filing of any &ldquo;road show&rdquo; (as defined in Rule 433(h) of the Securities Act Regulations) is required
in connection with the Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">2.45. <B><U>Margin Securities</U></B>.
The Company owns no &ldquo;margin securities&rdquo; as that term is defined in Regulation U of the Board of Governors of the Federal Reserve
System (the &ldquo;<B>Federal Reserve Board</B>&rdquo;), and none of the proceeds of Offering will be used, directly or indirectly, for
the purpose of purchasing or carrying any margin security, for the purpose of reducing or retiring any indebtedness which was originally
incurred to purchase or carry any margin security or for any other purpose which might cause any of the shares of Common Stock to be considered
a &ldquo;purpose credit&rdquo; within the meanings of Regulation T, U or X of the Federal Reserve Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">2.46. <B><U>Dividends and
Distributions</U></B>. Except as disclosed in the Pricing Disclosure Package, Registration Statement and the Prospectus, no Subsidiary
of the Company is currently prohibited or restricted, directly or indirectly, from paying any dividends to the Company, from making any
other distribution on such Subsidiary&rsquo;s capital stock (to the extent that any such prohibition or restriction on dividends and/or
distributions would have a material effect to the Company), from repaying to the Company any loans or advances to such Subsidiary from
the Company or from transferring any of such Subsidiary&rsquo;s property or assets to the Company or any other Subsidiary of the Company,
except as may otherwise be provided in current loan or mortgage-related documents<B>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">2.47. <B><U>Forward-Looking
Statements</U></B>. No forward-looking statement (within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange
Act) contained in the Registration Statement, the Pricing Disclosure Package or the Prospectus has been made or reaffirmed without a reasonable
basis or has been disclosed other than in good faith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">2.48. <B><U>Integration</U></B>.
Neither the Company, nor any of its affiliates, nor any person acting on its or their behalf has, directly or indirectly, made any offers
or sales of any security or solicited any offers to buy any security, under circumstances that would cause the Offering to be integrated
with prior offerings by the Company for purposes of the Securities Act that would require the registration of any such securities under
the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">2.49. <B><U>Confidentiality
and Non-Competition</U></B>. To the Company&rsquo;s knowledge, no director, officer, key employee or consultant of the Company is subject
to any confidentiality, non-disclosure, non-competition agreement or non-solicitation agreement with any employer (other than the Company)
or prior employer that could materially affect his or her ability to be and act in his or her respective capacity of the Company or be
expected to result in a Material Adverse Change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">2.50. <B><U>Corporate Records</U></B>.
The minute books of the Company have been made available to the Underwriters and counsel for the Underwriters, and such books (i) contain
a complete summary of all material meetings and actions of the board of directors (including each board committee) and stockholders of
the Company (or analogous governing bodies and interest holders, as applicable), since the time of its respective incorporation or organization
through the date of the latest meeting and action, and (ii) accurately in all material respects reflect all material transactions referred
to in such minutes. There are no material transactions, agreements, dispositions or other actions of the Company that are not properly
approved and/or accurately and fairly recorded in the minute books of the Company, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">2.51. <B><U>Diligence Materials</U></B>.
The Company has provided to the Representative and counsel to the Underwriters all materials required or necessary to respond in all material
respects to any diligence request submitted to the Company or counsel to the Company by the Representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">2.52. <B><U>Stabilization</U></B>.
Neither the Company nor, to its knowledge, any of its employees, directors or shareholders (without the consent of the Representative)
has taken, directly or indirectly, any action designed to or that has constituted or that might reasonably be expected to cause or result
in, under Regulation M of the Exchange Act, or otherwise, stabilization or manipulation of the price of any security of the Company to
facilitate the sale or resale of the Public Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">2.53. <B>[Reserved]</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">2.54. <B><U>Regulatory.</U></B>
(a) All preclinical studies and clinical trials conducted by or on behalf of the Company that are material to the Company and its Subsidiaries,
taken as a whole, are or have been adequately described in the Registration Statement, the Pricing Disclosure Package and the Prospectus
in all material respects. The preclinical studies and clinical trials conducted by or on behalf of the Company and its Subsidiaries that
are described in the Registration Statement, the Pricing Disclosure Package and the Prospectus or the results of which are referred to
in the Registration Statement, the Pricing Disclosure Package and the Prospectus were and, if still ongoing, are being conducted in material
compliance with all laws and regulations applicable thereto in the jurisdictions in which they are being conducted and with all laws and
regulations applicable to preclinical studies and clinical trials from which data will be submitted to support marketing approval. The
descriptions in the Registration Statement, the Pricing Disclosure Package and the Prospectus of the results of such studies are accurate
and complete in all material respects and fairly present the data derived from such studies, and the Company has no knowledge of, or reason
to believe that, any large well-controlled clinical study the aggregate results of which are inconsistent with or otherwise call into
question the results of any clinical study conducted by or on behalf of the Company that are described in the Registration Statement,
the Pricing Disclosure Package and the Prospectus or the results of which are referred to in the Registration Statement, the Pricing Disclosure
Package and the Prospectus. Except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the
Company has not received any written notices or statements from the FDA, the European Medicines Agency (&ldquo;<B>EMA</B>&rdquo;) or any
other governmental agency or authority imposing, requiring, requesting or suggesting a clinical hold, termination, suspension or material
modification for or of any preclinical studies and clinical trials that are described in the Registration Statement, the Pricing Disclosure
Package and the Prospectus or the results of which are referred to in the Registration Statement, the Pricing Disclosure Package and the
Prospectus. Except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company has not
received any written notices or statements from the FDA, the EMA or any other governmental agency, and otherwise has no knowledge of,
or reason to believe that, (i) any investigational new drug application for any potential product of the Company is or has been rejected
or placed on clinical hold; and (ii) any license, approval, permit or authorization to conduct any clinical trial of any potential product
of the Company has been, will be or may be suspended, revoked, modified or limited. Neither the Company nor any of its subsidiaries has
failed to file with the FDA or any foreign, federal, state or local governmental or regulatory authority performing functions similar
to those performed by the FDA, any filing, declaration, listing, registration, report or submission that is required to be so filed. &nbsp;All
such filings were in material compliance with applicable laws when filed and no deficiencies have been asserted by any applicable regulatory
authority (including, without limitation, the FDA or any foreign, federal, state or local governmental or regulatory authority performing
functions similar to those performed by the FDA) with respect to any such filings, declarations, listings, registrations, reports or submissions.
To the knowledge of the Company, there are no facts that would be reasonably likely to result in any warning, untitled or notice of violation
letter or Form FDA-483 from the FDA. The Company is not aware of any studies, tests or trials the results of which the Company believes
reasonably call into question (i) the study, test or trial results of any of its products, (ii) the efficacy or safety of any of its products
or (iii) any of the Company&rsquo;s filings with any Governmental Entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">(b) <U>Regulatory Filings
and Permits</U>. The Company and its Subsidiaries have such permits, licenses, clearances, registrations, exemptions, patents, franchises,
certificates of need and other approvals, consents and other authorizations (&ldquo;<B>Permits</B>&rdquo;) issued by the appropriate domestic
or foreign regional, federal, state, or local regulatory agencies or bodies necessary to conduct the business of the Company, including,
without limitation, any Investigational New Drug Application (an &ldquo;<B>IND</B>&rdquo;), Biologics License Application (&ldquo;BLA&rdquo;)
and/or New Drug Application (an &ldquo;<B>NDA</B>&rdquo;), as required by FDA, the Drug Enforcement Administration (the &ldquo;DEA&rdquo;),
or any other Permits issued by domestic or foreign regional, federal, state, or local agencies or bodies engaged in the regulation of
pharmaceuticals such as those being developed by the Company and its Subsidiaries (collectively, the &ldquo;<B>Regulatory Permits</B>&rdquo;),
except for any of the foregoing that would not reasonably be expected to, individually or in the aggregate, have a Material Adverse Effect;
the Company is in compliance in all material respects with the requirements of the Regulatory Permits, and all of such Regulatory Permits
are valid and in full force and effect; the Company has not received any notice of proceedings relating to the revocation, termination,
modification or impairment of rights of any of the Regulatory Permits that, individually or in the aggregate, if the subject of an unfavorable
decision, ruling or finding, would reasonably be expected to result in a Material Adverse Effect; the Company has not failed to submit
to the FDA any IND, BLA or NDA necessary to conduct the business of the Company, any such filings that were required to be made were in
material compliance with applicable laws when filed, and no material deficiencies have been asserted by the FDA with respect to any such
filings or submissions that were made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">(c) <U>Compliance with Health
Care Laws</U>. Each of the Company and its Subsidiaries is, and at all times has been, in compliance in all material respects with all
applicable Health Care Laws, and has not engaged in activities which are, as applicable, cause for false claims liability, civil penalties,
or mandatory or permissive exclusion from Medicare, Medicaid, or any other state or federal health care program. For purposes of this
Agreement, &ldquo;Health Care Laws&rdquo; means: (i) the Federal Food, Drug, and Cosmetic Act (21 U.S.C. &sect;&sect; 301 et seq.), the
Public Health Service Act (42 U.S.C. &sect;&sect; 201 et seq.), and the regulations promulgated thereunder; (ii) all applicable federal,
state, local and all applicable foreign health care related fraud and abuse laws, including, without limitation, the U.S. Anti-Kickback
Statute (42 U.S.C. Section 1320a-7b(b)), the U.S. Physician Payment Sunshine Act (42 U.S.C. &sect; 1320a-7h), the U.S. Civil False Claims
Act (31 U.S.C. Section 3729 et seq.), the criminal False Claims Law (42 U.S.C. &sect; 1320a-7b(a)), all criminal laws relating to health
care fraud and abuse, including but not limited to 18 U.S.C. Sections 286 and 287, and the health care fraud criminal provisions under
the U.S. Health Insurance Portability and Accountability Act of 1996 (&ldquo;HIPAA&rdquo;) (42 U.S.C. Section 1320d et seq.), the exclusion
laws (42 U.S.C. &sect; 1320a-7), the civil monetary penalties law (42 U.S.C. &sect; 1320a-7a), HIPAA, as amended by the Health Information
Technology for Economic and Clinical Health Act (42 U.S.C. Section 17921 et seq.), and the regulations promulgated pursuant to such statutes;
(iii) Medicare (Title XVIII of the Social Security Act); (iv) Medicaid (Title XIX of the Social Security Act); (v) the Controlled Substances
Act (21 U.S.C. &sect;&sect; 801 et seq.) and the regulations promulgated thereunder; and (vi) any and all other applicable health care
laws and regulations. Neither the Company nor, to the knowledge of the Company, any subsidiary has received notice of any claim, action,
suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any court or arbitrator or governmental or regulatory
authority or third party alleging that any product operation or activity is in material violation of any Health Care Laws, and, to the
Company&rsquo;s knowledge, no such claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action is
threatened. Neither the Company nor, to the knowledge of the Company, any subsidiary is a party to or has any ongoing reporting obligations
pursuant to any corporate integrity agreements, deferred prosecution agreements, monitoring agreements, consent decrees, settlement orders,
plans of correction or similar agreements with or imposed by any governmental or regulatory authority. Additionally, neither the Company,
its Subsidiaries nor any of its respective employees, officers or directors has been excluded, suspended or debarred from participation
in any U.S. federal health care program or human clinical research or, to the knowledge of the Company, is subject to a governmental inquiry,
investigation, proceeding, or other similar action that could reasonably be expected to result in debarment, suspension, or exclusion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">2.55 <U>Exchange Act Reports</U>.
The Company has filed in a timely manner all reports required to be filed pursuant to Sections 13(a), 13(e), 14 and 15(d) of the Exchange
Act during the preceding 12 months (except to the extent that Section 15(d) requires reports to be filed pursuant to Sections 13(d) and
13(g) of the Exchange Act, which shall be governed by the next clause of this sentence); and the Company has filed in a timely manner
all reports required to be filed pursuant to Sections 13(d) and 13(g) of the Exchange Act since January 1, 2022, except where the failure
to timely file could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">2.56 <U>Integration</U>. Neither
the Company, nor any of its affiliates, nor any person acting on its or their behalf has, directly or indirectly, made any offers or sales
of any security or solicited any offers to buy any security, under circumstances that would cause the Offering to be integrated with prior
offerings by the Company for purposes of the Securities Act that would require the registration of any such securities under the Securities
Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 40pt; text-align: left">3.</TD><TD STYLE="text-align: justify"><B><U>Covenants of the Company</U></B>. The Company covenants
and agrees as follows:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">3.1. <B><U>Amendments to Registration
Statement</U></B><I>.</I> The Company shall deliver to the Representative, prior to filing, any amendment or supplement to the Registration
Statement or Prospectus proposed to be filed after the Effective Date and not file any such amendment or supplement to which the Representative
shall reasonably object in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">3.2. <B><U>Federal Securities
Laws</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">3.2.1. <U>Compliance</U>.
The Company, subject to Section 3.2.2, shall comply with the requirements of Rule 430A of the Securities Act Regulations, and will notify
the Representative promptly, and confirm the notice in writing, (i) when any post-effective amendment to the Registration Statement shall
become effective or any amendment or supplement to the Prospectus shall have been filed; (ii) of the receipt of any comments from the
Commission; (iii) of any request by the Commission for any amendment to the Registration Statement or any amendment or supplement to the
Prospectus or for additional information; (iv) of the issuance by the Commission of any stop order suspending the effectiveness of the
Registration Statement or any post-effective amendment or of any order preventing or suspending the use of any Preliminary Prospectus
or the Prospectus, or of the suspension of the qualification of the Public Securities for offering or sale in any jurisdiction, or of
the initiation or threatening of any proceedings for any of such purposes or of any examination pursuant to Section 8(d) or 8(e) of the
Securities Act concerning the Registration Statement; and (v) if the Company becomes the subject of a proceeding under Section 8A of the
Securities Act in connection with the Offering of the Public Securities. The Company shall effect all filings required under Rule 424(b)
of the Securities Act Regulations, in the manner and within the time period required by Rule 424(b) (without reliance on Rule 424(b)(8)),
and shall take such steps as it deems necessary to ascertain promptly whether the form of prospectus transmitted for filing under Rule
424(b) was received for filing by the Commission and, in the event that it was not, it will promptly file such prospectus. The Company
shall use its best efforts to prevent the issuance of any stop order, prevention or suspension and, if any such order is issued, to obtain
the lifting thereof at the earliest possible moment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">3.2.2. <U>Continued
Compliance</U>. The Company shall comply with the Securities Act, the Securities Act Regulations, the Exchange Act and the Exchange Act
Regulations so as to permit the completion of the distribution of the Public Securities as contemplated in this Agreement and in the Registration
Statement, the Pricing Disclosure Package and the Prospectus. If at any time when a prospectus relating to the Public Securities is (or,
but for the exception afforded by Rule 172 of the Securities Act Regulations (&ldquo;<B>Rule 172</B>&rdquo;), would be) required by the
Securities Act to be delivered in connection with sales of the Public Securities, any event shall occur or condition shall exist as a
result of which it is necessary, in the opinion of counsel for the Underwriters or for the Company, to (i) amend the Registration Statement
in order that the Registration Statement will not include an untrue statement of a material fact or omit to state a material fact required
to be stated therein or necessary to make the statements therein not misleading; (ii) amend or supplement the Pricing Disclosure Package
or the Prospectus in order that the Pricing Disclosure Package or the Prospectus, as the case may be, will not include any untrue statement
of a material fact or omit to state a material fact necessary in order to make the statements therein not misleading in the light of the
circumstances existing at the time it is delivered to a purchaser or (iii) amend the Registration Statement or amend or supplement the
Pricing Disclosure Package or the Prospectus, as the case may be, in order to comply with the requirements of the Securities Act or the
Securities Act Regulations, the Company will promptly (A) give the Representative notice of such event; (B) prepare any amendment or supplement
as may be necessary to correct such statement or omission or to make the Registration Statement, the Pricing Disclosure Package or the
Prospectus comply with such requirements and, a reasonable amount of time prior to any proposed filing or use, furnish the Representative
with copies of any such amendment or supplement and (C) file with the Commission any such amendment or supplement; provided that the Company
shall not file or use any such amendment or supplement to which the Representative or counsel for the Underwriters shall reasonably object.
The Company will furnish to the Underwriters such number of copies of such amendment or supplement as the Underwriters may reasonably
request. The Company has given the Representative notice of any filings made pursuant to the Exchange Act or the Exchange Act Regulations
within forty-eight (48) hours prior to the Applicable Time. The Company shall give the Representative notice of its intention to make
any such filing from the Applicable Time until the later of the Closing Date and the exercise in full or expiration of the Over-allotment
Option specified in Section 1.2 hereof and will furnish the Representative with copies of the related document(s) a reasonable amount
of time prior to such proposed filing, as the case may be, and will not file or use any such document to which the Representative or counsel
for the Underwriters shall reasonably object.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">3.2.3. <U>Exchange
Act Registration</U>. For a period of three (3) years after the date of this Agreement, the Company shall use its commercially reasonable
efforts to maintain the registration of the Common Stock under the Exchange Act, unless the Company is taken private in a <I>bona fide</I>
acquisition transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">3.2.4. <U>Free Writing
Prospectuses</U>. The Company agrees that, unless it obtains the prior written consent of the Representative, it shall not make any offer
relating to the Public Securities that would constitute an Issuer Free Writing Prospectus or that would otherwise constitute a &ldquo;free
writing prospectus,&rdquo; or a portion thereof, required to be filed by the Company with the Commission or retained by the Company under
Rule 433; provided that the Representative shall be deemed to have consented to each Issuer General Use Free Writing Prospectus set forth
in Schedule 2-B. The Company represents that it has treated or agrees that it will treat each such free writing prospectus consented to,
or deemed consented to, by the Underwriters as an &ldquo;issuer free writing prospectus,&rdquo; as defined in Rule 433, and that it has
complied and will comply with the applicable requirements of Rule 433 with respect thereto, including timely filing with the Commission
where required, legending and record keeping. If at any time following issuance of an Issuer Free Writing Prospectus there occurred or
occurs an event or development as a result of which such Issuer Free Writing Prospectus conflicted or would conflict with the information
contained in the Registration Statement or included or would include an untrue statement of a material fact or omitted or would omit to
state a material fact necessary in order to make the statements therein, in the light of the circumstances existing at that subsequent
time, not misleading, the Company will promptly notify the Underwriters and will promptly amend or supplement, at its own expense, such
Issuer Free Writing Prospectus to eliminate or correct such conflict, untrue statement or omission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">3.2.5. <U>Testing-the-Waters
Communications</U>. If at any time following the distribution of any written Testing-the-Waters Communication there occurred or occurs
an event or development as a result of which such written Testing-the-Waters Communication included or would include an untrue statement
of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of
the circumstances existing at that subsequent time, not misleading, the Company shall promptly notify the Representative and shall promptly
amend or supplement, at its own expense, such written Testing-the-Waters Communication to eliminate or correct such untrue statement or
omission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">3.3. <B><U>Delivery to the
Underwriters of Registration Statements</U></B>. The Company has delivered or made available or shall deliver or make available to the
Representative and counsel for the Representative, without charge, signed copies of the Registration Statement as originally filed and
each amendment thereto (including exhibits filed therewith) and signed copies of all consents and certificates of experts, and will also
deliver to the Underwriters, without charge, a conformed copy of the Registration Statement as originally filed and each amendment thereto
(without exhibits) for each of the Underwriters. The copies of the Registration Statement and each amendment thereto furnished to the
Underwriters will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to
the extent permitted by Regulation S-T.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">3.4. <B><U>Delivery to the
Underwriters of Prospectuses</U></B>. The Company has delivered or made available or will deliver or make available to each Underwriter,
without charge, as many copies of each Preliminary Prospectus as such Underwriter reasonably requested, and the Company hereby consents
to the use of such copies for purposes permitted by the Securities Act. The Company will furnish to each Underwriter, without charge,
during the period when a prospectus relating to the Public Securities is (or, but for the exception afforded by Rule 172, would be) required
to be delivered under the Securities Act, such number of copies of the Prospectus (as amended or supplemented) as such Underwriter may
reasonably request. The Prospectus and any amendments or supplements thereto furnished to the Underwriters will be identical to the electronically
transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">3.5. <B><U>Effectiveness and
Events Requiring Notice to the Representative</U></B>. The Company shall use its best efforts to cause the Registration Statement to remain
effective with a current prospectus for at least nine (9) months after the Applicable Time, and shall notify the Representative promptly
and confirm the notice in writing: (i) of the effectiveness of the Registration Statement and any amendment thereto; (ii) of the issuance
by the Commission of any stop order or of the initiation, or the threatening, of any proceeding for that purpose; (iii) of the issuance
by any state securities commission of any proceedings for the suspension of the qualification of the Public Securities for offering or
sale in any jurisdiction or of the initiation, or the threatening, of any proceeding for that purpose; (iv) of the mailing and delivery
to the Commission for filing of any amendment or supplement to the Registration Statement or Prospectus; (v) of the receipt of any comments
or request for any additional information from the Commission; and (vi) of the happening of any event during the period described in this
Section 3.5 that, in the judgment of the Company, makes any statement of a material fact made in the Registration Statement, the Pricing
Disclosure Package or the Prospectus untrue or that requires the making of any changes in (a) the Registration Statement in order to make
the statements therein not misleading, or (b) in the Pricing Disclosure Package or the Prospectus in order to make the statements therein,
in light of the circumstances under which they were made, not misleading. If the Commission or any state securities commission shall enter
a stop order or suspend such qualification at any time, the Company shall use its commercially reasonable efforts to obtain promptly the
lifting of such order.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">3.6. <B><U>Review of Financial
Statements</U></B>. For a period of five (5) years after the date of this Agreement, the Company, at its expense, shall cause its regularly
engaged independent registered public accounting firm to review (but not audit) the Company&rsquo;s financial statements for each of the
three fiscal quarters immediately preceding the announcement of any quarterly financial information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">3.7. <B><U>Listing</U></B>.
The Company shall use its commercially reasonable efforts to maintain the listing of the Common Stock (including the Shares) and the Common
Warrants on the Exchange for at least three (3) years from the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">3.8. <B><U>Financial Public
Relations Firm</U>. </B>The Company has retained a financial public relations firm reasonably acceptable to the Representative and the
Company, which firm shall be experienced in assisting issuers in public offerings of securities and in their relations with their security
holders, and shall retain such firm or another firm reasonably acceptable to the Representative for a period of not less than two (2)
years after the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">3.9. <B><U>Reports to the
Representative</U></B><I>.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">3.9.1. <U>Periodic
Reports, etc</U>. For a period of three (3) years after the date of this Agreement, the Company shall furnish or make available to the
Representative copies of such financial statements and other periodic and special reports as the Company from time to time furnishes generally
to holders of any class of its securities and also promptly furnish to the Representative: (i) a copy of each periodic report the Company
shall be required to file with the Commission under the Exchange Act and the Exchange Act Regulations; (ii) a copy of every press release
and every news item and article with respect to the Company or its affairs which was released by the Company; (iii) a copy of each Form
8-K prepared and filed by the Company; (iv) five copies of each registration statement filed by the Company under the Securities Act;
(v) a copy of each report or other communication furnished to stockholders and (vi) such additional documents and information with respect
to the Company and the affairs of any future subsidiaries of the Company as the Representative may from time to time reasonably request;
provided that the Representative shall sign, if requested by the Company, a Regulation FD compliant confidentiality agreement which is
reasonably acceptable to the Representative and Representative&rsquo;s Counsel in connection with the Representative&rsquo;s receipt of
such information. Documents filed with the Commission pursuant to its EDGAR system or press releases shall be deemed to have been delivered
to the Representative pursuant to this Section 3.9.1. Any documents not filed with the Commission pursuant to its EDGAR system shall be
delivered to the Representative at Notices@think-equity.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">3.9.2. <U>Transfer
Agent; Transfer Sheets</U>. For a period of three (3) years after the date of this Agreement, the Company shall retain a transfer agent
and registrar acceptable to the Representative (the &ldquo;<B>Transfer Agent</B>&rdquo;) and shall furnish to the Representative at the
Company&rsquo;s sole cost and expense such transfer sheets of the Company&rsquo;s securities as the Representative may reasonably request,
including the daily and monthly consolidated transfer sheets of the Transfer Agent and DTC. West Coast Stock Transfer, Inc. is acceptable
to the Representative to act as Transfer Agent for the shares of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">3.9.3. <U>Trading
Reports</U>. During such time as the Public Securities are listed on the Exchange, the Company shall provide to the Representative, at
the Company&rsquo;s expense, such reports published by the Exchange relating to price trading of the Public Securities, as the Representative
shall reasonably request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">3.10. <B><U>Payment of Expenses</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">3.10.1. <U>General
Expenses Relating to the Offering</U>. The Company hereby agrees to pay on each of the Closing Date and the Option Closing Date, if any,
to the extent not paid at the Closing Date, all expenses incident to the performance of the obligations of the Company under this Agreement,
including, but not limited to: (a) all filing fees and communication expenses relating to the securities to be sold in this offering (including
the Option Securities) with the SEC; (b) all filing fees and expenses associated with the review of this offering by FINRA; (c) all fees
and expenses relating to the listing of the securities on the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select
Market, the NYSE or the NYSE American and on such other stock exchanges as the Company and the underwriters together determine, including
any fees charged by The Depository Trust Company (DTC) for new securities; (d) all fees, expenses and disbursements relating to the registration
or qualification of such Shares under the &ldquo;blue sky&rdquo; securities laws of such states, if applicable, and other jurisdictions
as the underwriters may reasonably designate; (e) all fees, expenses and disbursements relating to the registration, qualification or
exemption of such Securities under the securities laws of such foreign jurisdictions as the Representative may reasonably designate; (f)
the costs of all mailing and printing of the offering documents; (g) the costs of preparing, printing and delivering certificates representing
the Offered Shares; (h) fees and expenses of the transfer agent for the securities; (i) stock transfer and/or stamp taxes, if any, payable
upon the transfer of securities from the Company to the Representative; (j) [Intentionally Omitted]; (k) the fees and expenses of the
Company&rsquo;s accountants; (l) the fees and expenses of the Company&rsquo;s legal counsel and other agents and representatives; (m)
the fees and expenses of the underwriters&rsquo; legal counsel not to exceed $75,000; (n) the $15,000 cost associated with the use of
Ipreo&rsquo;s book building, prospectus tracking and compliance software for this offering; (o) [Intentionally Omitted], (p) [Intentionally
Omitted]; and (q) up to $7,500 of the Representative&rsquo;s market making and trading, and clearing firm settlement expenses for this
offering. Such reimbursement shall be paid at each closing (to the extent not paid at a prior closing) from the gross proceeds of the
Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">The Company has
paid to the Representative the sum of $50,000 (the &ldquo;<B>Advance</B>&rdquo;) against fees and expenses of legal counsel and other
out-of-pocket accountable expenses anticipated to be incurred, subject to reimbursement by the Representative to the Company if not actually
incurred, in accordance with FINRA Rule 5110(g)(4)(A) and Rule 5110(g)(5)(A). Such sum shall be credited against the legal fees and expenses
and other out-of-pocket expenses incurred by the Representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">The Company hereby
agrees to pay on each of the Closing Date and the Option Closing Date, if any, to the extent not paid at the Closing Date, to the Representative,
from the gross proceeds of the Offering, for accountable expenses actually incurred by the Representative in connection with the transaction.
The Representative may deduct from the net proceeds of the Offering payable to the Company on the Closing Date, or the Option Closing
Date, if any, the expenses set forth herein to be paid by the Company to the Underwriters, less the Advance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">3.10.2. <U>Non-Accountable
Expense Allowance</U>. The Company further agrees that, on the Closing Date, in addition to the expenses payable pursuant to Section 3.10.1,
it shall pay to the Representative a non-accountable expense allowance equal to one percent (1.0%) of the gross proceeds received by the
Company in the Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">3.11. <B><U>Application of
Net Proceeds</U></B>. The Company shall apply the net proceeds from the Offering received by it in a manner consistent with the application
thereof described under the caption &ldquo;Use of Proceeds&rdquo; in the Registration Statement, the Pricing Disclosure Package and the
Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">3.12. <B><U>Delivery of Earnings
Statements to Security Holders</U></B>. The Company shall make generally available to its security holders as soon as practicable, an
earnings statement covering a period of at least twelve months beginning with the first fiscal quarter of the Company occurring after
the date of this Agreement which shall satisfy the provisions of Section 11(a) of the Securities Act and the rules and regulations of
the Commission thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">3.13. <B><U>Stabilization</U></B>.
Neither the Company nor, to its knowledge, any of its employees, directors or shareholders (without the consent of the Representative)
has taken or shall take, directly or indirectly, any action designed to or that has constituted or that might reasonably be expected to
cause or result in, under Regulation M of the Exchange Act, or otherwise, stabilization or manipulation of the price of any security of
the Company to facilitate the sale or resale of the Public Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">3.14. <B><U>Internal Controls</U></B>.
The Company shall maintain a system of internal accounting controls sufficient to provide reasonable assurances that: (i) transactions
are executed in accordance with management&rsquo;s general or specific authorization; (ii) transactions are recorded as necessary in order
to permit preparation of financial statements in accordance with GAAP and to maintain accountability for assets; (iii) access to assets
is permitted only in accordance with management&rsquo;s general or specific authorization; and (iv) the recorded accountability for assets
is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">3.15. <B><U>Accountants</U></B>.
As of the date of this Agreement, the Company has retained a nationally recognized independent registered public accounting firm, as required
by the Securities Act, the Securities Act Regulations and the PCAOB, reasonably acceptable to the Representative, and the Company shall
continue to retain a nationally recognized independent registered public accounting firm for a period of at least three (3) years after
the date of this Agreement. The Representative acknowledges that the Auditor is acceptable to the Representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">3.16. <B><U>FINRA</U></B>.
The Company shall advise the Representative (who shall make an appropriate filing with FINRA) if it is or becomes aware that (i) any officer
or director of the Company, (ii) any beneficial owner of 5% or more of any class of the Company&rsquo;s securities or (iii) any beneficial
owner of the Company&rsquo;s unregistered equity securities which were acquired during the one hundred and eighty (180) days immediately
preceding the filing of the Registration Statement is or becomes an affiliate or associated person of a FINRA member participating in
the Offering (as determined in accordance with the rules and regulations of FINRA).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">3.17. <B><U>No Fiduciary Duties</U></B>.
The Company acknowledges and agrees that the Underwriters&rsquo; responsibility to the Company is solely contractual in nature and that
none of the Underwriters or their affiliates or any selling agent shall be deemed to be acting in a fiduciary capacity, or otherwise owes
any fiduciary duty to the Company or any of its affiliates in connection with the Offering and the other transactions contemplated by
this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">3.18. <B><U>Company Lock-Up
Agreement</U></B>. The Company, on behalf of itself and any successor entity, agrees that, without the prior written consent of the Representative,
it will not for a period of three (3) months days after the Effective Date (the &ldquo;<B>Lock-Up Period</B>&rdquo;), (i) offer, pledge,
sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant
to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of capital stock of the Company or any securities
convertible into or exercisable or exchangeable for shares of capital stock of the Company; (ii) file or cause to be filed any registration
statement with the Commission relating to the offering of any shares of capital stock of the Company or any securities convertible into
or exercisable or exchangeable for shares of capital stock of the Company other than a registration statement on Form S-4 or Form S-8;
(iii) complete any offering of debt securities of the Company, other than entering into a line of credit with a traditional bank or (iv)
enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership
of capital stock of the Company, whether any such transaction described in clause (i), (ii), (iii) or (iv) above is to be settled by delivery
of shares of capital stock of the Company or such other securities, in cash or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">The restrictions contained
in this Section 3.18 shall not apply to (i) the shares of Common Stock to be sold hereunder, (ii) the issuance by the Company of shares
of Common Stock upon the exercise of a stock option or warrant or the conversion of a security outstanding on the date hereof, which is
disclosed in the Registration Statement, Disclosure Package and Prospectus, provided that such options, warrants, and securities have
not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange
price or conversion price of such securities, (iii) the issuance by the Company of stock options, shares of capital stock of the Company
or other awards under any equity compensation plan of the Company, provided that in each of (ii) and (iii) above, the underlying shares
shall be restricted from sale during the entire Lock-Up Period, (iv) the issuance by the Company of restricted shares of Common Stock
in connection with mergers, acquisitions or joint ventures, provided that such securities are issued as &ldquo;restricted securities&rdquo;
(as defined in Rule 144) and carry no registration rights that require or permit the filing of any registration statement in connection
therewith during the Lock-Up Period, and provided that any such issuance shall only be to a Person (or to the equityholders of a Person)
which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business
of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction
in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing
in securities, and (v) the issuance by the Company of restricted shares of Common Stock to consultants in the Company&rsquo;s ordinary
course of business and not for capital raising transactions and carry no registration rights that require or permit the filing of any
registration statement in connection therewith during the Lock-Up Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">3.19. <B><U>Release of D&amp;O
Lock-up Period</U></B>. If the Representative, in its sole discretion, agrees to release or waive the restrictions set forth in the Lock-Up
Agreements described in Section 2.24 hereof for an officer or director of the Company and provide the Company with notice of the impending
release or waiver at least three (3) Business Days before the effective date of the release or waiver, the Company agrees to announce
the impending release or waiver by a press release substantially in the form of Exhibit C hereto through a major news service at least
two (2) Business Days before the effective date of the release or waiver.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">3.20. <B><U>Blue Sky Qualifications</U></B>.
The Company shall use its commercially reasonable efforts, in cooperation with the Underwriters, if necessary, to qualify the Public Securities
for offering and sale under the applicable securities laws of such states and other jurisdictions (domestic or foreign) as the Representative
may designate and to maintain such qualifications in effect so long as required to complete the distribution of the Public Securities;
provided, however, that the Company shall not be obligated to file any general consent to service of process or to qualify as a foreign
corporation or as a dealer in securities in any jurisdiction in which it is not so qualified or to subject itself to taxation in respect
of doing business in any jurisdiction in which it is not otherwise so subject.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">3.21. <B><U>Reporting Requirements</U></B>.
The Company, during the period when a prospectus relating to the Public Securities is (or, but for the exception afforded by Rule 172,
would be) required to be delivered under the Securities Act, will file all documents required to be filed with the Commission pursuant
to the Exchange Act within the time periods required by the Exchange Act and Exchange Act Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">3.22. <B><U>Reservation of
Common Stock</U></B>. As of the date hereof, the Company has reserved and the Company shall continue to reserve and keep available at
all times, free of pre-emptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company to issue
the Firm Shares, the Option Shares, the Warrant Shares and the Representative&rsquo;s Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">3.23. <B><U>Press Releases</U></B>.
Prior to the Closing Date and any Option Closing Date, the Company shall not issue any press release or other communication directly or
indirectly or hold any press conference with respect to the Company, its condition, financial or otherwise, or earnings, business affairs
or business prospects (except for routine oral marketing communications in the ordinary course of business and consistent with the past
practices of the Company and of which the Representative is notified), without the prior written consent of the Representative, which
consent shall not be unreasonably withheld, unless in the judgment of the Company and its counsel, and after notification to the Representative,
such press release or communication is required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">3.24. <B><U>Sarbanes-Oxley</U></B>.
The Company shall at all times comply in all material respects with all applicable provisions of the Sarbanes-Oxley Act in effect from
time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">3.25. <B><U>IRS Forms</U></B>.
If requested by the Representative, the Company shall deliver to each Underwriter (or its agent), prior to or at the Closing Date, a properly
completed and executed Internal Revenue Service (&ldquo;<B>IRS</B>&rdquo;) Form W-9, together with all required attachments to such form.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">3.26 <B><U>Board Composition
and Board Designations</U></B>. The Company shall ensure that: (i) the qualifications of the persons serving as members of the Board of
Directors and the overall composition of the Board comply with the Sarbanes-Oxley Act, with the Exchange Act and with the listing rules
of the Exchange or any other national securities exchange, as the case may be, in the event the Company seeks to have its Securities listed
on another exchange or quoted on an automated quotation system, and (ii) if applicable, at least one member of the Audit Committee of
the Board of Directors qualifies as an &ldquo;audit committee financial expert,&rdquo; as such term is defined under Regulation S-K and
the listing rules of the Exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Conditions
of Underwriters&rsquo; Obligations</U></B>. The obligations of the Underwriters to purchase and pay for the Public Securities, as provided
herein, shall be subject to (i) the continuing accuracy in all material respects of the representations and warranties of the Company
as of the date hereof and as of each of the Closing Date and the Option Closing Date, if any; (ii) the accuracy of the statements of officers
of the Company made pursuant to the provisions hereof; (iii) the performance by the Company of its obligations hereunder; and (iv) the
following conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">4.1. <B><U>Regulatory Matters</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">4.1.1. <U>Effectiveness
of Registration Statement; Rule 430A Information</U>. The Registration Statement has become effective not later than 5:30 p.m., New York
City time, on the date of this Agreement or such later date and time as shall be consented to in writing by you, and, at each of the Closing
Date and any Option Closing Date, no stop order suspending the effectiveness of the Registration Statement or any post-effective amendment
thereto has been issued under the Securities Act, no order preventing or suspending the use of any Preliminary Prospectus or the Prospectus
has been issued and no proceedings for any of those purposes have been instituted or are pending or, to the Company&rsquo;s knowledge,
contemplated by the Commission. The Company has complied with each request (if any) from the Commission for additional information. The
Prospectus containing the Rule 430A Information shall have been filed with the Commission in the manner and within the time frame required
by Rule 424(b) of the Securities Act Regulations (without reliance on Rule 424(b)(8)) or a post-effective amendment providing such information
shall have been filed with, and declared effective by, the Commission in accordance with the requirements of Rule 430A of the Securities
Act Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">4.1.2. <U>FINRA
Clearance</U>. On or before the date of this Agreement, the Representative shall have received clearance from FINRA as to the amount of
compensation allowable or payable to the Underwriters as described in the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">4.1.3. <U>Exchange
Stock Market Clearance</U>. On the Closing Date, the Public Shares, the Common Warrants and the Warrant Shares shall have been approved
for listing on the Exchange, subject only to official notice of issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">4.2. <B><U>Company Counsel
Matters</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">4.2.1. <U>Closing
Date Opinion of Counsel</U>. On the Closing Date, the Representative shall have received the favorable opinion and negative assurance
letter of McGuireWoods LLP, counsel to the Company (&ldquo;<B>Company Counsel</B>&rdquo;), dated the Closing Date and addressed to the
Representative as representative of the several Underwriters, each in a form and substance reasonably satisfactory to the Representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">4.2.2. <U>Closing
Date Opinion of Nevada Counsel for the Company</U>. On the Closing Date, the Representative shall have received the favorable opinion
of Fennemore Craig, P.C., Nevada counsel to the Company (&ldquo;<B>Nevada Counsel</B>&rdquo;), dated the Closing Date and addressed to
the Representative, in a form reasonably acceptable to the Representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">4.2.3. <U>Opinion
of Special Intellectual Property Counsel for the Company</U>. On the Closing Date, the Representative shall have received the opinions
of Knobbe Martens and Mcdonnell Boehnen Hulbert &amp; Berghoff LLP, as special intellectual property counsel for the Company (&ldquo;<B>IP
Company Counsels</B>&rdquo;), and a written statement providing certain &quot;10b-5&quot; negative assurances, dated the initial Closing
Date and addressed to the Representative, in a form reasonably acceptable to the Representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">4.2.3. <U>Option
Closing Date Opinions of Counsel</U>. On the Option Closing Date, if any, the Representative shall have received the favorable opinion
and negative assurance letter of Company Counsel, the favorable opinion of Nevada Counsel and the favorable opinion of IP Company Counsels,
dated the Option Closing Date, addressed to the Representative as representative of the several Underwriters and in form and substance
reasonably satisfactory to the Representative, confirming as of the Option Closing Date, the opinions rendered and statements made by
such respective counsel on the Closing Date pursuant to Sections 4.2.1, 4.2.2 and 4.2.3, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">4.3. <B><U>Comfort Letters</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">4.3.1. <U>Comfort
Letter</U>. At the time this Agreement is executed, the Representative shall have received a &ldquo;cold comfort letter&rdquo; from the
Auditor containing statements and information of the type customarily included in accountants&rsquo; comfort letters with respect to the
financial statements and certain financial information contained in the Registration Statement, the Pricing Disclosure Package and the
Prospectus, addressed to the Representative as representative of the several Underwriters and in form and substance satisfactory to the
Representative and counsel to the Underwriters, dated as of the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">4.3.2. <U>Bring-down
Comfort Letter</U>. At each of the Closing Date and the Option Closing Date, if any, the Representative shall have received from the Auditor
a letter, dated as of the Closing Date or the Option Closing Date, as applicable, addressed to the Representative as representative of
the several Underwriters and in form and substance reasonably satisfactory to the Representative to the effect that the Auditor reaffirms
the statements made in the letter furnished pursuant to Section 4.3.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">4.4. <B><U>Officers&rsquo;
Certificates</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">4.4.1. <U>Officers&rsquo;
Certificates</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 20pt">(a)</TD><TD STYLE="text-align: justify">The Company shall have delivered to the Representative as representative of the several Underwriters a
certificate, dated the Closing Date and any Option Closing Date (if such date is other than the Closing Date), of its Chief Executive
Officer and its Principal Accounting Officer certifying that (i) such officers have carefully examined the Registration Statement, the
Pricing Disclosure Package, any Issuer Free Writing Prospectus and the Prospectus and, in their opinion, the Registration Statement and
each amendment thereto, as of the Applicable Time and as of the Closing Date (or any Option Closing Date if such date is other than the
Closing Date) did not include any untrue statement of a material fact and did not omit to state a material fact required to be stated
therein or necessary to make the statements therein not misleading, and the Pricing Disclosure Package, as of the Applicable Time and
as of the Closing Date (or any Option Closing Date if such date is other than the Closing Date), any Issuer Free Writing Prospectus as
of its date and as of the Closing Date (or any Option Closing Date if such date is other than the Closing Date), the Prospectus and each
amendment or supplement thereto, as of the respective date thereof and as of the Closing Date, did not include any untrue statement of
a material fact and did not omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances
in which they were made, not misleading, (ii) since the effective date of the Registration Statement, no event has occurred which should
have been set forth in a supplement or amendment to the Registration Statement, the Pricing Disclosure Package or the Prospectus, (iii)
to the best of their knowledge after reasonable investigation, as of the Closing Date (or any Option Closing Date if such date is other
than the Closing Date), the representations and warranties of the Company in this Agreement are true and correct in all material respects
and the Company has complied with all agreements and satisfied all conditions on its part to be performed or satisfied hereunder at or
prior to the Closing Date (or any Option Closing Date if such date is other than the Closing Date), and (iv) there has not been, subsequent
to the date of the most recent audited financial statements included or incorporated by reference in the Pricing Disclosure Package, any
material adverse change in the financial position or results of operations of the Company, or any change or development that, singularly
or in the aggregate, involves a Material Adverse Change, except as set forth in the Prospectus.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: -20pt">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">4.4.2. <U>Secretary&rsquo;s
Certificate</U>. The Company shall have delivered to the Representative as representative of the several Underwriters a certificate, dated
the Closing Date and any Option Closing Date (if such date is other than the Closing Date), of its Secretary certifying: (i) that each
of the Charter and Bylaws is true and complete, has not been modified and is in full force and effect; (ii) that the resolutions of the
Company&rsquo;s Board of Directors relating to the Offering are in full force and effect and have not been modified; (iii) as to the accuracy
and completeness of all correspondence between the Company or its counsel and the Commission; and (iv) as to the incumbency of the officers
of the Company. The documents referred to in such certificate shall be attached as exhibits or annexes to such certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">4.5. <B><U>No Material Changes</U></B>.
Prior to and on each of the Closing Date and each Option Closing Date, if any: (i) there shall have been no Material Adverse Change from
the latest dates as of which such condition is set forth in the Registration Statement, the Pricing Disclosure Package and the Prospectus;
(ii) no action, suit or proceeding, at law or in equity, shall have been pending or threatened against the Company or any Insider before
or by any court or federal or state commission, board or other administrative agency wherein an unfavorable decision, ruling or finding
may reasonably be expected to result in a Material Adverse Change, except as set forth in the Registration Statement, the Pricing Disclosure
Package and the Prospectus; (iii) no stop order shall have been issued under the Securities Act and no proceedings therefor shall have
been initiated or threatened by the Commission; (iv) the Registration Statement, the Pricing Disclosure Package and the Prospectus and
any amendments or supplements thereto shall contain all material statements which are required to be stated therein in accordance with
the Securities Act and the Securities Act Regulations and shall conform in all material respects to the requirements of the Securities
Act and the Securities Act Regulations; (v) the Registration Statement nor any amendment or supplement thereto shall contain any untrue
statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein
not misleading and (vi) the Pricing Disclosure Package nor the Prospectus nor any amendment or supplement thereto shall contain any untrue
statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein,
in the light of the circumstances under which they were made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">4.6. <B><U>No Material Misstatement
or Omission</U></B>. The Underwriters shall not have discovered and disclosed to the Company on or prior to the Closing Date and any Option
Closing Date that the Registration Statement or any amendment or supplement thereto contains an untrue statement of a fact which, in the
opinion of counsel to the Underwriters, is material or omits to state any fact which, in the opinion of such counsel, is material and
is required to be stated therein or is necessary to make the statements therein not misleading, or that the Pricing Disclosure Package,
any Issuer Free Writing Prospectus or the Prospectus or any amendment or supplement thereto contains an untrue statement of fact which,
in the opinion of counsel to the Underwriters, is material or omits to state any fact which, in the opinion of counsel to the Underwriters,
is material and is necessary in order to make the statements, in the light of the circumstances under which they were made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">4.7. <B><U>Corporate Proceedings</U></B>.
All corporate proceedings and other legal matters incident to the authorization, form and validity of each of this Agreement, the Common
Warrants, the Pre-Funded Warrants, the Representative&rsquo;s Warrants, the Representative&rsquo;s Warrant Agreement, the Warrant Agent
Agreement and each Lock-Up Agreement, the Public Securities, the Registration Statement, the Pricing Disclosure Package, each Issuer Free
Writing Prospectus, if any, and the Prospectus and all other legal matters relating to this Agreement, the Common Warrants, the Pre-Funded
Warrants, the Representative&rsquo;s Warrants, the Representative&rsquo;s Warrant Agreement, the Warrant Agent Agreement and each Lock-Up
Agreement and the transactions contemplated hereby and thereby shall be reasonably satisfactory in all material respects to counsel to
the Underwriters, and the Company shall have furnished to such counsel all documents and information that they may reasonably request
to enable them to pass upon such matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">4.8. <B><U>Delivery of Agreements</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">4.8.1. <U>Lock-Up
Agreements</U>. On or before the date of this Agreement, the Company shall have delivered to the Representative executed copies of the
Lock-Up Agreements from each of the Lock-Up Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">4.8.2. <U>Representative&rsquo;s
Warrant Agreement</U>. At the Closing Date, the Representative&rsquo;s Warrant Agreement and, as to each Option Closing Date, if any,
the additional Representative&rsquo;s Warrant Agreement, in definitive form, in such denominations and registered in such names as the
Representative or its designees request, shall have been delivered to the Representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">4.8.3. <U>Pre-Funded
Warrants</U>. On or before each of the Closing Date and the Option Closing Date, if any, the Company shall have delivered to the Representative
executed copies of the Firm Pre-Funded Warrants and the Option Pre-Funded Warrants, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">4.8.4. <U>Warrant
Agent Agreement</U>. At the Closing Date, the Company shall have delivered to the Representative an executed copy of the Warrant Agent
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">4.9. <B><U>Additional Documents</U></B>.
At the Closing Date and at each Option Closing Date (if any) counsel to the Underwriters shall have been furnished with such documents
and opinions as they may require for the purpose of enabling counsel to the Underwriters to deliver an opinion to the Underwriters, or
in order to evidence the accuracy of any of the representations or warranties, or the fulfillment of any of the conditions, herein contained;
and all proceedings taken by the Company in connection with the issuance and sale of the Public Securities as herein contemplated shall
be satisfactory in form and substance to the Representative and counsel to the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5. <B><U>Indemnification</U>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">5.1. <B><U>Indemnification
of the Underwriters</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">5.1.1. <U>General</U>.
Subject to the conditions set forth below, the Company agrees to indemnify and hold harmless each Underwriter, its affiliates and each
of its and their respective directors, officers, members, employees, representatives, partners, shareholders, affiliates, counsel, and
agents and each person, if any, who controls any such Underwriter within the meaning of Section 15 of the Securities Act or Section 20
of the Exchange Act (collectively the &ldquo;<B>Underwriter Indemnified Parties</B>,&rdquo; and each an &ldquo;<B>Underwriter Indemnified
Party</B>&rdquo;), against any and all loss, liability, claim, damage and expense whatsoever (including but not limited to any and all
legal or other expenses reasonably incurred in investigating, preparing or defending against any litigation, commenced or threatened,
or any claim whatsoever, whether arising out of any action between any of the Underwriter Indemnified Parties and the Company or between
any of the Underwriter Indemnified Parties and any third party, or otherwise) to which they or any of them may become subject under the
Securities Act, the Exchange Act or any other statute or at common law or otherwise or under the laws of foreign countries (a &ldquo;<B>Claim</B>&rdquo;),
(i) arising out of or based upon any untrue statement or alleged untrue statement of a material fact contained in (A) the Registration
Statement, the Pricing Disclosure Package, any Preliminary Prospectus, the Prospectus, or in any Issuer Free Writing Prospectus or in
any Written Testing-the-Waters Communication (as from time to time each may be amended and supplemented); (B) any materials or information
provided to investors by, or with the approval of, the Company in connection with the marketing of the Offering, including any &ldquo;road
show&rdquo; or investor presentations made to investors by the Company (whether in person or electronically); or (C) any application or
other document or written communication (in this Section 5, collectively called &ldquo;application&rdquo;) executed by the Company or
based upon written information furnished by the Company in any jurisdiction in order to qualify the Public Securities and Representative&rsquo;s
Securities under the securities laws thereof or filed with the Commission, any state securities commission or agency, the Exchange or
any other national securities exchange; or the omission or alleged omission therefrom of a material fact required to be stated therein
or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, unless such
statement or omission was made in reliance upon, and in conformity with, the Underwriters&rsquo; Information or (ii) otherwise arising
in connection with or allegedly in connection with the Offering. The Company also agrees that it will reimburse each Underwriter Indemnified
Party for all fees and expenses (including but not limited to any and all legal or other expenses reasonably incurred in investigating,
preparing or defending against any litigation, commenced or threatened, or any claim whatsoever, whether arising out of any action between
any of the Underwriter Indemnified Parties and the Company or between any of the Underwriter Indemnified Parties and any third party,
or otherwise) (collectively, the &ldquo;<B>Expenses</B>&rdquo;), and further agrees wherever and whenever possible to advance payment
of Expenses as they are incurred by an Underwriter Indemnified Party in investigating, preparing, pursuing or defending any Claim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">5.1.2. <U>Procedure.</U>
If any action is brought against an Underwriter Indemnified Party in respect of which indemnity may be sought against the Company pursuant
to Section 5.1.1, such Underwriter Indemnified Party shall promptly notify the Company in writing of the institution of such action and
the Company shall assume the defense of such action, including the employment and fees of counsel (subject to the approval of such Underwriter
Indemnified Party) and payment of actual expenses if an Underwriter Indemnified Party requests that the Company do so. Such Underwriter
Indemnified Party shall have the right to employ its or their own counsel in any such case, but the fees and expenses of such counsel
shall be at the expense of the Company, and shall be advanced by the Company; provided however, that the Company shall not be obligated
to bear the reasonable fees and expenses of more than one firm of attorneys selected by the Underwriter Indemnified Party (in addition
to any local counsel). The Company shall not be liable for any settlement of any action effected without its consent (which shall not
be unreasonably withheld). In addition, the Company shall not, without the prior written consent of the Underwriters, settle, compromise
or consent to the entry of any judgment in or otherwise seek to terminate any pending or threatened action in respect of which advancement,
reimbursement, indemnification or contribution may be sought hereunder (whether or not such Underwriter Indemnified Party is a party thereto)
unless such settlement, compromise, consent or termination (i) includes an unconditional release of each Underwriter Indemnified Party,
acceptable to such Underwriter Indemnified Party, from all liabilities, expenses and claims arising out of such action for which indemnification
or contribution may be sought and (ii) does not include a statement as to or an admission of fault, culpability or a failure to act, by
or on behalf of any Underwriter Indemnified Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">5.2. <B><U>Indemnification
of the Company</U></B>. Each Underwriter, severally and not jointly, agrees to indemnify and hold harmless the Company, its directors,
its officers who signed the Registration Statement and persons who control the Company within the meaning of Section 15 of the Securities
Act or Section 20 of the Exchange Act against any and all loss, liability, claim, damage and expense described in the foregoing indemnity
from the Company to the several Underwriters, as incurred, but only with respect to untrue statements or omissions made in the Registration
Statement, any Preliminary Prospectus, the Pricing Disclosure Package or Prospectus or any amendment or supplement thereto or in any application,
in reliance upon, and in strict conformity with, the Underwriters&rsquo; Information. In case any action shall be brought against the
Company or any other person so indemnified based on any Preliminary Prospectus, the Registration Statement, the Pricing Disclosure Package
or Prospectus or any amendment or supplement thereto or any application, and in respect of which indemnity may be sought against any Underwriter,
such Underwriter shall have the rights and duties given to the Company, and the Company and each other person so indemnified shall have
the rights and duties given to the several Underwriters by the provisions of Section 5.1.2. The Company agrees promptly to notify the
Representative of the commencement of any litigation or proceedings against the Company or any of its officers, directors or any person,
if any, who controls the Company within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, in connection
with the issuance and sale of the Public Securities or in connection with the Registration Statement, the Pricing Disclosure Package,
the Prospectus, or any Issuer Free Writing Prospectus or any written Testing-the-Waters Communication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">5.3. <B><U>Contribution</U></B><I>.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">5.3.1. <U>Contribution
Rights</U>. If the indemnification provided for in this Section 5 shall for any reason be unavailable to or insufficient to hold harmless
an indemnified party under Section 5.1 or 5.2 in respect of any loss, claim, damage or liability, or any action in respect thereof, referred
to therein, then each indemnifying party shall, in lieu of indemnifying such indemnified party, contribute to the amount paid or payable
by such indemnified party as a result of such loss, claim, damage or liability, or action in respect thereof, (i) in such proportion as
shall be appropriate to reflect the relative benefits received by the Company, on the one hand, and the Underwriters, on the other, from
the Offering of the Public Securities, or (ii) if the allocation provided by clause (i) above is not permitted by applicable law, in such
proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) above but also the relative fault of
the Company, on the one hand, and the Underwriters, on the other, with respect to the statements or omissions that resulted in such loss,
claim, damage or liability, or action in respect thereof, as well as any other relevant equitable considerations. The relative benefits
received by the Company, on the one hand, and the Underwriters, on the other, with respect to such Offering shall be deemed to be in the
same proportion as the total net proceeds from the Offering of the Public Securities purchased under this Agreement (before deducting
expenses) received by the Company, as set forth in the table on the cover page of the Prospectus, on the one hand, and the total underwriting
discounts and commissions received by the Underwriters with respect to the securities purchased under this Agreement, as set forth in
the table on the cover page of the Prospectus, on the other hand. The relative fault shall be determined by reference to whether the untrue
or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to information supplied
by the Company or the Underwriters, the intent of the parties and their relative knowledge, access to information and opportunity to correct
or prevent such statement or omission. The Company and the Underwriters agree that it would not be just and equitable if contributions
pursuant to this Section 5.3.1 were to be determined by pro rata allocation (even if the Underwriters were treated as one entity for such
purpose) or by any other method of allocation that does not take into account the equitable considerations referred to herein. The amount
paid or payable by an indemnified party as a result of the loss, claim, damage or liability, or action in respect thereof, referred to
above in this Section 5.3.1 shall be deemed to include, for purposes of this Section 5.3.1, any legal or other expenses reasonably incurred
by such indemnified party in connection with investigating or defending any such action or claim. Notwithstanding the provisions of this
Section 5.3.1 in no event shall an Underwriter be required to contribute any amount in excess of the amount by which the total underwriting
discounts and commissions received by such Underwriter with respect to the Offering of the Public Securities exceeds the amount of any
damages that such Underwriter has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged
omission. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled
to contribution from any person who was not guilty of such fraudulent misrepresentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">5.3.2. <U>Contribution
Procedure</U>. Within fifteen (15) days after receipt by any party to this Agreement (or its representative) of notice of the commencement
of any action, suit or proceeding, such party will, if a claim for contribution in respect thereof is to be made against another party
(&ldquo;<B>contributing party</B>&rdquo;), notify the contributing party of the commencement thereof, but the failure to so notify the
contributing party will not relieve it from any liability which it may have to any other party other than for contribution hereunder.
In case any such action, suit or proceeding is brought against any party, and such party notifies a contributing party or its representative
of the commencement thereof within the aforesaid fifteen (15) days, the contributing party will be entitled to participate therein with
the notifying party and any other contributing party similarly notified. Any such contributing party shall not be liable to any party
seeking contribution on account of any settlement of any claim, action or proceeding affected by such party seeking contribution on account
of any settlement of any claim, action or proceeding affected by such party seeking contribution without the written consent of such contributing
party. The contribution provisions contained in this Section 5.3.2 are intended to supersede, to the extent permitted by law, any right
to contribution under the Securities Act, the Exchange Act or otherwise available. Each Underwriter&rsquo;s obligations to contribute
pursuant to this Section 5.3 are several and not joint.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6. <B><U>Default by an Underwriter</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">6.1. <B><U>Default Not Exceeding
10% of Firm Securities or Option Securities</U></B>. If any Underwriter or Underwriters shall default in its or their obligations to purchase
the Firm Securities or the Option Securities, if the Over-allotment Option is exercised hereunder, and if the number of the Firm Securities
or Option Securities with respect to which such default relates does not exceed in the aggregate 10% of the number of Firm Securities
or Option Securities that all Underwriters have agreed to purchase hereunder, then such Firm Securities or Option Securities to which
the default relates shall be purchased by the non-defaulting Underwriters in proportion to their respective commitments hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">6.2. <B><U>Default Exceeding
10% of Firm Securities or Option Securities</U></B>. In the event that the default addressed in Section 6.1 relates to more than 10% of
the Firm Securities or Option Securities, you may in your discretion arrange for yourself or for another party or parties to purchase
such Firm Securities or Option Securities to which such default relates on the terms contained herein. If, within one (1) Business Day
after such default, you do not arrange for the purchase of such Firm Securities or Option Securities, then the Company shall be entitled
to a further period of one (1) Business Day within which to procure another party or parties satisfactory to you to purchase said Firm
Securities or Option Securities on such terms. In the event that neither you nor the Company arrange for the purchase of the Firm Securities
or Option Securities to which a default relates as provided in this Section 6, this Agreement will automatically be terminated by you
or the Company without liability on the part of the Company (except as provided in Sections 3.10 and 5 hereof) or the several Underwriters
(except as provided in Section 5 hereof); <I>provided</I>, <I>however</I>, that if such default occurs with respect to the Option Securities,
this Agreement will not terminate as to the Firm Securities; and <I>provided</I>, <I>further</I>, that nothing herein shall relieve a
defaulting Underwriter of its liability, if any, to the other Underwriters and to the Company for damages occasioned by its default hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">6.3. <B><U>Postponement of
Closing Date</U></B>. In the event that the Firm Securities or Option Securities to which the default relates are to be purchased by the
non-defaulting Underwriters, or are to be purchased by another party or parties as aforesaid, you or the Company shall have the right
to postpone the Closing Date or Option Closing Date for a reasonable period, but not in any event exceeding five (5) Business Days, in
order to effect whatever changes may thereby be made necessary in the Registration Statement, the Pricing Disclosure Package or the Prospectus
or in any other documents and arrangements, and the Company agrees to file promptly any amendment to the Registration Statement, the Pricing
Disclosure Package or the Prospectus that in the opinion of counsel for the Underwriter may thereby be made necessary. The term &ldquo;Underwriter&rdquo;
as used in this Agreement shall include any party substituted under this Section 6 with like effect as if it had originally been a party
to this Agreement with respect to the Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7. <B><U>Additional Covenants</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">7.1. <B><U>Board Composition
and Board Designations</U></B>. The Company shall ensure that: (i) the qualifications of the persons serving as members of the Board of
Directors and the overall composition of the Board comply with the Sarbanes-Oxley Act, with the Exchange Act and with the listing rules
of the Exchange or any other national securities exchange, as the case may be, in the event the Company seeks to have its Common Stock
and the Common Warrants listed on another exchange or quoted on an automated quotation system, and (ii) if applicable, at least one member
of the Audit Committee of the Board of Directors qualifies as an &ldquo;audit committee financial expert,&rdquo; as such term is defined
under Regulation S-K and the listing rules of the Exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">7.2. <B><U>Prohibition on
Press Releases and Public Announcements</U></B>. For a period ending at 5:00 p.m., New York time, on the first (1st) Business Day following
the fortieth (40th) day after the Closing Date, the Company shall not issue press releases or engage in any other publicity without the
Representative&rsquo;s prior written consent, which consent shall not unreasonable be withheld or delayed; provided that the Representative&rsquo;s
consent shall not be required with regard to any press release or other public disclosure that is required by law or any normal and customary
press release or any other publicity issued in the ordinary course of the Company&rsquo;s business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">8. <B><U>Effective Date and Termination</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">8.1. <B><U>Effective Date</U></B>.
This Agreement shall become effective when both the Company and the Representative have executed the same and delivered counterparts of
such signatures to the other party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">8.2. <B><U>Termination</U></B>.
The Representative shall have the right to terminate this Agreement at any time prior to any Closing Date, (i) if any domestic or international
event or act or occurrence has materially disrupted, or in your reasonable judgment will in the immediate future materially disrupt, general
securities markets in the United States; or (ii) if trading on the New York Stock Exchange or the Nasdaq Stock Market LLC shall have been
suspended or materially limited, or minimum or maximum prices for trading shall have been fixed, or maximum ranges for prices for securities
shall have been required by FINRA or by order of the Commission or any other government authority having jurisdiction; or (iii) if the
United States shall have become involved in a new war or an increase in major hostilities; or (iv) if a banking moratorium has been declared
by an authority of the State of New York State or by a federal authority of the United States of America; or (v) if a moratorium on foreign
exchange trading has been declared which materially adversely impacts the United States securities markets; or (vi) if the Company shall
have sustained a material loss by fire, flood, accident, hurricane, earthquake, theft, sabotage or other calamity or malicious act which,
whether or not such loss shall have been insured, will, in your reasonable judgment, make it inadvisable to proceed with the delivery
of the Firm Securities or Option Securities; or (vii) if the Company is in material breach of any of its representations, warranties or
covenants hereunder; or (viii) if, prior to the Closing Date, the Public Shares, the Common Warrants and the Warrant Shares have not been
approved for listing on the Exchange, the Company has taken any action designed to, or likely to have the effect of, delisting shares
of the Company&rsquo;s Common Stock from the Exchange, or the Company has received any notification that the Exchange is contemplating
terminating such listing; or (ix) if the Representative shall have become aware after the date hereof of such a material adverse change
in the conditions or prospects of the Company, or such adverse material change in the securities market, or any event, act or occurrence
that has materially disrupted, or in the opinion of the Representative, will in the future materially disrupt, the securities market,
or there shall be such a material adverse change in general financial, political or economic conditions or the effect of international
conditions on the financial markets in the United States is such as to make it, in the judgment of the Representative, inadvisable or
impracticable to proceed with the offering, sale and/or delivery of the Public Securities or to enforce contracts made by the Underwriters
for the sale of the Public Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">8.3. <B><U>Expenses</U></B>.
Notwithstanding anything to the contrary in this Agreement, except in the case of a default by the Underwriters, pursuant to Section 6.2
above, in the event that this Agreement shall be terminated for any reason whatsoever, within the time specified herein or any extensions
thereof pursuant to the terms herein, the Company shall be obligated to pay to the Underwriters their actual and accountable out-of-pocket
and documented expenses related to the transactions contemplated herein then due and payable (including the fees and disbursements of
counsel to the Underwriters) up to $125,000, inclusive of the Advance, and upon demand the Company shall pay the full amount thereof to
the Representative on behalf of the Underwriters; provided, however, that such expense cap in no way limits or impairs the indemnification
and contribution provisions of this Agreement. Notwithstanding the foregoing, any Advance received by the Representative will be reimbursed
to the Company to the extent not actually incurred in compliance with FINRA Rule 5110(g)(4)(A).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">8.4. <B><U>Indemnification</U></B>.
Notwithstanding any contrary provision contained in this Agreement, any election hereunder or any termination of this Agreement, and whether
or not this Agreement is otherwise carried out, the provisions of Section 5 shall remain in full force and effect and shall not be in
any way affected by, such election or termination or failure to carry out the terms of this Agreement or any part hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">8.5. <B><U>Representations,
Warranties, Agreements to Survive</U></B>. All representations, warranties and agreements contained in this Agreement or in certificates
of officers of the Company submitted pursuant hereto, shall remain operative and in full force and effect regardless of (i) any investigation
made by or on behalf of any Underwriter or its Affiliates or selling agents, any person controlling any Underwriter, its officers or directors
or any person controlling the Company or (ii) delivery of and payment for the Public Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">9. <B><U>Miscellaneous</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">9.1. <B><U>Notices</U></B>.
All communications hereunder, except as herein otherwise specifically provided, shall be in writing and shall be mailed (registered or
certified mail, return receipt requested), personally delivered or sent by electronic mail transmission and confirmed and shall be deemed
given when so delivered and confirmed or if mailed, two (2) days after such mailing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">If to the Representative:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">ThinkEquity LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">17 State Street,
41<SUP>st</SUP> Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">New York, NY 10004</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">Attention: Head
of Investment Banking</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">E-mail: notices@think-equity.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">with a copy (which shall not
constitute notice) to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">Sheppard, Mullin,
Richter &amp; Hampton LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">30 Rockefeller Plaza,
39<SUP>th</SUP> Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">New York, New York
10112</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">Attn: Jeffrey Fessler
and Stephen Cohen</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">e-mail: jfessler@sheppardmullin.com
and scohen@sheppardmullin.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">If to the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">BioVie Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">680 W Nye Lane,
Suite 201</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">Carson City, Nevada
89703</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">Attention: Cuong
Do, Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">with a copy (which shall not
constitute notice) to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-indent: 40pt">McGuireWoods LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-indent: 40pt">1251 6th Ave 20th Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-indent: 40pt">New York, NY 10020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-indent: 40pt">Attn: Stephen Older and Carly Ginley</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-indent: 40pt">e-mail: solder@mcguirewoods.com and cginley@mcguirewoods.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">9.2. <B><U>Headings</U><I>.
</I></B>The headings contained herein are for the sole purpose of convenience of reference, and shall not in any way limit or affect the
meaning or interpretation of any of the terms or provisions of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">9.3. <B><U>Amendment</U></B>.
This Agreement may only be amended by a written instrument executed by each of the parties hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">9.4. <B><U>Entire Agreement</U></B>.
This Agreement (together with the other agreements and documents being delivered pursuant to or in connection with this Agreement) constitutes
the entire agreement of the parties hereto with respect to the subject matter hereof and thereof and supersedes all prior agreements and
understandings of the parties, oral and written, with respect to the subject matter hereof. Notwithstanding anything herein to the contrary,
the Engagement Agreement, dated May 2, 2025 (&ldquo;<B>Engagement Agreement</B>&rdquo;), between the Company and the Representative shall
continue to be effective and the terms therein shall continue to survive and be enforceable by the Representative in accordance with its
terms, provided that, in the event of a conflict between the terms of the Engagement Agreement and this Agreement, the terms of this Agreement
shall prevail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">9.5. <B><U>Binding Effect</U></B>.
This Agreement shall inure solely to the benefit of and shall be binding upon the Representative, the Underwriters, the Company and the
controlling persons, directors and officers referred to in Section 5 hereof, and their respective successors, legal representatives, heirs
and assigns, and no other person shall have or be construed to have any legal or equitable right, remedy or claim under or in respect
of or by virtue of this Agreement or any provisions herein contained. The term &ldquo;successors and assigns&rdquo; shall not include
a purchaser, in its capacity as such, of securities from any of the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">9.6. <B><U>Governing Law;
Consent to Jurisdiction</U></B>. This Agreement shall be governed by and construed in accordance with the laws of the State of New York.
The Company hereby agrees that any action, proceeding or claim against it arising out of, or relating in any way to this Agreement shall
be brought and enforced in the Supreme Court of the State of New York, sitting in the City and County of New York, or in the United States
District Court for the Southern District of New York, and irrevocably submits to such jurisdiction, which jurisdiction shall be exclusive.
The Company hereby waives any objection to such exclusive jurisdiction and that such courts represent an inconvenient forum. Any such
process or summons to be served upon the Company may be served by transmitting a copy thereof by registered or certified mail, return
receipt requested, postage prepaid, addressed to it at the address set forth in Section 9.1 hereof. Such mailing shall be deemed personal
service and shall be legal and binding upon the Company in any action, proceeding or claim. The Company agrees that the prevailing party(ies)
in any such action shall be entitled to recover from the other party(ies) all of its reasonable attorneys&rsquo; fees and expenses relating
to such action or proceeding and/or incurred in connection with the preparation therefor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>


<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">9.7. <B><U>Waiver of Trial
by Jury</U></B>. The Company (on its behalf and, to the extent permitted by applicable law, on behalf of its stockholders and affiliates)
and each of the Underwriters hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial
by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">9.8 <B><U>Execution in Counterparts</U></B>.
This Agreement may be executed in one or more counterparts, and by the different parties hereto in separate counterparts, each of which
shall be deemed to be an original, but all of which taken together shall constitute one and the same agreement and shall become effective
when one or more counterparts has been signed by each of the parties hereto and delivered to each of the other parties hereto. Delivery
of a signed counterpart of this Agreement by facsimile or email/pdf transmission shall constitute valid and sufficient delivery thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">9.9. <B><U>Waiver, etc</U></B>.
The failure of any of the parties hereto to at any time enforce any of the provisions of this Agreement shall not be deemed or construed
to be a waiver of any such provision, nor to in any way effect the validity of this Agreement or any provision hereof or the right of
any of the parties hereto to thereafter enforce each and every provision of this Agreement. No waiver of any breach, non-compliance or
non-fulfillment of any of the provisions of this Agreement shall be effective unless set forth in a written instrument executed by the
party or parties against whom or which enforcement of such waiver is sought; and no waiver of any such breach, non-compliance or non-fulfillment
shall be construed or deemed to be a waiver of any other or subsequent breach, non-compliance or non-fulfillment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">9.10 <B><U>Research Analyst
Independence</U></B>. The Company acknowledges that the Underwriters&rsquo; research analysts and research departments are required to
be independent from its investment banking division and are subject to certain regulations and internal policies, and that the Underwriters&rsquo;
research analysts may hold views and make statements or investment recommendations and/or publish research reports with respect to the
Company and/or the Offering that differ from the views of their investment banking division. The Company acknowledges that the Underwriters
are a full service securities firm and as such from time to time, subject to applicable securities laws, rules and regulations, may effect
transactions for its own account or the account of its customers and hold long or short positions in debt or equity securities of the
Company; provided, however, that nothing in this Section shall relieve the Underwriters of any responsibility or liability it may otherwise
bear in connection with activities in violation of applicable securities laws, rules or regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature Page Follows]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">If the foregoing correctly
sets forth the understanding between the Underwriters and the Company, please so indicate in the space provided below for that purpose,
whereupon this letter shall constitute a binding agreement between us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Very truly yours,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>BIOVIE INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Cuong Do</FONT></TD>
    <TD STYLE="width: 58%; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Cuong Do</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: President and Chief Executive Officer</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Confirmed as of the date first above written</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">on behalf of itself and as Representative of the
several</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Underwriters named on Schedule 1 hereto:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>THINKEQUITY LLC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Kevin Mangan</FONT></TD>
    <TD STYLE="width: 58%; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Kevin Mangan</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Managing Director, Head of Equity Syndicate</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Signature Page to Underwriting Agreement </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>between BioVie Inc. and ThinkEquity LLC, </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>as representative of the Underwriters named
herein</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE 1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">Underwriter</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Number of<BR> Firm Units</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>to be Purchased</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Number of Firm</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pre-Funded Units</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>to be purchased</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 66%; font-weight: bold; text-align: left">ThinkEquity LLC</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; font-weight: bold; text-align: right">5,620,000</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; font-weight: bold; text-align: right">380,000</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 3.5pt">TOTAL</TD><TD STYLE="font-weight: bold; padding-bottom: 3.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 3.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 3.5pt double; font-weight: bold; text-align: right">5,620,000</TD><TD STYLE="padding-bottom: 3.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 3.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 3.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 3.5pt double; font-weight: bold; text-align: right">380,000</TD><TD STYLE="padding-bottom: 3.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 38; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE 2-A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pricing Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 85%; text-align: justify">Number of Firm Units:</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">5,620,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Number of Firm Pre-Funded Units:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">380,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Number of Option Shares:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">900,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Number of Option Pre-Funded Warrants:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">900,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Number of Option Common Warrants:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">900,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Public Offering Price per Firm Unit:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Public Offering Price per Firm Pre-Funded Unit:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.9999</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Public Offering Price per Option Share:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.999</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Public Offering Price per Option Pre-Funded Warrant:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.9989</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Public Offering Price per Option Common Warrant:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.001</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Underwriting Discount per Firm Unit:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.14</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Underwriting Discount per Firm Pre-Funded Unit:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.14</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Underwriting Discount per Option Share:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.139</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Underwriting Discount per Option Pre-Funded Warrant:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.139</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Underwriting Discount per Option Common Warrant:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.00007</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Proceeds to Company per Firm Unit (before expenses):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.86</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Proceeds to Company per Firm Pre-Funded Unit (before expenses):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.86</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Proceeds to Company per Option Share (before expenses):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.859</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Proceeds to Company per Option Pre-Funded Warrant (before expenses):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.859</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Proceeds to Company per Option Common Warrant (before expenses):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.0009</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE 2-B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Issuer General Use Free Writing Prospectus</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>None</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE 3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>List of Lock-Up Parties</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jim Lang</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cuong Do</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Michael Sherman</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sigmund Rogich</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Joanne Wendy Kim</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Joseph M. Palumbo</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Kameel Farag</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Amy Chappell</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U></U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form of Representative&rsquo;s Warrant Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">THE REGISTERED HOLDER OF THIS PURCHASE WARRANT
BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT EXCEPT AS HEREIN PROVIDED AND THE REGISTERED
HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT FOR A PERIOD
OF ONE HUNDRED EIGHTY (180) DAYS FOLLOWING THE EFFECTIVE DATE (DEFINED BELOW) TO ANYONE OTHER THAN (I) THINKEQUITY LLC OR AN UNDERWRITER
OR A SELECTED DEALER IN CONNECTION WITH THE OFFERING, OR (II) A BONA FIDE OFFICER OR PARTNER OF THINKEQUITY LLC OR OF ANY SUCH UNDERWRITER
OR SELECTED DEALER.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">THIS PURCHASE WARRANT IS NOT EXERCISABLE PRIOR
TO AUGUST 11, 2025. VOID AFTER 5:00 P.M., EASTERN TIME ON AUGUST 11, 2030.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>COMMON STOCK PURCHASE WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the Purchase of [&#9679;] Shares of Common
Stock,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Par Value $0.0001 per Share,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">BioVie Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">1. <U>Purchase Warrant</U>.
THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of ThinkEquity LLC (&ldquo;<B>Holder</B>&rdquo;), as registered
owner of this Purchase Warrant, BioVie Inc., a Nevada corporation (the &ldquo;<B>Company</B>&rdquo;), Holder is entitled, at any time
or from time to time from August 11, 2025 (the &ldquo;<B>Commencement Date</B>&rdquo;), and at or before 5:00 p.m., New York City time,
August 11, 2030 (the &ldquo;<B>Expiration Date</B>&rdquo;), but not thereafter, to subscribe for, purchase and receive, in whole or in
part, up to [&#9679;] shares of common stock of the Company, par value $0.0001 per share (the &ldquo;<B>Shares</B>&rdquo;), subject to
adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions in the State of New York are
authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance
with the terms hereof. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate
this Purchase Warrant. This Purchase Warrant is initially exercisable at $2.50 per Share; <I>provided, however</I>, that upon the occurrence
of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share
and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term &ldquo;<B>Exercise Price</B>&rdquo;
shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term &ldquo;<B>Effective Date</B>&rdquo;
shall mean August 7, 2025, the date on which the Registration Statement on Form S-1 (File No. 333-288525) of the Company was declared
effective by the Securities and Exchange Commission (the &ldquo;<B>Commission</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">2. <U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">2.1 <U>Exercise Form</U>.
In order to exercise this Purchase Warrant, the exercise form attached hereto (the &ldquo;<B>Notice of Exercise</B>&rdquo;) must be duly
executed and completed and delivered to the Company, together with this Purchase Warrant and payment of the Exercise Price for the Shares
being purchased payable in cash by wire transfer of immediately available funds to an account designated by the Company or by certified
check or official bank check unless the cashless exercise procedure specified in Section 2.2 below is specified in the applicable Notice
of Exercise. If the subscription rights represented hereby shall not be exercised at or before 5:00 p.m., Eastern time, on the Expiration
Date, this Purchase Warrant shall become and be void without further force or effect, and all rights represented hereby shall cease and
expire. Each exercise hereof shall be irrevocable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">2.2 <U>Cashless Exercise</U>.
In lieu of exercising this Purchase Warrant by payment by wire transfer or cashier's check pursuant to Section 2.1 above, this Purchase
Warrant may also be exercised, in whole or in part, at such time by means of a &quot;cashless exercise&quot; in which the Holder shall
be entitled to receive the number of Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>


<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 40pt"></TD><TD STYLE="width: 20pt">(A)</TD><TD STYLE="text-align: justify">= as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice
of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2.1 hereof on a day that is not a Trading
Day or (2) both executed and delivered pursuant to Section 2.1 hereof on a Trading Day prior to the opening of &quot;regular trading hours&quot;
(as defined in Rule 600(b)(64) of Regulation NMS promulgated under the federal securities laws, &ldquo;Regular Trading Hours&rdquo;) on
such Trading Day, (ii) at the option of the Holder, either (x) the VWAP on the Trading Day immediately preceding the date of the applicable
Notice of Exercise or (y) the Bid Price of the Shares on the principal Trading Market as reported by Bloomberg L.P. as of the time of
the Holder's execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &quot;regular trading hours&quot;
on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of Regular Trading Hours
on a Trading Day) pursuant to Section 2(a) hereof, which Bid Price shall be shown on supporting documents provided by the Holder to the
Company within two (2) Trading Days of delivery of the Notice of Exercise or (iii) the VWAP on the date of the applicable Notice of Exercise
if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section
2(a) hereof after the close of Regular Trading Hours on such Trading Day;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60pt; text-align: justify; text-indent: -20pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 40pt"></TD><TD STYLE="width: 20pt">(B)</TD><TD STYLE="text-align: justify">= the Exercise Price of this Purchase Warrant, as adjusted hereunder; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60pt; text-align: justify; text-indent: -20pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 40pt"></TD><TD STYLE="width: 20pt; text-align: left">(X)</TD><TD STYLE="text-align: justify">= the number of Shares that would be issuable upon exercise of
this Purchase Warrant in accordance with the terms of this Purchase Warrant if such exercise were by means of a cash exercise rather
than a cashless exercise.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -21.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">If Shares are issued in such
a &ldquo;cashless exercise&rdquo;, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act of
1933, as amended (the &ldquo;<B>Securities Act</B>&rdquo;), the Shares shall take on the securities law characteristics of the Purchase
Warrants being exercised, and the holding period of the Purchase Warrants being exercised may be tacked on to the holding period of the
Shares. The Company agrees not to take any position contrary to this Section 2.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&ldquo;<B>Bid Price&rdquo;</B>
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Shares are then listed or quoted
on a Trading Market, the bid price of the Shares for the time in question (or the nearest preceding date) on the Trading Market on which
the Shares are then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02
p.m. (New York City time)), (b) if the Shares are then quoted on the OTCQB or the OTCQX but not listed on any Trading Market, the volume
weighted average price of a Share for such date (or the nearest preceding date) on the OTCQB or OTCQX as applicable, (c) if the Shares
are not then listed or quoted for trading on any of a Trading Market, the OTCQB or the OTCQX and if prices for the Shares are then reported
on the OTC Pink Open Market or successors thereto (or a similar organization or agency succeeding to its functions of reporting prices),
the most recent bid price per Share so reported, or (d) in all other cases, the fair market value of the Shares as determined by an independent
appraiser selected in good faith by the Holder and reasonably acceptable to the Company, the fees and expenses of which shall be paid
by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&ldquo;<B>Trading Day</B>&rdquo;
means a day on which the Trading Market is open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&ldquo;<B>Trading Market&rdquo;</B>
means any of the following markets or exchanges on which the Shares are listed or quoted for trading on the date in question: the NYSE
American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange or any successors
to any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&ldquo;<B>VWAP</B>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Shares are then listed or quoted
on a Trading Market, the daily volume weighted average price of the Shares for such date (or the nearest preceding date) on the Trading
Market on which the Shares are then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City
time) to 4:02 p.m. (New York City time)), (b) if the Shares are then quoted on the OTCQB or the OTCQX but not listed on any Trading Market,
the volume weighted average price of a Share for such date (or the nearest preceding date) on the OTCQB or the OTCQX as applicable, (c)
if Shares are not then listed or quoted for trading on the OTCQB or the OTCQX and if prices for the Shares are then reported on the OTC
Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the daily volume weighted average
price of the Shares for such date (or the nearest preceding date), or (d) in all other cases, the fair market value of the Shares as determined
by an independent appraiser selected in good faith by the Holder and reasonably acceptable to the Company, the fees and expenses of which
shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>


<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">2.3 <U>Mechanics of Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">2.3.1 <U>Delivery
of Shares Upon Exercise</U>. The Company shall cause the Shares purchased hereunder to be transmitted by its transfer agent to the Holder
by crediting the account of the Holder's or its designee's balance account with The Depository Trust Company through its Deposit or Withdrawal
at Custodian system (&quot;<B>DWAC</B>&quot;) if the Company is then a participant in such system and either (A) there is an effective
registration statement permitting the issuance of the Shares to or resale of the Shares by Holder, or (B) the Shares are eligible for
resale by the Holder without volume or manner-of-sale limitations pursuant to Rule 144 and, in either case, the Shares have been sold
by the Holder prior to the Warrant Share Delivery Date (as defined below), and otherwise by physical delivery of a certificate, registered
in the Company's share register in the name of the Holder or its designee, for the number of Shares to which the Holder is entitled pursuant
to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is two (2) Trading Days after the delivery
to the Company of the Notice of Exercise (such date, the &ldquo;<B>Warrant Share Delivery Date</B>&rdquo;); provided that the Company
shall not be obligated to deliver the Shares hereunder unless the Company has received the aggregate Exercise Price on or before the Warrant
Share Delivery Date. If the Shares can be delivered via DWAC, the transfer agent shall have received from the Company, at the expense
of the Company, any legal opinions or other documentation required by it to deliver such Warrant Shares without legend (subject to receipt
by the Company of reasonable back up documentation from the Holder, including with respect to affiliate status) and, if applicable and
requested by the Company prior to the Warrant Share Delivery Date, the transfer agent shall have received from the Holder a confirmation
of sale of the Shares (provided the requirement of the Holder to provide a confirmation as to the sale of Shares shall not be applicable
to the issuance of unlegended Shares upon a cashless exercise of this Purchase Warrant if the Shares are then eligible for resale pursuant
to Rule 144(b)(l)). The Shares shall be deemed to have been issued, and Holder or any other person so designated to be named therein shall
be deemed to have become a holder of record of such shares for all purposes, as of the date the Purchase Warrant has been exercised, with
payment to the Company of the Exercise Price (or by cashless exercise, if permitted) and all taxes required to be paid by the Holder,
if any, pursuant to Section 2.3.6 prior to the issuance of such shares, having been paid. If the Company fails for any reason to deliver
to the Holder the Shares subject to a Notice of Exercise by the second Trading Day following the Warrant Share Delivery Date; provided
that payment of the aggregate Exercise Price (other than in the instance of a cashless exercise) is received by the Company by such date,
the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Shares subject to such exercise
(based on the VWAP of the Shares on the date of the applicable Notice of Exercise), $5 per Trading Day (increasing to $10 per Trading
Day on the fifth Trading Day after such liquidated damages begin to accrue) for each Trading Day after the second Trading Day following
such Warrant Share Delivery Date until such Shares are delivered or Holder rescinds such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">2.3.2 <U>Delivery
of New Warrants Upon Exercise</U>. If this Purchase Warrant shall have been exercised in part, the Company shall, at the request of a
Holder and upon surrender of this Purchase Warrant certificate, at the time of delivery of the Shares, deliver to the Holder a new Warrant
evidencing the rights of the Holder to purchase the unpurchased Shares called for by this Warrant, which new Warrant shall in all other
respects be identical with this Purchase Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">2.3.3 <U>Rescission
Rights</U>. If the Company fails to cause its transfer agent to deliver to the Holder the Shares pursuant to Section 2.3.1 by the Warrant
Share Delivery Date, then the Holder will have the right to rescind such exercise; provided, however, that the Holder shall be required
to return any Shares subject to any such rescinded exercise notice concurrently with the return to Holder of the aggregate Exercise Price
paid to the Company for such Shares and the restoration of Holder's right to acquire such Shares pursuant to this Purchase Warrant (including,
issuance of a replacement warrant certificate evidencing such restored right).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">2.3.4 <U>Compensation
for Buy-In on Failure to Timely Deliver Shares Upon Exercise</U>. In addition to any other rights available to the Holder, if the Company
fails to cause its transfer agent to transmit to the Holder the Shares pursuant to an exercise on or before the Warrant Share Delivery
Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder's
brokerage firm otherwise purchases, Shares to deliver in satisfaction of a sale by the Holder of the Shares which the Holder anticipated
receiving upon such exercise (a &ldquo;<B>Buy-In</B>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount, if any,
by which (x) the Holder's total purchase price (including brokerage commissions, if any) for the Shares so purchased exceeds (y) the amount
obtained by multiplying (1) the number of Shares that the Company was required to deliver to the Holder in connection with the exercise
at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the
Holder, either reinstate the portion of the Purchase Warrant and equivalent number of Shares for which such exercise was not honored (in
which case such exercise shall be deemed rescinded) or deliver to the Holder the number of Shares that would have been issued had the
Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Shares having a total
purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of Shares with an aggregate sale price giving rise to
such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder
$1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and,
upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder's right to pursue any other remedies
available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief
with respect to the Company's failure to timely deliver Shares upon exercise of the Purchase Warrant as required pursuant to the terms
hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>


<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">2.3.5 <U>No Fractional
Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Purchase Warrant.
As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election,
either (a) pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price
or (b) round up to the next whole share if such fraction is greater than or equal to one-half or round down to the next whole share if
such fraction is less than one-half.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">2.3.6 <U>Charges,
Taxes and Expenses</U>. Issuance of Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental
expense in respect of the issuance of such Shares, all of which taxes and expenses shall be paid by the Company, and such Shares shall
be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided, however, that in the event that
Shares are to be issued in a name other than the name of the Holder, this Purchase Warrant when surrendered for exercise shall be accompanied
by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of
a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all transfer agent fees required for same-day
processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing
similar functions) required for same-day electronic delivery of the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">2.3.7 <U>Closing
of Books</U>. The Company will not close its shareholder books or records in any manner which prevents the timely exercise of this Purchase
Warrant, pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">2.3.8 <U>Signature</U>.
This Section 2 and the exercise form attached hereto set forth the totality of the procedures required of the Holder in order to exercise
this Purchase Warrant. Without limiting the preceding sentences, no ink-original exercise form shall be required, nor shall any medallion
guarantee (or other type of guarantee or notarization) of any exercise form be required in order to exercise this Purchase Warrant. No
additional legal opinion, other information or instructions shall be required of the Holder to exercise this Purchase Warrant. The Company
shall honor exercises of this Purchase Warrant and shall deliver Shares underlying this Purchase Warrant in accordance with the terms,
conditions and time periods set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">2.4 <U>Holder's Exercise Limitations</U>.
The Company shall not effect any exercise of this Purchase Warrant, and a Holder shall not have the right to exercise any portion of this
Purchase Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth
on the applicable Notice of Exercise, the Holder (together with the Holder's Affiliates (as defined below), and any other Persons (as
defined below) acting as a group together with the Holder or any of the Holder's affiliates), would beneficially own in excess of the
Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of Shares beneficially owned by
the Holder and its Affiliates shall include the number of Shares issuable upon exercise of this Purchase Warrant with respect to which
such determination is being made, but shall exclude the number of Shares which would be issuable upon (i) exercise of the remaining, nonexercised
portion of this Purchase Warrant beneficially owned by the Holder or any of its Affiliates and (ii) exercise or conversion of the unexercised
or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents (as
defined below)) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the
Holder or any of its Affiliates. Except as set forth in the preceding sentence, for purposes of this Section 2.4, beneficial ownership
shall be calculated in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended (the &ldquo;<B>Exchange Act</B>&rdquo;)
and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the
Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules
required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2.4 applies, the determination
of whether this Purchase Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates) and
of which portion of this Purchase Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice
of Exercise shall be deemed to be the Holder's determination of whether this Purchase Warrant is exercisable (in relation to other securities
owned by the Holder together with any Affiliates) and of which portion of this Purchase Warrant is exercisable, in each case subject to
the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination.
In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the
Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2.4, in determining the number of outstanding
Shares, a Holder may rely on the number of outstanding Shares as reflected in (A) the Company's most recent periodic or annual report
filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice
by the Company or the Company's transfer agent setting forth the number of Shares outstanding. Upon the written or oral request of a Holder,
the Company shall within two Trading Days (as defined herein) confirm orally and in writing to the Holder the number of Shares then outstanding.
In any case, the number of outstanding Shares shall be determined after giving effect to the conversion or exercise of securities of the
Company, including this Purchase Warrant, by the Holder or its Affiliates since the date as of which such number of outstanding Shares
was reported. The &ldquo;<B>Beneficial Ownership Limitation&rdquo;</B> shall be 4.99% of the number of Shares outstanding immediately
after giving effect to the issuance of Shares issuable upon exercise of this Purchase Warrant. The Holder, upon notice to the Company,
may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2.4, provided that the Beneficial Ownership Limitation
in no event exceeds 9.99% of the number of Shares outstanding immediately after giving effect to the issuance of Shares upon exercise
of this Warrant held by the Holder and the provisions of this Section 2.4 shall continue to apply. Any increase in the Beneficial Ownership
Limitation will not be effective until the 61st day after such notice is delivered to the Company. The provisions of this paragraph shall
be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2.4 to correct this paragraph
(or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to
make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph
shall apply to a successor holder of this Purchase Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>


<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&ldquo;<B>Affiliate</B>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&ldquo;<B>Common Stock Equivalents&rdquo;</B>
means any securities of the Company that would entitle the holder thereof to acquire Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&ldquo;<B>Person</B>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">2.5 <U>Legend</U>. Each certificate
for the securities purchased under this Purchase Warrant shall bear a legend as follows unless such securities have been registered under
the Securities Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify">&ldquo;THE SECURITIES REPRESENTED BY
THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;), OR APPLICABLE
STATE LAW. NEITHER THE SECURITIES NOR ANY INTEREST THEREIN MAY BE OFFERED FOR SALE, SOLD OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN
EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT, OR PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT AND
APPLICABLE STATE LAW WHICH, IN THE OPINION OF COUNSEL TO THE COMPANY, IS AVAILABLE.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">3. <U>Transfer</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">3.1 <U>General Restrictions</U>.
The registered Holder of this Purchase Warrant agrees by his, her or its acceptance hereof, that such Holder will not: (a) sell, transfer,
assign, pledge or hypothecate this Purchase Warrant or the securities issuable hereunder for a period of one hundred eighty (180) days
following the Effective Date to anyone other than: (i) ThinkEquity LLC (&ldquo;<B>ThinkEquity</B>&rdquo;) or an underwriter or a selected
dealer participating in the Offering, or (ii) a <I>bona fide</I> officer or partner of ThinkEquity or of any such underwriter or selected
dealer, in each case in accordance with FINRA Rule 5110(e)(1), or (b) for a period of one hundred eighty (180) days following the Effective
Date, cause this Purchase Warrant or the securities issuable hereunder to be the subject of any hedging, short sale, derivative, put or
call transaction that would result in the effective economic disposition of this Purchase Warrant or the securities hereunder, except
as provided for in FINRA Rule 5110(e)(2). On and after one hundred eighty (180) days after the Effective Date, transfers to others may
be made subject to compliance with or exemptions from applicable securities laws. In order to make any permitted assignment, the Holder
must deliver to the Company the assignment form attached hereto duly executed and completed, together with the Purchase Warrant and payment
of all transfer taxes, if any, payable in connection therewith. The Company shall within five (5) Trading Days transfer this Purchase
Warrant on the books of the Company and shall execute and deliver a new Purchase Warrant or Purchase Warrants of like tenor to the appropriate
assignee(s) expressly evidencing the right to purchase the aggregate number of Shares purchasable hereunder or such portion of such number
as shall be contemplated by any such assignment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">3.2 <U>Restrictions Imposed
by the Securities Act</U>. The securities evidenced by this Purchase Warrant shall not be transferred unless and until: (i) the Company
has received the opinion of counsel for the Holder that the securities may be transferred pursuant to an exemption from registration under
the Securities Act and applicable state securities laws, the availability of which is established to the reasonable satisfaction of the
Company (the Company hereby acknowledges and agrees that the opinion of McGuireWoods LLP shall be deemed satisfactory evidence of the
availability of an exemption), or (ii) a registration statement or a post-effective amendment to the Registration Statement relating to
the offer and sale of such securities has been filed by the Company and declared effective by the Commission and compliance with applicable
state securities law has been established.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">4. <U>Registration Rights</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">4.1 <U>Demand Registration</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">4.1.1 <U>Grant of
Right</U>. The Company, upon written demand (a &ldquo;<B>Demand Notice</B>&rdquo;) of the Holders of at least 51% of the Purchase Warrants
and/or underlying Shares, agrees to register, on one (1) occasion, all or any portion of the Shares underlying the Purchase Warrants (collectively,
the &ldquo;<B>Registrable Securities</B>&rdquo;). On such occasion, the Company will file a registration statement with the Commission
covering the Registrable Securities within sixty (60) days after receipt of a Demand Notice and use its reasonable best efforts to have
the registration statement declared effective promptly thereafter, subject to compliance with review by the Commission; provided, however,
that the Company shall not be required to comply with a Demand Notice if the Company has filed a registration statement with respect to
which the Holder is entitled to piggyback registration rights pursuant to Section 4.2 hereof and either: (i) the Holder has elected to
participate in the offering covered by such registration statement or (ii) if such registration statement relates to an underwritten primary
offering of securities of the Company, until the offering covered by such registration statement has been withdrawn or until thirty (30)
days after such offering is consummated. The Company covenants and agrees to give written notice of its receipt of any Demand Notice by
any Holders to all other registered Holders of the Purchase Warrants and/or the Registrable Securities within ten (10) days after the
date of the receipt of any such Demand Notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">4.1.2 <U>Terms</U>.
The Company shall bear all fees and expenses attendant to the registration of the Registrable Securities pursuant to Section 4.1.1, but
the Holders shall pay any and all underwriting commissions and the expenses of any legal counsel selected by the Holders to represent
them in connection with the sale of the Registrable Securities. The Company agrees to use its reasonable best efforts to cause the filing
required herein to become effective promptly and to qualify or register the Registrable Securities in such states as are reasonably requested
by the Holders; provided, however, that in no event shall the Company be required to register the Registrable Securities in a State in
which such registration would cause: (i) the Company to be obligated to register or license to do business in such State or submit to
general service of process in such State, or (ii) the principal shareholders of the Company to be obligated to escrow their shares of
capital stock of the Company. The Company shall cause any registration statement filed pursuant to the demand right granted under Section
4.1.1 to remain effective for a period of at least twelve (12) consecutive months after the date that the Holders of the Registrable Securities
covered by such registration statement are first given the opportunity to sell all of such securities. The Holders shall only use the
prospectuses provided by the Company to sell the shares covered by such registration statement, and will immediately cease to use any
prospectus furnished by the Company if the Company advises the Holder that such prospectus may no longer be used due to a material misstatement
or omission. Notwithstanding the provisions of this Section 4.1.2, the Holder shall be entitled to a demand registration under this Section
4.1.2 on only one (1) occasion and such demand registration right shall terminate on the fifth anniversary of the Commencement Date in
accordance with FINRA Rule 5110(g)(8)(C).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>


<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">4.2 &ldquo;<U>Piggy-Back&rdquo;
Registration</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">4.2.1 <U>Grant of
Right</U>. In addition to the demand right of registration described in Section 4.1 hereof, the Holder shall have the right, for a period
of five (5) years from the Commencement Date in accordance with FINRA Rule 5110(g)(8)(D), to include the Registrable Securities as part
of any other registration of securities filed by the Company (other than in connection with a transaction contemplated by Rule 145(a)
promulgated under the Securities Act or pursuant to Form S-8 or Form S-4 or any equivalent form); provided, however, that if, solely in
connection with any primary underwritten public offering for the account of the Company, the managing underwriter(s) thereof shall, in
its reasonable discretion, impose a limitation on the number of Shares which may be included in the Registration Statement because, in
such underwriter(s)&rsquo; judgment, marketing or other factors dictate such limitation is necessary to facilitate public distribution,
then the Company shall be obligated to include in such Registration Statement only such limited portion of the Registrable Securities
with respect to which the Holder requested inclusion hereunder as the underwriter shall reasonably permit. Any exclusion of Registrable
Securities shall be made pro rata among the Holders seeking to include Registrable Securities in proportion to the number of Registrable
Securities sought to be included by such Holders; <I>provided</I>, <I>however</I>, that the Company shall not exclude any Registrable
Securities unless the Company has first excluded all outstanding securities, the holders of which are not entitled to inclusion of such
securities in such Registration Statement or are not entitled to pro rata inclusion with the Registrable Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">4.2.2 <U>Terms</U>.
The Company shall bear all fees and expenses attendant to registering the Registrable Securities pursuant to Section 4.2.1 hereof, but
the Holders shall pay any and all underwriting commissions and the expenses of any legal counsel selected by the Holders to represent
them in connection with the sale of the Registrable Securities. In the event of such a proposed registration, the Company shall furnish
the then Holders of outstanding Registrable Securities with not less than fifteen (15) days&rsquo; written notice prior to the proposed
date of filing of such registration statement. Such notice to the Holders shall continue to be given for each registration statement filed
by the Company until such time as the registration rights have been terminated pursuant to Section 4.4. The holders of the Registrable
Securities shall exercise the &ldquo;piggy-back&rdquo; rights provided for herein by giving written notice within ten (10) days of the
receipt of the Company&rsquo;s notice of its intention to file a registration statement. Except as otherwise provided in this Purchase
Warrant, there shall be no limit on the number of times the Holder may request registration under this Section 4.2.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">4.3 <U>General Terms</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">4.3.1 <U>Indemnification</U>.
The Company shall indemnify the Holders of the Registrable Securities to be sold pursuant to any registration statement hereunder and
each person, if any, who controls such Holders within the meaning of Section 15 of the Securities Act or Section 20(a) of the Exchange
Act, against all loss, claim, damage, expense or liability (including all reasonable attorneys&rsquo; fees and other expenses reasonably
incurred in investigating, preparing or defending against any claim whatsoever) to which any of them may become subject under the Securities
Act, the Exchange Act or otherwise, arising from such registration statement but only to the same extent and with the same effect as the
provisions pursuant to which the Company has agreed to indemnify the Underwriters contained in Section 5.1 of the Underwriting Agreement
between the Underwriters and the Company, dated as of August 7, 2025. The Holders of the Registrable Securities to be sold pursuant to
such registration statement, and their successors and assigns, shall severally, and not jointly, indemnify the Company, against all loss,
claim, damage, expense or liability (including all reasonable attorneys&rsquo; fees and other expenses reasonably incurred in investigating,
preparing or defending against any claim whatsoever) to which they may become subject under the Securities Act, the Exchange Act or otherwise,
arising from information furnished by or on behalf of such Holders, or their successors or assigns, in writing, for specific inclusion
in such registration statement to the same extent and with the same effect as the provisions contained in Section 5.2 of the Underwriting
Agreement pursuant to which the Underwriters have agreed to indemnify the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>


<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">4.3.2 <U>Exercise
of Purchase Warrants</U>. Nothing contained in this Purchase Warrant shall be construed as requiring the Holders to exercise their Purchase
Warrants prior to or after the initial filing of any registration statement or the effectiveness thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">4.3.3 <U>Documents
Delivered to Holders</U>. The Company shall furnish to each Holder participating in any of the foregoing offerings and to each underwriter
of any such offering, if any, a signed counterpart, addressed to such Holder or underwriter, of: (i) an opinion of counsel to the Company,
dated the effective date of such registration statement (and, if such registration includes an underwritten public offering, an opinion
dated the date of the closing under any underwriting agreement related thereto), and (ii) a &ldquo;cold comfort&rdquo; letter dated the
effective date of such registration statement (and, if such registration includes an underwritten public offering, a letter dated the
date of the closing under the underwriting agreement) signed by the independent registered public accounting firm which has issued a report
on the Company&rsquo;s financial statements included in such registration statement, in each case covering substantially the same matters
with respect to such registration statement (and the prospectus included therein) and, in the case of such accountants&rsquo; letter,
with respect to events subsequent to the date of such financial statements, as are customarily covered in opinions of issuer&rsquo;s counsel
and in accountants&rsquo; letters delivered to underwriters in underwritten public offerings of securities. The Company shall also deliver
promptly to each Holder participating in the offering requesting the correspondence and memoranda described below and to the managing
underwriter, if any, copies of all correspondence between the Commission and the Company, its counsel or auditors and all memoranda relating
to discussions with the Commission or its staff with respect to the registration statement and permit each Holder and underwriter to do
such investigation, upon reasonable advance notice, with respect to information contained in or omitted from the registration statement
as it deems reasonably necessary to comply with applicable securities laws or rules of FINRA. Such investigation shall include access
to books, records and properties and opportunities to discuss the business of the Company with its officers and independent auditors,
all to such reasonable extent and at such reasonable times as any such Holder shall reasonably request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">4.3.4 <U>Underwriting
Agreement</U>. The Company shall enter into an underwriting agreement with the managing underwriter(s), if any, selected by any Holders
whose Registrable Securities are being registered pursuant to this Section 4, which managing underwriter shall be reasonably satisfactory
to the Company. Such agreement shall be reasonably satisfactory in form and substance to the Company, each Holder and such managing underwriters,
and shall contain such representations, warranties and covenants by the Company and such other terms as are customarily contained in agreements
of that type used by the managing underwriter. The Holders shall be parties to any underwriting agreement relating to an underwritten
sale of their Registrable Securities and may, at their option, require that any or all the representations, warranties and covenants of
the Company to or for the benefit of such underwriters shall also be made to and for the benefit of such Holders. Such Holders shall not
be required to make any representations or warranties to or agreements with the Company or the underwriters except as they may relate
to such Holders, their Shares and their intended methods of distribution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">4.3.5 <U>Documents
to be Delivered by Holders</U>. Each of the Holders participating in any of the foregoing offerings shall furnish to the Company a completed
and executed questionnaire provided by the Company requesting information customarily sought of selling security holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">4.3.6 <U>Damages</U>.
Should the registration or the effectiveness thereof required by Sections 4.1 and 4.2 hereof be delayed by the Company or the Company
otherwise fails to comply with such provisions, the Holders shall, in addition to any other legal or other relief available to the Holders,
be entitled to obtain specific performance or other equitable (including injunctive) relief against the threatened breach of such provisions
or the continuation of any such breach, without the necessity of proving actual damages and without the necessity of posting bond or other
security.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">4.4 <U>Termination
of Registration Rights</U>. The registration rights afforded to the Holders under this Section 4 shall terminate on the earliest date
when all Registrable Securities of such Holder either: (i) have been publicly sold by such Holder pursuant to a Registration Statement,
(ii) have been covered by an effective Registration Statement on Form S-1 or Form S-3 (or successor forms thereto), which may be kept
effective as an evergreen Registration Statement, or (iii) may be sold by the Holder within a 90-day period without registration pursuant
to Rule 144 or consistent with applicable SEC interpretive guidance (including CD&amp;I no. 201.04 (April 2, 2007) or similar interpretive
guidance).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>


<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">5. <U>New Purchase Warrants
to be Issued</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">5.1 <U>Partial Exercise or
Transfer</U>. Subject to the restrictions in Section 3 hereof, this Purchase Warrant may be exercised or assigned in whole or in part.
In the event of the exercise or assignment hereof in part only, upon surrender of this Purchase Warrant for cancellation, together with
the duly executed exercise or assignment form and funds sufficient to pay any Exercise Price and/or transfer tax if exercised pursuant
to Section 2.1 hereto, the Company shall cause to be delivered to the Holder without charge a new Purchase Warrant of like tenor to this
Purchase Warrant in the name of the Holder evidencing the right of the Holder to purchase the number of Shares purchasable hereunder as
to which this Purchase Warrant has not been exercised or assigned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">5.2 <U>Lost Certificate</U>.
Upon receipt by the Company of evidence satisfactory to it of the loss, theft, destruction or mutilation of this Purchase Warrant and
of reasonably satisfactory indemnification or the posting of a bond, the Company shall execute and deliver a new Purchase Warrant of like
tenor and date. Any such new Purchase Warrant executed and delivered as a result of such loss, theft, mutilation or destruction shall
constitute a substitute contractual obligation on the part of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">6. <U>Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">6.1 <U>Adjustments to Exercise
Price and Number of Securities</U>. The Exercise Price and the number of Shares underlying the Purchase Warrant shall be subject to adjustment
from time to time as hereinafter set forth:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">6.1.1 <U>Stock Dividends
and Splits</U>. If the Company, at any time while this Purchase Warrant is outstanding: (i) pays a stock dividend or otherwise makes a
distribution or distributions on the Shares or any other equity or equity equivalent securities payable in Shares (which, for avoidance
of doubt, shall not include any Shares issued by the Company upon (A) exercise of this Purchase Warrant or (B) exercise, conversion or
exchange of options, warrants, preferred stock, convertible notes, other convertible securities or other Common Stock Equivalents), (ii)
subdivides outstanding Shares into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding Shares
into a smaller number of shares, or (iv) issues by reclassification of any shares of capital stock of the Company, then in each case the
Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of Shares (excluding treasury shares, if any)
outstanding immediately before such event and of which the denominator shall be the number of Shares outstanding immediately after such
event, and the number of shares issuable upon exercise of this Purchase Warrant shall be proportionately adjusted such that the aggregate
Exercise Price of this Purchase Warrant shall remain unchanged. Any adjustment made pursuant to this Section 6.1 shall become effective
immediately after the record date for the determination of shareholders entitled to receive such dividend or distribution and shall become
effective immediately after the effective date in the case of a subdivision, combination or re-classification. For the purposes of clarification,
neither the Exercise Price of this Purchase Warrant nor the number of shares issuable upon exercise of this Purchase Warrant will be adjusted
in the event that the Company or any subsidiary thereof, as applicable, sells or grants any option to purchase, or sells or grants any
right to reprice, or otherwise disposes of or issues (or announces any offer, sale, grant or any option to purchase or other disposition)
any Shares or Common Stock Equivalents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">6.1.2 <U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to Section 6.1.1 above, if at any time the Company grants, issues or sells
any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any
class of Shares of the Company (the &ldquo;<B>Purchase Rights</B>&rdquo;), then the Holder will be entitled to acquire, upon the terms
applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number
of Shares acquirable upon complete exercise of this Purchase Warrant (without regard to any limitations on exercise hereof, including
without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance
or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of Shares are to be determined
for the grant, issue or sale of such Purchase Rights; provided, however, to the extent that the Holder's right to participate in any such
Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate
in such Purchase Right to such extent (or beneficial ownership of such Shares as a result of such Purchase Right to such extent) and such
Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result
in the Holder exceeding the Beneficial Ownership Limitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>


<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">6.1.3 <U>Pro Rata
Distributions</U>. During such time as this Purchase Warrant is outstanding, if the Company shall declare or make any dividend (other
than cash dividends) or other distribution of its assets (or rights to acquire its assets) to holders of Shares, by way of return of capital
or otherwise (including, without limitation, any distribution of shares or other securities, property or options by way of a dividend,
spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<B>Distribution&rdquo;</B>),
at any time after the issuance of this Purchase Warrant, then, in each such case, the Holder shall be entitled to participate in such
Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of Shares acquirable
upon complete exercise of this Purchase Warrant (without regard to any limitations on exercise hereof, including without limitation, the
Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is
taken, the date as of which the record holders of Shares are to be determined for the participation in such Distribution (provided, however,
to the extent that the Holder&rsquo;s right to participate in any such Distribution would result in the Holder exceeding the Beneficial
Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership
of any Shares as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the
benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership
Limitation). To the extent that this Purchase Warrant has not been partially or completely exercised at the time of such Distribution,
such portion of the Distribution shall be held in abeyance for the benefit of the Holder until the Holder has exercised this Purchase
Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">6.1.4 <U>Fundamental
Transaction</U>. If, at any time while this Purchase Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related
transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly,
effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one
or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company
or another Person) is completed pursuant to which holders of Shares of the Company are permitted to sell, tender or exchange their shares
for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Shares of the Company, (iv)
the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization
of Shares or any compulsory share exchange pursuant to which the Shares are effectively converted into or exchanged for other securities,
cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase
agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement)
with another Person or group of Persons whereby such other Person or group acquires more than 50% of the outstanding Shares of the Company
(not including any Shares held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons
making or party to, such stock or share purchase agreement or other business combination) (each a &ldquo;<B>Fundamental Transaction</B>&rdquo;),
then, upon any subsequent exercise of this Purchase Warrant, the Holder shall have the right to receive, for each Share that would have
been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without
regard to any limitation in Section 2.4 on the exercise of this Purchase Warrant), the number of Shares of the successor or acquiring
corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &ldquo;<B>Alternate Consideration</B>&rdquo;)
receivable by holders of Shares as a result of such Fundamental Transaction for each Share for which this Purchase Warrant is exercisable
immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2.4 on the exercise of this Warrant). For
purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration
based on the amount of Alternate Consideration issuable in respect of one Share in such Fundamental Transaction, and the Company shall
apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components
of the Alternate Consideration. If holders of Shares of the Company are given any choice as to the securities, cash or property to be
received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon
any exercise of this Purchase Warrant following such Fundamental Transaction. The Company shall cause any successor entity in a Fundamental
Transaction in which the Company is not the survivor (the &quot;<B>Successor Entity</B>&quot;) to assume in writing all of the obligations
of the Company under this Purchase Warrant in accordance with the provisions of this Section 6.1.4 pursuant to written agreements in form
and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental
Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity
evidenced by a written instrument substantially similar in form and substance to this Purchase Warrant which is exercisable for a corresponding
number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the Shares acquirable and receivable upon
exercise of this Purchase Warrant (without regard to any limitations on the exercise of this Purchase Warrant) prior to such Fundamental
Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account
the relative value of the Shares pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of
shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Purchase Warrant immediately
prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder.
Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and
after the date of such Fundamental Transaction, the provisions of this Purchase Warrant referring to the &quot;Company&quot; shall refer
instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the
Company under this Purchase Warrant with the same effect as if such Successor Entity had been named as the Company herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>


<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">6.1.5 <U>Calculations</U>.
All calculations under this Section 6.1 shall be made to the nearest cent or the nearest l/100th of a share, as the case may be. For purposes
of this Section 6.1, the number of Shares deemed to be issued and outstanding as of a given date shall be the sum of the number of Shares
(excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">6.1.6 <U>Notice
to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">i. <U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 6.1, the Company shall promptly
mail or email to the Holder a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number
of Shares and setting forth a brief statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">ii. <U>Notice to
Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Shares,
(B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Shares, (C) the Company shall authorize the
granting to all holders of the common stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or
of any rights, (D) the approval of any shareholders of the Company shall be required in connection with any reclassification of the Shares
(a reverse stock split shall not be deemed a reclassification), any consolidation or merger to which the Company is a party, any sale
or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the Shares are converted
into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding
up of the affairs of the Company, then, in each case, the Company shall cause to be mailed a notice to the Holder at its last address
as it shall appear upon the warrant register of the Company, at least 20 calendar days prior to the applicable record or effective date
hereinafter specified, stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption,
rights or warrants, or if a record is not to be taken, the date as of which the holders of the Shares of record to be entitled to such
dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation,
merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders
of the Shares of record shall be entitled to exchange their shares of the Shares for securities, cash or other property deliverable upon
such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to provide such notice or any
defect therein shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice
provided hereunder constitutes, or contains, material, non-public information regarding the Company or any of its subsidiaries, the Company
shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to
exercise this Purchase Warrant during the period commencing on the date of such notice to the effective date of the event triggering such
notice except as may otherwise be expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">6.1.7 <U>Changes
in Form of Purchase Warrant</U>. This form of Purchase Warrant need not be changed because of any change pursuant to this Section 6.1,
and Purchase Warrants issued after such change may state the same Exercise Price and the same number of Shares as are stated in the Purchase
Warrants initially issued pursuant to this Agreement. The acceptance by any Holder of the issuance of new Purchase Warrants reflecting
a required or permissive change shall not be deemed to waive any rights to an adjustment occurring after the Commencement Date or the
computation thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>


<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">6.2 <U>Substitute Purchase
Warrant</U>. In case of any consolidation of the Company with, or share reconstruction or amalgamation of the Company with or into, another
corporation (other than a consolidation or share reconstruction or amalgamation which does not result in any reclassification or change
of the outstanding Shares), the corporation formed by such consolidation or share reconstruction or amalgamation shall execute and deliver
to the Holder a supplemental Purchase Warrant providing that the holder of each Purchase Warrant then outstanding or to be outstanding
shall have the right thereafter (until the stated expiration of such Purchase Warrant) to receive, upon exercise of such Purchase Warrant,
the kind and amount of shares of stock and other securities and property receivable upon such consolidation or share reconstruction or
amalgamation, by a holder of the number of Shares for which such Purchase Warrant might have been exercised immediately prior to such
consolidation, share reconstruction or amalgamation, sale or transfer. Such supplemental Purchase Warrant shall provide for adjustments
which shall be identical to the adjustments provided for in this Section 6. The above provision of this Section shall similarly apply
to successive consolidations or share reconstructions or amalgamations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">7. <U>Reservation and Listing</U>.
The Company shall at all times reserve and keep available out of its authorized Shares, solely for the purpose of issuance upon exercise
of the Purchase Warrants, such number of Shares or other securities, properties or rights as shall be issuable upon the exercise thereof.
The Company covenants and agrees that, upon exercise of the Purchase Warrants and payment of the Exercise Price therefor, in accordance
with the terms hereby, all Shares and other securities issuable upon such exercise shall be duly and validly issued, fully paid and non-assessable
and not subject to pre-emptive rights of any shareholder. As long as the Purchase Warrants shall be outstanding, the Company shall use
its commercially reasonable efforts to cause all Shares issuable upon exercise of the Purchase Warrants to be listed (subject to official
notice of issuance) on all national securities exchanges (or, if applicable, on the OTC Bulletin Board or any successor trading market)
on which the Shares issued to the public in the Offering (as defined in that certain Underwriting Agreement dated as of August 7, 2025
by and between the Company and ThinkEquity) may then be listed and/or quoted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">8. <U>Certain Notice Requirements</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">8.1 <U>Holder&rsquo;s Right
to Receive Notice</U>. Nothing herein shall be construed as conferring upon the Holders the right to vote or consent or to receive notice
as a shareholder for the election of directors or any other matter, or as having any rights whatsoever as a shareholder of the Company.
If, however, at any time prior to the expiration of the Purchase Warrants and their exercise, any of the events described in Section 8.2
shall occur, then, in one or more of said events, the Company shall give written notice of such event at least fifteen (15) days prior
to the date fixed as a record date or the date of closing the transfer books for the determination of the shareholders entitled to such
dividend, distribution, conversion or exchange of securities or subscription rights, or entitled to vote on such proposed dissolution,
liquidation, winding up or sale. Such notice shall specify such record date or the date of the closing of the transfer books, as the case
may be. Notwithstanding the foregoing, the Company shall deliver to each Holder a copy of each notice given to the other shareholders
of the Company at the same time and in the same manner that such notice is given to the shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">8.2 <U>Events Requiring Notice</U>.
The Company shall be required to give the notice described in this Section 8 upon one or more of the following events: (i) if the Company
shall take a record of the holders of its Shares for the purpose of entitling them to receive a dividend or distribution payable otherwise
than in cash, or a cash dividend or distribution payable otherwise than out of retained earnings, as indicated by the accounting treatment
of such dividend or distribution on the books of the Company; (ii) the Company shall offer to all the holders of its Shares any additional
shares of capital stock of the Company or securities convertible into or exchangeable for shares of capital stock of the Company, or any
option, right or warrant to subscribe therefor; or (iii) a dissolution, liquidation or winding up of the Company (other than in connection
with a consolidation or share reconstruction or amalgamation) or a sale of all or substantially all of its property, assets and business
shall be proposed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">8.3 <U>Transmittal of Notices</U>.
All notices, requests, consents and other communications under this Purchase Warrant shall be in writing and shall be deemed to have been
duly made when hand delivered or mailed by express mail or private courier service: (i) if to the registered Holder of the Purchase Warrant,
to the address of such Holder as shown on the books of the Company, or (ii) if to the Company, to following address or to such other address
as the Company may designate by notice to the Holders:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>


<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">If to the Holder:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">ThinkEquity LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">17 State Street,
22nd Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">New York, NY 10004</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">Attention: Head
of Investment Banking</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E-mail:
</FONT>notices@think-equity.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">with a copy (which shall not
constitute notice) to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">Sheppard, Mullin,
Richter &amp; Hampton LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">30 Rockefeller Plaza,
39<SUP>th</SUP> Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">New York, New York
10112</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">Attn: Jeffrey Fessler
and Stephen Cohen</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">e-mail: jfessler@sheppardmullin.com
and scohen@sheppardmullin.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">If to the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">BioVie Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">680 W Nye Lane,
Suite 204</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">Carson City, Nevada
89703</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">Attention: Cuong
Do, CEO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">Email: cdo@bioviepharma.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">with a copy (which shall not
constitute notice) to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-indent: 40pt">McGuireWoods LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-indent: 40pt">1251 6th Ave 20th Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-indent: 40pt">New York, NY 10020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-indent: 40pt">Attn: Stephen Older and Carly Ginley</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-indent: 40pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e-mail:
solder@mcguirewoods.com and </FONT>cginley@mcguirewoods.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">9. <U>General</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">9.1 <U>Amendments</U>. The
Company and the ThinkEquity may from time to time supplement or amend this Purchase Warrant without the approval of any of the Holders
in order to cure any ambiguity, to correct or supplement any provision contained herein that may be defective or inconsistent with any
other provisions herein, or to make any other provisions in regard to matters or questions arising hereunder that the Company and the
Holder may deem necessary or desirable and that the Company and the Holder deem shall not adversely affect the interest of the Holders.
All other modifications or amendments shall require the written consent of and be signed by the party against whom enforcement of the
modification or amendment is sought.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">9.2 <U>Headings</U>. The headings
contained herein are for the sole purpose of convenience of reference, and shall not in any way limit or affect the meaning or interpretation
of any of the terms or provisions of this Purchase Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">9.3 <U>Entire Agreement</U>.
This Purchase Warrant (together with the other agreements and documents being delivered pursuant to or in connection with this Purchase
Warrant) constitutes the entire agreement of the parties hereto with respect to the subject matter hereof, and supersedes all prior agreements
and understandings of the parties, oral and written, with respect to the subject matter hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">9.4 <U>Binding Effect</U>.
This Purchase Warrant shall inure solely to the benefit of and shall be binding upon, the Holder and the Company and their permitted assignees,
respective successors, legal representative and assigns, and no other person shall have or be construed to have any legal or equitable
right, remedy or claim under or in respect of or by virtue of this Purchase Warrant or any provisions herein contained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">9.5 <U>Governing Law; Submission
to Jurisdiction</U>. This Purchase Warrant shall be governed by and construed and enforced in accordance with the laws of the State of
New York. The Company hereby agrees that any action, proceeding or claim against it arising out of, or relating in any way to this Purchase
Warrant shall be brought and enforced in the Supreme Court of the State of New York, sitting in the City and County of New York, or in
the United States District Court for the Southern District of New York, and irrevocably submits to such jurisdiction, which jurisdiction
shall be exclusive. The Company hereby waives any objection to such exclusive jurisdiction and that such courts represent an inconvenient
forum. Any process or summons to be served upon the Company may be served by transmitting a copy thereof by registered or certified mail,
return receipt requested, postage prepaid, addressed to it at the address set forth in Section 8 hereof. Such mailing shall be deemed
personal service and shall be legal and binding upon the Company in any action, proceeding or claim. The Company and the Holder agree
that the prevailing party(ies) in any such action shall be entitled to recover from the other party(ies) all of its reasonable attorneys&rsquo;
fees and expenses relating to such action or proceeding and/or incurred in connection with the preparation therefor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>


<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">9.6 <U>Waiver of Trial by
Jury</U>. The Company (on its behalf and, to the extent permitted by applicable law, on behalf of its shareholders and affiliates) and
the Holder hereby irrevocably waive, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal
proceeding arising out of or relating to this Agreement or the transactions contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">9.7 <U>Waiver, etc</U>. The
failure of the Company or the Holder to at any time enforce any of the provisions of this Purchase Warrant shall not be deemed or construed
to be a waiver of any such provision, nor to in any way affect the validity of this Purchase Warrant or any provision hereof or the right
of the Company or any Holder to thereafter enforce each and every provision of this Purchase Warrant. No waiver of any breach, non-compliance
or non-fulfillment of any of the provisions of this Purchase Warrant shall be effective unless set forth in a written instrument executed
by the party or parties against whom or which enforcement of such waiver is sought; and no waiver of any such breach, non-compliance or
non-fulfillment shall be construed or deemed to be a waiver of any other or subsequent breach, non-compliance or non-fulfillment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">9.8 <U>Execution in Counterparts</U>.
This Purchase Warrant may be executed in one or more counterparts, and by the different parties hereto in separate counterparts, each
of which shall be deemed to be an original, but all of which taken together shall constitute one and the same agreement, and shall become
effective when one or more counterparts has been signed by each of the parties hereto and delivered to each of the other parties hereto.
Such counterparts may be delivered by facsimile transmission or other electronic transmission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">9.9 <U>Exchange Agreement</U>.
As a condition of the Holder&rsquo;s receipt and acceptance of this Purchase Warrant, Holder agrees that, at any time prior to the complete
exercise of this Purchase Warrant by Holder, if the Company and ThinkEquity enter into an agreement (&ldquo;<B>Exchange Agreement</B>&rdquo;)
pursuant to which they agree that all outstanding Purchase Warrants will be exchanged for securities or cash or a combination of both,
then Holder shall agree to such exchange and become a party to the Exchange Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Signature Page Follows</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">IN WITNESS WHEREOF, the Company
has caused this Purchase Warrant to be signed by its duly authorized officer as of the ____ day of _______, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Very truly yours,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">BioVie</FONT>
INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="width: 40%; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 58%; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Form to be used to exercise Purchase Warrant</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: __________, 20___</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">The undersigned hereby elects
irrevocably to exercise the Purchase Warrant for [&#9679;] shares of common stock, par value $0.0001 per share (the &ldquo;<B>Shares</B>&rdquo;),
of BioVie Inc., a Nevada corporation (the &ldquo;<B>Company</B>&rdquo;), and hereby makes payment of $[&#9679;] (at the rate of $[&#9679;]
per Share) in payment of the Exercise Price pursuant thereto. Please issue the Shares as to which this Purchase Warrant is exercised in
accordance with the instructions given below and, if applicable, a new Purchase Warrant representing the number of Shares for which this
Purchase Warrant has not been exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">The undersigned hereby elects
irrevocably to convert its right to purchase [&#9679;] Shares of the Company under the Purchase Warrant for [&#9679;] Shares, as determined
in accordance with the Section 2.2 of the Purchase Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">The undersigned agrees and
acknowledges that the calculation set forth above is subject to confirmation by the Company and any disagreement with respect to the calculation
shall be resolved by the Company in its sole discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">Please issue the Shares as
to which this Purchase Warrant is exercised in accordance with the instructions given below and, if applicable, a new Purchase Warrant
representing the number of Shares for which this Purchase Warrant has not been converted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Signature <U>_________________</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Signature Guaranteed <U>____________________</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">INSTRUCTIONS FOR REGISTRATION OF SECURITIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="width: 40%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>________________________________</U></FONT></TD>
    <TD STYLE="width: 56%; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-left: 40pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Print in Block Letters)</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>________________________________</U></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>________________________________</U></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>________________________________</U></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NOTICE: The signature to this form must correspond
with the name as written upon the face of the Purchase Warrant without alteration or enlargement or any change whatsoever, and must be
guaranteed by a bank, other than a savings bank, or by a trust company or by a firm having membership on a registered national securities
exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Form to be used to assign Purchase Warrant</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ASSIGNMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(To be executed by the registered Holder to effect
a transfer of the within Purchase Warrant):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FOR VALUE RECEIVED, __________________ does hereby
sell, assign and transfer unto the right to purchase [&#9679;] shares of common stock, par value $0.0001 per share, of BioVie Inc., a
Nevada corporation (the &ldquo;<B>Company</B>&rdquo;), evidenced by the Purchase Warrant and does hereby authorize the Company to transfer
such right on the books of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dated: __________, 20__</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Signature <U>_________________</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Signature Guaranteed <U>____________________</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NOTICE: The signature to this form must correspond
with the name as written upon the face of the Purchase Warrant without alteration or enlargement or any change whatsoever, and must be
guaranteed by a bank, other than a savings bank, or by a trust company or by a firm having membership on a registered national securities
exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form of Lock-Up Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 59; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT C</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form of Press Release</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>BioVie Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>[Date]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BioVie Inc. (the &ldquo;<B>Company</B>&rdquo;)
announced today that ThinkEquity LLC, acting as representative of the underwriters in the Company&rsquo;s recent public offering of _______
units, each consisting of one share of the Company&rsquo;s common stock (the &ldquo;<B>Common Stock</B>&rdquo;) and one common stock purchase
warrant exercisable for one share of Common Stock (the &ldquo;<B>Warrant</B>&rdquo;), and/or __________ pre-funded units, each consisting
of one pre-funded common stock purchase warrant exercisable for one share of Common Stock and one Warrant, is [waiving] [releasing] a
lock-up restriction with respect to _________ shares of Common Stock held by [certain officers or directors] [an officer or director]
of the Company. The [waiver] [release] will take effect on _________, 20___, and the shares may be sold on or after such date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>This press release is not an offer or sale
of the securities in the United States or in any other jurisdiction where such offer or sale is prohibited, and such securities may not
be offered or sold in the United States absent registration or an exemption from registration under the Securities Act of 1933, as amended.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 60; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>3
<FILENAME>bivi-20250807_ex4z2.htm
<DESCRIPTION>EXHIBIT 4.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 4.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PRE-FUNDED COMMON STOCK PURCHASE WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>BIOVIE INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; font-size: 10pt"><FONT STYLE="font-size: 10pt">Warrant Shares: __________</FONT></TD>
    <TD STYLE="width: 40%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">Issue Date: August 11, 2025</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">THIS PRE-FUNDED COMMON STOCK
PURCHASE WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, __________ or its assigns (the &ldquo;<U>Holder</U>&rdquo;)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
the Issue Date and until this Warrant is exercised in full (the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe
for and purchase from BioVie, Inc., a Nevada corporation (the &ldquo;<U>Company</U>&rdquo;), up to __________ shares of Common Stock (as
subject to adjustment hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;). The purchase price of one share of Common Stock under this
Warrant shall be equal to the Exercise Price, as defined in Section 2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 1</U>. <U>Definitions</U>.
In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this Section 1:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common Stock</U>&rdquo;
means the Class A common stock of the Company, par value $0.0001 per share, and any other class of securities into which such securities
may hereafter be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common Stock Equivalents</U>&rdquo;
means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including,
without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable
or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exchange Act</U>&rdquo;
means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Liens</U>&rdquo;
means a lien, charge pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Proceeding</U>&rdquo;
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding,
such as a deposition), whether commenced or threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Rule 144</U>&rdquo;
means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time,
or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Registration Statement</U>&rdquo;
means the Company&rsquo;s registration statement on Form S-1 (File No. 333-288525).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities Act</U>&rdquo;
means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading Day</U>&rdquo;
means a day on which the Common Stock is traded on a Trading Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading Market</U>&rdquo;
means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the
OTCQB, OTCQX or Pink Open Market operated by OTC Markets Group, the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market,
the Nasdaq Global Select Market, or the New York Stock Exchange (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transfer Agent</U>&rdquo;
means West Coast Stock Transfer, Inc., 721 N. Vulcan Ave. 1st FL, Encinitas, CA 92024&nbsp;, and any successor transfer agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrants</U>&rdquo;
means this Warrant and other Pre-Funded Common Stock Purchase Warrants issued by the Company pursuant to the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 2</U>. <U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a) Exercise of the
purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Issue Date and on or
before the Termination Date by delivery to the Company of a duly executed facsimile copy (or e-mail attachment) of the Notice of Exercise
in the form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;). Within the earlier of (i) one (1) Trading Day and (ii) the number
of Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid,
the Holder shall deliver to the Company the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice of Exercise
by wire transfer or cashier&rsquo;s check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c)
below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion
guarantee (or other type of guarantee or notarization) of any Notice of Exercise form be required. Notwithstanding anything herein to
the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all
of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant
to the Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise is delivered to the Company.
Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall
have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number
of Warrant Shares purchased in connection with such partial exercise. The Holder and the Company shall maintain records showing the number
of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one
(1) Trading Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that,
by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant
Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b) <U>Exercise Price</U>.
The aggregate exercise price of this Warrant, except for a nominal exercise price of $0.0001 per Warrant Share, was pre-funded to the
Company on or prior to the Issue Date and, consequently, no additional consideration (other than the nominal exercise price of $0.001
per Warrant Share) shall be required to be paid by the Holder to any Person to effect any exercise of this Warrant. The Holder shall not
be entitled to the return or refund of all, or any portion, of such pre-paid aggregate exercise price under any circumstance or for any
reason whatsoever, including in the event this Warrant shall not have been exercised prior to the Termination Date. The remaining unpaid
exercise price per share of Common Stock under this Warrant shall be $0.0001, subject to adjustment hereunder (the &ldquo;<U>Exercise
Price</U>&rdquo;).<FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Cashless Exercise</U>.
This Warrant may also be exercised, in whole or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder
shall be entitled to receive a number of Warrant Shares for the deemed surrender of the Warrant in whole or in part equal to the quotient
obtained by dividing [(A-B) (X)] by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.35in; font-size: 10pt"><FONT STYLE="font-size: 10pt">(A) =</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">as applicable: (i) the Closing Sale Price of the Common Stock on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule 600(b)(68) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (x) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (y) the Bid Price of the Common Stock as of the time of the Holder&rsquo;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading hours&rdquo; on a Trading Day and is delivered within two (2) hours thereafter pursuant to Section 2(a) hereof (including until two (2) hours after the close of &ldquo;regular trading hours&rdquo; on a Trading Day), or (iii) the Closing Sale Price of the Common Stock on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of &ldquo;regular trading hours&rdquo; on such Trading Day;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.35in; font-size: 10pt"><FONT STYLE="font-size: 10pt">(B) =</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the Exercise Price of this Warrant, as adjusted hereunder; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.35in; font-size: 10pt"><FONT STYLE="font-size: 10pt">(X) =</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">The
issue price for each such Warrant Share to be issued pursuant to the cashless exercise of a Warrant will be equal to (B), as defined above,
and the total issue price for the aggregate number of Warrant Shares issued pursuant to the cashless exercise of a Warrant will be deemed
paid and satisfied in full by the deemed surrender to the Company of the portion of such Warrant being exercised in accordance with this
Section 1(c). Notwithstanding anything herein to the contrary, the Company shall not be required to make any cash payments or net cash
settlement to the Holder in lieu of delivery of the Warrant Shares. If Warrant Shares are issued in such a cashless exercise, the parties
acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the Warrant Shares shall take on the registered characteristics
of the Warrants being exercised. The Company agrees not to take any position contrary to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Bid Price</U>&rdquo;
means, for any security as of the particular time of determination, the bid price for such security on the Trading Market as reported
by Bloomberg as of such time of determination, or, if the Trading Market is not the principal securities exchange or trading market for
such security, the bid price of such security on the principal securities exchange or trading market where such security is listed or
traded as reported by Bloomberg as of such time of determination, or if the foregoing does not apply, the bid price of such security in
the over-the-counter market on the electronic bulletin board for such security as reported by Bloomberg as of such time of determination,
or, if no bid price is reported for such security by Bloomberg as of such time of determination, the average of the bid prices of any
market makers for such security as reported on the Pink Open Market as of such time of determination. If the Bid Price cannot be calculated
for a security as of the particular time of determination on any of the foregoing bases, the Bid Price of such security as of such time
of determination shall be the fair market value as mutually determined by the Company and the Holder. If the Company and the Holder are
unable to agree upon the fair market value of such security, then such fair market value shall be determined pursuant to the provisions
set forth in clause (d) of the definition of VWAP. All such determinations to be appropriately adjusted for any stock dividend, share
split, share consolidation, reclassification or other similar transaction during the applicable calculation period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing
Sale Price</U>&rdquo; means, for any security as of any date, the last closing trade price for such security on the Trading Market, as
reported by Bloomberg, or, if the Trading Market begins to operate on an extended hours basis and does not designate the closing trade
price, then the last trade price of such security prior to 4:00:00 p.m., New York time, as reported by Bloomberg, or, if the Trading Market
is not the principal securities exchange or trading market for such security, the last trade price of such security on the principal securities
exchange or trading market where such security is listed or traded as reported by Bloomberg, or if the foregoing do not apply, the last
trade price of such security in the over-the-counter market on the electronic bulletin board for such security as reported by Bloomberg,
or, if no last trade price is reported for such security by Bloomberg, the average of the ask prices of any market makers for such security
as reported on the in the OTC Link or on the Pink Open Market. If the Closing Sale Price cannot be calculated for a security on a particular
date on any of the foregoing bases, Closing Sale Price of such security on such date shall be the fair market value as mutually determined
by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair market value of such security, then such
fair market value shall be determined pursuant to the provisions set forth in clause (d) of the definition of VWAP. All such determinations
to be appropriately adjusted for any stock dividend, share split, share consolidation, reclassification or other similar transaction during
the applicable calculation period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted for trading on a Trading Market other than the OTCQB, OTCQX or Pink Open Market operated by OTC Markets Group, the daily volume
weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock
is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York
City time)), (b) if the Common Stock is then quoted for trading on the OTCQB or OTCQX operated by OTC Markets Group, the volume weighted
average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, or (c) in all other cases,
the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the holders of a
majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be
paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d) <U>Mechanics
of Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">i. <U>Delivery of
Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent
to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository Trust Company
through its Deposit or Withdrawal at Custodian system (the &ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant in such system
and either (A) there is an effective registration statement or offering statement permitting the issuance of the Warrant Shares to or
resale of the Warrant Shares by the Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by physical delivery
of a certificate, registered in the Company&rsquo;s share register in the name of the Holder or its designee, for the number of Warrant
Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the
date that is the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period after
the delivery to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;). Upon delivery
of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the Holder of record of the Warrant Shares
with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment
of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i) one (1) Trading
Days after the delivery to the Company of the Notice of Exercise and (ii) the number of Trading Days comprising the Standard Settlement
Period following delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject
to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not
as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable
Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the third Trading Day after the Warrant Share Delivery
Date) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered to said Holder or the Holder
rescinds such exercise. The Company agrees to maintain a Transfer Agent that is a participant in the Fast Automated Securities Transfer
or FAST program so long as this Warrant remains outstanding and exercisable. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo;
means the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s primary Trading Market with respect
to the Common Stock as in effect on the date of delivery of the Notice of Exercise. Notwithstanding the foregoing, with respect to any
Notice(s) of Exercise delivered on or prior to 12:00 p.m. (New York City time) on the Issue Date, which may be delivered at any time after
the time of execution of the Underwriting Agreement, dated August 7, 2025 between the Company and ThinkEquity LLC, the Company agrees
to deliver the Warrant Shares subject to such notice(s) by 4:00 p.m. (New York City time) on the Issue Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii. <U>Delivery
of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and
upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing
the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects
be identical with this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">iii. <U>Rescission
Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i)
by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">iv. <U>Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to the Holder, if
the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section
2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its
broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares of Common
Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise
(a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&rsquo;s
total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained
by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise
at issue by (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder,
either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which
case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued
had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases shares of Common
Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of Common Stock with an aggregate
sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall
be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder
in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&rsquo;s
right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific
performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common Stock upon exercise
of the Warrant as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">v. <U>No Fractional
Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As
to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election,
either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or
round up to the next whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">vi. <U>Charges,
Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental
expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant
Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>, <U>however</U>,
that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for
exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition
thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent
fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing
corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">vii. <U>Closing
of Books</U>. The Company shall not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e) <U>Holder&rsquo;s
Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise
any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise
as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other Persons acting
as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;Attribution Parties&rdquo;)), would
beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number
of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of shares
of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number
of shares of Common Stock which would be issuable upon (i) exercise of the remaining, non-exercised portion of this Warrant beneficially
owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or non-converted
portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation
on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution
Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in
accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder
that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the
Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained
in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder
together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion
of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination of whether this Warrant
is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which
portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation
to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall
be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes
of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding
shares of Common Stock as reflected in (A) the Company&rsquo;s most recent periodic or annual report filed with the Commission, as the
case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent
setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within
two Trading Days confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number
of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company,
including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares
of Common Stock was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be 4.99% (or, upon election by a Holder prior
to the issuance of any Warrants, 9.99%) of the number of shares of Common Stock outstanding immediately after giving effect to the issuance
of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial
Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the
number of shares of Common Stock outstanding immediately after giving effect to the issuance of Common Stock upon exercise of this Warrant
held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation
will not be effective until the 61<SUP>st</SUP> day after such notice is delivered to the Company. The provisions of this paragraph shall
be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph
(or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to
make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph
shall apply to a successor holder of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 3</U>. <U>Certain
Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a) <U>Stock Dividends
and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution
or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which,
for avoidance of doubt, shall not include any Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding
shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split or consolidation) outstanding
Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of Common Stock any shares of the Company,
then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common
Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of
shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall
be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant
to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive
such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination
or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b) <U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells
any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of shares
of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire, upon the terms applicable to
such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of
Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without
limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale
of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined
for the grant, issue or sale of such Purchase Rights (provided, however, to the extent that the Holder&rsquo;s right to participate in
any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled
to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase
Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its
right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Pro Rata Distributions</U>.
During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets
(or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation,
any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement,
scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;), at any time after the issuance of this Warrant,
then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have
participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without
regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the
date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares
of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>, <U>however</U>, to the extent that the
Holder&rsquo;s right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation,
then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares
of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the
benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership
Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d) <U>Fundamental
Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions
effects any merger or amalgamation or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly,
effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one
or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company
or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other
securities, cash or property and has been accepted by the holders of 50% or more of the outstanding shares of Common Stock or 50% or more
of the voting power of the common equity of the Company, (iv) the Company, directly or indirectly, in one or more related transactions
effects any reclassification, reorganization or recapitalization of shares of Common Stock or any compulsory share exchange pursuant to
which shares of Common Stock are effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly
or indirectly, in one or more related transactions consummates a share purchase agreement or other business combination (including, without
limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person or group of Persons whereby such
other Person or group acquires more than 50% of the outstanding shares of Common Stock or more of the outstanding Common Stock or 50%
or more of the voting power of the common equity of the Company (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon any
subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable
upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to
any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation
or of the Company, if it is the surviving corporation or is otherwise the continuing corporation, and any additional consideration (the
&ldquo;<U>Alternate Consideration</U>&rdquo;) receivable as a result of such Fundamental Transaction by a holder of the number of shares
of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation
in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be
appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of
shares of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration
in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common
Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be
given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction.
The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<U>Successor
Entity</U>&rdquo;) to assume in writing all of the obligations of the Company under this Warrant in accordance with the provisions of
this Section 3(d) pursuant to written agreements prior to such Fundamental Transaction and shall, at the option of the Holder, deliver
to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar
in form and substance to this Warrant which is exercisable for a corresponding number of shares or other securities of such Successor
Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without
regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies
the exercise price hereunder to such shares of or other securities (but taking into account the relative value of the shares of Common
Stock pursuant to such Fundamental Transaction and the value of such shares or securities, such number of shares or securities and such
exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental
Transaction). Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so
that from and after the date of such Fundamental Transaction, the provisions of this Warrant referring to the &ldquo;Company&rdquo; shall
refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations
of the Company under this Warrant with the same effect as if such Successor Entity had been named as the Company herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e) <U>Calculations</U>.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes
of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the
number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f) <U>Notice to
Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">i. <U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly
deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii. <U>Notice to
Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock,
(B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize
the granting to all holders of the shares of Common Stock rights or warrants to subscribe for or purchase any shares of the Company or
of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification of the Common
Stock, any consolidation or merger, amalgamation or arrangement to which the Company is a party, any sale or transfer of all or substantially
all of the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or
property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the
Company, then, in each case, the Company shall cause to be delivered by facsimile or email to the Holder at its last facsimile number
or email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record
or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend,
distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock
of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which
such reclassification, consolidation, merger, amalgamation, arrangement, sale, transfer or share exchange is expected to become effective
or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares
of Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, amalgamation, arrangement
sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall
not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this
Warrant constitutes, or contains, material, non-public information regarding the Company or any of its subsidiaries (the &ldquo;<U>Subsidiaries</U>&rdquo;),
the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain
entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering
such notice except as may otherwise be expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 4</U>. <U>Transfer
of Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a) <U>Transferability</U>.
This Warrant and all rights hereunder are transferable, in whole or in part, upon surrender of this Warrant at the principal office of
the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly
executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer.
Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the
assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue
to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding
anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder
has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days
of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. This Warrant, if properly assigned
in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b) <U>New Warrants</U>.
This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together
with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent
or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company
shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with
such notice. All Warrants issued on transfers or exchanges shall be dated the original Issue Date of this Warrant and shall be identical
with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Warrant Register</U>.
The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;<U>Warrant Register</U>&rdquo;),
in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the
absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual
notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 5</U>. <U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a) <U>No Rights
as Stockholder Until Exercise</U>. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder
of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3. <FONT STYLE="background-color: white">Without
limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant to Section 2(c) or to receive
cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event, including if the Company is for any reason unable
to issue and deliver Warrant Shares upon exercise of this Warrant as required pursuant to the terms thereof, shall the Company be required
to net cash settle an exercise of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b) <U>Loss, Theft,
Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to
it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which shall in no event include the posting of
any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company shall make and deliver
a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Saturdays,
Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or granted
herein shall not be a Trading Day, then, such action may be taken or such right may be exercised on the next succeeding Trading Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d) <U>Authorized
Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">The Company covenants
that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued shares of Common Stock a sufficient
number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company
further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing
the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company shall take all such reasonable action
as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation,
or of any requirements of the Trading Market upon which the Common Stock may be listed or quoted for trading. The Company covenants that
all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the
purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued,
fully paid and non-assessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other
than taxes in respect of any transfer occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Except and to the
extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate
of incorporation or through any reorganization, transfer of assets, consolidation, merger, amalgamation, arrangement dissolution, issue
or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this
Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may
be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality
of the foregoing, the Company shall (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise
immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company
may validly and legally issue fully paid and non-assessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially
reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof,
as may be, necessary to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Before taking any
action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price,
the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e) <U>Governing
Law</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and
construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflict of
laws thereof. Each party agrees that all legal Proceedings concerning the interpretation, enforcement and defense of this Warrant shall
be commenced in the state and federal courts sitting in the City of New York, Borough of Manhattan (the &ldquo;<U>New York Courts</U>&rdquo;).
Each party hereto hereby irrevocably submits to the exclusive jurisdiction of the New York Courts for the adjudication of any dispute
hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement
of any provision hereunder), and hereby irrevocably waives, and agrees not to assert in any suit, action or Proceeding, any claim that
it is not personally subject to the jurisdiction of such New York Courts, or such New York Courts are improper or inconvenient venue for
such Proceeding. If any party shall commence an action or Proceeding to enforce any provisions of this Warrant, then the prevailing party
in such action or Proceeding shall be reimbursed by the other party for its attorneys&rsquo; fees and other costs and expenses incurred
in the investigation, preparation and prosecution of such action or Proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f) <U>Restrictions</U>.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not
utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">g) <U>Nonwaiver
and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as
a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision of this
Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages
to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but
not limited to, reasonable attorneys&rsquo; fees, including those of appellate Proceedings, incurred by the Holder in collecting any amounts
due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">h) <U>Notices</U>.
Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without limitation, any Notice
of Exercise, shall be in writing and delivered personally, by facsimile or by e-mail, or sent by a nationally recognized overnight courier
service, addressed to the Company, at 680 W Nye Lane Suite 204, Carson City, NV 89703, Attention: Wendy Kim, email address: wkim@bioviepharma.com
or such other email address or address as the Company may specify for such purposes by notice to the Holders. Any and all notices or other
communications or deliveries to be provided by the Company hereunder shall be in writing and delivered personally, by facsimile, email
or sent by a nationally recognized overnight courier service addressed to each Holder at the facsimile number, email address or address
of such Holder appearing on the books of the Company. Any notice or other communication or deliveries hereunder shall be deemed given
and effective on the earliest of (i) the time of transmission, if such notice or communication is delivered via facsimile at the facsimile
number or e-mail at the e-mail address set forth in this Section prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading
Day after the date of transmission, if such notice or communication is delivered via facsimile at the facsimile number or e-mail at the
e-mail address set forth in this Section on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading
Day, (iii) the second Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (iv)
upon actual receipt by the party to whom such notice is required to be given.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">i) <U>Limitation
of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant
Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase
price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">j) <U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any
action for specific performance that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">k) <U>Successors
and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the
benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder.
The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable
by the Holder or holder of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">l) <U>Amendment</U>.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand, and
the Holder on the other hand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">m) <U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">n) <U>No Expense
Reimbursement</U>. The Holder shall in no way be required the pay, or to reimburse the Company for, any fees or expenses of the Company&rsquo;s
transfer agent in connection with the issuance or holding or sale of the Common Stock, Warrant and/or Warrant Shares. The Company shall
solely be responsible for any and all such fees and expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">o) <U>Headings</U>.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Page Follows)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>BIOVIE, INC.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 46%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.75pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.75pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Name:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;Cuong V Do</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%; font-size: 10pt"><FONT STYLE="font-size: 10pt; text-transform: uppercase">To:</FONT></TD>
    <TD STYLE="width: 60%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase">BIOVIE INC.</FONT></TD>
    <TD STYLE="width: 20%">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(1) The undersigned hereby elects
to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders
herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(2) Payment shall take the form
of (check applicable box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT>
in lawful money of the United States; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT>
the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise
this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in
subsection 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(3) Please issue said Warrant
Shares in the name of the undersigned or in such other name as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrant Shares shall be delivered to the following
DWAC Account Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 5%; padding-bottom: 1.75pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Name of Investing Entity:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="width: 95%; border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 5%; padding-bottom: 1.75pt; font-size: 10pt"><FONT STYLE="font-size: 10pt"><I>Signature of Authorized Signatory of Investing Entity</I>:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="width: 95%; border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 5%; padding-bottom: 1.75pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Name of Authorized Signatory:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="width: 95%; border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 5%; padding-bottom: 1.75pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Title of Authorized Signatory:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="width: 95%; border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 5%; padding-bottom: 1.75pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="width: 95%; border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.75pt solid; white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ASSIGNMENT FORM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt"><I>(To assign the foregoing
Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">FOR VALUE RECEIVED, the foregoing
Warrant and all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-bottom: 1.75pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="padding-bottom: 1.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.75pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">(Please Print)</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-bottom: 1.75pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="padding-bottom: 1.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.75pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">(Please Print)</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-bottom: 1.75pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Phone Number:</FONT></TD>
    <TD STYLE="padding-bottom: 1.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.75pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-bottom: 1.75pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Email Address:</FONT></TD>
    <TD STYLE="padding-bottom: 1.75pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.75pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Dated: _____________________ __, ______</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 5%; padding-bottom: 1.75pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Holder&rsquo;s Signature:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="width: 40%; border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="width: 5%; padding-bottom: 1.75pt">&nbsp;</TD>
    <TD STYLE="width: 40%; padding-bottom: 1.75pt">&nbsp;</TD>
    <TD STYLE="width: 10%; padding-bottom: 1.75pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.75pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Holder&rsquo;s Address:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.75pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.75pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.75pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->-</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>4
<FILENAME>bivi-20250807_ex4z3.htm
<DESCRIPTION>EXHIBIT 4.3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 4.3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Representative&rsquo;s Warrant Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">THE REGISTERED HOLDER OF THIS PURCHASE WARRANT
BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT EXCEPT AS HEREIN PROVIDED AND THE REGISTERED
HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT FOR A PERIOD
OF ONE HUNDRED EIGHTY (180) DAYS FOLLOWING THE EFFECTIVE DATE (DEFINED BELOW) TO ANYONE OTHER THAN (I) THINKEQUITY LLC OR AN UNDERWRITER
OR A SELECTED DEALER IN CONNECTION WITH THE OFFERING, OR (II) A BONA FIDE OFFICER OR PARTNER OF THINKEQUITY LLC OR OF ANY SUCH UNDERWRITER
OR SELECTED DEALER.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">THIS PURCHASE WARRANT IS NOT EXERCISABLE PRIOR
TO AUGUST 11, 2025. VOID AFTER 5:00 P.M., EASTERN TIME ON AUGUST 11, 2030.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>COMMON STOCK PURCHASE WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the Purchase of __________ Shares of Common
Stock,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Par Value $0.0001 per Share,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">BioVie Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1. <U>Purchase Warrant</U>.
THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of ThinkEquity LLC (&ldquo;<B>Holder</B>&rdquo;), as registered
owner of this Purchase Warrant, BioVie Inc., a Nevada corporation (the &ldquo;<B>Company</B>&rdquo;), Holder is entitled, at any time
or from time to time from August 11, 2025 (the &ldquo;<B>Commencement Date</B>&rdquo;), and at or before 5:00 p.m., New York City time,
August 11, 2030 (the &ldquo;<B>Expiration Date</B>&rdquo;), but not thereafter, to subscribe for, purchase and receive, in whole or in
part, up to _________ shares of common stock of the Company, par value $0.0001 per share (the &ldquo;<B>Shares</B>&rdquo;), subject to
adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions in the State of New York are
authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance
with the terms hereof. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate
this Purchase Warrant. This Purchase Warrant is initially exercisable at $2.50 per Share; <I>provided, however</I>, that upon the occurrence
of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share
and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term &ldquo;<B>Exercise Price</B>&rdquo;
shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term &ldquo;<B>Effective Date</B>&rdquo;
shall mean August 7, 2025, the date on which the Registration Statement on Form S-1 (File No. 333-288525) of the Company was declared
effective by the Securities and Exchange Commission (the &ldquo;<B>Commission</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2. <U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.1 <U>Exercise Form</U>.
In order to exercise this Purchase Warrant, the exercise form attached hereto (the &ldquo;<B>Notice of Exercise</B>&rdquo;) must be duly
executed and completed and delivered to the Company, together with this Purchase Warrant and payment of the Exercise Price for the Shares
being purchased payable in cash by wire transfer of immediately available funds to an account designated by the Company or by certified
check or official bank check unless the cashless exercise procedure specified in Section 2.2 below is specified in the applicable Notice
of Exercise. If the subscription rights represented hereby shall not be exercised at or before 5:00 p.m., Eastern time, on the Expiration
Date, this Purchase Warrant shall become and be void without further force or effect, and all rights represented hereby shall cease and
expire. Each exercise hereof shall be irrevocable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.2 <U>Cashless Exercise</U>.
In lieu of exercising this Purchase Warrant by payment by wire transfer or cashier's check pursuant to Section 2.1 above, this Purchase
Warrant may also be exercised, in whole or in part, at such time by means of a &quot;cashless exercise&quot; in which the Holder shall
be entitled to receive the number of Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(A)</TD><TD STYLE="text-align: justify">= as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice
of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2.1 hereof on a day that is not a Trading
Day or (2) both executed and delivered pursuant to Section 2.1 hereof on a Trading Day prior to the opening of &quot;regular trading hours&quot;
(as defined in Rule 600(b)(64) of Regulation NMS promulgated under the federal securities laws, &ldquo;Regular Trading Hours&rdquo;) on
such Trading Day, (ii) at the option of the Holder, either (x) the VWAP on the Trading Day immediately preceding the date of the applicable
Notice of Exercise or (y) the Bid Price of the Shares on the principal Trading Market as reported by Bloomberg L.P. as of the time of
the Holder's execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &quot;regular trading hours&quot;
on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of Regular Trading Hours
on a Trading Day) pursuant to Section 2(a) hereof, which Bid Price shall be shown on supporting documents provided by the Holder to the
Company within two (2) Trading Days of delivery of the Notice of Exercise or (iii) the VWAP on the date of the applicable Notice of Exercise
if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section
2(a) hereof after the close of Regular Trading Hours on such Trading Day;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(B)</TD><TD STYLE="text-align: justify">= the Exercise Price of this Purchase Warrant, as adjusted hereunder; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -21.25pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(X)</TD><TD STYLE="text-align: justify">= the number of Shares that would be issuable upon exercise of
this Purchase Warrant in accordance with the terms of this Purchase Warrant if such exercise were by means of a cash exercise rather
than a cashless exercise.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If Shares are issued in such
a &ldquo;cashless exercise&rdquo;, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act of
1933, as amended (the &ldquo;<B>Securities Act</B>&rdquo;), the Shares shall take on the securities law characteristics of the Purchase
Warrants being exercised, and the holding period of the Purchase Warrants being exercised may be tacked on to the holding period of the
Shares. The Company agrees not to take any position contrary to this Section 2.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Bid Price&rdquo;</B>
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Shares are then listed or quoted
on a Trading Market, the bid price of the Shares for the time in question (or the nearest preceding date) on the Trading Market on which
the Shares are then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02
p.m. (New York City time)), (b) if the Shares are then quoted on the OTCQB or the OTCQX but not listed on any Trading Market, the volume
weighted average price of a Share for such date (or the nearest preceding date) on the OTCQB or OTCQX as applicable, (c) if the Shares
are not then listed or quoted for trading on any of a Trading Market, the OTCQB or the OTCQX and if prices for the Shares are then reported
on the OTC Pink Open Market or successors thereto (or a similar organization or agency succeeding to its functions of reporting prices),
the most recent bid price per Share so reported, or (d) in all other cases, the fair market value of the Shares as determined by an independent
appraiser selected in good faith by the Holder and reasonably acceptable to the Company, the fees and expenses of which shall be paid
by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Trading Day</B>&rdquo;
means a day on which the Trading Market is open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Trading Market&rdquo;</B>
means any of the following markets or exchanges on which the Shares are listed or quoted for trading on the date in question: the NYSE
American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange or any successors
to any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>VWAP</B>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Shares are then listed or quoted
on a Trading Market, the daily volume weighted average price of the Shares for such date (or the nearest preceding date) on the Trading
Market on which the Shares are then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City
time) to 4:02 p.m. (New York City time)), (b) if the Shares are then quoted on the OTCQB or the OTCQX but not listed on any Trading Market,
the volume weighted average price of a Share for such date (or the nearest preceding date) on the OTCQB or the OTCQX as applicable, (c)
if Shares are not then listed or quoted for trading on the OTCQB or the OTCQX and if prices for the Shares are then reported on the OTC
Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the daily volume weighted average
price of the Shares for such date (or the nearest preceding date), or (d) in all other cases, the fair market value of the Shares as determined
by an independent appraiser selected in good faith by the Holder and reasonably acceptable to the Company, the fees and expenses of which
shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.3 <U>Mechanics of Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">2.3.1 <U>Delivery
of Shares Upon Exercise</U>. The Company shall cause the Shares purchased hereunder to be transmitted by its transfer agent to the Holder
by crediting the account of the Holder's or its designee's balance account with The Depository Trust Company through its Deposit or Withdrawal
at Custodian system (&quot;<B>DWAC</B>&quot;) if the Company is then a participant in such system and either (A) there is an effective
registration statement permitting the issuance of the Shares to or resale of the Shares by Holder, or (B) the Shares are eligible for
resale by the Holder without volume or manner-of-sale limitations pursuant to Rule 144 and, in either case, the Shares have been sold
by the Holder prior to the Warrant Share Delivery Date (as defined below), and otherwise by physical delivery of a certificate, registered
in the Company's share register in the name of the Holder or its designee, for the number of Shares to which the Holder is entitled pursuant
to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is two (2) Trading Days after the delivery
to the Company of the Notice of Exercise (such date, the &ldquo;<B>Warrant Share Delivery Date</B>&rdquo;); provided that the Company
shall not be obligated to deliver the Shares hereunder unless the Company has received the aggregate Exercise Price on or before the Warrant
Share Delivery Date. If the Shares can be delivered via DWAC, the transfer agent shall have received from the Company, at the expense
of the Company, any legal opinions or other documentation required by it to deliver such Warrant Shares without legend (subject to receipt
by the Company of reasonable back up documentation from the Holder, including with respect to affiliate status) and, if applicable and
requested by the Company prior to the Warrant Share Delivery Date, the transfer agent shall have received from the Holder a confirmation
of sale of the Shares (provided the requirement of the Holder to provide a confirmation as to the sale of Shares shall not be applicable
to the issuance of unlegended Shares upon a cashless exercise of this Purchase Warrant if the Shares are then eligible for resale pursuant
to Rule 144(b)(l)). The Shares shall be deemed to have been issued, and Holder or any other person so designated to be named therein shall
be deemed to have become a holder of record of such shares for all purposes, as of the date the Purchase Warrant has been exercised, with
payment to the Company of the Exercise Price (or by cashless exercise, if permitted) and all taxes required to be paid by the Holder,
if any, pursuant to Section 2.3.6 prior to the issuance of such shares, having been paid. If the Company fails for any reason to deliver
to the Holder the Shares subject to a Notice of Exercise by the second Trading Day following the Warrant Share Delivery Date; provided
that payment of the aggregate Exercise Price (other than in the instance of a cashless exercise) is received by the Company by such date,
the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Shares subject to such exercise
(based on the VWAP of the Shares on the date of the applicable Notice of Exercise), $5 per Trading Day (increasing to $10 per Trading
Day on the fifth Trading Day after such liquidated damages begin to accrue) for each Trading Day after the second Trading Day following
such Warrant Share Delivery Date until such Shares are delivered or Holder rescinds such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">2.3.2 <U>Delivery
of New Warrants Upon Exercise</U>. If this Purchase Warrant shall have been exercised in part, the Company shall, at the request of a
Holder and upon surrender of this Purchase Warrant certificate, at the time of delivery of the Shares, deliver to the Holder a new Warrant
evidencing the rights of the Holder to purchase the unpurchased Shares called for by this Warrant, which new Warrant shall in all other
respects be identical with this Purchase Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">2.3.3 <U>Rescission
Rights</U>. If the Company fails to cause its transfer agent to deliver to the Holder the Shares pursuant to Section 2.3.1 by the Warrant
Share Delivery Date, then the Holder will have the right to rescind such exercise; provided, however, that the Holder shall be required
to return any Shares subject to any such rescinded exercise notice concurrently with the return to Holder of the aggregate Exercise Price
paid to the Company for such Shares and the restoration of Holder's right to acquire such Shares pursuant to this Purchase Warrant (including,
issuance of a replacement warrant certificate evidencing such restored right).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">2.3.4 <U>Compensation
for Buy-In on Failure to Timely Deliver Shares Upon Exercise</U>. In addition to any other rights available to the Holder, if the Company
fails to cause its transfer agent to transmit to the Holder the Shares pursuant to an exercise on or before the Warrant Share Delivery
Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder's
brokerage firm otherwise purchases, Shares to deliver in satisfaction of a sale by the Holder of the Shares which the Holder anticipated
receiving upon such exercise (a &ldquo;<B>Buy-In</B>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount, if any,
by which (x) the Holder's total purchase price (including brokerage commissions, if any) for the Shares so purchased exceeds (y) the amount
obtained by multiplying (1) the number of Shares that the Company was required to deliver to the Holder in connection with the exercise
at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the
Holder, either reinstate the portion of the Purchase Warrant and equivalent number of Shares for which such exercise was not honored (in
which case such exercise shall be deemed rescinded) or deliver to the Holder the number of Shares that would have been issued had the
Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Shares having a total
purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of Shares with an aggregate sale price giving rise to
such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder
$1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and,
upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder's right to pursue any other remedies
available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief
with respect to the Company's failure to timely deliver Shares upon exercise of the Purchase Warrant as required pursuant to the terms
hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">2.3.5 <U>No Fractional
Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Purchase Warrant.
As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election,
either (a) pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price
or (b) round up to the next whole share if such fraction is greater than or equal to one-half or round down to the next whole share if
such fraction is less than one-half.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">2.3.6 <U>Charges,
Taxes and Expenses</U>. Issuance of Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental
expense in respect of the issuance of such Shares, all of which taxes and expenses shall be paid by the Company, and such Shares shall
be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided, however, that in the event that
Shares are to be issued in a name other than the name of the Holder, this Purchase Warrant when surrendered for exercise shall be accompanied
by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of
a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all transfer agent fees required for same-day
processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing
similar functions) required for same-day electronic delivery of the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">2.3.7 <U>Closing
of Books</U>. The Company will not close its shareholder books or records in any manner which prevents the timely exercise of this Purchase
Warrant, pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">2.3.8 <U>Signature</U>.
This Section 2 and the exercise form attached hereto set forth the totality of the procedures required of the Holder in order to exercise
this Purchase Warrant. Without limiting the preceding sentences, no ink-original exercise form shall be required, nor shall any medallion
guarantee (or other type of guarantee or notarization) of any exercise form be required in order to exercise this Purchase Warrant. No
additional legal opinion, other information or instructions shall be required of the Holder to exercise this Purchase Warrant. The Company
shall honor exercises of this Purchase Warrant and shall deliver Shares underlying this Purchase Warrant in accordance with the terms,
conditions and time periods set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.4 <U>Holder's Exercise Limitations</U>.
The Company shall not effect any exercise of this Purchase Warrant, and a Holder shall not have the right to exercise any portion of this
Purchase Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth
on the applicable Notice of Exercise, the Holder (together with the Holder's Affiliates (as defined below), and any other Persons (as
defined below) acting as a group together with the Holder or any of the Holder's affiliates), would beneficially own in excess of the
Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of Shares beneficially owned by
the Holder and its Affiliates shall include the number of Shares issuable upon exercise of this Purchase Warrant with respect to which
such determination is being made, but shall exclude the number of Shares which would be issuable upon (i) exercise of the remaining, nonexercised
portion of this Purchase Warrant beneficially owned by the Holder or any of its Affiliates and (ii) exercise or conversion of the unexercised
or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents (as
defined below)) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the
Holder or any of its Affiliates. Except as set forth in the preceding sentence, for purposes of this Section 2.4, beneficial ownership
shall be calculated in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended (the &ldquo;<B>Exchange Act</B>&rdquo;)
and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the
Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules
required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2.4 applies, the determination
of whether this Purchase Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates) and
of which portion of this Purchase Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice
of Exercise shall be deemed to be the Holder's determination of whether this Purchase Warrant is exercisable (in relation to other securities
owned by the Holder together with any Affiliates) and of which portion of this Purchase Warrant is exercisable, in each case subject to
the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination.
In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the
Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2.4, in determining the number of outstanding
Shares, a Holder may rely on the number of outstanding Shares as reflected in (A) the Company's most recent periodic or annual report
filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice
by the Company or the Company's transfer agent setting forth the number of Shares outstanding. Upon the written or oral request of a Holder,
the Company shall within two Trading Days (as defined herein) confirm orally and in writing to the Holder the number of Shares then outstanding.
In any case, the number of outstanding Shares shall be determined after giving effect to the conversion or exercise of securities of the
Company, including this Purchase Warrant, by the Holder or its Affiliates since the date as of which such number of outstanding Shares
was reported. The &ldquo;<B>Beneficial Ownership Limitation&rdquo;</B> shall be 4.99% of the number of Shares outstanding immediately
after giving effect to the issuance of Shares issuable upon exercise of this Purchase Warrant. The Holder, upon notice to the Company,
may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2.4, provided that the Beneficial Ownership Limitation
in no event exceeds 9.99% of the number of Shares outstanding immediately after giving effect to the issuance of Shares upon exercise
of this Warrant held by the Holder and the provisions of this Section 2.4 shall continue to apply. Any increase in the Beneficial Ownership
Limitation will not be effective until the 61st day after such notice is delivered to the Company. The provisions of this paragraph shall
be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2.4 to correct this paragraph
(or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to
make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph
shall apply to a successor holder of this Purchase Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Affiliate</B>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Common Stock Equivalents&rdquo;</B>
means any securities of the Company that would entitle the holder thereof to acquire Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Person</B>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.5 <U>Legend</U>. Each certificate
for the securities purchased under this Purchase Warrant shall bear a legend as follows unless such securities have been registered under
the Securities Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;THE SECURITIES REPRESENTED BY
THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;), OR APPLICABLE
STATE LAW. NEITHER THE SECURITIES NOR ANY INTEREST THEREIN MAY BE OFFERED FOR SALE, SOLD OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN
EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT, OR PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT AND
APPLICABLE STATE LAW WHICH, IN THE OPINION OF COUNSEL TO THE COMPANY, IS AVAILABLE.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3. <U>Transfer</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.1 <U>General Restrictions</U>.
The registered Holder of this Purchase Warrant agrees by his, her or its acceptance hereof, that such Holder will not: (a) sell, transfer,
assign, pledge or hypothecate this Purchase Warrant or the securities issuable hereunder for a period of one hundred eighty (180) days
following the Effective Date to anyone other than: (i) ThinkEquity LLC (&ldquo;<B>ThinkEquity</B>&rdquo;) or an underwriter or a selected
dealer participating in the Offering, or (ii) a <I>bona fide</I> officer or partner of ThinkEquity or of any such underwriter or selected
dealer, in each case in accordance with FINRA Rule 5110(e)(1), or (b) for a period of one hundred eighty (180) days following the Effective
Date, cause this Purchase Warrant or the securities issuable hereunder to be the subject of any hedging, short sale, derivative, put or
call transaction that would result in the effective economic disposition of this Purchase Warrant or the securities hereunder, except
as provided for in FINRA Rule 5110(e)(2). On and after one hundred eighty (180) days after the Effective Date, transfers to others may
be made subject to compliance with or exemptions from applicable securities laws. In order to make any permitted assignment, the Holder
must deliver to the Company the assignment form attached hereto duly executed and completed, together with the Purchase Warrant and payment
of all transfer taxes, if any, payable in connection therewith. The Company shall within five (5) Trading Days transfer this Purchase
Warrant on the books of the Company and shall execute and deliver a new Purchase Warrant or Purchase Warrants of like tenor to the appropriate
assignee(s) expressly evidencing the right to purchase the aggregate number of Shares purchasable hereunder or such portion of such number
as shall be contemplated by any such assignment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.2 <U>Restrictions Imposed
by the Securities Act</U>. The securities evidenced by this Purchase Warrant shall not be transferred unless and until: (i) the Company
has received the opinion of counsel for the Holder that the securities may be transferred pursuant to an exemption from registration under
the Securities Act and applicable state securities laws, the availability of which is established to the reasonable satisfaction of the
Company (the Company hereby acknowledges and agrees that the opinion of McGuireWoods LLP shall be deemed satisfactory evidence of the
availability of an exemption), or (ii) a registration statement or a post-effective amendment to the Registration Statement relating to
the offer and sale of such securities has been filed by the Company and declared effective by the Commission and compliance with applicable
state securities law has been established.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4. <U>Registration Rights</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.1 <U>Demand Registration</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">4.1.1 <U>Grant of
Right</U>. The Company, upon written demand (a &ldquo;<B>Demand Notice</B>&rdquo;) of the Holders of at least 51% of the Purchase Warrants
and/or underlying Shares, agrees to register, on one (1) occasion, all or any portion of the Shares underlying the Purchase Warrants (collectively,
the &ldquo;<B>Registrable Securities</B>&rdquo;). On such occasion, the Company will file a registration statement with the Commission
covering the Registrable Securities within sixty (60) days after receipt of a Demand Notice and use its reasonable best efforts to have
the registration statement declared effective promptly thereafter, subject to compliance with review by the Commission; provided, however,
that the Company shall not be required to comply with a Demand Notice if the Company has filed a registration statement with respect to
which the Holder is entitled to piggyback registration rights pursuant to Section 4.2 hereof and either: (i) the Holder has elected to
participate in the offering covered by such registration statement or (ii) if such registration statement relates to an underwritten primary
offering of securities of the Company, until the offering covered by such registration statement has been withdrawn or until thirty (30)
days after such offering is consummated. The Company covenants and agrees to give written notice of its receipt of any Demand Notice by
any Holders to all other registered Holders of the Purchase Warrants and/or the Registrable Securities within ten (10) days after the
date of the receipt of any such Demand Notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">4.1.2 <U>Terms</U>.
The Company shall bear all fees and expenses attendant to the registration of the Registrable Securities pursuant to Section 4.1.1, but
the Holders shall pay any and all underwriting commissions and the expenses of any legal counsel selected by the Holders to represent
them in connection with the sale of the Registrable Securities. The Company agrees to use its reasonable best efforts to cause the filing
required herein to become effective promptly and to qualify or register the Registrable Securities in such states as are reasonably requested
by the Holders; provided, however, that in no event shall the Company be required to register the Registrable Securities in a State in
which such registration would cause: (i) the Company to be obligated to register or license to do business in such State or submit to
general service of process in such State, or (ii) the principal shareholders of the Company to be obligated to escrow their shares of
capital stock of the Company. The Company shall cause any registration statement filed pursuant to the demand right granted under Section
4.1.1 to remain effective for a period of at least twelve (12) consecutive months after the date that the Holders of the Registrable Securities
covered by such registration statement are first given the opportunity to sell all of such securities. The Holders shall only use the
prospectuses provided by the Company to sell the shares covered by such registration statement, and will immediately cease to use any
prospectus furnished by the Company if the Company advises the Holder that such prospectus may no longer be used due to a material misstatement
or omission. Notwithstanding the provisions of this Section 4.1.2, the Holder shall be entitled to a demand registration under this Section
4.1.2 on only one (1) occasion and such demand registration right shall terminate on the fifth anniversary of the Commencement Date in
accordance with FINRA Rule 5110(g)(8)(C).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">4.2 &ldquo;<U>Piggy-Back&rdquo;
Registration</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">4.2.1 <U>Grant of
Right</U>. In addition to the demand right of registration described in Section 4.1 hereof, the Holder shall have the right, for a period
of five (5) years from the Commencement Date in accordance with FINRA Rule 5110(g)(8)(D), to include the Registrable Securities as part
of any other registration of securities filed by the Company (other than in connection with a transaction contemplated by Rule 145(a)
promulgated under the Securities Act or pursuant to Form S-8 or Form S-4 or any equivalent form); provided, however, that if, solely in
connection with any primary underwritten public offering for the account of the Company, the managing underwriter(s) thereof shall, in
its reasonable discretion, impose a limitation on the number of Shares which may be included in the Registration Statement because, in
such underwriter(s)&rsquo; judgment, marketing or other factors dictate such limitation is necessary to facilitate public distribution,
then the Company shall be obligated to include in such Registration Statement only such limited portion of the Registrable Securities
with respect to which the Holder requested inclusion hereunder as the underwriter shall reasonably permit. Any exclusion of Registrable
Securities shall be made pro rata among the Holders seeking to include Registrable Securities in proportion to the number of Registrable
Securities sought to be included by such Holders; <I>provided</I>, <I>however</I>, that the Company shall not exclude any Registrable
Securities unless the Company has first excluded all outstanding securities, the holders of which are not entitled to inclusion of such
securities in such Registration Statement or are not entitled to pro rata inclusion with the Registrable Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">4.2.2 <U>Terms</U>.
The Company shall bear all fees and expenses attendant to registering the Registrable Securities pursuant to Section 4.2.1 hereof, but
the Holders shall pay any and all underwriting commissions and the expenses of any legal counsel selected by the Holders to represent
them in connection with the sale of the Registrable Securities. In the event of such a proposed registration, the Company shall furnish
the then Holders of outstanding Registrable Securities with not less than fifteen (15) days&rsquo; written notice prior to the proposed
date of filing of such registration statement. Such notice to the Holders shall continue to be given for each registration statement filed
by the Company until such time as the registration rights have been terminated pursuant to Section 4.4. The holders of the Registrable
Securities shall exercise the &ldquo;piggy-back&rdquo; rights provided for herein by giving written notice within ten (10) days of the
receipt of the Company&rsquo;s notice of its intention to file a registration statement. Except as otherwise provided in this Purchase
Warrant, there shall be no limit on the number of times the Holder may request registration under this Section 4.2.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">4.3 <U>General Terms</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">4.3.1 <U>Indemnification</U>.
The Company shall indemnify the Holders of the Registrable Securities to be sold pursuant to any registration statement hereunder and
each person, if any, who controls such Holders within the meaning of Section 15 of the Securities Act or Section 20(a) of the Exchange
Act, against all loss, claim, damage, expense or liability (including all reasonable attorneys&rsquo; fees and other expenses reasonably
incurred in investigating, preparing or defending against any claim whatsoever) to which any of them may become subject under the Securities
Act, the Exchange Act or otherwise, arising from such registration statement but only to the same extent and with the same effect as the
provisions pursuant to which the Company has agreed to indemnify the Underwriters contained in Section 5.1 of the Underwriting Agreement
between the Underwriters and the Company, dated as of August 7, 2025. The Holders of the Registrable Securities to be sold pursuant to
such registration statement, and their successors and assigns, shall severally, and not jointly, indemnify the Company, against all loss,
claim, damage, expense or liability (including all reasonable attorneys&rsquo; fees and other expenses reasonably incurred in investigating,
preparing or defending against any claim whatsoever) to which they may become subject under the Securities Act, the Exchange Act or otherwise,
arising from information furnished by or on behalf of such Holders, or their successors or assigns, in writing, for specific inclusion
in such registration statement to the same extent and with the same effect as the provisions contained in Section 5.2 of the Underwriting
Agreement pursuant to which the Underwriters have agreed to indemnify the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">4.3.2 <U>Exercise
of Purchase Warrants</U>. Nothing contained in this Purchase Warrant shall be construed as requiring the Holders to exercise their Purchase
Warrants prior to or after the initial filing of any registration statement or the effectiveness thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">4.3.3 <U>Documents
Delivered to Holders</U>. The Company shall furnish to each Holder participating in any of the foregoing offerings and to each underwriter
of any such offering, if any, a signed counterpart, addressed to such Holder or underwriter, of: (i) an opinion of counsel to the Company,
dated the effective date of such registration statement (and, if such registration includes an underwritten public offering, an opinion
dated the date of the closing under any underwriting agreement related thereto), and (ii) a &ldquo;cold comfort&rdquo; letter dated the
effective date of such registration statement (and, if such registration includes an underwritten public offering, a letter dated the
date of the closing under the underwriting agreement) signed by the independent registered public accounting firm which has issued a report
on the Company&rsquo;s financial statements included in such registration statement, in each case covering substantially the same matters
with respect to such registration statement (and the prospectus included therein) and, in the case of such accountants&rsquo; letter,
with respect to events subsequent to the date of such financial statements, as are customarily covered in opinions of issuer&rsquo;s counsel
and in accountants&rsquo; letters delivered to underwriters in underwritten public offerings of securities. The Company shall also deliver
promptly to each Holder participating in the offering requesting the correspondence and memoranda described below and to the managing
underwriter, if any, copies of all correspondence between the Commission and the Company, its counsel or auditors and all memoranda relating
to discussions with the Commission or its staff with respect to the registration statement and permit each Holder and underwriter to do
such investigation, upon reasonable advance notice, with respect to information contained in or omitted from the registration statement
as it deems reasonably necessary to comply with applicable securities laws or rules of FINRA. Such investigation shall include access
to books, records and properties and opportunities to discuss the business of the Company with its officers and independent auditors,
all to such reasonable extent and at such reasonable times as any such Holder shall reasonably request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">4.3.4 <U>Underwriting
Agreement</U>. The Company shall enter into an underwriting agreement with the managing underwriter(s), if any, selected by any Holders
whose Registrable Securities are being registered pursuant to this Section 4, which managing underwriter shall be reasonably satisfactory
to the Company. Such agreement shall be reasonably satisfactory in form and substance to the Company, each Holder and such managing underwriters,
and shall contain such representations, warranties and covenants by the Company and such other terms as are customarily contained in agreements
of that type used by the managing underwriter. The Holders shall be parties to any underwriting agreement relating to an underwritten
sale of their Registrable Securities and may, at their option, require that any or all the representations, warranties and covenants of
the Company to or for the benefit of such underwriters shall also be made to and for the benefit of such Holders. Such Holders shall not
be required to make any representations or warranties to or agreements with the Company or the underwriters except as they may relate
to such Holders, their Shares and their intended methods of distribution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">4.3.5 <U>Documents
to be Delivered by Holders</U>. Each of the Holders participating in any of the foregoing offerings shall furnish to the Company a completed
and executed questionnaire provided by the Company requesting information customarily sought of selling security holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">4.3.6 <U>Damages</U>.
Should the registration or the effectiveness thereof required by Sections 4.1 and 4.2 hereof be delayed by the Company or the Company
otherwise fails to comply with such provisions, the Holders shall, in addition to any other legal or other relief available to the Holders,
be entitled to obtain specific performance or other equitable (including injunctive) relief against the threatened breach of such provisions
or the continuation of any such breach, without the necessity of proving actual damages and without the necessity of posting bond or other
security.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">4.4 <U>Termination
of Registration Rights</U>. The registration rights afforded to the Holders under this Section 4 shall terminate on the earliest date
when all Registrable Securities of such Holder either: (i) have been publicly sold by such Holder pursuant to a Registration Statement,
(ii) have been covered by an effective Registration Statement on Form S-1 or Form S-3 (or successor forms thereto), which may be kept
effective as an evergreen Registration Statement, or (iii) may be sold by the Holder within a 90-day period without registration pursuant
to Rule 144 or consistent with applicable SEC interpretive guidance (including CD&amp;I no. 201.04 (April 2, 2007) or similar interpretive
guidance).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5. <U>New Purchase Warrants
to be Issued</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.1 <U>Partial Exercise or
Transfer</U>. Subject to the restrictions in Section 3 hereof, this Purchase Warrant may be exercised or assigned in whole or in part.
In the event of the exercise or assignment hereof in part only, upon surrender of this Purchase Warrant for cancellation, together with
the duly executed exercise or assignment form and funds sufficient to pay any Exercise Price and/or transfer tax if exercised pursuant
to Section 2.1 hereto, the Company shall cause to be delivered to the Holder without charge a new Purchase Warrant of like tenor to this
Purchase Warrant in the name of the Holder evidencing the right of the Holder to purchase the number of Shares purchasable hereunder as
to which this Purchase Warrant has not been exercised or assigned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.2 <U>Lost Certificate</U>.
Upon receipt by the Company of evidence satisfactory to it of the loss, theft, destruction or mutilation of this Purchase Warrant and
of reasonably satisfactory indemnification or the posting of a bond, the Company shall execute and deliver a new Purchase Warrant of like
tenor and date. Any such new Purchase Warrant executed and delivered as a result of such loss, theft, mutilation or destruction shall
constitute a substitute contractual obligation on the part of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6. <U>Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.1 <U>Adjustments to Exercise
Price and Number of Securities</U>. The Exercise Price and the number of Shares underlying the Purchase Warrant shall be subject to adjustment
from time to time as hereinafter set forth:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">6.1.1 <U>Stock Dividends
and Splits</U>. If the Company, at any time while this Purchase Warrant is outstanding: (i) pays a stock dividend or otherwise makes a
distribution or distributions on the Shares or any other equity or equity equivalent securities payable in Shares (which, for avoidance
of doubt, shall not include any Shares issued by the Company upon (A) exercise of this Purchase Warrant or (B) exercise, conversion or
exchange of options, warrants, preferred stock, convertible notes, other convertible securities or other Common Stock Equivalents), (ii)
subdivides outstanding Shares into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding Shares
into a smaller number of shares, or (iv) issues by reclassification of any shares of capital stock of the Company, then in each case the
Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of Shares (excluding treasury shares, if any)
outstanding immediately before such event and of which the denominator shall be the number of Shares outstanding immediately after such
event, and the number of shares issuable upon exercise of this Purchase Warrant shall be proportionately adjusted such that the aggregate
Exercise Price of this Purchase Warrant shall remain unchanged. Any adjustment made pursuant to this Section 6.1 shall become effective
immediately after the record date for the determination of shareholders entitled to receive such dividend or distribution and shall become
effective immediately after the effective date in the case of a subdivision, combination or re-classification. For the purposes of clarification,
neither the Exercise Price of this Purchase Warrant nor the number of shares issuable upon exercise of this Purchase Warrant will be adjusted
in the event that the Company or any subsidiary thereof, as applicable, sells or grants any option to purchase, or sells or grants any
right to reprice, or otherwise disposes of or issues (or announces any offer, sale, grant or any option to purchase or other disposition)
any Shares or Common Stock Equivalents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">6.1.2 <U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to Section 6.1.1 above, if at any time the Company grants, issues or sells
any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any
class of Shares of the Company (the &ldquo;<B>Purchase Rights</B>&rdquo;), then the Holder will be entitled to acquire, upon the terms
applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number
of Shares acquirable upon complete exercise of this Purchase Warrant (without regard to any limitations on exercise hereof, including
without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance
or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of Shares are to be determined
for the grant, issue or sale of such Purchase Rights; provided, however, to the extent that the Holder's right to participate in any such
Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate
in such Purchase Right to such extent (or beneficial ownership of such Shares as a result of such Purchase Right to such extent) and such
Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result
in the Holder exceeding the Beneficial Ownership Limitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">6.1.3 <U>Pro Rata
Distributions</U>. During such time as this Purchase Warrant is outstanding, if the Company shall declare or make any dividend (other
than cash dividends) or other distribution of its assets (or rights to acquire its assets) to holders of Shares, by way of return of capital
or otherwise (including, without limitation, any distribution of shares or other securities, property or options by way of a dividend,
spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<B>Distribution&rdquo;</B>),
at any time after the issuance of this Purchase Warrant, then, in each such case, the Holder shall be entitled to participate in such
Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of Shares acquirable
upon complete exercise of this Purchase Warrant (without regard to any limitations on exercise hereof, including without limitation, the
Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is
taken, the date as of which the record holders of Shares are to be determined for the participation in such Distribution (provided, however,
to the extent that the Holder&rsquo;s right to participate in any such Distribution would result in the Holder exceeding the Beneficial
Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership
of any Shares as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the
benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership
Limitation). To the extent that this Purchase Warrant has not been partially or completely exercised at the time of such Distribution,
such portion of the Distribution shall be held in abeyance for the benefit of the Holder until the Holder has exercised this Purchase
Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">6.1.4 <U>Fundamental
Transaction</U>. If, at any time while this Purchase Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related
transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly,
effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one
or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company
or another Person) is completed pursuant to which holders of Shares of the Company are permitted to sell, tender or exchange their shares
for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Shares of the Company, (iv)
the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization
of Shares or any compulsory share exchange pursuant to which the Shares are effectively converted into or exchanged for other securities,
cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase
agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement)
with another Person or group of Persons whereby such other Person or group acquires more than 50% of the outstanding Shares of the Company
(not including any Shares held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons
making or party to, such stock or share purchase agreement or other business combination) (each a &ldquo;<B>Fundamental Transaction</B>&rdquo;),
then, upon any subsequent exercise of this Purchase Warrant, the Holder shall have the right to receive, for each Share that would have
been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without
regard to any limitation in Section 2.4 on the exercise of this Purchase Warrant), the number of Shares of the successor or acquiring
corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &ldquo;<B>Alternate Consideration</B>&rdquo;)
receivable by holders of Shares as a result of such Fundamental Transaction for each Share for which this Purchase Warrant is exercisable
immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2.4 on the exercise of this Warrant). For
purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration
based on the amount of Alternate Consideration issuable in respect of one Share in such Fundamental Transaction, and the Company shall
apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components
of the Alternate Consideration. If holders of Shares of the Company are given any choice as to the securities, cash or property to be
received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon
any exercise of this Purchase Warrant following such Fundamental Transaction. The Company shall cause any successor entity in a Fundamental
Transaction in which the Company is not the survivor (the &quot;<B>Successor Entity</B>&quot;) to assume in writing all of the obligations
of the Company under this Purchase Warrant in accordance with the provisions of this Section 6.1.4 pursuant to written agreements in form
and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental
Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity
evidenced by a written instrument substantially similar in form and substance to this Purchase Warrant which is exercisable for a corresponding
number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the Shares acquirable and receivable upon
exercise of this Purchase Warrant (without regard to any limitations on the exercise of this Purchase Warrant) prior to such Fundamental
Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account
the relative value of the Shares pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of
shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Purchase Warrant immediately
prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder.
Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and
after the date of such Fundamental Transaction, the provisions of this Purchase Warrant referring to the &quot;Company&quot; shall refer
instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the
Company under this Purchase Warrant with the same effect as if such Successor Entity had been named as the Company herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">6.1.5 <U>Calculations</U>.
All calculations under this Section 6.1 shall be made to the nearest cent or the nearest l/100th of a share, as the case may be. For purposes
of this Section 6.1, the number of Shares deemed to be issued and outstanding as of a given date shall be the sum of the number of Shares
(excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">6.1.6 <U>Notice
to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">i. <U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 6.1, the Company shall promptly
mail or email to the Holder a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number
of Shares and setting forth a brief statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">ii. <U>Notice to
Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Shares,
(B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Shares, (C) the Company shall authorize the
granting to all holders of the common stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or
of any rights, (D) the approval of any shareholders of the Company shall be required in connection with any reclassification of the Shares
(a reverse stock split shall not be deemed a reclassification), any consolidation or merger to which the Company is a party, any sale
or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the Shares are converted
into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding
up of the affairs of the Company, then, in each case, the Company shall cause to be mailed a notice to the Holder at its last address
as it shall appear upon the warrant register of the Company, at least 20 calendar days prior to the applicable record or effective date
hereinafter specified, stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption,
rights or warrants, or if a record is not to be taken, the date as of which the holders of the Shares of record to be entitled to such
dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation,
merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders
of the Shares of record shall be entitled to exchange their shares of the Shares for securities, cash or other property deliverable upon
such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to provide such notice or any
defect therein shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice
provided hereunder constitutes, or contains, material, non-public information regarding the Company or any of its subsidiaries, the Company
shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to
exercise this Purchase Warrant during the period commencing on the date of such notice to the effective date of the event triggering such
notice except as may otherwise be expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">6.1.7 <U>Changes
in Form of Purchase Warrant</U>. This form of Purchase Warrant need not be changed because of any change pursuant to this Section 6.1,
and Purchase Warrants issued after such change may state the same Exercise Price and the same number of Shares as are stated in the Purchase
Warrants initially issued pursuant to this Agreement. The acceptance by any Holder of the issuance of new Purchase Warrants reflecting
a required or permissive change shall not be deemed to waive any rights to an adjustment occurring after the Commencement Date or the
computation thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.2 <U>Substitute Purchase
Warrant</U>. In case of any consolidation of the Company with, or share reconstruction or amalgamation of the Company with or into, another
corporation (other than a consolidation or share reconstruction or amalgamation which does not result in any reclassification or change
of the outstanding Shares), the corporation formed by such consolidation or share reconstruction or amalgamation shall execute and deliver
to the Holder a supplemental Purchase Warrant providing that the holder of each Purchase Warrant then outstanding or to be outstanding
shall have the right thereafter (until the stated expiration of such Purchase Warrant) to receive, upon exercise of such Purchase Warrant,
the kind and amount of shares of stock and other securities and property receivable upon such consolidation or share reconstruction or
amalgamation, by a holder of the number of Shares for which such Purchase Warrant might have been exercised immediately prior to such
consolidation, share reconstruction or amalgamation, sale or transfer. Such supplemental Purchase Warrant shall provide for adjustments
which shall be identical to the adjustments provided for in this Section 6. The above provision of this Section shall similarly apply
to successive consolidations or share reconstructions or amalgamations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7. <U>Reservation and Listing</U>.
The Company shall at all times reserve and keep available out of its authorized Shares, solely for the purpose of issuance upon exercise
of the Purchase Warrants, such number of Shares or other securities, properties or rights as shall be issuable upon the exercise thereof.
The Company covenants and agrees that, upon exercise of the Purchase Warrants and payment of the Exercise Price therefor, in accordance
with the terms hereby, all Shares and other securities issuable upon such exercise shall be duly and validly issued, fully paid and non-assessable
and not subject to pre-emptive rights of any shareholder. As long as the Purchase Warrants shall be outstanding, the Company shall use
its commercially reasonable efforts to cause all Shares issuable upon exercise of the Purchase Warrants to be listed (subject to official
notice of issuance) on all national securities exchanges (or, if applicable, on the OTC Bulletin Board or any successor trading market)
on which the Shares issued to the public in the Offering (as defined in that certain Underwriting Agreement dated as of August 7, 2025
by and between the Company and ThinkEquity) may then be listed and/or quoted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8. <U>Certain Notice Requirements</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.1 <U>Holder&rsquo;s Right
to Receive Notice</U>. Nothing herein shall be construed as conferring upon the Holders the right to vote or consent or to receive notice
as a shareholder for the election of directors or any other matter, or as having any rights whatsoever as a shareholder of the Company.
If, however, at any time prior to the expiration of the Purchase Warrants and their exercise, any of the events described in Section 8.2
shall occur, then, in one or more of said events, the Company shall give written notice of such event at least fifteen (15) days prior
to the date fixed as a record date or the date of closing the transfer books for the determination of the shareholders entitled to such
dividend, distribution, conversion or exchange of securities or subscription rights, or entitled to vote on such proposed dissolution,
liquidation, winding up or sale. Such notice shall specify such record date or the date of the closing of the transfer books, as the case
may be. Notwithstanding the foregoing, the Company shall deliver to each Holder a copy of each notice given to the other shareholders
of the Company at the same time and in the same manner that such notice is given to the shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.2 <U>Events Requiring Notice</U>.
The Company shall be required to give the notice described in this Section 8 upon one or more of the following events: (i) if the Company
shall take a record of the holders of its Shares for the purpose of entitling them to receive a dividend or distribution payable otherwise
than in cash, or a cash dividend or distribution payable otherwise than out of retained earnings, as indicated by the accounting treatment
of such dividend or distribution on the books of the Company; (ii) the Company shall offer to all the holders of its Shares any additional
shares of capital stock of the Company or securities convertible into or exchangeable for shares of capital stock of the Company, or any
option, right or warrant to subscribe therefor; or (iii) a dissolution, liquidation or winding up of the Company (other than in connection
with a consolidation or share reconstruction or amalgamation) or a sale of all or substantially all of its property, assets and business
shall be proposed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.3 <U>Transmittal of Notices</U>.
All notices, requests, consents and other communications under this Purchase Warrant shall be in writing and shall be deemed to have been
duly made when hand delivered or mailed by express mail or private courier service: (i) if to the registered Holder of the Purchase Warrant,
to the address of such Holder as shown on the books of the Company, or (ii) if to the Company, to following address or to such other address
as the Company may designate by notice to the Holders:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If to the Holder:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">ThinkEquity LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">17 State Street,
22nd Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">New York, NY 10004</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Attention: Head
of Investment Banking</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">E-mail: notices@think-equity.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">with a copy (which shall not
constitute notice) to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Sheppard, Mullin,
Richter &amp; Hampton LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">30 Rockefeller Plaza,
39<SUP>th</SUP> Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">New York, New York
10112</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Attn: Jeffrey Fessler
and Stephen Cohen</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">E-mail: jfessler@sheppardmullin.com
and scohen@sheppardmullin.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If to the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">BioVie Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">680 W Nye Lane,
Suite 204</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Carson City, Nevada
89703</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Attention: Cuong
Do, CEO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">E-mail: cdo@bioviepharma.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">with a copy (which shall not
constitute notice) to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">McGuireWoods LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">1251 6th Ave 20th Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">New York, NY 10020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">Attn: Stephen Older and Carly Ginley</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">E-mail: solder@mcguirewoods.com and cginley@mcguirewoods.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9. <U>General</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.1 <U>Amendments</U>. The
Company and the ThinkEquity may from time to time supplement or amend this Purchase Warrant without the approval of any of the Holders
in order to cure any ambiguity, to correct or supplement any provision contained herein that may be defective or inconsistent with any
other provisions herein, or to make any other provisions in regard to matters or questions arising hereunder that the Company and the
Holder may deem necessary or desirable and that the Company and the Holder deem shall not adversely affect the interest of the Holders.
All other modifications or amendments shall require the written consent of and be signed by the party against whom enforcement of the
modification or amendment is sought.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.2 <U>Headings</U>. The headings
contained herein are for the sole purpose of convenience of reference, and shall not in any way limit or affect the meaning or interpretation
of any of the terms or provisions of this Purchase Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.3 <U>Entire Agreement</U>.
This Purchase Warrant (together with the other agreements and documents being delivered pursuant to or in connection with this Purchase
Warrant) constitutes the entire agreement of the parties hereto with respect to the subject matter hereof, and supersedes all prior agreements
and understandings of the parties, oral and written, with respect to the subject matter hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.4 <U>Binding Effect</U>.
This Purchase Warrant shall inure solely to the benefit of and shall be binding upon, the Holder and the Company and their permitted assignees,
respective successors, legal representative and assigns, and no other person shall have or be construed to have any legal or equitable
right, remedy or claim under or in respect of or by virtue of this Purchase Warrant or any provisions herein contained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.5 <U>Governing Law; Submission
to Jurisdiction</U>. This Purchase Warrant shall be governed by and construed and enforced in accordance with the laws of the State of
New York. The Company hereby agrees that any action, proceeding or claim against it arising out of, or relating in any way to this Purchase
Warrant shall be brought and enforced in the Supreme Court of the State of New York, sitting in the City and County of New York, or in
the United States District Court for the Southern District of New York, and irrevocably submits to such jurisdiction, which jurisdiction
shall be exclusive. The Company hereby waives any objection to such exclusive jurisdiction and that such courts represent an inconvenient
forum. Any process or summons to be served upon the Company may be served by transmitting a copy thereof by registered or certified mail,
return receipt requested, postage prepaid, addressed to it at the address set forth in Section 8 hereof. Such mailing shall be deemed
personal service and shall be legal and binding upon the Company in any action, proceeding or claim. The Company and the Holder agree
that the prevailing party(ies) in any such action shall be entitled to recover from the other party(ies) all of its reasonable attorneys&rsquo;
fees and expenses relating to such action or proceeding and/or incurred in connection with the preparation therefor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.6 <U>Waiver of Trial by
Jury</U>. The Company (on its behalf and, to the extent permitted by applicable law, on behalf of its shareholders and affiliates) and
the Holder hereby irrevocably waive, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal
proceeding arising out of or relating to this Agreement or the transactions contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.7 <U>Waiver, etc</U>. The
failure of the Company or the Holder to at any time enforce any of the provisions of this Purchase Warrant shall not be deemed or construed
to be a waiver of any such provision, nor to in any way affect the validity of this Purchase Warrant or any provision hereof or the right
of the Company or any Holder to thereafter enforce each and every provision of this Purchase Warrant. No waiver of any breach, non-compliance
or non-fulfillment of any of the provisions of this Purchase Warrant shall be effective unless set forth in a written instrument executed
by the party or parties against whom or which enforcement of such waiver is sought; and no waiver of any such breach, non-compliance or
non-fulfillment shall be construed or deemed to be a waiver of any other or subsequent breach, non-compliance or non-fulfillment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.8 <U>Execution in Counterparts</U>.
This Purchase Warrant may be executed in one or more counterparts, and by the different parties hereto in separate counterparts, each
of which shall be deemed to be an original, but all of which taken together shall constitute one and the same agreement, and shall become
effective when one or more counterparts has been signed by each of the parties hereto and delivered to each of the other parties hereto.
Such counterparts may be delivered by facsimile transmission or other electronic transmission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.9 <U>Exchange Agreement</U>.
As a condition of the Holder&rsquo;s receipt and acceptance of this Purchase Warrant, Holder agrees that, at any time prior to the complete
exercise of this Purchase Warrant by Holder, if the Company and ThinkEquity enter into an agreement (&ldquo;<B>Exchange Agreement</B>&rdquo;)
pursuant to which they agree that all outstanding Purchase Warrants will be exchanged for securities or cash or a combination of both,
then Holder shall agree to such exchange and become a party to the Exchange Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Signature Page Follows</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the Company
has caused this Purchase Warrant to be signed by its duly authorized officer as of the 11th day of August, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Very truly yours,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">BioVie</FONT>
INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 58%; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Cuong V Do</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Chief Executive Officer</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Form to be used to exercise Purchase Warrant</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: __________, 20___</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned hereby elects
irrevocably to exercise the Purchase Warrant for [&#9679;] shares of common stock, par value $0.0001 per share (the &ldquo;<B>Shares</B>&rdquo;),
of BioVie Inc., a Nevada corporation (the &ldquo;<B>Company</B>&rdquo;), and hereby makes payment of $[&#9679;] (at the rate of $[&#9679;]
per Share) in payment of the Exercise Price pursuant thereto. Please issue the Shares as to which this Purchase Warrant is exercised in
accordance with the instructions given below and, if applicable, a new Purchase Warrant representing the number of Shares for which this
Purchase Warrant has not been exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned hereby elects
irrevocably to convert its right to purchase [&#9679;] Shares of the Company under the Purchase Warrant for [&#9679;] Shares, as determined
in accordance with the Section 2.2 of the Purchase Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned agrees and
acknowledges that the calculation set forth above is subject to confirmation by the Company and any disagreement with respect to the calculation
shall be resolved by the Company in its sole discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Please issue the Shares as
to which this Purchase Warrant is exercised in accordance with the instructions given below and, if applicable, a new Purchase Warrant
representing the number of Shares for which this Purchase Warrant has not been converted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Signature <U>_________________</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Signature Guaranteed <U>____________________</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">INSTRUCTIONS FOR REGISTRATION OF SECURITIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="width: 95%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>________________________________</U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-left: 40pt; white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Print in Block Letters)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-left: 40pt; white-space: nowrap; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>________________________________</U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>________________________________</U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>________________________________</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NOTICE: The signature to this form must correspond
with the name as written upon the face of the Purchase Warrant without alteration or enlargement or any change whatsoever, and must be
guaranteed by a bank, other than a savings bank, or by a trust company or by a firm having membership on a registered national securities
exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Form to be used to assign Purchase Warrant</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ASSIGNMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(To be executed by the registered Holder to effect
a transfer of the within Purchase Warrant):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FOR VALUE RECEIVED, __________________ does hereby
sell, assign and transfer unto the right to purchase [&#9679;] shares of common stock, par value $0.0001 per share, of BioVie Inc., a
Nevada corporation (the &ldquo;<B>Company</B>&rdquo;), evidenced by the Purchase Warrant and does hereby authorize the Company to transfer
such right on the books of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dated: __________, 20__</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Signature <U>_________________</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Signature Guaranteed <U>____________________</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NOTICE: The signature to this form must correspond
with the name as written upon the face of the Purchase Warrant without alteration or enlargement or any change whatsoever, and must be
guaranteed by a bank, other than a savings bank, or by a trust company or by a firm having membership on a registered national securities
exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>5
<FILENAME>bivi-20250807_ex10z1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: right">EXHIBIT 10.1</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><U>&nbsp;</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><U>WARRANT AGENT
AGREEMENT</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WARRANT AGENT AGREEMENT (this
&ldquo;<U>Warrant Agreement</U>&rdquo;) dated as of August 11, 2025 (the &ldquo;<U>Issuance Date</U>&rdquo;) between BioVie Inc., a Nevada
corporation (the &ldquo;<U>Company</U>&rdquo;), and West Coast Stock Transfer, Inc., a California corporation (the &ldquo;<U>Warrant Agent</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, pursuant to the terms
of that certain Underwriting Agreement (&ldquo;<U>Underwriting Agreement</U>&rdquo;), dated August 7, 2025, by and between the Company
and ThinkEquity LLC, as representative of the underwriters set forth therein, the Company is engaged in a public offering (the &ldquo;<U>Offering</U>&rdquo;)
of (A) 5,620,000 units, each unit consisting of (i) one share (the &ldquo;<U>Shares</U>&rdquo;) of Class A common stock, par value $0.0001
per share (the &ldquo;<U>Common Stock</U>&rdquo;) of the Company and (ii) one warrant (the &ldquo;<U>Warrants</U>&rdquo;) to purchase
shares of Common Stock (the &ldquo;<U>Warrant Shares</U>&rdquo;) and (B) 380,000 pre-funded units, each pre-funded unit consisting of
(i) one pre-funded warrant (the &ldquo;<U>Pre-funded Warrants</U>&rdquo;), and up to 900,000 Shares and/or Warrants and/or Pre-funded
Warrants issuable pursuant to the underwriters&rsquo; over-allotment option;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Company has filed
with the Securities and Exchange Commission (the &ldquo;<U>Commission</U>&rdquo;) a Registration Statement on Form S-1 (File No. 333-288525)
(as the same may be amended from time to time, the &ldquo;<U>Registration Statement</U>&rdquo;), for the registration under the Securities
Act of 1933, as amended (the &ldquo;<U>Securities Act</U>&rdquo;), of the Shares, Warrants and Warrant Shares, and such Registration Statement
was declared effective on August 7, 2025;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Company desires
the Warrant Agent to act on behalf of the Company, and the Warrant Agent is willing to so act, in accordance with the terms set forth
in this Warrant Agreement in connection with the issuance, registration, transfer, exchange and exercise of the Warrants;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Company desires
to provide for the provisions of the Warrants, the terms upon which they shall be issued and exercised, and the respective rights, limitation
of rights, and immunities of the Company, the Warrant Agent, and the holders of the Warrants; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, all acts and things
have been done and performed which are necessary to make the Warrants the valid, binding and legal obligations of the Company, and to
authorize the execution and delivery of this Warrant Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in consideration
of the mutual agreements herein contained, the parties hereto agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Appointment
of Warrant Agent</U>. The Company hereby appoints the Warrant Agent to act as agent for the Company with respect to the Warrants, and
the Warrant Agent hereby accepts such appointment and agrees to perform the same in accordance with the express terms and conditions set
forth in this Warrant Agreement (and no implied terms or conditions).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Warrants</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Form
of Warrant</U>. The Warrants shall be registered securities and shall be initially evidenced by a global Warrant certificate (&ldquo;<U>Global
Certificate</U>&rdquo;) in the form of <U>Annex A</U> to this Warrant Agreement, which shall be deposited on behalf of the Company with
a custodian for The Depository Trust Company (&ldquo;<U>DTC</U>&rdquo;) and registered in the name of Cede &amp; Co., a nominee of DTC.
If DTC subsequently ceases to make its settlement system available for the Warrants, the Company may instruct the Warrant Agent regarding
making arrangements for book-entry settlement. In the event that the Warrants are not eligible for, or it is no longer necessary to have
the Warrants available in, registration in the name of Cede &amp; Co., a nominee of DTC, the Company may instruct the Warrant Agent to
provide written instructions to DTC to deliver to the Warrant Agent for cancellation the Global Certificate, and the Company shall instruct
the Warrant Agent to deliver to each Holder (as defined below) a separate certificate evidencing the Warrants (&ldquo;<U>Definitive Certificates</U>&rdquo;
and, together with the Global Certificate, &ldquo;<U>Warrant Certificates</U>&rdquo;), in the form of <U>Annex B</U> to this Warrant Agreement.
The Warrants represented by the Global Certificate are referred to as &ldquo;Global Warrants&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Issuance
and Registration of Warrants</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.2.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Warrant
Register</U>. The Warrant Agent shall maintain books (&ldquo;<U>Warrant Register</U>&rdquo;) for the registration of original issuance
and the registration of transfer of the Warrants. Any Person in whose name ownership of a beneficial interest in the Warrants evidenced
by a Global Certificate is recorded in the records maintained by DTC or its nominee shall be deemed the &ldquo;beneficial owner&rdquo;
thereof, provided that all such beneficial interests shall be held through a Participant (as defined below), which shall be the registered
holder of such Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.2.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Issuance
of Warrants</U>. Upon the initial issuance of the Warrants, the Warrant Agent shall issue the Global Certificate and deliver the Warrants
in the DTC settlement system in accordance with written instructions delivered to the Warrant Agent by the Company. Ownership of beneficial
interests in the Warrants shall be shown on, and the transfer of such ownership shall be effected through, records maintained (i) by DTC
and (ii) by institutions that have accounts with DTC (each, a &ldquo;<U>Participant</U>&rdquo;), subject to a Holder&rsquo;s right to
elect to receive a Warrant in certificated form in the form of <U>Annex B</U> to this Warrant Agreement. Any Holder desiring to elect
to receive a Warrant in certificated form shall make such request in writing delivered to the Warrant Agent pursuant to Section 2.2.8,
and shall surrender to the Warrant Agent the interest of the Holder on the books of the Participant evidencing the Warrants which are
to be represented by a Definitive Certificate through the DTC settlement system. Thereupon, the Warrant Agent shall countersign and deliver
to the person entitled thereto a Warrant Certificate or Warrant Certificates, as the case may be, as so requested.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.2.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Beneficial
Owner; Holder</U>. Prior to due presentment for registration of transfer of any Warrant, the Company and the Warrant Agent may deem and
treat the person in whose name that Warrant shall be registered on the Warrant Register (the &ldquo;<U>Holder</U>&rdquo;) as the absolute
owner of such Warrant for purposes of any exercise thereof, and for all other purposes, and neither the Company nor the Warrant Agent
shall be affected by any notice to the contrary. Notwithstanding the foregoing, nothing herein shall prevent the Company, the Warrant
Agent or any agent of the Company or the Warrant Agent from giving effect to any written certification, proxy or other authorization furnished
by DTC governing the exercise of the rights of a holder of a beneficial interest in any Warrant. The rights of beneficial owners in a
Warrant evidenced by the Global Certificate shall be exercised by the Holder or a Participant through the DTC system, except to the extent
set forth herein or in the Global Certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.2.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Execution</U>.
The Warrant Certificates shall be executed on behalf of the Company by any authorized officer of the Company (an &ldquo;<U>Authorized
Officer</U>&rdquo;), which need not be the same authorized signatory for all of the Warrant Certificates, either manually or by facsimile
signature. The Warrant Certificates shall be countersigned by an authorized signatory of the Warrant Agent, which need not be the same
signatory for all of the Warrant Certificates, and no Warrant Certificate shall be valid for any purpose unless so countersigned. In case
any Authorized Officer of the Company that signed any of the Warrant Certificates ceases to be an Authorized Officer of the Company before
countersignature by the Warrant Agent and issuance and delivery by the Company, such Warrant Certificates, nevertheless, may be countersigned
by the Warrant Agent, issued and delivered with the same force and effect as though the person who signed such Warrant Certificates had
not ceased to be such officer of the Company; and any Warrant Certificate may be signed on behalf of the Company by any person who, at
the actual date of the execution of such Warrant Certificate, shall be an Authorized Officer of the Company authorized to sign such Warrant
Certificate, although at the date of the execution of this Warrant Agreement any such person was not such an Authorized Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.2.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Registration
of Transfer</U>. At any time at or prior to the Expiration Date (as defined below), a transfer of any Warrants may be registered and any
Warrant Certificate or Warrant Certificates may be split up, combined or exchanged for another Warrant Certificate or Warrant Certificates
evidencing the same number of Warrants as the Warrant Certificate or Warrant Certificates surrendered. Any Holder desiring to register
the transfer of Warrants or to split up, combine or exchange any Warrant Certificate shall make such request in writing delivered to the
Warrant Agent, and shall surrender to the Warrant Agent the Warrant Certificate or Warrant Certificates evidencing the Warrants the transfer
of which is to be registered or that is or are to be split up, combined or exchanged. Thereupon, the Warrant Agent shall countersign and
deliver to the person entitled thereto a Warrant Certificate or Warrant Certificates, as the case may be, as so requested. The Warrant
Agent may require reasonable and customary payment, by the Holder requesting a registration of transfer of Warrants or a split-up, combination
or exchange of a Warrant Certificate (but, for purposes of clarity, not upon the exercise of the Warrants and issuance of Warrant Shares
to the Holder), of a sum sufficient to cover any tax or governmental charge that may be imposed in connection with such registration of
transfer, split-up, combination or exchange, together with reimbursement to the Warrant Agent of all reasonable expenses incidental thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.2.6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Loss,
Theft and Mutilation of Warrant Certificates</U>. Upon receipt by the Company and the Warrant Agent of evidence reasonably satisfactory
to them of the loss, theft, destruction or mutilation of a Warrant Certificate, and, in case of loss, theft or destruction, of indemnity
or security in customary form and amount, (which shall in no event include the posting of any bond), and reimbursement to the Company
and the Warrant Agent of all reasonable expenses incidental thereto, and upon surrender to the Warrant Agent and cancellation of the Warrant
Certificate if mutilated, the Warrant Agent shall, on behalf of the Company, countersign and deliver a new Warrant Certificate of like
tenor to the Holder in lieu of the Warrant Certificate so lost, stolen, destroyed or mutilated. The Warrant Agent may charge the Holder
an administrative fee for processing the replacement of lost Warrant Certificates, which shall be charged only once in instances where
a single surety bond obtained covers multiple certificates. The Warrant Agent may receive compensation from the surety companies or surety
bond agents for administrative services provided to them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.2.7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Proxies</U>.
The Holder of a Warrant may grant proxies or otherwise authorize any person, including the Participants and beneficial holders that may
own interests through the Participants, to take any action that a Holder is entitled to take under this Warrant Agreement or the Warrants;
<U>provided</U>, <U>however</U>, that at all times that Warrants are evidenced by a Global Certificate, exercise of those Warrants shall
be effected on their behalf by Participants through DTC in accordance the procedures administered by DTC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.2.8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Warrant
Certificate Request</U>. A Holder has the right to elect at any time or from time to time a Warrant Exchange (as defined below) pursuant
to a Warrant Certificate Request Notice (as defined below). Upon written notice by a Holder to the Warrant Agent for the exchange of some
or all of such Holder&rsquo;s Global Warrants for a Definitive Certificate evidencing the same number of Warrants, which request shall
be in the form attached hereto as <U>Annex D</U> (a &ldquo;<U>Warrant Certificate Request Notice</U>&rdquo; and the date of delivery of
such Warrant Certificate Request Notice by the Holder, the &ldquo;Warrant Certificate Request Notice Date&rdquo; and the deemed surrender
upon delivery by the Holder of a number of Global Warrants for the same number of Warrants evidenced by a Definitive Certificate, a &ldquo;<U>Warrant
Exchange</U>&rdquo;), the Warrant Agent shall promptly effect the Warrant Exchange and shall promptly issue and deliver to the Holder
a Definitive Certificate for such number of Warrants in the name set forth in the Warrant Certificate Request Notice. Such Definitive
Certificate shall be dated the original issue date of the Warrants, shall be manually executed by an authorized signatory of the Company,
shall be in the form attached hereto as <U>Annex B</U>, and shall be reasonably acceptable in all respects to such Holder. In connection
with a Warrant Exchange, the Company agrees to deliver, or to direct the Warrant Agent to deliver, the Definitive Certificate to the Holder
within the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period of the Warrant
Certificate Request Notice pursuant to the delivery instructions in the Warrant Certificate Request Notice (&ldquo;Warrant Certificate
Delivery Date&rdquo;). If the Company fails for any reason to deliver to the Holder the Definitive Certificate subject to the Warrant
Certificate Request Notice by the Warrant Certificate Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages
and not as a penalty, for each $1,000 of Warrant Shares evidenced by such Definitive Certificate (based on the VWAP (as defined in the
Warrants) of the Common Stock on the Warrant Certificate Request Notice Date), $10 per Trading Day for each Trading Day after such Warrant
Certificate Delivery Date until such Definitive Certificate is delivered or, prior to delivery of such Warrant Certificate, the Holder
rescinds such Warrant Exchange. The Company covenants and agrees that, upon the date of delivery of the Warrant Certificate Request Notice,
the Holder shall be deemed to be the holder of the Definitive Certificate and, notwithstanding anything to the contrary set forth herein,
the Definitive Certificate shall be deemed for all purposes to contain all of the terms and conditions of the Warrants evidenced by such
Warrant Certificate and the terms of this Warrant Agreement, other than Sections 3(c) and 9 herein, shall not apply to the Warrants evidenced
by the Definitive Certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.2.9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
purposes of clarity, if there is a conflict between the express terms of this Warrant Agreement and the Warrant certificate in the form
of <U>Annex B</U> hereto with respect to terms of the Warrants, the terms of the Warrant certificate shall govern and control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 40pt; text-align: left">3.</TD><TD STYLE="text-align: justify"><U>Terms and Exercise of Warrants</U>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exercise
Price</U>. Each Warrant shall entitle the Holder, subject to the provisions of the applicable Warrant Certificate and of this Warrant
Agreement, to purchase from the Company the number of shares of Common Stock stated therein, at the price of $2.50 per whole share, subject
to the subsequent adjustments provided in Section 4 hereof. The term &ldquo;<U>Exercise Price</U>&rdquo; as used in this Warrant Agreement
refers to the price per share at which shares of Common Stock may be purchased at the time a Warrant is exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Duration
of Warrants</U>. Warrants may be exercised only during the period (&ldquo;<U>Exercise Period</U>&rdquo;) commencing on the Issuance Date
and terminating at 5:00 P.M., New York City time (the &ldquo;<U>close of business</U>&rdquo;) on the five (5) year anniversary of the
Issuance Date (&ldquo;<U>Expiration Date</U>&rdquo;). Each Warrant not exercised on or before the Expiration Date shall become void, and
all rights thereunder and all rights in respect thereof under this Warrant Agreement shall cease at the close of business on the Expiration
Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exercise
of Warrants</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.3.1.&nbsp;&nbsp;&nbsp;&nbsp;<U>Exercise
and Payment</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exercise
of the purchase rights represented by a Warrant may be made, in whole or in part, at any time or times on or after the Issuance Date and
on or before the Expiration Date by delivery to the Company of a duly executed facsimile copy (or.pdf copy via e-mail attachment) of the
Notice of Exercise in the form attached as <U>Exhibit A</U> to <U>Annex B</U> hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;). Within
the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period following the date
of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice
of Exercise by wire transfer drawn on a United States bank unless the cashless exercise procedure specified in Section 3.3.7 below is
specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee
(or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the
Holder shall not be required to physically surrender a Warrant Certificate to the Company until the Holder has purchased all of the Warrant
Shares available thereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender such Warrant to the
Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise is delivered to the Company.
Partial exercises of a Warrant resulting in purchases of a portion of the total number of Warrant Shares available thereunder shall have
the effect of lowering the outstanding number of Warrant Shares purchasable thereunder in an amount equal to the applicable number of
Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date
of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Trading Day of receipt of such notice.&nbsp;<B>The
Holder and any assignee, by acceptance of a Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following
the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given
time may be less than the amount stated on the face thereof.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
the foregoing in this&nbsp;Section 3.3.1, a holder whose interest in a Warrant is a beneficial interest in certificate(s) representing
such Warrant held in book-entry form through DTC (or another established clearing corporation performing similar functions), shall effect
exercises made pursuant to this&nbsp;Section 3.3.1&nbsp;by delivering to DTC (or such other clearing corporation, as applicable) the appropriate
instruction form for exercise, complying with the procedures to effect exercise that are required by DTC (or such other clearing corporation,
as applicable), subject to a Holder&rsquo;s right to elect to receive a Warrant in certificated form pursuant to the terms of the Warrant
Agent Agreement, in which case this sentence shall not apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.3.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Issuance
of Warrant Shares</U>. (a) The Warrant Agent shall, on the Trading Day following the date of exercise of any Warrant, advise the Company,
the transfer agent and registrar for the Company&rsquo;s Common Stock, in respect of (i) the number of Warrant Shares indicated on the
Notice of Exercise as issuable upon such exercise with respect to such exercised Warrants, (ii) the instructions of the Holder or Participant,
as the case may be, provided to the Warrant Agent with respect to the delivery of the Warrant Shares and the number of Warrants that remain
outstanding after such exercise and (iii) such other information as the Company or such transfer agent and registrar shall reasonably
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account
of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian
system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant in such system and either (A) there is an effective registration
statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by Holder or (B) the Warrant is being exercised
via cashless exercise, and otherwise by physical delivery of a certificate, registered in the Company&rsquo;s share register in the name
of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address
specified by the Holder in the Notice of Exercise by the date that is the earlier of (i) one (1) Trading Day and (ii) the number of Trading
Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant
Share Delivery Date</U>&rdquo;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have
become the holder of record of the Warrant Shares with respect to which the Warrant has been exercised, irrespective of the date of delivery
of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received
within the earlier of (i) one (1) Trading Day of and (ii) the number of Trading Days comprising the Standard Settlement Period following
delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice
of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty,
for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice
of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the fifth Trading Day after such liquidated damages begin to accrue)
for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise.
The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as the Warrant remains outstanding and
exercisable. As used herein, &ldquo;Standard Settlement Period&rdquo; means the standard settlement period, expressed in a number of Trading
Days, on the Company&rsquo;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice
of Exercise. Notwithstanding the foregoing, with respect to any Notice(s) of Exercise delivered on or prior to 12:00 p.m. (New York City
time) on the Issuance Date, which may be delivered at any time after the time of execution of the Warrant, the Company agrees to deliver
the Warrant Shares subject to such notice(s) by 4:00 p.m. (New York City time) on the Issuance Date and the Issuance Date shall be the
Warrant Share Delivery Date for purposes hereunder, provided that payment of the aggregate Exercise Price (other than in the case of a
cashless exercise) is received by such Warrant Share Delivery Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.3.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Valid
Issuance</U>. All Warrant Shares issued by the Company upon the proper exercise of a Warrant in conformity with this Warrant Agreement
shall be validly issued, fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.3.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Fractional Shares or Scrip</U>. No fractional Warrant Shares or scrip representing fractional Warrant Shares shall be issued upon the
exercise of the Warrants. As to any fraction of a Warrant Share which the Holder would otherwise be entitled to purchase upon such exercise,
the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction
multiplied by the Exercise Price or round up to the next whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.3.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Charges,
Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental
expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant
Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder;&nbsp;<U>provided</U>,&nbsp;<U>however</U>,
that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, the Warrant when surrendered for exercise
shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto,
the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees
required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing
corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.3.6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>[RESERVED]</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.3.7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Restrictive
Legend Events; Cashless Exercise Under Certain Circumstances</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company shall provide to the Warrant Agent and each Holder prompt written notice of any time that the Company is unable to deliver the
Warrant Shares via DTC transfer or otherwise without restrictive legend because (A) the Commission has issued a stop order with respect
to the Registration Statement, (B) the Commission otherwise has suspended or withdrawn the effectiveness of the Registration Statement,
either temporarily or permanently, (C) the Company has suspended or withdrawn the effectiveness of the Registration Statement, either
temporarily or permanently, (D) the prospectus contained in the Registration Statement is not available for the issuance of the Warrant
Shares to the Holder or (E) otherwise (each a &ldquo;<U>Restrictive Legend Event</U>&rdquo;). To the extent that the Warrants cannot be
exercised as a result of a Restrictive Legend Event or a Restrictive Legend Event occurs after a Holder has exercised Warrants in accordance
with the terms of the Warrants but prior to the delivery of the Warrant Shares, the Company shall, at the election of the Holder, which
shall be given within five (5) days of receipt of such notice of the Restrictive Legend Event, either (A) rescind the previously submitted
Election to Purchase and the Company shall return all consideration paid by registered holder for such shares upon such rescission or
(B) treat the attempted exercise as a cashless exercise as described in paragraph (ii) below and refund the cash portion of the exercise
price to the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
a Restrictive Legend Event has occurred, the Warrant may also be exercisable on a cashless basis. Upon a &ldquo;cashless exercise&rdquo;,
the Holder shall be entitled to receive the number of Warrant Shares determined according to the following formula:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">Net Number =&nbsp;<U>(A
x B) - (A x C)</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify">B</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">For purposes of
the foregoing formula:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(A) = the total number of shares with
respect to which the Warrant is then being exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(B) = as applicable: (i) the VWAP on the
Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered
pursuant to Section 3.3.7(i) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 3.3.7(i)
hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule 600(b) of Regulation NMS promulgated
under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately
preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common Stock on the principal Trading Market as reported
by Bloomberg L.P. as of the time of the Holder&rsquo;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed
during &ldquo;regular trading hours&rdquo; on a Trading Day and is delivered within two (2) hours thereafter (including until two (2)
hours after the close of &ldquo;regular trading hours&rdquo; on a Trading Day) pursuant to Section 3.3.7(i) hereof or (iii) the VWAP on
the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both
executed and delivered pursuant to Section 3.3.7(i) hereof after the close of &ldquo;regular trading hours&rdquo; on such Trading Day;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(C) = the Exercise Price then in effect
for the applicable Warrant Shares at the time of such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If Warrant Shares are issued in such a cashless
exercise, the Company acknowledges and agrees that in accordance with Section 3(a)(9) of the Securities Act, the Warrant Shares shall
take on the registered characteristics of the Warrants being exercised. The Company agrees not to take any position contrary to this Section
3.3.7(ii) Notwithstanding anything to the contrary,&nbsp;without limiting the rights of the Holder to receive Warrant Shares on a &ldquo;cashless
exercise&rdquo; hereunder or to receive cash payments pursuant to Section 3.3.2(a) and Section 3.3.9 herein, there are no circumstances
that would require the Company to make any cash payments or net cash settle the purchase warrants to the holders. Upon receipt of an Election
to Purchase for a cashless exercise, the Warrant Agent will promptly deliver a copy of the Election to Purchase to the Company to confirm
the number of Warrant Shares issuable in connection with the cashless exercise. The Company shall calculate and transmit to the Warrant
Agent in a written notice, and the Warrant Agent shall have no duty, responsibility or obligation under this section to calculate, the
number of Warrant Shares issuable in connection with any cashless exercise. The Warrant Agent shall be entitled to rely conclusively on
any such written notice provided by the Company, and the Warrant Agent shall not be liable for any action taken, suffered or omitted to
be taken by it in accordance with such written instructions or pursuant to this Warrant Agreement. Notwithstanding anything herein to
the contrary, on the Termination Date, the Warrant shall be automatically exercised via cashless exercise pursuant to this Section 3.3.7.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.3.8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>[RESERVED]</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.3.9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise.</U> In addition to any other rights available to the Holder, if
the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section
3.3.2(b) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by
its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares of
Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such
exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&rsquo;s
total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained
by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise
at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the
Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in
which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been
issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common
Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with
an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the
Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable
to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit
a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree
of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common Stock
upon exercise of the Warrant as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.3.10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Beneficial
Ownership Limitation</U>. The Company shall not effect any exercise of the Warrant, and a Holder shall not have the right to exercise
any portion of a Warrant, pursuant to Section 3 or otherwise, to the extent that after giving effect to such issuance after exercise as
set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other Persons acting
as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;Attribution Parties&rdquo;)), would
beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number
of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of shares
of Common Stock issuable upon exercise of such Warrant with respect to which such determination is being made, but shall exclude the number
of shares of Common Stock which would be issuable upon (i) exercise of the remaining, non-exercised portion of such Warrant beneficially
owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or non-converted
portion of any other securities of the Company (including, without limitation, any other securities of the Company which would entitle
the holder thereof to acquire at any time shares of Common Stock, including, without limitation, any debt, preferred stock, right, option,
warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder
thereof to receive, shares of Common Stock (&ldquo;Common Stock Equivalents&rdquo;)) subject to a limitation on conversion or exercise
analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties. Except
as set forth in the preceding sentence, for purposes of this Section 3.3.10, beneficial ownership shall be calculated in accordance with
Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company
is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely
responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section
3.3.10 applies, the determination of whether a Warrant is exercisable (in relation to other securities owned by the Holder together with
any Affiliates and Attribution Parties) and of which portion of a Warrant is exercisable shall be in the sole discretion of the Holder,
and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination of whether a Warrant is exercisable
(in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of a Warrant
is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm
the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance
with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 3.3.10, in determining
the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in
(A) the Company&rsquo;s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public
announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares
of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within two Trading Days confirm orally and
in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common
Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including such Warrant, by the
Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported.
The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be 4.99% of the number of shares of the Common Stock outstanding immediately
after giving effect to the issuance of shares of Common Stock issuable upon exercise of a Warrant. The Holder, upon notice to the Company,
may increase or decrease the Beneficial Ownership Limitation provisions of this Section 3.3.10, provided that the Beneficial Ownership
Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance
of shares of Common Stock upon exercise of the Warrant held by the Holder and the provisions of this Section 3.3.10 shall continue to
apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61<SUP>st</SUP> day after such notice is delivered
to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with
the terms of this Section 3.3.10 to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended
Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such
limitation. The limitations contained in this paragraph shall apply to a successor holder of the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Adjustment
upon Subdivisions or Combinations</U>. If the Company, at any time while the Warrants are outstanding: (i) pays a stock dividend or otherwise
makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares
of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of the
Warrants), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse
stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common
Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the
numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event
and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of
shares issuable upon exercise of each Warrant shall be proportionately adjusted such that the aggregate Exercise Price of such Warrant
shall remain unchanged. Any adjustment made pursuant to this Section 4.1 shall become effective immediately after the record date for
the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective
date in the case of a subdivision, combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Adjustment
for Other Distributions.</U> (a) <U>Subsequent Rights Offerings</U>. In addition to any adjustments pursuant to Section 4.1 above, if
at any time the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other
property pro rata to the record holders of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder
will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have
acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of a Warrant (without regard to
any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on
which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which
the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however,
that to the extent that the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial
Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership
of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held
in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership
Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Pro
Rata Distributions</U>. During such time as the Warrants are outstanding, if the Company shall declare or make any dividend or other distribution
of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including,
without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification,
corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;), at any time after
the issuance of the Warrants, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent
that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise
of such Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation)
immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the
record holders of shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>, <U>however</U>,
to the extent that the Holder&rsquo;s right to participate in any such Distribution would result in the Holder exceeding the Beneficial
Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership
of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance
for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership
Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Fundamental
Transaction</U>. If, at any time while the Warrants are outstanding, (i) the Company, directly or indirectly, in one or more related transactions
effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly, effects any
sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series
of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another
Person) is completed pursuant to which holders of shares of Common Stock are permitted to sell, tender or exchange their shares for other
securities, cash or property and has been accepted by the holders of 50% or more of the outstanding shares of Common Stock or 50% or more
of the voting power of the common equity of the Company, (iv) the Company, directly or indirectly, in one or more related transactions
effects any reclassification, reorganization or recapitalization of the shares of Common Stock or any compulsory share exchange pursuant
to which the shares of Common Stock are effectively converted into or exchanged for other securities, cash or property, or (v) the Company,
directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination
(including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or
group of Persons whereby such other Person or group acquires 50% or more of the outstanding shares of Common Stock or 50% or more of the
voting power of the common equity of the Company (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon any subsequent exercise
of a Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately
prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 3.3.10
on the exercise of a Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it
is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;) receivable as a result
of such Fundamental Transaction by a holder of the number of shares of Common Stock for which the Warrant is exercisable immediately prior
to such Fundamental Transaction (without regard to any limitation in Section 3.3.10) on the exercise of a Warrant). For purposes of any
such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based
on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company
shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different
components of the Alternate Consideration. If holders of shares of Common Stock are given any choice as to the securities, cash or property
to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives
upon any exercise of a Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental
Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&rsquo;s option, exercisable at any time concurrently
with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later, the date of the public announcement of the
applicable Fundamental Transaction), purchase a Warrant from the Holder by paying to the Holder an amount of cash equal to the Black Scholes
Value (as defined below) of the remaining unexercised portion of a Warrant on the date of the consummation of such Fundamental Transaction;
provided, however, that, if the Fundamental Transaction is not within the Company's control, including not approved by the Company's Board
of Directors, Holder shall only be entitled to receive from the Company or any Successor Entity, the same type or form of consideration
(and in the same proportion), at the Black Scholes Value of the unexercised portion of a Warrant, that is being offered and paid to the
holders of Common Stock of the Company in connection with the Fundamental Transaction, whether that consideration be in the form of cash,
stock or any combination thereof, or whether the holders of Common Stock are given the choice to receive from among alternative forms
of consideration in connection with the Fundamental Transaction; provided further, that if holders of Common Stock of the Company are
not offered or paid any consideration in such Fundamental Transaction, such holders of Common Stock will be deemed to have received common
stock of the Successor Entity (which Entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction.
&ldquo;<U>Black Scholes Value</U>&rdquo; means the value of a Warrant based on the Black-Scholes Option Pricing Model obtained from the
&ldquo;<U>OV</U>&rdquo; function on Bloomberg, L.P. (&ldquo;<U>Bloomberg</U>&rdquo;) determined as of the day of consummation of the applicable
Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for
a period equal to the time between the date of the public announcement of the applicable contemplated Fundamental Transaction and the
Termination Date, (B) an expected volatility equal to the greater of 100% and the 100 day volatility obtained from the HVT function on
Bloomberg (determined utilizing a 365 day annualization factor) as of the Trading Day immediately following the public announcement of
the applicable contemplated Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the greater
of (i) the sum of the price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered
in such Fundamental Transaction and (ii) the greater of (x) the last VWAP immediately prior to the public announcement of such applicable
contemplated Fundamental Transaction and (y) the last VWAP immediately prior to the consummation of such Fundamental Transaction and (D)
a remaining option time equal to the time between the date of the public announcement of the applicable contemplated Fundamental Transaction
and the Termination Date and (E) a zero cost of borrow. The payment of the Black Scholes Value will be made by wire transfer of immediately
available funds within five Business Days of the Holder&rsquo;s election (or, if later, on the effective date of the Fundamental Transaction).
The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<U>Successor
Entity</U>&rdquo;) to assume in writing all of the obligations of the Company under the Warrants and the other transaction documents in
accordance with the provisions of this Section 4.3 pursuant to written agreements in form and substance reasonably satisfactory to the
Holder prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for the Warrants
a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to the Warrants which
is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the
shares of Common Stock acquirable and receivable upon exercise of the Warrants (without regard to any limitations on the exercise of the
Warrants) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares
of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and
the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting
the economic value of a Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory
in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and
be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of the Warrants and the other transaction
documents referring to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity), and may exercise every right and power
of the Company and shall assume all of the obligations of the Company under the Warrants and the other transaction documents with the
same effect as if such Successor Entity had been named as the Company therein. All calculations under this Section 4.3 shall be made to
the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section 4.3, the number of shares of Common
Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury
shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The Company shall instruct the
Warrant Agent in writing to mail by first class mail, postage prepaid, to each Holder, written notice of the execution of any such amendment,
supplement or agreement with the Successor Entity. Any supplemented or amended agreement entered into by the successor corporation or
transferee shall provide for adjustments, which shall be as nearly equivalent as may be practicable to the adjustments provided for in
this Section 4.3. The Warrant Agent shall have no duty, responsibility or obligation to determine the correctness of any provisions contained
in such agreement or such notice, including but not limited to any provisions relating either to the kind or amount of securities or other
property receivable upon exercise of warrants or with respect to the method employed and provided therein for any adjustments, and shall
be entitled to rely conclusively for all purposes upon the provisions contained in any such agreement. The provisions of this Section
4.3 shall similarly apply to successive reclassifications, changes, consolidations, mergers, sales and conveyances of the kind described
above</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices
to Holder</U>. (a) <U>Adjustment to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section
4, the Company shall promptly deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment
and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice
to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the shares
of Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the shares of Common Stock,
(C) the Company shall authorize the granting to all holders of the shares of Common Stock rights or warrants to subscribe for or purchase
any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection
with any reclassification of the shares of Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer
of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the shares of Common Stock is converted
into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding
up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by facsimile or email to the Holder at its
last facsimile number or email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to
the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the
purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders
of the shares of Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined
or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective
or close, and the date as of which it is expected that holders of the shares of Common Stock of record shall be entitled to exchange their
shares Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer
or stock exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect
the validity of the corporate action required to be specified in such notice, and provided, further, that no notice shall be required
if the information is disseminated in a press release or document filed with the Securities and Exchange Commission. To the extent that
any notice provided in a Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries,
the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain
entitled to exercise a Warrant during the period commencing on the date of such notice to the effective date of the event triggering such
notice except as may otherwise be expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>[RESERVED]</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices
of Changes in Warrant</U>. Upon every adjustment of the Exercise Price or the number of Warrant Shares issuable upon exercise of a Warrant,
the Company shall give written notice thereof to the Warrant Agent, which notice shall state the Exercise Price resulting from such adjustment
and the increase or decrease, if any, in the number of Warrant Shares purchasable at such price upon the exercise of a Warrant, setting
forth in reasonable detail the method of calculation and the facts upon which such calculation is based. Upon the occurrence of any event
specified in Sections 4.1 or 4.2, then, in any such event, the Company shall give written notice to each Holder, at the last address set
forth for such holder in the Warrant Register, as of the record date or the effective date of the event. Failure to give such notice,
or any defect therein, shall not affect the legality or validity of such event. The Warrant Agent shall be entitled to rely conclusively
on, and shall be fully protected in relying on, any certificate, notice or instructions provided by the Company with respect to any adjustment
of the Exercise Price or the number of shares issuable upon exercise of a Warrant, or any related matter, and the Warrant Agent shall
not be liable for any action taken, suffered or omitted to be taken by it in accordance with any such certificate, notice or instructions
or pursuant to this Warrant Agreement. The Warrant Agent shall not be deemed to have knowledge of any such adjustment unless and until
it shall have received written notice thereof from the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in; text-align: left">5.</TD><TD STYLE="text-align: justify"><U>Restrictive Legends; Fractional Warrants</U>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event that a Warrant
Certificate surrendered for transfer bears a restrictive legend, the Warrant Agent shall not register that transfer until the Warrant
Agent has received an opinion of counsel for the Company stating that such transfer may be made and indicating whether the Warrants must
also bear a restrictive legend upon that transfer. The Warrant Agent shall not be required to effect any registration of transfer or exchange
which will result in the transfer of or delivery of a Warrant Certificate for a fraction of a Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in; text-align: left">6.</TD><TD STYLE="text-align: justify"><U>[RESERVED]</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in; text-align: left">7.</TD><TD STYLE="text-align: justify"><U>Other Provisions Relating to Rights of Holders of Warrants</U>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Rights as Stockholder</U>. Except as otherwise specifically provided herein, a Holder, solely in its capacity as a holder of Warrants,
shall not be entitled to vote or receive dividends or be deemed the holder of share capital of the Company for any purpose, nor shall
anything contained in this Warrant Agreement be construed to confer upon a Holder, solely in its capacity as the registered holder of
Warrants, any of the rights of a stockholder of the Company or any right to vote, give or withhold consent to any corporate action (whether
any reorganization, issue of stock, reclassification of share capital, consolidation, merger, conveyance or otherwise), receive notice
of meetings, receive dividends or subscription rights or rights to participate in new issues of shares, or otherwise, prior to the issuance
to the Holder of the Warrant Shares which it is then entitled to receive upon the due exercise of Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Reservation
of Common Stock</U>. The Company shall at all times reserve and keep available a number of its authorized but unissued shares of Common
Stock that will be sufficient to permit the exercise in full of all outstanding Warrants issued pursuant to this Warrant Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in; text-align: left">8.</TD><TD STYLE="text-align: justify"><U>Concerning the Warrant Agent and Other Matters</U>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
instructions given to the Warrant Agent orally, as permitted by any provision of this Warrant Agreement, shall be confirmed in writing
by the Company as soon as practicable. The Warrant Agent shall not be liable or responsible and shall be fully authorized and protected
for acting, or failing to act, in accordance with any oral instructions which do not conform with the written confirmation received in
accordance with this Section 8.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)
Whether or not any Warrants are exercised, for the Warrant Agent&rsquo;s services as agent for the Company hereunder, the Company shall
pay to the Warrant Agent such fees as may be separately agreed between the Company and Warrant Agent and the Warrant Agent&rsquo;s out
of pocket expenses in connection with this Warrant Agreement, including, without limitation, the fees and expenses of the Warrant Agent&rsquo;s
counsel. While the Warrant Agent endeavors to maintain out-of-pocket charges (both internal and external) at competitive rates, these
charges may not reflect actual out-of-pocket costs, and may include handling charges to cover internal processing and use of the Warrant
Agent&rsquo;s billing systems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
amounts owed by the Company to the Warrant Agent under this Warrant Agreement are due within 45 days of the Company&rsquo;s receipt of
an invoice. Delinquent payments are subject to a late payment charge of one percent (1.0%) per month commencing 60 days from the invoice
date. The Company agrees to reimburse the Warrant Agent for any attorney&rsquo;s fees and any other costs associated with collecting delinquent
payments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
provision of this Warrant Agreement shall require Warrant Agent to expend or risk its own funds or otherwise incur any financial liability
in the performance of any of its duties under this Warrant Agreement or in the exercise of its rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">8.3.</TD><TD STYLE="text-align: justify"><U>As agent for the Company hereunder the Warrant Agent</U>:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shall
have no duties or obligations other than those specifically set forth herein or as may subsequently be agreed to in writing by the Warrant
Agent and the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shall
be regarded as making no representations and having no responsibilities as to the validity, sufficiency, value, or genuineness of the
Warrants or any Warrant Shares;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shall
not be obligated to take any legal action hereunder; if, however, the Warrant Agent determines to take any legal action hereunder, and
where the taking of such action might, in its judgment, subject or expose it to any expense or liability it shall not be required to act
unless it has been furnished with an indemnity reasonably satisfactory to it;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;may
rely on and shall be fully authorized and protected in acting or failing to act upon any certificate, instrument, opinion, notice, letter,
telegram, telex, facsimile transmission or other document or security delivered to the Warrant Agent and believed by it to be genuine
and to have been signed by the proper party or parties;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shall
not be liable or responsible for any recital or statement contained in the Registration Statement or any other documents relating thereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shall
not be liable or responsible for any failure on the part of the Company to comply with any of its covenants and obligations relating to
the Warrants, including without limitation obligations under applicable securities laws;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;may
rely on and shall be fully authorized and protected in acting or failing to act upon the written, telephonic or oral instructions with
respect to any matter relating to its duties as Warrant Agent covered by this Warrant Agreement (or supplementing or qualifying any such
actions) of officers of the Company, and is hereby authorized and directed to accept instructions with respect to the performance of its
duties hereunder from the Company or counsel to the Company, and may apply to the Company, for advice or instructions in connection with
the Warrant Agent&rsquo;s duties hereunder, and the Warrant Agent shall not be liable for any delay in acting while waiting for those
instructions; any applications by the Warrant Agent for written instructions from the Company may, at the option of the Agent, set forth
in writing any action proposed to be taken or omitted by the Warrant Agent under this Warrant Agreement and the date on or after which
such action shall be taken or such omission shall be effective; the Warrant Agent shall not be liable for any action taken by, or omission
of, the Warrant Agent in accordance with a proposal included in such application on or after the date specified in such application (which
date shall not be less than five business days after the date such application is sent to the Company, unless the Company shall have consented
in writing to any earlier date) unless prior to taking any such action, the Warrant Agent shall have received written instructions in
response to such application specifying the action to be taken or omitted;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;may
consult with counsel satisfactory to the Warrant Agent, including its in-house counsel, and the advice of such counsel shall be full and
complete authorization and protection in respect of any action taken, suffered, or omitted by it hereunder in good faith and in accordance
with the advice of such counsel;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;may
perform any of its duties hereunder either directly or by or through nominees, correspondents, designees, or subagents, and it shall not
be liable or responsible for any misconduct or negligence on the part of any nominee, correspondent, designee, or subagent appointed with
reasonable care by it in connection with this Warrant Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;is
not authorized, and shall have no obligation, to pay any brokers, dealers, or soliciting fees to any person and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shall
not be required hereunder to comply with the laws or regulations of any country other than the United States of America or any political
subdivision thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)
In the absence of gross negligence or willful or illegal misconduct on its part, the Warrant Agent shall not be liable for any action
taken, suffered, or omitted by it or for any error of judgment made by it in the performance of its duties under this Warrant Agreement.
Anything in this Warrant Agreement to the contrary notwithstanding, in no event shall Warrant Agent be liable for special, indirect, incidental,
consequential or punitive losses or damages of any kind whatsoever (including but not limited to lost profits), even if the Warrant Agent
has been advised of the possibility of such losses or damages and regardless of the form of action. Any liability of the Warrant Agent
will be limited in the aggregate to the amount of fees paid by the Company hereunder. The Warrant Agent shall not be liable for any failures,
delays or losses, arising directly or indirectly out of conditions beyond its reasonable control including, but not limited to, acts of
government, exchange or market ruling, suspension of trading, work stoppages or labor disputes, fires, civil disobedience, riots, rebellions,
storms, electrical or mechanical failure, computer hardware or software failure, communications facilities failures including telephone
failure, war, terrorism, insurrection, earthquakes, floods, acts of God or similar occurrences.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event any question or dispute arises with respect to the proper interpretation of the Warrants or the Warrant Agent&rsquo;s duties
under this Warrant Agreement or the rights of the Company or of any Holder, the Warrant Agent shall not be required to act and shall not
be held liable or responsible for its refusal to act until the question or dispute has been judicially settled (and, if appropriate, it
may file a suit in interpleader or for a declaratory judgment for such purpose) by final judgment rendered by a court of competent jurisdiction,
binding on all persons interested in the matter which is no longer subject to review or appeal, or settled by a written document in form
and substance satisfactory to Warrant Agent and executed by the Company and each such Holder. In addition, the Warrant Agent may require
for such purpose, but shall not be obligated to require, the execution of such written settlement by all the Holders and all other persons
that may have an interest in the settlement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company covenants to indemnify the Warrant Agent and hold it harmless from and against any loss, liability, claim or expense (&ldquo;<U>Loss</U>&rdquo;)
arising out of or in connection with the Warrant Agent&rsquo;s duties under this Warrant Agreement, including the costs and expenses of
defending itself against any Loss, unless such Loss shall have been determined by a court of competent jurisdiction to be a result of
the Warrant Agent&rsquo;s gross negligence or willful misconduct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless
terminated earlier by the parties hereto, this Warrant Agreement shall terminate 90 days after the earlier of the Expiration Date and
the date on which no Warrants remain outstanding (the &ldquo;<U>Termination Date</U>&rdquo;). On the business day following the Termination
Date, the Agent shall deliver to the Company any entitlements, if any, held by the Warrant Agent under this Warrant Agreement. The Agent&rsquo;s
right to be reimbursed for fees, charges and out-of-pocket expenses as provided in this Section 8 shall survive the termination of this
Warrant Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
any provision of this Warrant Agreement shall be held illegal, invalid, or unenforceable by any court, this Warrant Agreement shall be
construed and enforced as if such provision had not been contained herein and shall be deemed an Agreement among the parties to it to
the full extent permitted by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company represents and warrants that (a) it is duly incorporated and validly existing under the laws of its jurisdiction of incorporation,
(b) the offer and sale of the Warrants and the execution, delivery and performance of all transactions contemplated thereby (including
this Warrant Agreement) have been duly authorized by all necessary corporate action and will not result in a breach of or constitute a
default under the articles of association, bylaws or any similar document of the Company or any indenture, agreement or instrument to
which it is a party or is bound, (c) this Warrant Agreement has been duly executed and delivered by the Company and constitutes the legal,
valid, binding and enforceable obligation of the Company, (d) the Warrants will comply in all material respects with all applicable requirements
of law and (e) to the best of its knowledge, there is no litigation pending or threatened as of the date hereof in connection with the
offering of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event of inconsistency between this Warrant Agreement and the descriptions in the Registration Statement, as they may from time to
time be amended, the terms of this Warrant Agreement shall control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Set
forth in <U>Annex C</U> hereto is a list of the names and specimen signatures of the persons authorized to act for the Company under this
Warrant Agreement (the &ldquo;<U>Authorized Representatives</U>&rdquo;). The Company shall, from time to time, certify to you the names
and signatures of any other persons authorized to act for the Company under this Warrant Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
notice, statement or demand authorized by this Warrant Agreement to be given or made by the Warrant Agent or by the holder of any Warrant
to or on the Company shall be delivered by e-mail, hand or sent by registered or certified mail or overnight courier service, addressed
(until another address is filed in writing by the Company with the Warrant Agent) as set forth below and if to any holder any notice,
statement or demand shall be given to the last address set forth for such holder (if any) in the Warrant Register:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">BioVie Inc.<BR>
680 W Nye Lane, Suite 204<BR>
Carson City, NV 89703<BR>
Email: wkim@bioviepharma.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">with a copy (which shall not constitute notice)
to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">McGuireWoods LLP<BR>
1251 Avenue of the Americas<BR>
New York, NY 10020<BR>
Email: solder@mcguirewoods.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any notice, statement or demand authorized by
this Warrant Agreement to be given or made by the holder of any Warrant or by the Company to or on the Warrant Agent shall be delivered
by hand or sent by registered or certified mail or overnight courier service, addressed (until another address is filed in writing by
the Warrant Agent with the Company), as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">West Coast Stock Transfer Inc.<BR>
721 N. Vulcan Ave., 1<SUP>st</SUP> Floor<BR>
Encinitas, California 92024<BR>
Email: cs@wcsti.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)
This Warrant Agreement shall be governed by and construed in accordance with the laws of the State of New York. All actions and proceedings
relating to or arising from, directly or indirectly, this Warrant Agreement may be litigated in courts located within the Borough of Manhattan
in the City and State of New York. The Company hereby submits to the personal jurisdiction of such courts and consents that any service
of process may be made by certified or registered mail, return receipt requested, directed to the Company at its address last specified
for notices hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Warrant Agreement shall inure to the benefit of and be binding upon the successors and assigns of the parties hereto. This Warrant Agreement
may not be assigned, or otherwise transferred, in whole or in part, by either party without the prior written consent of the other party,
which the other party will not unreasonably withhold, condition or delay; except that (i) consent is not required for an assignment or
delegation of duties by Warrant Agent to any affiliate of Warrant Agent and (ii) any reorganization, merger, consolidation, sale of assets
or other form of business combination by Warrant Agent or the Company shall not be deemed to constitute an assignment of this Warrant
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
provision of this Warrant Agreement may be amended, modified or waived, except in a written document signed by both parties. The Company
and the Warrant Agent may amend or supplement this Warrant Agreement without the consent of any Holder for the purpose of curing any ambiguity,
or curing, correcting or supplementing any defective provision contained herein or adding or changing any other provisions with respect
to matters or questions arising under this Warrant Agreement as the parties may deem necessary or desirable and that the parties determine,
in good faith, shall not adversely affect the interest of the Holders. All other amendments and supplements shall require the vote or
written consent of Holders of at least 50.1% of the then outstanding Warrants, provided that adjustments may be made to the Warrant terms
and rights in accordance with Section 4 without the consent of the Holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Payment
of Taxes</U>. The Company will from time to time promptly pay all taxes and charges that may be imposed upon the Company or the Warrant
Agent in respect of the issuance or delivery of Warrant Shares upon the exercise of Warrants, but the Company may require the Holders
to pay any transfer taxes in respect of the Warrants or such shares. The Warrant Agent may refrain from registering any transfer of Warrants
or any delivery of any Warrant Shares unless or until the persons requesting the registration or issuance shall have paid to the Warrant
Agent for the account of the Company the amount of such tax or charge, if any, or shall have established to the reasonable satisfaction
of the Company and the Warrant Agent that such tax or charge, if any, has been paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Resignation
of Warrant Agent</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.14.1.&nbsp;&nbsp;&nbsp;&nbsp;<U>Appointment
of Successor Warrant Agent</U>. The Warrant Agent, or any successor to it hereafter appointed, may resign its duties and be discharged
from all further duties and liabilities hereunder after giving thirty (30) days&rsquo; notice in writing to the Company, or such shorter
period of time agreed to by the Company. The Company may terminate the services of the Warrant Agent, or any successor Warrant Agent,
after giving thirty (30) days&rsquo; notice in writing to the Warrant Agent or successor Warrant Agent, or such shorter period of time
as agreed. If the office of the Warrant Agent becomes vacant by resignation, termination or incapacity to act or otherwise, the Company
shall appoint in writing a successor Warrant Agent in place of the Warrant Agent. If the Company shall fail to make such appointment within
a period of 30 days after it has been notified in writing of such resignation or incapacity by the Warrant Agent, then the Warrant Agent
or any Holder may apply to any court of competent jurisdiction for the appointment of a successor Warrant Agent at the Company&rsquo;s
cost. Pending appointment of a successor to such Warrant Agent, either by the Company or by such a court, the duties of the Warrant Agent
shall be carried out by the Company. Any successor Warrant Agent (but not including the initial Warrant Agent), whether appointed by the
Company or by such court, shall be a person organized and existing under the laws of any state of the United States of America, in good
standing, and authorized under such laws to exercise corporate trust powers and subject to supervision or examination by federal or state
authority. After appointment, any successor Warrant Agent shall be vested with all the authority, powers, rights, immunities, duties,
and obligations of its predecessor Warrant Agent with like effect as if originally named as Warrant Agent hereunder, without any further
act or deed, and except for executing and delivering documents as provided in the sentence that follows, the predecessor Warrant Agent
shall have no further duties, obligations, responsibilities or liabilities hereunder, but shall be entitled to all rights that survive
the termination of this Warrant Agreement and the resignation or removal of the Warrant Agent, including but not limited to its right
to indemnity hereunder. If for any reason it becomes necessary or appropriate or at the request of the Company, the predecessor Warrant
Agent shall execute and deliver, at the expense of the Company, an instrument transferring to such successor Warrant Agent all the authority,
powers, and rights of such predecessor Warrant Agent hereunder; and upon request of any successor Warrant Agent the Company shall make,
execute, acknowledge, and deliver any and all instruments in writing for more fully and effectually vesting in and confirming to such
successor Warrant Agent all such authority, powers, rights, immunities, duties, and obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.14.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice
of Successor Warrant Agent</U>. In the event a successor Warrant Agent shall be appointed, the Company shall give notice thereof to the
predecessor Warrant Agent and the transfer agent for the Common Stock not later than the effective date of any such appointment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.14.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Merger
or Consolidation of Warrant Agent</U>. Any person into which the Warrant Agent may be merged or converted or with which it may be consolidated
or any person resulting from any merger, conversion or consolidation to which the Warrant Agent shall be a party or any person succeeding
to the shareowner services business of the Warrant Agent or any successor Warrant Agent shall be the successor Warrant Agent under this
Warrant Agreement, without any further act or deed. For purposes of this Warrant Agreement, &ldquo;person&rdquo; shall mean any individual,
firm, corporation, partnership, limited liability company, joint venture, association, trust or other entity, and shall include any successor
(by merger or otherwise) thereof or thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in; text-align: left">9.</TD><TD STYLE="text-align: justify"><U>Miscellaneous Provisions</U>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Persons
Having Rights under this Warrant Agreement</U>. Nothing in this Warrant Agreement expressed and nothing that may be implied from any of
the provisions hereof is intended, or shall be construed, to confer upon, or give to, any person or corporation other than the parties
hereto and the Holders any right, remedy, or claim under or by reason of this Warrant Agreement or of any covenant, condition, stipulation,
promise, or agreement hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Examination
of the Warrant Agreement</U>. A copy of this Warrant Agreement shall be available at all reasonable times at the office of the Warrant
Agent designated for such purpose for inspection by any Holder. Prior to such inspection, the Warrant Agent may require any such holder
to provide reasonable evidence of its interest in the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Counterparts</U>.
This Warrant Agreement may be executed in any number of original, facsimile or electronic counterparts and each of such counterparts shall
for all purposes be deemed to be an original, and all such counterparts shall together constitute but one and the same instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Effect
of Headings</U>. The Section headings herein are for convenience only and are not part of this Warrant Agreement and shall not affect
the interpretation thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in; text-align: left">10.</TD><TD STYLE="text-align: justify"><U>Certain Definitions</U>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As used herein, the following
terms shall have the following meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Bid
Price</U>&rdquo; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock
is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or a
similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of Common Stock so
reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected
in good faith by the Holders of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the
fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Trading
Day</U>&rdquo; means any weekday on which the Trading Market is open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock
Exchange, the OTCQB or the OTCQX (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>VWAP</U>&rdquo;
means for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or a
similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock
so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected
in good faith by the Holders of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the
fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">[SIGNATURE PAGE FOLLOWS]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, this Warrant
Agent Agreement has been duly executed by the parties hereto as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">BIOVIE INC.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 50%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 2%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify; width: 48%">/s/ Cuong V Do</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">Name: Cuong V Do</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">Title: Chief Executive Officer</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">WEST COAST STOCK TRANSFER, INC.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">As Warrant Agent</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">By:&nbsp;&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">/s/ Frank Brickell</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">Name: Frank Brickell</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">Title: President</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Annex A Form of Global Certificate</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Annex B Form of Certificated Warrant</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Annex C Authorized Representatives</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Annex D Form of Warrant Certificate Request Notice</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: right">ANNEX A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: right">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">[FORM OF GLOBAL
CERTIFICATE]</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>UNLESS THIS CERTIFICATE IS PRESENTED BY AN
AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION (&ldquo;DTC&rdquo;), TO ISSUER OR ITS AGENT FOR REGISTRATION
OF TRANSFER, EXCHANGE, OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE &amp; CO. OR IN SUCH OTHER NAME AS IS
REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE &amp; CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY
AN AUTHORIZED REPRESENTATIVE OF DTC), ANY TRANSFER, PLEDGE, OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL
INASMUCH AS THE REGISTERED OWNER HEREOF, CEDE &amp; CO., HAS AN INTEREST HEREIN.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">BIOVIE INC.<BR>
WARRANT CERTIFICATE<BR>
NOT EXERCISABLE AFTER AUGUST 11, 2030</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This certifies that the person
whose name and address appears below, or registered assigns, is the registered owner of the number of Warrants set forth below. Each Warrant
entitles its registered holder to purchase from BioVie Inc., a company incorporated under the laws of the State of Nevada (the &ldquo;<B>Company</B>&rdquo;),
at any time prior to 5:00 P.M. (New York City time) on August 11, 2030, one share of common stock, par value $0.0001 per share, of the
Company (each, a &ldquo;<B>Warrant Share</B>&rdquo; and collectively, the &ldquo;<B>Warrant Shares</B>&rdquo;), at an exercise price of
$2.50 per share, subject to possible adjustments as provided in the Warrant Agreement (as defined below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Warrant Certificate,
with or without other Warrant Certificates, upon surrender at the designated office of the Warrant Agent, may be exchanged for another
Warrant Certificate or Warrant Certificates evidencing the same number of Warrants as the Warrant Certificate or Warrant Certificates
surrendered. A transfer of the Warrants evidenced hereby may be registered upon surrender of this Warrant Certificate at the designated
office of the Warrant Agent by the registered holder in person or by a duly authorized attorney, properly endorsed or accompanied by proper
instruments of transfer, a signature guarantee, and such other and further documentation as the Warrant Agent may reasonably request and
duly stamped as may be required by the laws of the State of New York and of the United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The terms and conditions of
the Warrants and the rights and obligations of the holder of this Warrant Certificate are set forth in the Warrant Agent Agreement dated
as of August 11, 2025 (the &ldquo;<B>Warrant Agreement</B>&rdquo;) between the Company and West Coast Stock Transfer, Inc. (the &ldquo;<B>Warrant
Agent</B>&rdquo;). A copy of the Warrant Agreement is available for inspection during business hours at the office of the Warrant Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Warrant Certificate shall
not be valid or obligatory for any purpose until it shall have been countersigned by an authorized signatory of the Warrant Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WITNESS the facsimile signature
of a proper officer of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">BIOVIE INC.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 50%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 2%">By:&nbsp;&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify; width: 48%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">Name: Cuong V Do</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">Title: Chief Executive Officer</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dated: ____________, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Countersigned:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">WEST COAST STOCK TRANSFER, INC.,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As Warrant Agent</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%; text-align: justify">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 58%; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Name:&nbsp;&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Title:</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>PLEASE DETACH HERE</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Certificate No.:_________ Number of Warrants:__________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">WARRANT CUSIP NO.: ___________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 50%; text-align: justify">BIOVIE INC.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">[Name &amp; Address of Holder] West Coast Stock
Transfer, Inc., Warrant Agent</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 50%; text-align: justify">By Mail:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">By hand or overnight courier:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: right"><A NAME="annexb"></A>ANNEX B</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: right">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">[FORM OF CERTIFICATED
WARRANT]</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>COMMON STOCK PURCHASE WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>biovie
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%; text-align: left"><FONT STYLE="font-size: 10pt">Warrant Shares: </FONT></TD>
    <TD STYLE="width: 75%; text-align: right; text-indent: 9.05pt"><FONT STYLE="font-size: 10pt">Initial Exercise Date: August 11, 2025</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">Issue Date:&nbsp;&nbsp;August 11, 2025</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">THIS COMMON STOCK PURCHASE WARRANT
(the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, _______ or its assigns (the &ldquo;<U>Holder</U>&rdquo;) is entitled,
upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof
(the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on or prior to 5:00 p.m. (New York City time) on the five (5) year anniversary of
the Initial Exercise Date&nbsp;(the &ldquo;<U>Termination Date</U>&rdquo;), but not thereafter, to subscribe for and purchase from BioVie
Inc., a Nevada corporation (the &ldquo;<U>Company</U>&rdquo;), up to ______ shares of common stock, par value $0.0001 per share (the &ldquo;<U>Common
Stock</U>&rdquo;) (as subject to adjustment hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;). The purchase price of one share of Common
Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant shall initially be issued and
maintained in the form of a security held in book-entry form and the Depository Trust Company or its nominee (&ldquo;<U>DTC</U>&rdquo;)
shall initially be the sole registered holder of this Warrant, subject to a Holder&rsquo;s right to elect to receive a Warrant in certificated
form pursuant to the terms of that certain&nbsp;Warrant Agent Agreement (the &ldquo;<U>Warrant Agent Agreement</U>&rdquo;), dated as of
the Initial Exercise Date, between the Company and West Coast Stock Transfer, Inc., the Company&rsquo;s warrant agent for the Warrants,
and any successor appointed in such capacity (the &ldquo;<U>Warrant Agent</U>&rdquo;), in which case this sentence shall not apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 1</U>. <U>Definitions</U>.
Except as set forth below, capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Underwriting
Agreement (the &ldquo;<U>Agreement</U>&rdquo;), dated August 7, 2025, between the Company and ThinkEquity LLC, as representative of the
several underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading Day</U>&rdquo;
means any weekday on which the Trading Market is open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading Market</U>&rdquo;
means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the
NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange, the
OTCQB or the OTCQX (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transfer Agent</U>&rdquo;
means West Coast Stock Transfer, Inc., the Company&rsquo;s transfer agent and registrar for the Common Stock, and any successor appointed
in such capacity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 2</U>.&nbsp;<U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)&nbsp;<U>Exercise
of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on
or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed facsimile copy
(or.pdf copy via e-mail attachment) of the Notice of Exercise in the form annexed hereto as Exhibit A (the &ldquo;<U>Notice of Exercise</U>&rdquo;).
Within the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined
in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the
Warrant Shares specified in the applicable Notice of Exercise by wire transfer drawn on a United States bank unless the cashless exercise
procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall
be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding
anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder
has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall
surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise
is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares
available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal
to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant
Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Trading
Day of receipt of such notice.&nbsp;<B>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason
of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares
available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Notwithstanding
the foregoing in this&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">Section 2(a)</FONT>, a holder whose interest in this
Warrant is a beneficial interest in certificate(s) representing this Warrant held in book-entry form through DTC (or another established
clearing corporation performing similar functions), shall effect exercises made pursuant to this&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">Section
2(a)&nbsp;</FONT>by delivering to DTC (or such other clearing corporation, as applicable) the appropriate instruction form for exercise,
complying with the procedures to effect exercise that are required by DTC (or such other clearing corporation, as applicable), subject
to a Holder&rsquo;s right to elect to receive a Warrant in certificated form pursuant to the terms of the Warrant Agent Agreement, in
which case this sentence shall not apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)&nbsp;<U>Exercise
Price</U>. The exercise price per share of Common Stock under this Warrant shall be $2.50, subject to adjustment hereunder (the &ldquo;<U>Exercise
Price</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)&nbsp;<U>Cashless
Exercise</U>. If at any time during the term of this Warrant and on or after the Initial Exercise Date, there is no effective registration
statement registering, or no current prospectus available for the issuance of the Warrant Shares by the Holder, then this Warrant may
be exercised, in whole or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to
receive a number of Warrant Shares determined according to the following formula (a &ldquo;<U>Cashless Exercise</U>&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">Net Number =&nbsp;<U>(A
x B) - (A x C)</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify">B</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">For purposes of
the foregoing formula:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(A) = the total number of shares with
respect to which this Warrant is then being exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(B) = as applicable: (i) the VWAP on the
Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered
pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof
on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule 600(b) of Regulation NMS promulgated
under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately
preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common Stock on the principal Trading Market as reported
by Bloomberg L.P. as of the time of the Holder&rsquo;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed
during &ldquo;regular trading hours&rdquo; on a Trading Day and is delivered within two (2) hours thereafter (including until two (2)
hours after the close of &ldquo;regular trading hours&rdquo; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the
date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both
executed and delivered pursuant to Section 2(a) hereof after the close of &ldquo;regular trading hours&rdquo; on such Trading Day; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(C) = the Exercise Price then in effect
for the applicable Warrant Shares at the time of such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If Warrant Shares are issued in such a cashless
exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the Warrant Shares shall take
on the registered characteristics of the Warrants being exercised. The Company agrees not to take any position contrary to this Section
2(c). Notwithstanding anything to the contrary,&nbsp;<FONT STYLE="background-color: white">without limiting the rights of the Holder to
receive Warrant Shares on a &ldquo;cashless exercise&rdquo; hereunder or to receive cash payments pursuant to Section 2(d)(i) and Section
2(d)(iv) herein</FONT>, there are no circumstances that would require the Company to make any cash payments or net cash settle the purchase
warrants to the holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Bid Price</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading
Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York
City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the
Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed
or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or a similar organization
or agency succeeding to its functions of reporting prices), the most recent bid price per share of Common Stock so reported, or (d) in
all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by
the Holders of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses
of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or a
similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock
so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected
in good faith by the Holders of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the
fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)&nbsp;<U>Mechanics
of Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">i.&nbsp;<U>Delivery
of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer
Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository Trust Company
through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant in such system
and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant
Shares by the Holder or (B) this Warrant is exercised via cashless exercise), and otherwise by book-entry, registered in the Company&rsquo;s
share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to
such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earlier of (i) one (1) Trading
Day and (ii) the number of Trading Days comprising the Standard Settlement Period, in each case after the delivery to the Company of the
Notice of Exercise (such date, the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;). Upon delivery of the Notice of Exercise, the Holder
shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant
has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price
(other than in the case of a cashless exercise) is received within the earlier of (i) one (1) Trading Day and (ii) the number of Trading
Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the Company fails for any reason to deliver
to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder,
in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of
the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the fifth
Trading Day after such liquidated damages begin to accrue) for each Trading Day after such Warrant Share Delivery Date until such Warrant
Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST
program so long as this Warrant remains outstanding and exercisable. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means
the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the
Common Stock as in effect on the date of delivery of the Notice of Exercise. Notwithstanding the foregoing, with respect to any Notice(s)
of Exercise delivered on or prior to 12:00 p.m. (New York City time) on the Initial Exercise Date, which may be delivered at any time
after the time of execution of the Agreement, the Company agrees to deliver the Warrant Shares subject to such notice(s) by 4:00 p.m.
(New York City time) on the Initial Exercise Date and the Initial Exercise Date shall be the Warrant Share Delivery Date for purposes
hereunder, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by such Warrant
Share Delivery Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii.&nbsp;<U>Delivery
of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and
upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing
the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects
be identical with this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">iii.&nbsp;<U>Rescission
Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i)
by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">iv.&nbsp;<U>Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to the Holder, if
the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section
2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its
broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares of Common
Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise
(a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&rsquo;s
total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained
by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise
at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the
Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in
which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been
issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common
Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with
an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the
Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable
to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit
a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree
of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common Stock
upon exercise of the Warrant as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">v.&nbsp;<U>No Fractional
Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As
to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election,
either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or
round up to the next whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">vi.&nbsp;<U>Charges,
Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental
expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant
Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder;&nbsp;<U>provided</U>,&nbsp;<U>however</U>,
that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for
exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition
thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent
fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing
corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">vii.&nbsp;<U>Closing
of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)&nbsp;<U>Holder&rsquo;s
Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise
any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise
as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other Persons acting
as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)),
would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&nbsp; For purposes of the foregoing sentence,
the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number
of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude
the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant
beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or
nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject
to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its
Affiliates or Attribution Parties.&nbsp; Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial
ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder,
it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section
13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the
extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation
to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is
exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s
determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates
and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation,
and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any
group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations
promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may
rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&rsquo;s most recent periodic or annual report
filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice
by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.&nbsp; Upon the written or oral request
of a Holder, the Company shall within one (1) Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock
then outstanding.&nbsp; In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion
or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date
as of which such number of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall
be 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock
issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation
provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of the shares
of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held
by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will
not be effective until the 61<SUP>st</SUP>&nbsp;day after such notice is delivered to the Company. The provisions of this paragraph shall
be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph
(or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to
make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph
shall apply to a successor holder of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 3</U>.&nbsp;<U>Certain
Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)&nbsp;<U>Stock
Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes
a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of
Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse
stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of Common
Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the
numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event
and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant
shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for
the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective
date in the case of a subdivision, combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)&nbsp;[Reserved].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)&nbsp;<U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells
any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any
class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire, upon the terms
applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number
of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including
without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance
or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are
to be determined for the grant, issue or sale of such Purchase Rights (provided, however, that to the extent that the Holder&rsquo;s right
to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall
not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result
of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time,
if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)&nbsp;<U>Pro Rata
Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution
of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including,
without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification,
corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;), at any time after
the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent
that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise
of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation)
immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the
record holders of shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>,&nbsp;<U>however</U>,
to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership
Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of
any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance
for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership
Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)&nbsp;<U>Fundamental
Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions
effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly, effects any
sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series
of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another
Person) is completed pursuant to which holders of shares of Common Stock are permitted to sell, tender or exchange their shares for other
securities, cash or property and has been accepted by the holders of 50% or more of the outstanding shares of Common Stock or 50% or more
of the voting power of the common equity of the Company, (iv) the Company, directly or indirectly, in one or more related transactions
effects any reclassification, reorganization or recapitalization of the shares of Common Stock or any compulsory share exchange pursuant
to which the shares of Common Stock are effectively converted into or exchanged for other securities, cash or property, or (v) the Company,
directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination
(including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or
group of Persons whereby such other Person or group acquires 50% or more of the outstanding shares of Common Stock or 50% or more of the
voting power of the common equity of the Company (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon any subsequent exercise
of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately
prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e)
on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if
it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;) receivable as a result
of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately
prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes
of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration
based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the
Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any
different components of the Alternate Consideration. If holders of shares of Common Stock are given any choice as to the securities, cash
or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration
it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the
event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&rsquo;s option, exercisable
at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later, the date of the
public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder an amount
of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the date of the consummation
of such Fundamental Transaction; provided, however, that, if the Fundamental Transaction is not within the Company's control, including
not approved by the Company's Board of Directors, Holder shall only be entitled to receive from the Company or any Successor Entity, the
same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of this Warrant,
that is being offered and paid to the holders of Common Stock of the Company in connection with the Fundamental Transaction, whether that
consideration be in the form of cash, stock or any combination thereof, or whether the holders of Common Stock are given the choice to
receive from among alternative forms of consideration in connection with the Fundamental Transaction; provided further, that if holders
of Common Stock of the Company are not offered or paid any consideration in such Fundamental Transaction, such holders of Common Stock
will be deemed to have received common stock of the Successor Entity (which Entity may be the Company following such Fundamental Transaction)
in such Fundamental Transaction. &ldquo;<U>Black Scholes Value</U>&rdquo; means the value of this Warrant based on the Black-Scholes Option
Pricing Model obtained from the &ldquo;<U>OV</U>&rdquo; function on Bloomberg, L.P. (&ldquo;<U>Bloomberg</U>&rdquo;) determined as of
the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding
to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the applicable contemplated Fundamental
Transaction and the Termination Date, (B) an expected volatility equal to the greater of 100% and the 100 day volatility obtained from
the HVT function on Bloomberg (determined utilizing a 365 day annualization factor) as of the Trading Day immediately following the public
announcement of the applicable contemplated Fundamental Transaction, (C) the underlying price per share used in such calculation shall
be the greater of (i) the sum of the price per share being offered in cash, if any, plus the value of any non-cash consideration, if any,
being offered in such Fundamental Transaction and (ii) the greater of (x) the last VWAP immediately prior to the public announcement of
such applicable contemplated Fundamental Transaction and (y) the last VWAP immediately prior to the consummation of such Fundamental Transaction
and (D) a remaining option time equal to the time between the date of the public announcement of the applicable contemplated Fundamental
Transaction and the Termination Date and (E) a zero cost of borrow. The payment of the Black Scholes Value will be made by wire transfer
of immediately available funds within five Business Days of the Holder&rsquo;s election (or, if later, on the effective date of the Fundamental
Transaction). The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the
&ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all of the obligations of the Company under this Warrant and the other Transaction
Documents in accordance with the provisions of this Section 3(e) pursuant to written agreements in form and substance reasonably satisfactory
to the Holder prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this
Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant
which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent
to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise
of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such
shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction
and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of
protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably
satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall
succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant and
the other Transaction Documents referring to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity), and may exercise
every right and power of the Company and shall assume all of the obligations of the Company under this Warrant and the other Transaction
Documents with the same effect as if such Successor Entity had been named as the Company herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f) &nbsp;&nbsp;<U>Calculations</U>.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes
of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the
number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">g)&nbsp;<U>Notice
to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">i.&nbsp;<U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly
deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii.&nbsp;<U>Notice
to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the shares
of Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the shares of Common Stock,
(C) the Company shall authorize the granting to all holders of the shares of Common Stock rights or warrants to subscribe for or purchase
any capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with
any reclassification of the shares of Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer
of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the shares of Common Stock are converted
into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding
up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by facsimile or email to the Holder at its
last facsimile number or email address as it shall appear upon the Warrant Register of the Company, at least 5 calendar days prior to
the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the
purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders
of the shares of Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined
or (y) the date on which such reclassification, consolidation, merger, sale, transfer or stock exchange is expected to become effective
or close, and the date as of which it is expected that holders of the shares of Common Stock of record shall be entitled to exchange their
shares of Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer
or stock exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect
the validity of the corporate action required to be specified in such notice and provided, further that no notice shall be required if
the information is disseminated in a press release or document filed with the Securities and Exchange Commission . To the extent that
any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries,
the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain
entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering
such notice except as may otherwise be expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Section 4</U>.&nbsp;<U>Transfer of Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)&nbsp;<U>Transferability</U>.
This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part,
upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this
Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any
transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute
and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations
specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so
assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required
to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall
surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the
Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for
the purchase of Warrant Shares without having a new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)&nbsp;<U>New Warrants</U>.
If this Warrant is not held in global form through DTC (or any successor depository), this Warrant may be divided or combined with other
Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations
in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to
any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in
exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges
shall be dated the Issue Date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable
pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)&nbsp;<U>Warrant
Register</U>. The Warrant Agent shall register this Warrant, upon records to be maintained by the Warrant Agent for that purpose (the&nbsp;&ldquo;<U>Warrant
Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company and the Warrant Agent may deem and treat
the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder,
and for all other purposes, absent actual notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 5</U>.&nbsp;<U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)&nbsp;<U>No Rights
as Stockholder Until Exercise</U>. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder
of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)&nbsp;<U>Loss,
Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include
the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make
and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)&nbsp;<U>Saturdays,
Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or granted
herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)&nbsp;<U>Authorized
Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 40pt">The Company covenants
that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued shares of Common Stock a sufficient
number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company
further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing
the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action
as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation,
or of any requirements of the Trading Market upon which the shares of Common Stock may be listed. The Company covenants that all Warrant
Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights
represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid
and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes
in respect of any transfer occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 40pt">&nbsp;</P>


<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Except and to the
extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate
of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or
any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all
times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate
to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the
Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior
to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and
legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts
to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary
to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Before taking any
action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price,
the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)&nbsp;<U>Jurisdiction</U>.
All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance
with the provisions of the Underwriting Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f) &nbsp;&nbsp;<U>Restrictions</U>.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not
utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">g)&nbsp;<U>Nonwaiver
and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as
a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies, notwithstanding the fact that the Holder&rsquo;s
right to exercise this Warrant terminates on the Termination Date. If the Company willfully and knowingly fails to comply with any provision
of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient
to cover any costs and expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings,
incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">h)&nbsp;<U>Notices</U>.
Any notices, consents, waivers or other document or communications required or permitted to be given or delivered under the terms of this
Warrant must be in writing and will be deemed to have been delivered: (i) upon receipt, if delivered personally; (ii) when sent, if sent
by facsimile (<I>provided</I> confirmation of transmission is mechanically or electronically generated and kept on file by the sending
party); (iii) when sent, if sent by e-mail (<I>provided</I> that such sent e-mail is kept on file (whether electronically or otherwise)
by the sending party and the sending party does not receive an automatically generated message from the recipient&rsquo;s e-mail server
that such e-mail could not be delivered to such recipient) and (iv) if sent by overnight courier service, one (1) Trading Day after deposit
with an overnight courier service with next day delivery specified, in each case, properly addressed to the party to receive the same.
If notice is given by facsimile or email, a copy of such notice shall be dispatched no later than the next business day by first class
mail, postage prepaid. The addresses, facsimile numbers and e-mail addresses for such communications shall be:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">If to the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">BioVie Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">680 W Nye Lane,
Suite 204</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Carson City, Nevada
89703</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Attn:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Email:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">If to a Holder,
to its address, facsimile number or e-mail address set forth herein or on the books and records of the Warrant Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Or, in each of the
above instances, to such other address, facsimile number or e-mail address and/or to the attention of such other Person as the recipient
party has specified by written notice given to each other party at least five (5) days prior to the effectiveness of such change. Written
confirmation of receipt (A) given by the recipient of such notice, consent, waiver or other communication, (B) mechanically or electronically
generated by the sender&rsquo;s facsimile machine containing the time, date and recipient facsimile number or (C) provided by an overnight
courier service shall be rebuttable evidence of personal service, receipt by facsimile or receipt from an overnight courier service in
accordance with clause (i), (ii) or (iv) above, respectively. A copy of the e-mail transmission containing the time, date and recipient
e- mail address shall be rebuttable evidence of receipt by e-mail in accordance with clause (iii) above. Notwithstanding anything in this
Warrant to the contrary, the Company shall not publicly disclose the name of Holder or any of its Affiliates, or include the name of Holder
or any of its Affiliates in any press release or in any filing with the Commission or any regulatory agency or Trading Market, without
the prior written consent of Holder, except (i) as required by the federal or state securities laws and (ii) to the extent such disclosure
is required by law, rules or regulation of any applicable governmental authority or self-regulatory organization (including Nasdaq or
other stock exchange).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Notwithstanding
any other provision of this Warrant, where this Warrant provides for notice of any event to the Holder, if this Warrant is held in global
form by DTC (or any successor depositary), such notice shall be sufficiently given if given to DTC (or any successor depositary) pursuant
to the procedures of DTC (or such successor depositary), subject to a Holder&rsquo;s right to elect to receive a Warrant in certificated
form pursuant to the terms of the&nbsp;Warrant
Agent&nbsp;Agreement, in which case this sentence shall not apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">i) &nbsp;&nbsp;Warrant
Agent&nbsp;Agreement.&nbsp;If this Warrant is held in global form through DTC (or any successor depositary), this Warrant is issued
subject to the&nbsp;Warrant
Agent&nbsp;Agreement. To the extent any provision of this Warrant conflicts with the express provisions of the&nbsp;Warrant
Agent&nbsp;Agreement, the provisions of this Warrant shall govern and be controlling; provided, however, that with respect to the
rights, duties, obligations, protections, immunities and liability of the Warrant Agent, the Warrant Agent Agreement shall govern and
be controlling.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">j) &nbsp;&nbsp;<U>Limitation
of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant
Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase
price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">k) &nbsp;&nbsp;<U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any
action for specific performance that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">l)&nbsp;<U>Successors
and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the
benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder.
The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable
by the Holder or holder of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">m) &nbsp;&nbsp;<U>Amendment</U>.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">n)&nbsp;<U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">n)&nbsp;<U>Headings</U>.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Page Follows)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="font-size: 10pt"><B>BIOVIE INC.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 2%; text-align: left"><FONT STYLE="font-size: 10pt">By:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="width: 48%; border-bottom: black 1.5pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Name: Cuong V Do</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Title: Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt; text-transform: uppercase">TO:</FONT>&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B>BIOVIE
INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(1)&nbsp;&nbsp; The undersigned
hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full),
and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(2) Payment shall take the form
of (check applicable box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT>&nbsp;in
lawful money of the United States; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT>&nbsp;if
permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c),
to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure
set forth in subsection 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(3) Please issue said Warrant
Shares in the name of the undersigned or in such other name as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 21%; border-bottom: black 1.5pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 67%; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrant Shares (subject to the receipt of
appropriate representations and warranties from Holder) shall be delivered to the following DWAC Account Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 21%; border-bottom: black 1.5pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 67%; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 5%; text-align: left"><FONT STYLE="font-size: 10pt">Name of Investing Entity:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 95%; text-align: left">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 5%; text-align: left"><FONT STYLE="font-size: 10pt"><I>Signature of Authorized Signatory of Investing Entity</I>:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 95%; text-align: left">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 5%; text-align: left"><FONT STYLE="font-size: 10pt">Name of Authorized Signatory:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 95%; text-align: left">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 5%; text-align: left"><FONT STYLE="font-size: 10pt">Title of Authorized Signatory:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 95%; text-align: left">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 5%; text-align: left"><FONT STYLE="font-size: 10pt">Date:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 95%; text-align: left">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit B</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ASSIGNMENT FORM</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt"><I>(To assign the foregoing
Warrant, execute this form and supply required information. Do not use this form to exercise the Warrant to purchase shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">FOR VALUE RECEIVED, the foregoing
Warrant and all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48%; text-align: justify"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="width: 4%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 48%; border-bottom: black 1.5pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(Please Print)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(Please Print)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Phone Number:</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Email Address:</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Dated: _______________ __, ______</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Holder&rsquo;s Signature:<U>______________________</U></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Holder&rsquo;s Address:<U>______________________</U></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 41; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: right">ANNEX C</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">AUTHORIZED REPRESENTATIVES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; width: 30%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid">Name</P></TD>
    <TD STYLE="padding-bottom: 1pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 36%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid">Title</P></TD>
    <TD STYLE="padding-bottom: 1pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 30%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid">Signature</P></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Cuong V Do</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Chief Executive Officer</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Joanne Wendy Kim</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Chief Financial Officer</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 42; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">ANNEX D</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">Form of WARRANT
CERTIFICATE REQUEST NOTICE</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">To:</TD><TD STYLE="text-align: justify">West Coast Stock Transfer, Inc., as Warrant Agent for BioVie Inc. (the &ldquo;Company&rdquo;)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned Holder of Common Stock Purchase
Warrants (&ldquo;Warrants&rdquo;) in the form of Global Warrants issued by the Company hereby elects to receive a Definitive Certificate
evidencing the Warrants held by the Holder as specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1)</TD><TD STYLE="text-align: justify">Name of Holder of Warrants in form of Global Warrants:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2)</TD><TD STYLE="text-align: justify">Name of Holder in Definitive Certificate (if different from name of Holder of Warrants in form of Global
Warrants):</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3)</TD><TD STYLE="text-align: justify">Number of Warrants in name of Holder in form of Global Warrants:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4)</TD><TD STYLE="text-align: justify">Number of Warrants for which Definitive Certificate shall be issued:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5)</TD><TD STYLE="text-align: justify">Number of Warrants in name of Holder in form of Global Warrants after issuance of Definitive Certificate,
if any:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">6)</TD><TD STYLE="text-align: justify">Definitive Certificate shall be delivered to the following address:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned hereby acknowledges and agrees
that, in connection with this Warrant Exchange and the issuance of the Definitive Certificate, the Holder is deemed to have surrendered
the number of Warrants in form of Global Warrants in the name of the Holder equal to the number of Warrants evidenced by the Definitive
Certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">[SIGNATURE OF HOLDER]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 5%; text-align: justify">Name of Investing Entity:&nbsp;&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 95%; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 5%; text-align: left"><I>Signature of Authorized Signatory of Investing Entity</I>&nbsp;&nbsp;:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 95%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 5%; text-align: left">Name of Authorized Signatory:&nbsp;&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 95%; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 5%; text-align: left">Title of Authorized Signatory:&nbsp;&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 95%; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 5%; text-align: left">Date:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 95%; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 43; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>6
<FILENAME>bivi-20250807_ex99z1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>BioVie Inc. Announces Pricing of $12 Million
Public Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Carson City, Nevada, August 7, 2025 </B>-- BioVie Inc. (NASDAQ:
BIVI, BIVIW), (&ldquo;BioVie&rdquo; or the &ldquo;Company&rdquo;), a clinical-stage company developing innovative drug therapies to treat
chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the pricing
of its underwritten public offering of 6,000,000 units, with each unit consisting of one share of common stock and one warrant (the &ldquo;Warrants&rdquo;)
(or pre-funded units in lieu thereof, with each pre-funded unit consisting of one pre-funded warrant (the &ldquo;Pre-Funded Warrants&rdquo;)
and one Warrant). Each unit is being sold to the public at a price of $2.00 per unit (and each pre-funded unit is being sold to the public
at the public offering price of each unit less the $0.0001 per share nominal exercise price for each Pre-Funded Warrant). The gross proceeds
to the Company from this offering are expected to be approximately $12 million, before deducting underwriting discounts and commissions
and other estimated offering expenses. The Warrants included in the units and pre-funded units have been approved for listing on the Nasdaq
Capital Market and are expected to commence trading under the symbol &ldquo;BIVIW&rdquo; on August 8, 2025. Each Warrant will be immediately
exercisable, will entitle the holder to purchase one share of common stock at an exercise price of $2.50 per share and will expire five
years from the date of issuance. Each Pre-Funded Warrant will be immediately exercisable, will entitle the holder to purchase one share
of common stock and may be exercised at any time until exercised in full. The common stock (or Pre-Funded Warrants in lieu thereof) and
Warrants can only be purchased together in the offering but will be issued separately. The Company has granted the underwriter a 45-day
option to purchase up to an additional 900,000 shares of common stock and/or Pre-Funded Warrants and/or Warrants, or any combination thereof,
solely to cover over-allotments, if any, at the public offering price, less underwriting discounts and commissions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company intends to use the proceeds for working
capital and general corporate purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The offering is expected to close on August 11,
2025, subject to satisfaction of customary closing conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ThinkEquity is acting as sole book-running manager
for the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A registration statement on Form S-1, as amended
(File No. 333-288525), relating to the securities was filed with the Securities and Exchange Commission (&ldquo;SEC&rdquo;) and was declared
effective on August 7, 2025.&nbsp;This offering is being made only by means of a preliminary prospectus forming a part of the registration
statement and a final prospectus. The registration statement and the preliminary prospectus relating to the offering are available for
free on the SEC&rsquo;s website at <U>www.sec.gov</U>. Copies of the final prospectus, when available, may be obtained from ThinkEquity,
17 State Street, 41<SUP>st</SUP> Floor, New York, New York 10004. The final prospectus will be filed with the SEC and will be available
on the SEC&rsquo;s website located at&nbsp;<U>http://www.sec.gov</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release shall not constitute an offer
to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such
an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or
jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About BioVie Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BioVie Inc. (NASDAQ: BIVI) is a clinical-stage
company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders Alzheimer's disease (AD)
and Parkinson&rsquo;s disease (PD) and LongCovid (LC) and advanced liver disease. In neurodegenerative disease, the Company&rsquo;s drug
candidate bezisterim inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor, Nuclear
factor- kB, and the associated neuroinflammation and insulin resistance but not ERK and NFkB homeostatic functions (e.g., insulin signaling
and neuron growth and survival). Both neuroinflammation and insulin resistance are drivers of AD and PD.&#8239;Persistent systematic
inflammation and neuroinflammation are key features in patients with neurological symptoms of Long COVID.In liver disease, the Company&rsquo;s
Orphan drug candidate BIV201 (continuous infusion terlipressin), with FDA Fast Track status, is being evaluated and discussed with guidance
received from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the reduction of further decompensation in participants
with liver cirrhosis and ascites. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced
liver cirrhosis. For more information, visit <U>www.bioviepharma.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release contains forward-looking statements,
which may be identified by words such as &quot;expect,&quot; &quot;look forward to,&quot; &quot;anticipate&quot; &quot;intend,&quot; &quot;plan,&quot;
&quot;believe,&quot; &quot;seek,&quot; &quot;estimate,&quot; &quot;will,&quot; &quot;project&quot; or words of similar meaning. Although
BioVie Inc. believes such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations
will be attained. Actual results may vary materially from those expressed or implied by the statements herein and are subject to a variety
of risks and uncertainties, including but not limited to:&nbsp; expectations regarding the completion of the proposed offering; the Company's
ability to successfully raise sufficient capital on reasonable terms or at all; available cash on hand and contractual and statutory limitations
that could impair our ability to pay future dividends; our ability to complete our pre-clinical or clinical studies and to obtain approval
for our product candidates; our ability to successfully defend potential future litigation; and changes in local or national economic
conditions. Various additional risks, many of which are now unknown and generally out of the Company's control, are detailed from time
to time in reports filed by the Company with the SEC, including annual reports on Form 10-K, quarterly reports on Form 10-Q and current
reports on Form 8-K. BioVie Inc. does not undertake any duty to update any statements contained herein (including any forward-looking
statements), except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>For Investor Relations Inquiries:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Bruce Mackle</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Managing Director, LifeSci Advisors,
LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">bmackle@lifesciadvisors.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>For Media Relations Inquiries:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Melyssa Weible</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Managing Partner, Elixir Health Public
Relations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">mweible@elixirhealthpr.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection Last; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>7
<FILENAME>bivi-20250807_ex99z2.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 99.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>BioVie Inc. Announces Closing of $12 Million
Public Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Carson City, Nevada, August 11, 2025 </B>-- BioVie Inc. (NASDAQ:
BIVI, BIVIW), (&ldquo;BioVie&rdquo; or the &ldquo;Company&rdquo;), a clinical-stage company developing innovative drug therapies to treat
chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the closing
of its previously announced underwritten public offering of 6,000,000 units, with each unit consisting of one share of common stock and
one warrant (the &ldquo;Warrants&rdquo;) (or pre-funded units in lieu thereof, with each pre-funded unit consisting of one pre-funded
warrant (&ldquo;Pre-Funded Warrants&rdquo;) and one Warrant). Each unit was sold to the public at a price of $2.00 per unit (and each
pre-funded unit was sold to the public at the public offering price of each unit less the $0.0001 per share nominal exercise price for
each Pre-Funded Warrant). In addition, the underwriter exercised in part its option to purchase up to an additional 667,300 Warrants pursuant
to the over-allotment option granted to the underwriter in connection with the offering. The gross proceeds to the Company from the offering
were approximately $12 million, before deducting underwriting discounts and commissions and other offering expenses. The Warrants included
in the units and pre-funded units were approved for listing on the Nasdaq Capital Market and commenced trading under the symbol &ldquo;BIVIW&rdquo;
on August 8, 2025. Each Warrant is immediately exercisable, entitles the holder to purchase one share of common stock at an exercise price
of $2.50 per share and expires five years from the date of issuance. Each Pre-Funded Warrant is immediately exercisable, entitles the
holder to purchase one share of common stock and may be exercised at any time until exercised in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company intends to use the proceeds for working
capital and general corporate purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ThinkEquity acted as sole book-running manager
for the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A registration statement on Form S-1, as amended
(File No. 333-288525), relating to the securities was filed with the Securities and Exchange Commission (&ldquo;SEC&rdquo;) and was declared
effective on August 7, 2025.&nbsp;This offering was made only by means of a prospectus. Copies of the final prospectus may be obtained
from ThinkEquity, 17 State Street, 41<SUP>st</SUP> Floor, New York, New York 10004. The final prospectus has been filed with the SEC and
is available on the SEC&rsquo;s website located at&nbsp;<U>http://www.sec.gov</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release shall not constitute an offer
to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such
an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or
jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About BioVie Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BioVie Inc. (NASDAQ: BIVI) is a clinical-stage
company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders Alzheimer's disease (AD)
and Parkinson&rsquo;s disease (PD) and LongCovid (LC) and advanced liver disease. In neurodegenerative disease, the Company&rsquo;s drug
candidate bezisterim inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor, Nuclear
factor- kB, and the associated neuroinflammation and insulin resistance but not ERK and NFkB homeostatic functions (e.g., insulin signaling
and neuron growth and survival). Both neuroinflammation and insulin resistance are drivers of AD and PD.&#8239;Persistent systematic
inflammation and neuroinflammation are key features in patients with neurological symptoms of Long COVID.In liver disease, the Company&rsquo;s
Orphan drug candidate BIV201 (continuous infusion terlipressin), with FDA Fast Track status, is being evaluated and discussed with guidance
received from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the reduction of further decompensation in participants
with liver cirrhosis and ascites. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced
liver cirrhosis. For more information, visit <U>www.bioviepharma.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release contains forward-looking statements,
which may be identified by words such as &quot;expect,&quot; &quot;look forward to,&quot; &quot;anticipate&quot; &quot;intend,&quot; &quot;plan,&quot;
&quot;believe,&quot; &quot;seek,&quot; &quot;estimate,&quot; &quot;will,&quot; &quot;project&quot; or words of similar meaning. Although
BioVie Inc. believes such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations
will be attained. Actual results may vary materially from those expressed or implied by the statements herein and are subject to a variety
of risks and uncertainties, including but not limited to:&nbsp; the Company's ability to successfully raise sufficient capital on reasonable
terms or at all; available cash on hand and contractual and statutory limitations that could impair our ability to pay future dividends;
our ability to complete our pre-clinical or clinical studies and to obtain approval for our product candidates; our ability to successfully
defend potential future litigation; and changes in local or national economic conditions. Various additional risks, many of which are
now unknown and generally out of the Company's control, are detailed from time to time in reports filed by the Company with the SEC, including
annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. BioVie Inc. does not undertake any duty to
update any statements contained herein (including any forward-looking statements), except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>For Investor Relations Inquiries:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Bruce Mackle</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Managing Director, LifeSci Advisors,
LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">bmackle@lifesciadvisors.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>For Media Relations Inquiries:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Melyssa Weible</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Managing Partner, Elixir Health Public
Relations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">mweible@elixirhealthpr.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Value: 2; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>bivi-20250807_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Plus; Version: 6.1a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>bivi-20250807_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Plus; Version: 6.1a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="bivi-20250807.xsd#Cover" roleURI="http://bioviepharma.com/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>bivi-20250807.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Plus; Version: 6.1a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: /aI5s7xRiXgen8uLbXcsOayH+bPtxZd2CYlBuWV5HVmqLy0ps2fDeSKnh2UWwQwH -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:bivi="http://bioviepharma.com/20250807" elementFormDefault="qualified" targetNamespace="http://bioviepharma.com/20250807">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://bioviepharma.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="bivi-20250807_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="bivi-20250807_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Aug. 07, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  07,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39015<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BioVie Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001580149<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-2510769<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">680 W Nye Lane Suite 201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Carson City<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">89703<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">775<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">888-3162<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Class A Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BIVI<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="bivi-20250807_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioviepharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>bivi-20250807.xsd</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="bivi-20250807_8k.htm">bivi-20250807_8k.htm</File>
    <File>bivi-20250807_lab.xml</File>
    <File>bivi-20250807_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "bivi-20250807_8k.htm": {
   "nsprefix": "bivi",
   "nsuri": "http://bioviepharma.com/20250807",
   "dts": {
    "schema": {
     "local": [
      "bivi-20250807.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "inline": {
     "local": [
      "bivi-20250807_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "bivi-20250807_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bivi-20250807_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 22
   },
   "report": {
    "R1": {
     "role": "http://bioviepharma.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-08-07",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20250807_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-08-07",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20250807_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001520138-25-000249-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001520138-25-000249-xbrl.zip
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M':^*"L^[S1:F"BB;V!!%J3A=IKU/[,EPIR17LJ5R/5NJ5G=7Q^2;API)^"'
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MFBSRCXO[BRJ;U>.RFCY)EO-Y7@VS.I<_99/B%#Y=%:=GBWO/#O[[EU?/7YW
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MK9?P^N2PW$D>/7IT_^$//SQ^^!@$P18,#%]29],<IGP)TBR!?]*I&E?E-%G
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M;NO+MT<'J8C*&NYOY:\0KN-TN5C"!F2Z3G7"G@I^'-TNO)1TV[.*[A?^%=4
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MC;NZ+9SYZ*:--BV)("OMBR1*'/7,BD/P&:H2XF2)=6X[LB.-KWV!JH.DM>B
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M/E"5$Z6LX4XM9XN..-ZB.X=F;]:Z"\ 6BGMJ!%P.1IC&'!U=Q\7!E:/%8$O
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MF5GA.FJ<8^I,,#*M3\[JF%]X1HEII&(C\V0^KS)PB#'Z.J%:RJB^0X6#+:V
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M4RPXUF.84NF*2QP..7%88^*0ZILEO?BWW9W=W=T'/H>9RM@]%]86EN+@Q/W
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M6?(5P_,5P_,9,#Q?* L>XGDV*$CXP_^]=<?@KX46^GQ9=_KOHYV'#5:&:T[
MOT"+_DGR?\W_L3G_I5^\;\VZ/UL/Y8ZWK,%,I5\\B]_ 0%WKJOX9E;+3!QU3
M_ - 3]4!NUW/7J5W5,G]<(4O?V9Q2B)[O6;\/%"T+S<-%NS7/O8_-S!+$UL_
MO7KV[O7!WC$FNT_V]G^A).5/W[SZ4AE*]UY]O'$KCI:3_+ZZ%EU^WJ,6;^91
MDVK)?-LZ=<8AI*>U>(.Z[.CZR'^MZQ,,\@LNT+7LOHWD')8[3YQID!PVPOO^
MC__W"X_J6J;N,M'OCU^]2P[?[@2VT?7.\$^L3Q__(:77^>5NA_>O9YG_#^IA
MP8WL2?K>=?_]WT:@O-\+(^7I5U/P=AW=R^1-5DR>W(H"@)NI1?C$BH);5#AQ
MBX8"Y^DLXW;Q);QWAGE ZIQ6Y-770_9Y#MG-*94U*9#'=RT%\O@NIT"NC#?_
M:8\0N_^XEV$YQP#=J3T!P3__"H)_PXAGAS!]X7"G?VD8O'.MGS_;?_OFS=M#
MB4V^>W^T_PMZ^+((7Q!_?+WS?/GV\"10'VT;0>LQ*,KS(N_WT%[FZ>-WKWD5
M_L2F\L/'D;4K65J[ Y'BN!<!4I\D;M%7F-7?QR\BV1)A"7[<V7T\7_OZ5]*A
M]D!1KY@!>1*#F>R@/H_QPDMS52,JDITW.XHU"UK72UE%&S2^TH)^J6#I#>+S
MB<"(ZXQ62=M^+T"RO7_F2DW?>Y!<B.]GEFL&D2,C5G&.]%8:F4/\&H%M"<.?
M1$_GJ$'P\*)VO6;3?H]0LHL ?F@PWX3EQ*9<"B\TJ'%%(AJT(I.A<[-OART4
MN+G [(4:;+P0##]1I7%S@,;2M%[98"[D"-$30_A^)Q><<IF-,=>[]7B;"6O
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MHE)GH0XG)<=//V5@V^ON">UL4;2)E8T$1B,VWK[:S55;\6&\_OW>I]W_/["
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M*T2UE9C4EEI7"ZEK,A%''?J?^R2-]-6]M8>VWD@87 YAS&YJW*D5I)9T0?9
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M*[#N!\3M6[/ZJ$"YI;'$R/7?<5)["A&4UK=F(4GW>]&T$(8"(Q'I\$$= (,
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M.8%_GB/K&*'<6#1!0-9F/U()!S2J+XR=;K@!>R S3K111UHG48T_1:PO540
M+-DI4B$A*[:7$A-&K/>",@/T=[?'G6T%2:D9DE(>/JX\$- LFCSNX@.J5OP%
M+$Q]" :7\/\[2PWA@(8$@.4AMFR,[1,GO.=LN)'F<G8%'@?(UM7.Y)ODF/5J
M6Z?WO/_>-)CP@C5F6#]A8O 5!F%B/"KYC)";ITP&\LR$@I?0%L3.0,%R1B=/
M%+4>!<E"C78$H$E@;'!:I\$JHNR]/1ABW!X55='D4P-0A:M_5.-1"C .N$Y
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MDQMZ#CU3VH)U9(M7*2A%W_IEWW1?W7\*JS0I&\-V#H$6J3!T\N"D , FUUZ
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M#$JRMR<T#4\PV (.U<K:.=%E&KC44." ]$.))JJR,#K%?5A:&%_@6 V[O_)
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MKH?CE^0)?2;3N%?%%,1,QJ/G)D&RB^+?6ED11$0WV55D:,O=N PQ=U;<780
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M<6&Y!?BZ]_XL#X''/L^)*DGNM2A@D>8@7&3HE>>P'<7>XI.L*R4J01IUU:)
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M0.*\6%]@GX!.<\S/%XHG<K((8(BL1K(K<+N8#.O)K(V@AW#+H''FH]ADO'7
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M502I(43LM-P8F,W/='R&0H;2N>YG<]@N&#QC<9>CPE&0.[^M D];6>!XXX8
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M-\K@V_;[/ E7I>7&"TDL_5QHFH(>HL>%Z2ZD@0C792@5'A.L_+3[&[QGX<7
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M$ZN%&7@Y\3&3U 4O4E<-1VH%'?NIU+AU H1B"CJKCYP%M)%Y]M!F#>!Q7"R
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MSH ";6*>WV/F]JFJ+@99NYZ2E(KDT$L28+FJ6_3@O>6LM<*P)0Y0X.^9,G!
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M3P!=;!<3;.Q68 B#&I8P)IS!MOX]B4 M*[ NBFE_O"&Y0=([RW;?E,61#Q7
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MXJ":FGK44[@G%5<6.O5A^]AH*X$.KFO"JAQW7'JZ9^XD@J0!K8<E\*8F1YB
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MXTZT@0B9#7HURY?X$K>T %_2<-..C7)CK=74HFOJ-5+^"[@L:OF+7UHZ[98
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MW$ISR@33V3@3F(UZ/K*IG:D.4>9AE0YI(22O%+=-U3A@9@Y.!IP&0?F +RA
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ML;QM3-V2YR%2D$7#(SN>MNWD8<W;MXV:"3.KFJ^CMIV5%R \7-9PBW:Y/5Q
MFLD]8L%)-@2 :2D^K_C5ED>VAN>L9B=2<V95+/-?QO[A*R;$IB =1EN/(F?8
M1E)73_0_1*=OV0%06!L?HEC"6"PEG%NN02)%0D<C;MEB\%.VM%O8&D=&!C1:
M+;I%*!T!I&UA%WB*7BD39M:^DZ;4-_[/5^CSW%5>S#8^?I]5 ]B7)$^+V2-
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M#=WK)"M1XN!,&(KCWSR*P6C) ,8'RAU,\L/[89\FDS(!80^KD(Y ]+*B/2M
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M&^&\).< ,8$%V*2GNJ@&$4W42U1TC(]3 Z;LQ21%$&)T><*,181Q;VYJ,L;
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M&1^X:>HP$-._7AXST]-8#8:&0I=6E9 .DM$ N5W%?VXAV5I_@I6T38HM2U3
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M.;4%\)XH)(BA K&G8#=*QM0U7'&6F[P&QVJZ=^$X7*S#XJH*B70PB1=K9&'
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M,O*(*LO2DGYJUE+%*/J77J0]E%K'V24'F5$HEWC&RZXUI70K3F,G,< YWD"
M2&_MYLI%8\CN SD_]\EE4Y20:9#IH9L3,(18>8>#4RZG-'E]SH:3N5;"K_G
MEH#&P/0R%\ZOL]!"KAEMWHSJZ@(^5=3**S:!U#,I(!.Z);Q.OX0<B7=$CR+R
M&-K4'>PY4Q[N%/D6!,?!FWDX(*\<9Q;:8LTJ;>?[U8]>7.132%X^V,76"3A;
M\0LS9Q3/ F$K%<%JN>3]ZX9=S<V'+^K*HOPP'(CL;,S![5Z6J(5;$9TL\SFU
M\@06IR^6JRK=UN'MC!0\Z&"AD+$FZ%OY!+D)VADF\[_4\*F1"[UQBYP?40,
MF1Y,C?EA))-E75(&J36*E@>9C<\+4E\.LV641/77@W29V_/3JCP%3AF&+XX9
M*I^ 2U(#)!LLMHP;NY(KMN%(ZPEV5KL -J#R\2P+6OXU%V7=U4P7;B<_%UR/
M%N\NQ6+8B!4&9)Z-*W8]VA5LZ[C#+0_53;*RA-PYH<AUDF>Y]$V]$.NVJ9!V
MNKWU9'MK_TOB>=\ [7A\ZZ =#W;NL!W7X-WN:G[CW;,W$*?>>^X6B8)2/U_J
M["N-!G;7Y-!:<@<=%Z":A"9P#/Y)<4*@=6.D#0RD9:E#.IHT\!&P6*IES94+
M2)I 5K%C-S?B#\ALOMA&@AI+2M+C<V;8D<-56\,='88[)A<0+1*T=,7:,446
M8 ;:!4>6VWNTE6WCX:U]R7VP_X1ZE-5O0_[#HWM/X/?\[^\DJ6CXYZ'RO;W&
MG7<OCWD2"DS?M9Z!)!HA3])*GE!WL"8HI.K6DA4.U-;= LM.47S!XT^@+BR0
M>R:;A7&THBG/(9!".QM0W;4I11:QQL.@T8S7A5)K]M227! &3C2-HPV7<</]
M:]V Q7&[;WQ*'AHI8F "24#D5"5KW,!'5  *6\:0'4/[SMS+=)^'PAE\E&=V
M#&,K7.Q<(-_N(JX]T8XC9.U+C-+SC.@%^3&%G#'K?.XH1X_=_5[H$X?22%<>
MK6KN/+?X(WH.$Y,2[H.:+Y'/1X@AS)B& [,W0F98M] 3][P9$ NSHZG>>YZ_
MYSYMF:?^F!0P##PG0ONKJZMW)-!2M!"^5%ENXN!K:/W3X3/9CH#?2N$7O"OI
MYS7Y8F$X@M_V#:-'7I>"(+X Y5QL8ZZW=K1;3?!*;QD"*1R"\<#]2^;0R6V9
M;OZA;Q76T6OJ&_07UQQ-3U[F[JS_A)D_R9QLJ.+T5 .,4W"3$G^'EB%9T@09
M68DF#R/&"(6ZQ.0T'VC,39;#;L,UF7+<*9Y6'$+/'#/GCRAS+B=3*^<?:,/*
M@'UNG?*1^DSQ-,3]Y,CTJ0=$%TVD?_XDYV2+:G>N2T=U.$*,)B?R3?*Q$:M)
M^=8@#<W'/4OS.\KEG/5FER*GBJ'LU/HJ%LGNG?C@0^MC%ITI+&4KX3=HO95H
MZ4.P-*;68>:%WV_3*N9@=[P<5&M+MI;XS*APR;"E63W"]8LNFC]I(1N$FBP=
MQXNDFXQ#("S;.;+6K$W3H/G8O?7&_*&%\WN3?NNGA>+90_?K64F=B!+JQTZ[
M@C\7'@KKBUADN5PXU,8#]J;3C6L+S&EHZN;<]BW0WXNSRK>26T]0;0#$1GE6
MLAE6EJM'$2Y #@25@&,'NBQ:='C#@?L4H%$R8"C&,Q;$E5(0HBIF*2LMIW*N
M4H5$D'M&:RYPS$&!S84T9>[/&?4CN'%6CFGOS -9#(IZHG$IRG-G!9!W#&#W
M[FR>$Z4\$F],<CH ==A0VH8!NPG,%DT%[O&VCSD\X>J, SRLG0EF(Q9%\[S8
MJ9+Y-!2W;D@-";A4L[6%!: =Q4"*CT,@N!=B0$K:JW^A13T^RC#BE^2W76H^
MGK*>.U8:V=^VJ_J=CZ-:I".R/AZY3<.KXYUUL_;@BI2G/\D7%SD'E\$%6PQR
M:3+F-FVXXM[R%-#WCU.W!'<?A562C]ED'&JO*X)P<4S84ACN@'#M)N5=W\ J
M 6XN^@HX3-@>/D56*SMW7HFCO4V&@RO?)TG_-H&E\F?VB;OEZK(;)+G$_A@.
M@@UB*=&#NA-\"4A:249G$AB^E!M>PM<)X:"\3<^J1JE#E5S3F!!YJ-9MSP_?
ME;8BU;.;=F.[R=D5V4X]FSG85^BR]FUIJ>U^.:?]AOK/D]M7_WEP5_^Y%O\/
M<QP'E@"N@SD3F382D>SR</424EC.-!'2*%KYPU#" :Q7)U)J?+0-YDP!#D7I
M+$4V-<'V&J>24^D*L"@YFW<GK(++ ..C%]5HB?QMP\$+2YG'[ZJKE!.D8?!5
M9KYIN=-[:^C\/8^^%#L:@6/A)4PR6^M) 7C31P)9@LUP8\Q=N<_#;5.HQ$%;
M'(W?ME(+R)PN[@[-"2&?4(F[T_?4X8T<"\VM@>I(TF?=P;D%6JYQ7"WGM)LN
MEC8L!Z5FC'8@%L\Y(G6C1,*G59@(S/1()0@O$_8N*A9QX&8BSLF,P)UT_@W@
M[20K,\T7L/WT[BX\NX9YB RC?Q:"XD@P"]NR=#A5!MMBGN/>L)A<(>VE*AQZ
M:<!72YX(A!*LXI8I3W 5E)4TQ01:C242+>J$-$$%;:V['O2/:TN <STAS;D@
MRG[UP6:0?:XCQ:5-+T=\-L$IZ? 6PM=+;Y">$,>BF5N:H SYPQJS7-+N,%@=
M"T:/1[U'S=E%%)NP5""7(V?2G#FLB^E*<5^%[A",F/#%U#K_O*N)LI\KX-$!
MMRA#E];3+-:OSB8L<L?L939M5,Z=RM34);'!?"XL2)ZS?W*:(EDH,/)3^R \
MWRR?5>[T'&<&:( J$F)H;?5X. B,HMC6D9M,+A%@,CJXB8UQ6\U[02P(Z52Q
MIW!^N_ANH9&FNZP?J'0<#@< *BT:]X8I<(ATQ0A]AEL8DTE'YJ23V3;016@P
MQW)H,-W4(>M+J AKY0#:!(^0@V)!;A^;CL\114$9Y+0S&!O.!=X3H?FP'5^A
M&O%18Y]UL<"FT2#&#0K>0:-++S4  IV1R=V]5P1]<"$B>,R6&$V&$26^&&Q_
M3U7]#N<325T)!0(AN2)!.3?![Q(?4)'"+0"ORMXS\T;#3.#>),O*@7!Y.C7&
M3-^$"4D%<FG^2FGTK/'>1("NZ4*X[_Q"4N'JB<O[_$&,%J&"$K8'A0Z(;ND>
M (LW0K86:5IH -4.F)4^-%*=L\!*<));B+8MDJ0*:^F.QLK0Z1*Q?=NX+6RB
M@?:3?]A-%P!C0&P:B)G%$[W+6MZQ5[B&8R/&+:*$%&QS9#]P^19WN5LL%Q1D
MR=[UC4^1[FURP0F@1;RKL:/86#B=@H:YQ0&# 2*$B';F.\2>( 811]G?6FS*
M)N>602DM9])9=%^8=L%FW^J! S1;H4@W?;":D_'G3@QZ%-9>D(:-R\\M0 ?M
MY%)H*W@O$C[R)?' _S ^A,!S\#''O5_G6>15&<ZI.[.0?,8VF"A;3.MY8(CF
MB3@<US<<G-)6EB(8?J[%4DVB4BR"FRA,:-+,BXB'9JN5N7R6+\Z 5\$]J$5V
MW9EMHALUX3S5!WQ0?[(*@WID(VTU;W]H_-Y)!@36P], D6E2BB#R8ZNRS&!;
M]?5Z&'\W<*>,X6&@&+K?TZE!7ZT$GG"W,$@K_@768 34='2&76 =YW-=QLS;
M"_>>^!!M$+P,[];T+R/1R31;==]HJ%GCC@?%3DRR8MJT_5GIG^%:0AHL506Y
M!@AL#T)FX=E:,<G3(I\(7\RTC;U)T2):]%QU0@>H%$Q8HINT-)3C&&CA1/9*
MREA%^5\HW7V>;^MMN<9$H"7G$3AK!M-3Y[P)6X^*73\4Y"$82*'4ZL;25[W0
M(*)',#!@VAB\&&K-+8!7FFIPC99NXM^I:+N=5.58'U*1B%]2,>5Z]M)W @ZT
M4G-]["OHS<2@5AETLXX]+Y&LZ!B0IZ]=*L]JD+];8.X$W&(7E,,'>WR;T"T(
MV 4\\(NR&FA5IVVT;8CCZ &BNDV$V41_2=.;E]E.QUXXM2#P'Q@T_D-D'O?J
M'K -&Y/%#,#I[Y'BSS ?86X1:KG@M)1](^?N4S=XOH[,@4%@,<HD2Y[NW /=
M&6[4E-T4O&J9+CR&N47A.Q:&"V193,Q^=+!/T@ES@.B[L9\N"^K5,,9E_\5?
ML]G\QT/GQ=U/=G<>W-_Y+MG:F[O3,-D%#,'.8V3*;(J9LW-U<#W0!Z<+?D5M
M<4]O7UET]ZXL>E4<38^0/^M5A*=1'>A#3/3?$!*I#YD91 F^@8# N0\'7D5Y
M. @HHEV$J>P^Y$\:YD.#^7AH>MQB!62VNRK'[&$LE%:X. ,15*)KA3"%%/\6
M%DN./QBY9\-;RJXI?Q?A9IS4;0 O5*XE<H8@>P1V<SH57+HE-:6P/B1![1F&
M)GPF[K"'4@CD/0LNA0B>7^?Z3<UL3<C^8@A1(4_F)RHX:[RBV .F9XVAZ)E%
MHV)?/51*,\<=G&MN+NK3O)?.M,M<6KB]TQ5E98 S%*J"H#/.81I^I,UH>DD>
MTXPVL<"'8J\62GE$'Y67\;5WRW8]8D->@C3JOA<JX:CQ'15!"%+?#NTFGLDR
M2'-",43?)\%GW;\FH"@%EF(YDL!SMEP44T.1$Z549UGE_IQJ &J6@%/B&N1"
M@^ FMB<^A,.7%KU;7;CJ\1MNFJC7CJAR8U\+*)+]M@,75?BOQ5$/)LK.3!U,
M&TL5(N:F6.#H*9=,/R!:F@- HU3,,019PI *Y38M]N_Q\-\;PV<P9W;K#OGO
MZ9 W4P#;U2/#] !*7GF+:V@0)<KMGEAQ,[V!C='G_ UC8*:#&PZH8@J=3'#0
M<$<38128["U?D.#QC=<NZGN?]$9)W.U%@19Y3%R;R9&+-"4W<=AJ*^?"!LZI
M.R^G?4H!12!"2QF$.9+-,;72F.\9@)VQO. ^,QS8G#T:,_-S(X9)U&YKD\[+
M58"!_V5:\ZUZEJ>'YZMLX?'/Q GG%07 >(B,J^7)(C4]P5KX=G<U:L3=/"8Z
MCJ HOE&>&/,*S_T'TU!)>CC(!2 .[8OSL(;48&\'$VOC],K7%P4\I!LS+!Z:
M(/L'2[XHJ<H^V;_M%"%@ 'LXH9?7Q/2RJ;2;3,$7K,W.;IBRE9(GHVIV I5^
MF[%P<W>1K8@* YX\YY72P'+<C@I7\\V:F7LST;MAMN9\FUX/EBUKX")U+IL_
M^CE9*AQ@R3H*,#QJRQ!NA1"SEF7S+?+NL"[< W!N*YG4GDS<P]7=P/,Z6U2F
MG!RUBUO43(YV$5R;9;W21Z62N'L_?>+/%/*3VT"A$.(Q[#C<AJPP?[AQ).L5
MIJDQ'6^21JQ\\U$*WJ;2JU0!?%,T_3G7H+697_4,.J]GPRV8<&U9TI8;D[_F
M#Q@F/N@##,!I*6,-^07=BNW,%<7"@)<A?)M4:D5OWK.C6(8[6X%@@GXFU#)V
M-3"BON9/H[+)S_BH6NC-%JPOL[*.*>]H=3[K_%ZXS^Y#EI;<R64-'=&TUYR=
MT(^DPT%)&6=NB;G<.ROYNG]Z?2'IVTFNRPD[7GSBH$,2P><.^-$%:-BNI )&
M,$1-V"),A51M3X6H=<5&W(:L*6L#M3\Z'*A>!U3=$4<6G)HD>4,SBC*Y:.Q(
MAK.LW#+.^990CTU9>.=4CIWX8/R!8 1UMHFHUI^[?8?%%Y0WOB[_"@/D(\6P
M,AU4HPI33909*@L,39ST@;RW[*0"S:1B$OAD=GV>LF_ ZT$6%[W#OC>'FY=&
M:E<#>Q7>X8BY#@SU6WE&$<WUH7TS3 "XK-%"V$,E1/VAOH81QI6Q2.W,DZOS
ML1PDI2+LA20OS/D\++$"4,G-AZ^M",ZD=;,T/%#:?^[2\HRP;DZ=9R,NAQ=!
MKNHL R;:J3T;T=L42 M^RYLO@4A<PHYMF4I35H]E67DV)'2@]3IBL]03(T0V
M7,!_A2;@.:*'$'3]^H+5AI.7^J'MF+_A@=NE=!++>G"#7SB'O]0S[Y3(#]!P
MD_==AWHBG==2$2*Y5+QG<.'4WSUK0E>GNR1EXFN?\*03&$Z"R B)P7;-Z.(D
M8!6GGQ?!F4*+XG\W1IHII&R7@KY)F>)=HK)HDC']]RC/E?YSP\OK[J& -#\@
M#/)#\UVAK6')1N('A</HQ ^@T@'(W,GL1W)<:Z^\K>##SLRTAJ#N(^XZF-*3
M?(5ETY:"48L-!1<8O3P$6NL[8E4S>@$P331N=1L^YBU\00?G^H+KHYW;5W!]
M>%=PO197"AL0WSB?XJWS*8:#%S871%[4BR4W/ 4,1IL34VF;HIF,! N68+5!
M *\:6&TQV@DYH5PTY&.N9COPFDT"BXB#G+>3+\@Q]RX6NP?F T@FT#F8TB!!
MLEC6I4E6$/NS!@0^J^*!7_8LI^<)!]BH4T\/8.GIU+&K!.S<F-%D.@$N@FOF
MT+PRF:2=3 O$B"[RJ^% <UL"7L<I@VJ:T5E.]3[S:S,4!JD8>L_MENJ0>1@5
MYG[^;!NP[L8[-OW![&+T>E%T'/K..EQ:(XS2.D=D__$HC7OAHHU1);0\ 3Y5
MT($TU]-6N\W.9!+S)8>#JW8FH^L/4V9_SIF<K'4F2:S$,GKV>HIN(W]*5U&=
M"0.1Q@;6[IB2K:AVT3H'4=L5-[F)X8T^PD<<#CZ=DQA_^HB'R$.+.8K:ZKW&
M45QS^6U-0[;%2H,O;?01 ?ZK'12?SF?\8,=].# [Y7YR'%LT&W$,<P+M3%<$
M."2;0.@4QC?PXD/C&9NPE+L@6VRV'S:GR;HI#8Q<8X869\[[@OSGZ_*6$'S\
M\[(<@Y@G^@;'_MR4JM['5O+2MA1,Z@Y_9R 7M(C<:/@G/#E1T=WY4!6JX""K
M@#-P?C0-YY@I/3G+L6;$X%?P_C.[J()FT$J;",E%>,,<<*H,LVEXDO[FCD],
MB8*("OR'U&O24 >;855<65N%^/Z6Z#C+#8;]]ZQW8AQ!FB'TW4"?OF8$MO(O
MF(F2PIEY)/M J<G;4I)W(5BU"4VIJ1_";[8NS@B8%E8L:2S!G&Z3%AHWZ$3X
MEKKG8NN%P3'IQ<59F<6/T(QM8>1X*.?2]471XZY,LA$,NPJ^02_RW)#3FL$]
MVOF++D8>8:1^V:[W0?DPZ,?[T 6?]*[WKH/L?*?Z-"N+_S%U%/;P^7<V1<BY
M>W@WRVE322W03V><&\LX+UKAH=Y,J LCB)+:]^0ZY--TW@2()86O@NJMYW_*
M/H33Y37X/'*@XA6B2][Y^-K>J0/55G);F-H8%[7>0-J9?Q>KN #GGMM$.(Y8
MW++-C!;A-J*23K7$C!?]"M+&I!IM>F?;G^;PL*%)PI@3%_(E%_!PL.41"]CF
MXUTH/(]YG[1O;G\&0:+W3(<'+@-@]5*&/E:C M\:DB\!V1+^I-V>P66&@]AU
M6# M^F:32[Y8%PUBD&9#0G,")L$!:,H&1///!0&IY3'GR,;0:*,(AZG-IIZ8
M&2>?7#0?XX%;";B"H&+)[BL/PT9# <-T-4(J0PYF\4L]SRXMRU+N"_TMB?2
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M,^=>3Q9K+ T!3'P29YV+;:=<:PV ";5@%A8Q)3$P;53H2A5D0(1]0M&R 2J
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M8K6>]<M+,^(8)R%BQ_/*@!) 08@-BA(ALG9^<*:Y\H"$1F*8B?3H!0X7>2I
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MF2M AIN2EET ,;X83"S\_M?_]?3[QT]__,.2-QFYNA32 BSO_1\[]W=V=AY
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MR[7,PR_/E;%1%(,9SZ92Q,%@[,7;-]8<9 MJ#D1P)G_C9O3>!*80J'-C,X!
M=[BK^61TS,F'#UGF0.D27*CU.["]N/O^D?Q>HWW#?V?# 4 ;[BWG )U$1DBE
MKC. 2_]</I<4W/',G6D0Y?P.U(<9<)I0UVY#PM5 +5_5C;MWIG^R?_FC33)$
MY%^_$T.-#CG_@^@.4"^<,H@0/K72(O]*/24)C5;8'*LIS O1:@-Y TEL.YMQ
M0_)$;GDBZ0SI!O.<P<M';OJ2!<"!'B(#7EV><L,5P=L\I!(EAEU/$120<EY
MRH[5?.W5$QQ&=5:<%,AS2433P$+C[P:O!>5I3G+Z,K$4X6N*CB0[0:9/"I9]
M:)]AW\$,G5]B@PP^X1'C1_[>>T1]^N#IPX<($4?.>P2*?GY[_B$Q]O<[QJU_
MF36+K\Z-_\A ^_)N_-?@5/_Y;HYOG[]^\4_  WS[Z_'?7S[[_U!+ P04
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MV>]9FQ]-D.[F<%:TL360'4Z\C8"$]=CC;@=G\*1>T*)(QC$.F6<Q3Z Q/@U
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MRC!3!RP,-DSPY_0/O7[RW4UJ&,:9GMG-\1")%[80=;FK+6$;/H,'/V_E</N
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MMD3;U0YVQUHBM3A_LX7%>D,-30[YZBEI'8BN*'JP1O&2B%$=N>R#!9K%K1J
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M62D/-7J\WQJ/B^I9W65WA[4PN^4SOTUO:\"[JA$$)9-*+2.A!'-2)UV;4%S
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M1FAP*=K"VLH]K<3_C-OWK[SX;'0C@TUE)4JG[(W!9M!I(B"!]#Y%*\%11$G
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M!$7<2=_,^!W!AQ_T.E\&UY_B%\;Q;BVN\\.]B^O\<%_C.E\_HK-WBG;C+T?
MF=Z\^_#+MP_G?!,'QL[V<]' !V>J3;7RLC',K863H_JSDCN-^YIC>B'8VNG2
MI+PF&55UH9=K.SC,J3BL+NU?V=Y[;NFP?;,):U=9^BWN.M!5\.O>VX]'P8>C
M@Z/C7X\.PXZ]UYFT4I]EZK$J5997Q+I"3[?ESN_"COZA5)N6A*0-U9B-'>J-
M]).5NLUUTGRN)+>O,^(U]!9K8]>J1>MR4:ZUU0-Q0[\ODJP:MN[Y;2SQ:^B(
MWYB(]P25YH&.'^CXCTS'[\^QYE/'2!Z(^4][TD<$L// M^[(4=_$D:*7".S,
M_VG['WP:RC=K^>6W6OOM'L+->O"N=6 >K*L. %W9H_MLYZINO\Y<_\XE;Y;;
MO_-EO]_=\/<WE#I^)RCP&U+81NS^J[/N;_6;AZC%ZHQCY^5_& _WCR^#=]PM
MYD7P%OL7WP\W]X]7<'-_NV*"Q_OO#O^%1/#XY[-?WK[^_U!+ P04    "  G
M@PM;.B)B0E!:  !OR $ %P   &)I=FDM,C R-3 X,#=?97@T>C,N:'1M[7UI
M<]M(ENUW1O _X/E55Y,1M"S)^]*.H23:YHPLZ4ETN2LF)B8@$I30)@$V $K%
M_O7O;IEY$PLEN;V5I8[HJA() HE<[GKNN:_>C=[OOVZW7KT;]/?@WP'^[]5H
M.-H?O'[U@/\-WSZ0KU_M'.[]'IR,?M\?_.W>-$V*%\'6YJ((1O$\RH.#Z#(X
M3N=ATN,/>L%)E,73>_!#^.G137_W,IB'V5F<O CPTLV701']4=P/9_$9?)3%
M9^?%O=>O=EX/_OYNN#,<!8\V'KYZL .C/OH:SQM'21%E],!?D]-\\?+;/.LX
M6F11#G^'17P1_9KE_URF+_/@8YAE85($_;,LBN;P]4_RYO]8YD4\7=U[/7HW
M"(X';X<GH\'Q8"]X=[B_-S@.#M\$HW?#D^#HP_'NN_[)(/C8/S[N'XS:K9W?
M@^'H).CO[@Z.1OV#W4'P#GYX^*87]-\>#P8G\+O^""X)/@[W]X.#PU%P,MC?
MAY'!ST_>X*V/@_[)R?#M0?T3@L'?\<YP#=UX>! <'1_^-MR#L?4/]@)_N.W6
M%>.]YJ!Z,J1><+0_V'L[P$&^^_WH$)ZVVQ\-&N[]!E\E.!H<#P]A)#"$PP.8
MC0\'>SB1@^';=Z/?@\[6L\UNL-?__00NW]\__#@\>$LO,7CS9K [&OXV@"_A
M"9V]P9OA ?QN9P 7=8/1(;SN[WA#',0QOL!!T!EV<2@'_S7X?Q^&<//]_5V:
MSH, 'CHX_G@\A%F!D>"PX 7A_G##O4%_'VX $[E[>'" SSP\@'D8O:-A',(P
MCF%,/;Q19P@/Z <[AP?]X U,.7X[W.4U.^H?CP[L3)>' )_"<(.3#[OO*F,I
MC63C:^]H<W:^]KFIVQ+P&>ZNP=\'Q[O#D_[._@"V[_ 0)@(7],/;#R>C8&NK
M%VQO;C_>"'X[',*N?@,3%3Q^L;D9'&V\W^@%@SYN;C@>P_>P @?^SQYN?JWY
M,]+GJTZ?$G&[A^_?P]N=C YW_ZLRD3^)E#7/>I-F07$>!4?+;'P>YE&03H/_
MM?\+3LY#T#WXX6XZGZ=)NW52I.-/O9]AI8_"+/@MG"VCX)?-C<W-S:U@$67\
MQC_%^Z73G^$M=N+TMS@*ALGX3RU>1#K+AW$RB?"FFQN/X^3>ZZV-X-6'U_8(
MBF7WZL&'UQL@GE&<@ZH;#=\,Q5[H!7$2C-,DCR=1!E9AFN )G2Z321Y,EK-5
ML CC27"Z"N!PPW>GT7DXF^(EH_,X^33XYS(N5J0?.[_.)FA-@L1YE\[@9BAQ
M?LWHLVXO"/,@B\[B'*8GFK1;Z64"!P1N4YS'>5 >;B]02P6_A6FZ""<AC#-;
MI#+*#HH:]TR0*8LP6?D/Y8$$\ 28HKB811.X61' =4$!LPW#R()IEL[IKZ!(
M^=_T27]Y!M-LU5C-X\!.'I.Q'.R%151ZVV2"#X+;GT;3-(M8\RTVYO VN.2_
MI]FG8!>G#I_8:[>\QSW<+#]N\,<BEO>N/NQT601)6J#LS:)P"C/<PW?)EZ?Y
M.(M/X852^&1AYAC'ED7C"!P 6OS+\W06X5!C$,F+,(/97R[P!DYTYU9TCTET
M!SE*;EZ^*)"IAT> %+RH2$'Z<?F%6!GX[P$#_D<TAO=(VZUP@KN<9A=VSB)+
M+V!_3G"X)W )SL.3 %\WG6X$0QY&:8YPU<-@$JYPVUZ>Q^/SX#1,/L7)&=P%
M#E"QQ$MSO"7^^J3 W\ ;V>6! <(XEL5YFL7_BN@,S,)+G)CQ+,UA[N!G2?W^
MA=.[@I4/HC^B;!SG\..4GY+ B87W'(^C:((CP>'QV. NN(;PW;D,&P86CF''
M3T+89^W695R<TSU@?>>Y??F]988WPB]@LN-T EN=;BU/+,U*3Z]8$**_QP_&
MS1]^BNALA#S#Q3ELX<MT.9O0,^,$?M]NU;[P!HJ#FGF(<7[C(@YG($ED-L)3
MV&YPYU^V-QYO.CWY,G@U?&T6NA><IY?1!0J1X>L>CV2YD%=*Q^-EED4T*[!@
M.&+9B?"+I,B#?!&-XVE<OU]X!LC?SX,S'"6O;8,@BI/Q;#DQ4VP6%'9D/([<
MX&&CP*FB%5[.3UFRB;T#$PL[00[<A-^"5MG<JX<G9#;#JWC7PU6PY^DTP_CM
MR^ <\^I[@D$&=(0#4N>IW>*[SJ.09TW6H?P*8K/9)_M?]X))M/ W%.@*U#OU
MHYE.<;8OHK*4\D8CLNXI2U9>CPF=/G-0\9-CTA:R=>ETDC2 /\#.G <G][>"
MSIL8MM)!NA$\?/CP_O:S9X^W'W=+4BFXA+F<1.-92'HGLB.D)8]P>\ )*F)8
M*5S"P1^P_LD9_7P>YWF]II%OM/CZ*1R^>I-BFTP*L]/(E/ABP^!_XG-N,*#O
M.15;>BYH*XIM-03#*4-K PZ\/40-0L43)5/<SF%1A.-S.']XZN$.I3UWD!9T
M6*>!6P:W]X(YGB>0'VBPP1[_ _8T21'8T*"P%[/(_#6)9K#WX220O->ZNTC/
M(A0Y@>B9.FF.=UB$*SZ'1NEJ^8/OPJ>*9%^[=1JAY#"F!_V:Q#_:G&%^CH?P
M,@;K ,YYDD]9;L9@64UB..^@,L*+,)[1+]@BA5&'K!:7,(9)E,.2A5: NT./
MAM<*K/&L(-'9;L'<HL&"#YC&8Y2#: P$_/$RF45YSM(-1D5_*#F8CJ/)$@99
MJU:V-[9AYF?I)>HZ[PH2JXO%+![3"_ 2DL8RDV9-%S'5%G1'44V9"=7*IH#W
M81F*VMJS+9H,S4&(UG;")F;5'FBWC$%0M]9&)\'^89,1'GF1@BN ^R,%BW.Z
MS&B_P%-9C;!H%=L7?GO5>XPCL49QQ\*@8#H&H=*+HJ^==HQ!Z5^D-)NW6 !M
MHP#:-=O4D\HDA&9QM,1C)-/(EDO="I^N[&&N'L.,3D(<97_-Y9# (<Z7^#LX
M@V[S;P7A:7I1WD7MEC:$PUF>>CNV['8$['6$8OZ2$P9#0F.!G(XP^!7D7/&R
M<CCY8[Z;L1O$YZ-=@P+(NGXX<#'#ZBVUZ)]+D LB&/'.,0FZTR*,$Q8QDQBL
M4YS1_^[T[^]T@\[?N_^#GW?ZX+Y<XGY]\3TVA;\=X=G_Y_[]X$T<S28O@J/P
M#$SK$W@W-)AA',']^Y*8>[4W_,T,DA]]OT@7+X(GB\*,Y?YI6A3I7#X[)05G
M/]N9A; OMC8>PW#S=!9/[KUV;ZW>10_PU0-X:,WS3\%S_72?9=@+V \XZ&N,
MZ:9/5!/S &>&)^,+K-8]%UP=44!\=["_?]3?VQL>O/W;O<U[]/?)47_7_/UQ
MN#=Z][=[6YN;?[GWN<_FJ=FLF1J:@U>C8W/G"]2$XW!FMA/\$-.HKT9[YHK+
M>%*<VQWUZL%H[W7=M]OT->SW\A6U-NO?T)%Q.O!%T(F[=+I^^]@_,AIIE(5T
MIO;0YU6Z?X&'U7I>$W'/K]:J03QE.5(UFE!'=[:ZL)$+TC/.3'*&49.<$VT$
M?[%[3CZI>.VA>0G4J61]=+;__:?HB0%O+,V,;$K!)2./;"J",8O.EN#@H/RF
M7X""SG+^JMWJD ,T)1D&DO)X"=/V9'.S<]KM/'E$[M(Q_9S&</#^!"V>^7)V
M1G856%T1FW33" .$LR!W#M,LO(0M*5;JL8S!C/H=C<%8J&ANT**HE^K!=H#]
M$!;R4B;XZ*1X+XAB,C(Z?WS9?=-NU6P.7+85/V<'#!VV:.6G)GG!CX;52,;Q
M F;##.)]F'V*"HYR+M),3-*=69JBDCD+]C>.-O!;N1VIN'2*T13SKG_-9:^H
M6:AL].#Z^]QNO E'B*ZQ4RJ[#O=LG*MMB\8?FK:7*>UP^K6*.\*"VG )&.CQ
MK'0E7T1V-H;0W-XK;9OJ4+KU)Z83=FU8ATT MW+6;LS/T\LDH+#+ M>& F_I
M>#FG8)&-+8H+(?8#'[5VRX81_#=70Z-%E2FRD:B&[17'-0)PK6C3MVBWXJGW
MBS7+7UW(-1??4%*U6VKBK[VH@0E\J8&]9#7R8'2,_T#%^46M^J=-9GW%A+\-
M2GOGNDJ[QK%OSM2@AC?!0]P1I#%>XB;ZFFO[^,G&4YS"JVWD^]M;, &^37B#
M)??G$E?^9?!-E[QA_W[N/O!O-XNF, !P8VZP,ZH1;I<G0"\]!W&!\HLBW=:9
M9V57FR/0>8Z@E.9HVG=6^=D'7,+>*WF-%&*R%V0A*BH<!8:0JI&>#9H#1"=^
M)6ET;6'T#5W'H5U%3-+AVK&5B'/;;H7&N*MZWFS8<2@3W7<*H(\_)>DEN-IG
M'#*B])(8RM5%-DK\(>B2SG,;MU<!^?ZXH'VS]?SA0Q8TH+)159>3B=Y/_*2B
M,M[8(* LEVA>WY8-8(=EX1@V7@PS-K;&6B6J 0J3XIHJH&'2/^=@/5#(DW-Q
MI3L$33<P"<,"IE"RA6GS_=HM?B/.P5R1S%ND>4SSC(F;+ 03A6X-9TJ%,&]M
M/,UM(FLXRM[!;=1ND33I45P;)W-B4ZB</9M$G!EUYN,TSG(;'9^FLUEZB>LW
MGH7+W,A*,O*B'-QAL*)BS\' 4TAYY5E,&A6>B\8Y02:T2<S^!@_E%$:^J'%6
M3#">G TX@/]<1CE#)^2+),+K"N4QX?MURPZ6^#8F.\=.RU7CO<(5ZIR&DA;W
M#57"7CQ_\7 S"#?F<%D5+-'%_?OHQ>9VN[5HN@3./;BW35,K Y2W/!SM_K\=
MDP;%/_YN 17FG1):^[JIOTAG2\217$88[,:W!@V.<26['B$_GA:#%!;9[M=<
M 3LV'I<73(%7')=>$00V/$F@(#5+0AM"WD)>BD98]V8UTT+>X)1?+2^E>MSL
MFD6G#2L_#H[BY%-PN("OS6;*& :1YZGQ(#'KA<<LR.-YC-Y#FIV%2?PO 27!
M-V=1,EYI^ 3\) 9A.ETF8P9SP.OP\TEFTD"[/=ZP\Q3F&:<9X]WVQ-@,?I"G
M=N@]\M4F7=):H#)2BD& #D2!0^<ZC#,4.?@F#'CQ3QY%7+1D (L#!0^FTN'Y
ML$Z+11:"X(=9B&8@AEGIGJ4@XN'>Q7G)&67(3IBG":P\XC/&T:(@(ZN2QJ-(
MC22SHS_@@3D#=]@[MCXQHKK:+3]K]I53V#^NZ%<"R,,LL"E9 A'52$;0I1B2
MT^?K)X8#5.>-IZ&J-S4TQZE"/C<YI0P%;9'[TZM$RE4RS$9#E'Y[P1&8WT\&
M[59_#B\[QI>GS\)\$OXSV T7<1'./'DG7[V=I:=KOSFA\^I?8!00X9D=A$1L
M!B?G0!"E_IQDT5EZ6W8+AKRJQ^L'MZTF80P"E]5\T*SE2U;7C16]31^4;*UK
M#?]KF%JP5;6M%7Q74XL5^)6+\&5,+67O5,PM"L"J=[RVJ?5%+"IUHW:K8E%]
M'=OIZD, 9OB_>PJ^K+U%9HUO< 7?R=XRL$<QN(*O96]] :=[/6I@^R7L-=HF
M+W!($CEXR34O\/4W A7@]-S/XW]%/$=UM1?7C;FJES6O^3(8K19PZWX6GL;C
MEZ#XYQ%/Q4&*+[CMP0?,K_";6X)L^*8XIX>(<WH?H2TEL;B?%X'Z66. *6(T
MZI[D'@D%(1+Q P;?O0GS8H6"P$.[2<M1!]2TF1S!KQ,R;!X78F*@YK!@,=0M
MA9&,+$%)!H\SD/&%2<0;T*:7X/\KN0%X-\9R1A%\ F8V18G-+RA:C*/?BRB8
MF69H(2#DU;Q.<9ZER[-SNI%<A/?]"#^<9.%E. ./&ZZ&GZ23&%1#O@)U/0\Z
MG/@&VW3O8W^7;%/ZP)HSYOYQSIHXY% WIOXY<4$J3NY&&D#@"OTNQS0H$YL$
M%G7>;F4:UIY;6/L"E5=A)XN2*$E%J\(<PVO!?X6S\E<PWP8S@<ITIULV)6"3
MG,6$I$TS' ;=PU=[!MHIFCY%G9LD()S3Z7VZ? ;611&RN:#SPH0IV7KT".>
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MH^/^P0E<AM<-_KX[.!H%1Q^.3S[T#^!VAW#[=FL M]D=#6$:^.V/^Z/AX4%
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MK'W5)FZW*HS$@OG'94<B=-!JEE2C#&U2HS2=)-7#JQ0N+,E8D'F,Y(VQ"1;
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MCF!DB&\*/"+G=^5=SW)602PF)0+]%A5LG#NE*@I!74 EZ151U/."),4R2U3
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M@[4QN8I2IUM9A79+@OH<58_F01(A:%&J^S'.[L@8FVYB$@/T>U6%.R$2!FI
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M57]2F:FR0K=SAXT! 5 QHPX==@$6E6F6,=? +P)PA7#*4"/'*)@7RP/0_HX
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M,!^&2TWI!Y:653LJE2Q 4$QO?9A(O1=(YCO.&Z[A&0>6.KLIVV.VNC\+Z((
MI<=<ZZZMDC= \30#7= \R5_EHW37N\V*<$OCVA)7;$#F-!-F>1 L *9,!I0,
M21U20B\]K^\2T%P^Q @VQY2Y)<!NLDE!4Q,0"59C  T';?%,J1<BYF)DXCA=
MT)CL?R&O8+M:.K=, #:;4!BB@*BP.P.P*,6H4",A]P+&+4\VF+\NDZAGJF@+
MW:(!&6VR8:H"@@.P!M!1JM%R,?<YD]SC_2(6H"8/B7H>O(<24.\6EA[;368
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MX6^"QQ+B"2'0/ !22Q\B3I#)7JA4H$^VEB3:B?GQ=3I;W2=Y:CNY;$N<S4F
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MM(1:G]F2?B )V7KHX^\J >6/.*'H%XNV?EX-S(UG)OUSYD>&4-J(2V%+I:%
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M>@K2OS9ZT>AZ\T"G5-EE"H]TG5R;AI[\#T6 XM#XH+Y1"(RA)$P7[1-=M^:
M?4]M_HW]9=_%:H[\!%!+ 0(4 Q0    ( ">#"UM+VU(**@,  .H+   1
M          "  0    !B:79I+3(P,C4P.# W+GAS9%!+ 0(4 Q0    ( ">#
M"UL>AE 1#!P   B.   4              "  5D#  !B:79I+3(P,C4P.# W
M7SAK+FAT;5!+ 0(4 Q0    ( ">#"ULMJVY,>+(  ,?] P 8
M  "  9<?  !B:79I+3(P,C4P.# W7V5X,3!Z,2YH=&U02P$"% ,4    "  G
M@PM;_(B.9-TF 0 D,P8 %P              @ %%T@  8FEV:2TR,#(U,#@P
M-U]E>#%Z,2YH=&U02P$"% ,4    "  G@PM;%NTL3(Y(  #ZA@$ %P
M        @ %7^0$ 8FEV:2TR,#(U,#@P-U]E>#1Z,BYH=&U02P$"% ,4
M"  G@PM;.B)B0E!:  !OR $ %P              @ $:0@( 8FEV:2TR,#(U
M,#@P-U]E>#1Z,RYH=&U02P$"% ,4    "  G@PM;A$]>U% -  "U*P  &
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H:2TR,#(U,#@P-U]P<F4N>&UL4$L%!@     *  H J (  (S) @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>bivi-20250807_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="bivi-20250807.xsd" xlink:type="simple"/>
    <context id="AsOf2025-08-07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
        </entity>
        <period>
            <startDate>2025-08-07</startDate>
            <endDate>2025-08-07</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-08-07" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-08-07" id="Fact000004">0001580149</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-08-07" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-08-07" id="Fact000010">2025-08-07</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2025-08-07" id="Fact000011">BioVie Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-08-07" id="Fact000012">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2025-08-07" id="Fact000013">001-39015</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-08-07" id="Fact000014">46-2510769</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-08-07" id="Fact000015">680 W Nye Lane Suite 201</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-08-07" id="Fact000016">Carson City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-08-07" id="Fact000017">NV</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-08-07" id="Fact000018">89703</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2025-08-07" id="Fact000019">775</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-08-07" id="Fact000020">888-3162</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-08-07" id="Fact000021">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-08-07" id="Fact000022">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-08-07" id="Fact000023">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-08-07" id="Fact000024">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2025-08-07" id="Fact000025">Class A Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2025-08-07" id="Fact000026">BIVI</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2025-08-07" id="Fact000027">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-08-07" id="Fact000028">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
